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Cancer immunotherapy represents a rapidly developing field with potential to 
address shortcomings from current therapies. A compact marker-suicide gene 
reliant upon off-the-shelf reagents would offer considerable utility for these 
adoptive cellular therapies.  
Marker genes enable measurement of transduction efficiency and allow 
purification of transduced cells while suicide genes facilitate deletion of T-cells 
in case of toxicity. Previous marker genes include Neomycin resistance, 
truncated nerve growth factor receptor and CD34. However limitations of 
current marker genes include immunogenicity, unexpected biological activity 
and long coding regions respectively. Similarly, several suicide genes have 
been described with Herpes Simplex Virus Thymidine Kinase and inducible 
Caspase 9 in clinical use. Here, limitations include either immunogenicity or 
limited availability of the inducing drug. We sought to generate a compact 
marker-suicide gene that enables clinical grade sorting and effective deletion 
using CD34 cliniMACS and rituximab respectively. By using minimal epitopes 
required for binding, we hoped to reduce the size of the construct. We first 
sought to locate the epitope from CD34 which binds QBEnd10, the monoclonal 
antibody used in Miltenyi cliniMACS CD34 selection system. By epitope 
mapping, we identified a 16 amino acid linear fragment of CD34, which 
demonstrates approximately equivalent binding of QBEnd10 as the native 
antigen. Next, we sought to incorporate rituximab binding epitopes to 
engender rituximab mediated deletion. Following optimisation we established 
a 136 amino acid construct, designated RQR8, composed of two rituximab 
binding epitopes flanking the QBEnd10 epitope on a CD8 stalk which enables 
selection with the cliniMACS CD34 system and deletion through both CDC and 
ADCC with rituximab. 
Further, we demonstrate functional co-expression of RQR8 alongside chimeric 
antigen receptors and transgenic T-cell receptors. Finally, we validate 
functional efficacy of RQR8 deletion  through a murine haploidentical 
transfer model.  
We predict that RQR8 will make T-cell gene therapy both safer and cheaper. 
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a.a.   Amino acid 
AAV    Adeno-associated virus 
ACT   Adoptive cellular therapy 
ACK   Ammonium chloride potassium (lysis buffer) 
ADCC   Antibody dependent cellular cytotoxicity 
APC   Allophycocyanin 
AZT   Azidothymidine 
ADA-SCID  Adenosine deaminase severe combined immunodeficiency 
AKT   Protein kinase B 
Apaf-1  Apoptotic protease activating factor 1 
BCR   B-cell receptor 
BCR-Abl Breakpoint cluster region – Abelson murine leukaemia 
viral oncogene homolog 1 (aka Philadelphia chromosome) 
BME   β-mercaptoethanol 
BSA   Bovine serum albumin 
CAR   Chimeric antigen receptor 
CD   Cluster of differentiation marker 
CDC   Complement dependent cellular cytotoxicity 
cDNA   Complementary deoxyribonucleic acid 
CDR   Complementarity determining region 
CML   Chronic myeloid leukaemia 
CLL   Chronic lymphocytic leukaemia 
CMV   Cytomegalovirus 
ConA   Conconavalin A 
CO
2
   Carbon dioxide 
CTL   Cytotoxic T-lymphocyte 
ΔEGFR   Truncated epidermal growth factor receptor 
ΔlNGFR  Truncated low affinity nerve growth factor receptor 
DLI    Donor lymphocyte infusion 
DNA   Deoxyribonucleic acid 
DMSO   Dimethyl sulfoxide 
DTT   Dithiothreitol 
ELISA   Enzyme linked immunosorbant assay 
eBFP2   Enhanced blue fluorescent protein 
eGFP   Enhanced green fluorescent protein 
EBV   Epstein Barr virus 
EDTA   Ethylenediaminetetraacetic acid 
FACS   Fluorescence activated cell sorting 
Fab   antigen binding Fragment 
Fc   constant Fragment 
FCS/FBS  Foetal calf/bovine serum 
FDA   (US) Food and Drug Administration 
FITC   Fluorescein isothiocyanate 
GAPDH  Glyceraldehyde 3-phosphate dehydrogenase 
GM   Genetically modified 
GM-CSF  Granulocyte macrophage colony stimulating factor 
GPI   Glycophosphatidylinositol anchor 
GvHD   Graft versus host disease 
GvL   Graft versus leukaemia 
Gy   Gray 
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HACA   Human anti-chimeric antibody 
HBSS   Hanks buffered saline solution 
H&E   Haematoxylin and eosin staining 
HIV-1   Human immunodeficiency virus type I 
HLA   Human leukocyte antigen 
HPLC   High performance liquid chromatography 
HSC   Haematopoietic stem cell 
HSCT   Haematopoietic stem cell transplant 
HSVtk   Herpes simplex virus thymidine kinase 
iFas   Inducible Fas 
iCaspase9  Inducible Caspase 9 
IFN   Interferon 
Ig   Immunoglobulin 
IHC   Immunohistochemistry 
IL   Interleukin 
IM   Insertional mutagenesis 
IMDM   Iscove’s modified Dulbecco’s medium 
IMPDH  Inosine 5’ monophosphate dehydrogenase 
i.p.    Intraperitoneal 
iPS   Inducible pluripotent stem cell 
IRES   Internal ribosomal entry site 
i.v.   Intravenous 
LB   Luria Bertani broth 
LTR   Long terminal repeat 
LV   Lentiviral 
mAb   Monoclonal antibody 
MACS   Magnetic activated cell sorting 
MAPK   Mitogen activated protein kinase 
MFI   Mean fluorescence intensity 
MHC   Major histocompatibility complex 
MLV   Murine leukaemia virus 
MWCO  Molecular weight cut off 
NFκB   Nuclear factor kappa B 
NHL   Non-Hodgkins lymphoma 
NK   Natural killer cell 
NT   non-transduced/transfected 
ORF   Open reading frame 
OTNA   Off-target nuclease activity   
OTOT   On-target, off tumour toxicity 
PBMC   Peripheral blood mononuclear cell 
PBS   Phosphate buffered saline 
PCR   Polymerase chain reaction 
PE   Phycoerythrin 
PFA   Paraformaldehyde 
PHA   Phytohaemagglutinin 
PI   Propidium iodide 
PIC   Pre-integration complex 
PNH   Paroxysmal nocturnal hemoglobinuria 
PPT   Polypurine tract 
Q   QBEnd10 binding epitope 
R   Rituximab binding epitope 
RCF   Relative centrifugal force 
RCL   Replication competent lentivirus 
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RIC   Reduced intensity conditioning regimen 
RIPA   Radio immunoprecipitation assay (buffer) 
RNA   Ribonucleic acid 
RPM   Revolutions per minute 
RPMI   Roswell Park memorial institute 
RV   Retrovirus 
scFv   Single chain variable fragment 
SCID   Severe combined immunodeficiency disorder 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis 
SIN   Self inactivating 
S/MAR  Scaffold/Matrix attachment region 
SOE-PCR  Splicing by overlap extension PCR 
TAA   Tumour associated antigen 
   Thermus aquaticus DNA polymerase 
TaV 2A   virus 2A sequence 
TBI   Total body irradiation 
TCR   T-cell receptor 
TGE   Transient gene expression 
TIL   Tumour infiltrating lymphocyte 
TNF   Tumour necrosis factor 
Treg   Regulatory T-lymphocyte 
VSVg   Vesicular stomatitis virus glycoprotein 
WT1   Wilms tumour antigen-1 
X-gal   5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
wt   Wild-type 
ZFN   Zinc finger nuclease 
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Due to rapid advances in genetic engineering and molecular biology, cancer 
immunotherapy has evolved into a broad term broadly encompassing any 
therapeutic strategy that modulates the native immune response. These 
include therapeutic monoclonal antibodies, cancer vaccines, adoptive cell 
transfer technologies and recombinant proteins1. In light of the aim of this 
project, subsequent discussion will focus upon cancer immunotherapy 
mediated by adoptive cell therapy. 
 
Adoptive immunotherapy represents an established and evolving therapeutic 
strategy for the treatment of malignant and infectious diseases. The graft-
versus leukaemia (GvL) effect in haematopoietic stem cell transplantation 
(HSCT) can result in sustained remissions of certain haematological 
malignancies. More directed approaches, such as administration of  
expanded tumour infiltrating lymphocytes (TILs) shown to achieve dramatic 
remissions of metastatic melanoma, are also possible2. Further, adoptive 
cellular therapy (ACT) with virus specific T-cells has been shown to 
reconstitute antiviral immunity against Epstein Barr virus (EBV)3 and 
Cytomegalovirus (CMV)4 resulting from concomitant immunosuppression 
following HSCT. However, apart from these examples, it is typically difficult or 
impossible to generate therapeutic T-cell product with traditional methods of 
selection and expansion. Advances in gene-therapy afford us alternative 
strategies: namely transgenic re-targeting of T-cells to tumour-antigens. One 
such strategy is the use of chimeric antigen receptors (CAR’s) which allow 
specific targeting without the imposition of MHC-restriction. In a recent 
neuroblastoma clinical trial, cytotoxic-T-lymphocytes (CTL’s) specific for 
Epstein-Barr virus (EBV) were modified with an anti-GD2 CAR achieving clinical 
response in half of the subjects treated5. An alternative strategy involves 
transgenic expression of native alpha-beta T-cell receptor (TCR) chains specific 
for a cancer antigen. In a small clinical trial, two of seventeen melanoma 
patients responded to this therapy and this strategy is currently being 
evaluated in a larger clinical trial6. 
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However, although cellular therapy offers great promise, identification of the 
potential risks which may result remain less defined. In contrast to a 
therapeutic protein or small molecule drug whose adverse events usually abate 
with the half-life of the therapeutic, T-cells engraft and replicate, potentially 
resulting in escalating and fulminant toxicity. With advanced engineering 
designed to establish non-immunogenic therapeutic product, there remains a 
need to identify a uniform strategy to enable simple discontinuation of cellular 
therapies in case of undesirable toxicities. 
As ACT remains a rapidly developing field, this introduction commences with 
a brief overview of immunotherapy and adoptive cell therapy. A brief synopsis 
of the evolution of ACT pre- and post-genetic engineering is followed by a 
discussion of the various genetic engineering strategies employed in T-cell 
cancer immunotherapy. As marker genes and suicide gene strategies have both 
evolved concurrently with advances in adoptive cellular therapy, and due to 
their primary role within this project, these will be examined independently. 
Finally, in consideration of the aim to be compatible with current therapeutic 
antibodies, the final section of the introduction briefly introduces monoclonal 
antibody technology.  
In this thesis, I describe the creation of a novel modular gene cassette which 
offers potential for application as a universal safety mechanism for adoptive 
cellular therapy. 
 
Coincident advances in immunology and molecular biology have enabled the 
rapid evolution of the developing field of immunotherapy, which can be 
defined as: the clinical modulation of the immune response to facilitate 
suppression of immune-mediated pathology or to enhance an immune 
response against infectious or malignant disease. Immunotherapeutic 
strategies include nonspecific stimulation of endogenous immunity, active 
immunisation mediated through cancer vaccines, monoclonal antibody 
modulation of immune responses and adoptive cellular immunotherapy7. As 
the focus of this research was to establish a marker/suicide gene for cellular 
therapy, the following will offer a general introduction to immunotherapy 
approaches, with the primary focus directed toward adoptive cellular 
immunotherapy. 
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The first reproducible successful application of anti-cancer immunotherapy 
was achieved through stimulation of endogenous immunity mediated by 
cytokine therapy, clearly reviewed by Rosenberg8. However, although clinical 
benefit was observed, cytokine therapy also imposes significant toxicity, thus 
subsequent research sought less toxic strategies. Observations of tumour 
infiltrating lymphocytes isolated from tumour resections suggested potential 
for the presence of endogenous immunity against malignant disease. Although 
observations of TIL’s proved variable and typically limited, this observation 
suggested there might exist endogenous immunity which could theoretically 
be enhanced through vaccination. However, although vaccination programmes 
against infectious disease represent a triumph of modern medicine, similar 
attempts to apply vaccination against malignant disease have proven largely 
disappointing. Although further discussion of vaccination for cancer 
immunotherapy remains beyond the scope of this thesis, the current state of 
cancer vaccination as an immunotherapeutic approach is reviewed by Lichty 
9. Finally, monoclonal antibody technology offers great potential for 
modulating the immune response. Antibodies can be directed against cellular 
antigens to block signalling pathways modifying immune responses, succinctly 
reviewed by Blank 10. 
 
Adoptive cell transfer represents a complex and rapidly developing field 
within immunotherapy with reports citing clinical efficacy against 
autoimmunity, malignant and infectious diseases.  expansion of 
regulatory T-cells (Tregs) has demonstrated promise in therapy against 
Crohn's disease11 and is currently being investigated as a therapy against type 
1 diabetes12. Immune suppression, commonly coincident with ACT modalities, 
may impair infectious immunity which would otherwise control environmental 
and endogenous pathogens. Attempts to address these co-morbidities using 
ACT has demonstrated efficacy in restoring or mediating antiviral immunity 
against Epstein-Barr virus3 and Cytomegalovirus4 as well as antifungal 
immunity against . Further, advances in molecular 
biology and genetic engineering vastly extend the potential for therapeutic 
application of cellular therapies such as T-cell re-targeting through expression 
of engineered T-cell receptors or chimeric antigen receptors. Reflecting the 
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proposed application for our marker-suicide gene, subsequent discussion 
regarding immunotherapy will be restricted to cellular cancer immunotherapy.  
Advances in HSCT and applications for DLI as therapeutic strategies 
established the groundwork to enable further adoptive cell therapies. Genetic 
engineering enables the ability to correct genetic deficits and endow cells with 
novel functional capabilities. The following will briefly introduce the premise 
for adoptive cell therapy. 
 
Observations of clinical efficacy frequently highlight further barriers, similarly 
necessary to be overcome, to achieve therapeutic success. Thus, progressive 
evolution of cancer immunotherapy continues to increase the range of 
transgenes required to overcome obstacles presented by tumour targets. 
Cellular retargeting of T-cells can be achieved through inclusion of a 
transgenic T-cell receptor (TCR) or chimeric antigen receptor (CAR) directed 
against tumour associated antigens (TAA), which are otherwise invisible due to 
immune tolerance mechanisms. Where cellular retargeting has proven 
insufficient to mediate remission in itself, efficacy can be enhanced through 
modifications to T-cell trafficking capacity and enhanced functionality 
achieved by later generations CAR's ( ). Inclusion of drug resistance 
genes or selective engineering of virus specific cytotoxic T-lymphocytes (CTL) 
can facilitate a selective advantage for enhanced  persistence. 
Modifications designed to enhance T-cell survival and proliferation can 
improve efficacy in the face of oppressive tumour microenvironments, whilst 
inclusion of marker and suicide genes offer assessment of T-cell survival and 
persistence, or can facilitate cellular deletion in the face of toxicity 
respectively14. Figure 1 illustrates strategies currently employed in T-cell 
engineering, further addressed in 1.2.2, p36 and 6.2, p180. 
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Adapted from Kershaw et al14. Coincident advances in molecular biology and immunology 
enable an ever increasing array of potential modifications to T-cell biology such as facilitating 
redirected targeting or trafficking, with many further engineering modifications already 
described. To ensure sustained gene expression by modified T-cells despite cellular 
proliferation, genetic modification strategies commonly employ integrating retro- or lentiviral 
vector cassettes to mediate gene delivery. 
A report citing sustained engraftment of CD4ζ CAR T-cells more than a decade 
following adoptive transfer15 provides evidence for the promise of long-term 
persistence and highlights the coincident potential for chronic toxicities yet to 
be identified. Similarly adverse events such as graft versus host disease and 
cytokine storms represent acute toxicities resulting from cellular 
immunotherapy.  
The range of risks associated with adoptive cellular therapies is multifaceted 
and dependent upon the desired therapeutic effect, concomitant therapies and 
the adoptive cellular strategy employed. Toxicity can result from engineering 
strategies, source of donor cells and potential re-targeting toxicity. Engineering 
strategies which require transgenic integration or deletion impose risks of 
insertional mutagenesis (IM)15, 16 and toxicity resulting from off-target nuclease 
toxicity (OTNA)16, 17. Use of allogeneic derived donor cells imposes risk of graft 
versus host disease (GvHD)18, 19. Re-targeting strategies impose risks of on-
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target, off-tumour toxicity (OTOT)20. Furthermore, therapeutic administration 
protocols and even disease burden can result in toxicities such as tumour lysis 
syndrome21, macrophage activation syndrome22 and cytokine storms20. 
Currently identified potential toxicities associated with adoptive cellular 
therapies are summarised by Table 1. 
Adapted from Sadelain, 201123 
 
Donor T cells Graft versus tumour GvHD18 
Engineered T cells Tumour deletion OTOT, cytokine storm20, 
tumour lysis syndrome21, 
macrophage activation 
syndrome22, GvHD19 
Haematopoietic stem 
cells 
Correction of monogenic 
disorders 
Genotoxicity from IM or 
OTNA16 
Pluripotent stem cell 
progeny (embryonic or 
iPS derived) 
Regenerative medicine 
for genetic or 
degenerative disorders 
Genotoxicity from IM or 
OTNA16, 17, residual 
teratoma forming cells17 
However, despite these concerns, adverse events following ACT have largely 
been restricted to isolated cases. From a 10 year review of adoptive T-cell 
therapy involving 381 T-cell products, no grade 3-4 infusion reactions were 
observed; of the twenty four mild reactions which were observed most 
resulted from the cryoprotectant. The conclusion from this review was that 
infusion of T cell products is safe in the outpatient setting24. Most importantly, 
no adverse events related to insertional mutagenesis (IM) of T cells have yet 
been reported to date despite over twenty years of adoptive T-cell therapy25. 
This is in marked contrast with the experience involving retroviral 
transduction of haematopoietic stem cells. However, although therapeutic 
benefit was observed from GT trials for both adenosine deaminase - severe 
combined immunodeficiency (ADA-SCID) and common γ-chain X-SCID, IM 
mediated clonal proliferation was only observed from the X–SCID trial. 
Observations have been made noting the relationship between the clonal 
proliferation and the potential biologic consequences mediated by the 
therapeutic transgene. In X-SCID, the common γ-chain provides a proliferation 
signal which may pose an untenable risk when this is associated with an 
oncogenic insertional mutagenic event26. Similarly, from a gene therapy trial to 
resolve Wiskott Aldrich syndrome, although all patients demonstrate positive 
clinical outcomes to cell mediated therapy, 6 out of the 10 patients treated 
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developed T-cell acute lymphoblastic leukaemia. This reflects the predilection 
of retroviral vectors to target proto-oncogenes such as the LMO2 or MSD1 gene 
loci when used to transduce haematopoietic stem cells27. 
In light of the intended application of putative marker-suicide gene for 
application in neuroblastoma solid tumour cancer immunotherapy following 
from previous clinical trial results5, research was performed using the MLV-
based splicing gammaretroviral vector SFG28.  
All genetic modification strategies will impose a degree of risk which can only 
be predicted. However, a defining divergence between adoptive cellular 
therapies and conventional chemotherapy lies in the resolution of adverse 
events and therapeutic toxicities. In contrast to the resolution of undesirable 
side effects resulting from chemotherapy which can most frequently be 
resolved by passive discontinuation of therapy, the potential permanence of 
the therapeutic benefit from ACT represents both the primary reward and the 
greatest risk of these therapies. The greatest challenge of cancer therapy is to 
establish suitable targets that enable specific discrimination of the desired 
target for elimination. Adverse events following ACT represent a parallel with 
this scenario where specific elimination of the problematic adoptive cell 
population also poses a specificity challenge. Genetic modification with an 
entirely novel target imposes a risk for immunogenic deletion by the recipient, 
whilst a non-immunogenic host-derived target extends specificity of deletion 
beyond the adoptively transferred population. The challenge is to establish a 
suitable safety switch which enables effective deletion only when deletion is 
the desired outcome. 
 
 
The evolution of adoptive cellular therapies owes much to parallel pioneering 
research; HSCT/DLI therapy for haematological malignancies, TIL’s for 
metastatic melanoma and EBV-CTL’s for latent EBV reactivation each represent 
independent research tangents, all of which demonstrate the vast potential of 
adoptive cellular immunotherapy to resolve conditions which otherwise exceed 
the capacity for endogenous or compromised immunity alone. 
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The rationale behind allogeneic haematopoietic stem cell transplantation 
(HSCT) was two-fold: as a rescue strategy, HSCT enables application of high-
dose myeloablative radiation and/or chemotherapy, designed to improve anti-
tumour therapeutic efficacy, but without supplementary haematopoietic 
rescue would prove lethal. Additionally, it was hoped that destruction of the 
bone marrow resulting from myeloablative conditioning followed by stem cell 
transfer would achieve replacement of the diseased haematopoietic system 
with one derived from the healthy donor29. Despite promise from animal 
modelling, initial attempts at HSCT proved largely unsuccessful; although the 
earliest cited attempt at a bone marrow transplant dates to 193930, it wasn’t 
until 1959 that the first successful transplant was achieved31. Following from 
this success, it was a further six years before the first demonstration of 
sustained engraftment of donor marrow32. Finally by 1968, the first successful 
marrow transplants were achieved in patients with severe combined 
immunodeficiency and Wiskott-Aldrich syndrome. During the ensuing 
decades, successes from continuous advances to improve efficacy and reduce 
toxicity have converted HSCT from a treatment of last resort into a common, 
and in some instances, a first line therapeutic strategy against a wide array of 
haematological diseases33. In addition to malignant disease, HSCT is also 
considered for many non-malignant conditions including benign 
haematological disorders, immune deficiencies, autoimmune disorders, and 
even as a strategy to establish tolerance induction in preparation for solid 
organ transplant29. 
Early animal modelling experiments identified many of the key mechanisms 
underlying allogeneic HSCT, including: demonstration of bone marrow 
infusion as a successful rescue strategy against lethal irradiation, 
identification of the separate graft versus leukaemia effect in addition to the 
therapeutic benefit mediated by high dose therapy, and identification of graft 
versus host disease as highlighted by Figure 229. 
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Adapted from Jenq et al.29 Ongoing advances in the fields of transplantation therapy and 
molecular biology have enabled development of adoptive cell transplants to progress from a 
treatment of last choice into a first line therapy in many instances. This timeline highlights some 
of the key advances in HSCT. 
 
However, further understanding of the underlying mechanisms involved in the 
GvL and GvHD effects required identification of the major histocompatibility 
complex (MHC). The MHC was initially identified as the genetic region 
encoding tissue antigens which elicit graft rejection when recognised as 
variant from ‘self’34. Discovery of the human leukocyte antigen (HLA) system 
led to development of histocompatibility tissue typing methods; initially 
achieved through serological techniques, recent advances in molecular typing 
have reduced donor-recipient mis-matching thereby reducing toxicity but thus 
imposing a concurrent reduction in the potential donor pool. Following 
identification of the role of T-cells as mediators of the GvHD effect, T-cell 
depletion from allografts was premised as a strategy to reduce toxicity. 
However, although this successfully resolves GvHD, it also increases the risk of 
relapse highlighting the relationship between the GvL and GvHD effects33. 
These observations helped to establish the immunological capacity for effector 
cells from the donor inoculum against malignancy, thus establishing HSCT as 
the earliest form of individualised adoptive cellular cancer immune therapy29. 
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A biological definition for haematopoietic stem cells is: the population of cells 
which are capable of rescuing lethally irradiated animals33. Although 
demonstration of the bone marrow as a source of stem cells had been 
established through recovery of rodents following lethal irradiation35, a 
breakthrough in the identification of human stem cells was the identification 
and association of the CD34 cell surface protein as an identifying marker on 
haematopoietic progenitors followed by the subsequent demonstration of 
haematopoietic reconstitution in lethally irradiated baboons using this 
subpopulation36. Subsequent discovery for the potential of granulocyte 
macrophage colony stimulating factor (GM-CSF) to mobilise CD34 stem cells 
into the peripheral blood enabled blood to be exploited as a source of stem 
cells expanding the potential scope for HSCT therapy37.  
Following from identification of the major histocompatibility complex (MHC), 
preparative regimens perform two key functions: to eradicate underlying 
disease, and to provide sufficient immunosuppression to enable 
administration of the graft without subsequent rejection. However, much of 
the expense associated with HSCT results from risks and complications 
occurring both during and following treatment requiring hospitalisation 
and/or further therapy. In addition to GvHD, mucositis, veno-occlusive disease 
and pulmonary complications pose the most common therapy related 
complications whilst fungal and viral re-activation resulting from 
immunosuppression pose frequent infection related complications. Finally, 
long-term survivors remain at increased risk for secondary malignancies and 
patients whose preparatory regimen included total body irradiation are at 
greater risk for developing cataracts. Thus, strategies designed to reduce 
toxicity and complications not only reduce morbidity and mortality related to 
HSCT, they also reduce therapeutic expense. 
 
As the effectors of cell mediated immunity, T-lymphocytes offer great 
potential for therapeutic resolution of both malignant and infectious disease. 
Consideration of the therapeutic potential for T-cell mediated immunity 
facilitated through donor lymphocyte infusion (DLI) therapy resulted in 
parallel research tangents, three of which are discussed further below. 
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Prior to the advent of donor lymphocyte infusion (DLI), therapeutic options for 
patients who developed graft failure or disease relapse were limited to HSCT. 
However, the identification of T-cells as the mediators of the GvL effect 
coupled with observations that T-cells reactive to minor histocompatibility 
antigens could inhibit leukaemia, (as observed through  and  
modelling experiments) led to the development of DLI, proving to become the 
next major advance for adoptive cellular therapy38. The initial test of DLI was 
as a salvage therapy for relapsed haematological malignancy following allo 
HSCT39. In this trial, three chronic myeloid leukaemia (CML) patients who had 
relapsed post HSCT were given supplementary DLI in the absence of additional 
chemo- or radiotherapy. Following DLI therapy, all patients demonstrated 
effective haematologic and cytogenetic remission, thus supporting the 
capability of subsequent adoptive immunotherapy to achieve therapeutic 
efficacy. Subsequently, DLI therapy post-transplant relapse was extended to 
further haematological malignancies including multiple myeloma, lymphomas 
and acute leukaemias, although therapeutic efficacy appears disease 
dependent with response rates optimal against CML followed by lymphoma, 
multiple myeloma and acute leukaemias respectively38. 
Building upon initial promise, DLI offered the potential for cellular infusion 
following reduced intensity conditioning (RIC) regimens, promising to achieve 
the beneficial allogeneic GvL effect but with a reduced transplant related 
toxicity associated with autologous stem cell transplants. In this scenario, RIC 
provides haematological space to enable donor cells to engraft whilst imposing 
sufficient immunosuppression to prevent rejection. The lower toxicities 
associated with RIC regimens enable application for patients who are older or 
who present with significant co-morbidities38. 
However, as with HSCT, GvHD remains a common therapeutic complication 
following DLI, typically occurring in 50-60% of recipients but with the benefit 
of indicating an anti-tumour response typically associated with longer disease-
free survival. Further, there is a lower mortality resulting from DLI-associated 
GvHD thought to result from the absence of preconditioning regimens. Post-
DLI aplasia represents the other primary therapy-associated complication 
occurring at a frequency up to 40%38. 
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Further, in contrast with HSCT, DLI offers greater potential to resolve GvHD 
through genetic modification of the adoptive cellular population. Concurrent 
advances in cellular engineering presented a novel solution to the problem 
posed by GvHD through inclusion of dlNGFR and HSVtk as marker and suicide 
genes respectively40. Thus, DLI represented a bridging technological advance; 
coupled with the potential for genetic modification of the DLI, all that 
remained outstanding was the development of strategies to mediate cellular 
retargeting. 
 
Early pioneering research by Rosenberg 41 demonstrated the potential to 
exploit endogenous anti-tumour immunity as a novel therapeutic modality. It 
was observed that tumour infiltrating lymphocytes (TIL’s) could be isolated 
from tumour resections, expanded  and returned to the patient 
demonstrating therapeutic benefit. The TCR receptors of these TIL’s 
recognised tumour associated antigens (TAA’s) present in the metastatic 
melanoma resections. However, identification and isolation of effective TIL’s 
from tumours is variable dependent on the immunogenicity of the TAA’s 
present in the tumour.  
 
One further demonstration of successful DLI therapy follows from resolution 
of Epstein-Barr virus (EBV) associated post-transplant lymphoproliferative 
disorder (PTLD) facilitated through EBV-specific cytotoxic T-lymphocyte (CTL) 
DLI. Although more than 95% of the global adult population are infected with 
EBV, disease is typically self-limiting controlled by the T-cell mediated cellular 
response. However profound immunosuppression applied alongside HSCT or 
solid organ transplant can induce viral reactivation resulting in unchecked 
EBV-driven B-cell lymphoproliferation. Peak incidence occurring 6-12 months 
post-transplant suggests a role of impaired T-cell function in this pathology42. 
One solution to this problem, first demonstrated by Papadopoulos , 
involves adoptive transfer of virus-specific CTL's. Additionally, EBV-CTL’s 
represent an attractive source for therapeutic product for two reasons: Firstly, 
the selection of EBV-CTLs as the source for allogeneic cellular product 
presents a considerably reduced risk for potential GvHD due to the defined 
specificity of the T-cell receptor44, and secondly, exploitation of  anti-viral 
immunity concurrent with T-cell re-engineering strategies offers potential for 
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enhanced persistence and anti-tumour efficacy of CAR-modified T-cell 
product5.  
 
Advances in molecular biology have increased the opportunities for genetic 
engineering and allow for ever-increasing modifications to optimise the 
capacity of GM T-cells to achieve a safe and effective anti-tumour immune 
response and even novel functional capabilities, such as: molecular re-
targeting mediated through inclusion of a TCR or a CAR moiety; drug 
resistance capability such as calcineurin or mycophenolate resistance; 
modifications to trafficking behaviour to home toward tumours; ability to 
secrete cytokines to enhance a desired immune response; enhanced 
proliferative capacity and/or survival; and, inclusion of a marker gene for 
assessing persistence and a suicide gene for resolution of therapeutic toxicity 
as illustrated by Figure 1. 
 
However, despite initial success demonstrated by application of TILs against 
metastatic melanoma, this process remains costly, time consuming and limited 
by the inherent immunogenicity posed by novel tumour antigens. Hence, 
concurrent with advances in molecular biology, research shifted towards 
identification of alternative TAA-specific TCR’s. Using integrating retroviral 
transduction, T-cells can be transduced with TCR α and β chains 
demonstrating a desired specificity to redirect T-cells against tumours 
expressing the appropriate TAA’s. However, despite the promise which this 
strategy offers, it is not without limitation or risk. As TCR-mediated 
cytotoxicity is MHC restricted, down-regulation of MHC-I presentation 
represents a common immune escape mechanism available to cancer45. Also, 
due to MHC-restriction, transgenic TCR genes identified from tumour 
resections remain restricted to application within a subset of potential 
patients limiting the breadth of application. Further, this strategy imposes the 
risk for TCR mispairing whereby hybrid TCR’s could result from cross pairing 
of the endogenous and transgenic TCR’s within the cell, resulting in novel 
receptor specificities which could lead to pathological autoimmunity as 
demonstrated through mouse modelling experiments46. One strategy employed 
to circumvent this potential involves engineering of a hybrid TCR composed of 
murine and human regions to prevent mispairing. However this strategy may 
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restrict potential for clinical application due to induction of neutralising 
antibodies against the murine epitopes14. Despite these limitations, therapeutic 
application of TIL’s has proven highly effective against metastatic melanoma 
highlighting the potential for TCR-mediated gene transfer as a strategy to 
mediate physiological anti-tumour adoptive T-cell therapy. 
 
Advances in the understanding of both the similarity and variation between T- 
and B- cell receptor-mediated antigen recognition led to consideration of the 
potential for ectopic expression of antibody defined specificity on T-
lymphocytes to enable targeted re-definition of the cell mediated immune 
response in an MHC independent manner. Development of this research 
tangent resulted in the evolution of T-bodies, clearly reviewed by Eshhar47, 
which represent the precursor of chimeric antigen receptors (CAR’s). 
However, initial CAR trials employing first generation CAR-retargeted T-cells 
against solid tumour targets typically proved disappointing; although cellular 
infusions were well tolerated, reports of therapeutic success were rare. In 
contrast, later trials involving later generation CAR-mediated therapy against 
haematological malignancies remain a developing clinical success story21, 48.  
MHC-independence also presents a challenge to CAR T-cell function due to 
alterations of endogenous T-cell signalling mechanisms. Optimal T-cell 
stimulation requires 3 signals: signal 1, Antigen recognition mediated via the 
TCR; signal 2, target validation mediated through co-stimulation (e.g. CD28); 
and signal 3, a cytokine support signal (e.g. IL2). Therefore, although inclusion 
of the CD3ζ stimulation domain alone enables some anti-tumour capacity by a 
CAR, achieving effective engraftment and sustained anti-tumour activity has 
required generation of second and third generation CARs containing 
additional co-stimulation domains.  
CARs, as illustrated by Figure 3, offers a ready solution to limitations imposed 
by TCR-retargeting strategies. CARs exploit the humoral equivalent to the TCR, 
notably antibodies, which compose the soluble form of the B-cell receptor, to 
enable HLA-independent, target specific re-direction of T-cell immunity. 
Genetic retargeting of T-cells using CARs has a number of distinct advantages 
over the TAA-specific TCR strategy: MHC I restriction independence, a shorter 
and simpler production protocol required to generate therapeutic T-cell 
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product, and enhanced proliferation and survival profile according to variation 
of the signalling endodomain component of the receptor. First generation 
CAR’s were bipartite constructs composed of an antibody-derived binding 
moiety for target recognition fused to a lymphocyte activating signalling chain. 
Observations of limited  persistence from first generation CARs resulted 
in the generation of second and third generation CARs including addition of 
second and third signalling components within the endodomain respectively. 
 
Chimeric antigen receptors offer the potential for molecular retargeting of T-cells. They are 
composed of the variable regions derived from a monoclonal antibody joined by a serine-
glycine peptide linker sequence. A molecular spacer or hinge domain facilitates projection of 
the binding domain away from the cellular surface whilst intracellular co-stimulation signalling 
domains mediate signalling to compensate for the lack of TCR and MHC co-stimulation.  
scFv - single chain, VH/VL Variable chain heavy and light chain respectively, CH2-CH3, 
antibody IgG1 constant heavy domains (2 and 3 respectively). 
 
However, despite the promise, clinical trial results from ACT employing T-cells 
re-directed with first generation CAR’s proved somewhat disappointing as the 
therapeutic T-cell product demonstrated limited  survival and anti-
tumour activity49, 50. Evolution on this theme led to co-stimulation strategies to 
enhance transduced T-cell persistence. Transduction of EBV-CTL’s with a GD2-
CAR for neuroblastoma therapy exploited the endogenous stimulation 
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afforded by EBV-positive patients and demonstrated prolonged persistence 
compared with a polyclonal transgenic T-cell population, demonstrating 
tumour regression in half of the subjects treated5. Alternative strategies 
involve inclusion of additional co-stimulation domains to enhance T-cell 
persistence and anti-tumour activity. 
 
The field of ACT has evolved substantially from initial successes. Ever 
increasing potential for cellular engineering offers vast potential for cancer 
immunotherapy. However, as clinical experience from application of 
engineered cells remains limited, there are likely many lessons left to learn. 
Novel hazards arise coincident with technological and therapeutic advances. 
Clear benefit demonstrated by gene therapy for primary immunodeficiencies51 
was swiftly overshadowed by the risk posed by insertional mutagenesis52; gene 
therapy for cancer has shown great promise, yet challenges with target 
specificity, dosage, toxicity and the potential of unchecked 
lymphoproliferation of therapeutic product remain. Inducible pluripotent stem 
cell (iPS) technologies offer great promise, however teratoma formation, 
inherent to the nature of iPS cells, also represents the greatest risk posed by 
this new technology. Future applications such as universal donor T-cells and 
advanced genetic engineering strategies involving zinc finger nucleases (ZFNs), 
TALENS, and genomic integration strategies each present further potential 
concerns.  
Owing to limitations in the predictive value of animal modelling and safety 
profiling, the ever increasing applications of cell based technologies highlight 
the pressing need for a universal safety mechanism which offers simplicity, 
efficacy and compatibility to complement present and future cellular 
therapeutic modalities. This said, as animal modelling offers the only 
mechanism by which to model the complexity imposed by cellular therapies, it 
remains a necessary process in the pre-clinical work-up to validate these novel 
therapies prior to clinical application. 
Reflecting research presented in this thesis, the following will briefly 
summarise the common allogeneic transfer toxicity: graft versus host disease. 
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Graft versus host disease is an immunological therapeutic toxicity which has 
been identified following the advent of grafting. GvHD is a multi-organ 
disorder with damage most obvious to the skin, gastrointestinal tract and liver 
and remains a potentially lethal toxicity despite advances in chemotherapeutic 
resolution. 
 
GvHD is a severe inflammatory reaction representing the most serious 
complication following HSCT. Without post-transplant immunosuppression, 
most patients will develop GvHD. Observations regarding presentation of 
GvHD led Billingham to propose the following three preconditions as 
necessary to establish GvHD53: immunologically competent mediators (mature 
T-cells) must be present within the graft to produce the response; the recipient 
must be immunocompromised to prevent allograft rejection, and finally, the 
recipient must express tissue antigens variant from donor antigens to act as 
an antigenic target to trigger the response. Although corticosteroids remain 
the first line therapy, successful resolution is only achieved in approximately 
one-half of cases54. Therapeutic strategies for steroid-refractory GvHD vary but 
may include immunosuppressive cocktails, anti-thymocyte globulin or 
antibody therapy55, however even these strategies only achieve therapeutic 
resolution in approximately 75% of cases whilst imposing increased risk for 
infection resulting from immunosuppression56. Thus, despite advances in 
prevention of GvHD, progression to grade IV acute GvHD remains a fatal 
outcome in most cases54.  
 
GvHD results from T-cell allorecognition, which is defined as the ability of T-
cells to recognise non-self MHC molecules derived from the same species. Such 
GvHD reflects the ability of T-cells to respond against cellular antigens which 
differ in their expression pattern between the donor and the host. With human 
leukocyte antigen (HLA) mismatched transplants, alloreactive T-cell responses 
occur against both epitopes on HLA molecules as well as peptide HLA 
complexes. However, GvHD responses can also result from a matched donor 
transplant induced by polymorphic genes known as minor histocompatibility 
antigens57. As proposed by Janeway58, the adaptive immune system evolved to 
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enable organisms to discriminate the infectious non-self from the non-
infectious self. A central feature of the adaptive immune response is the T-cell 
recognition principle, in that thymic development restricts T-cell recognition 
of peptide to that presented in the context of self-MHC. Strongly self-reactive 
T-cells are negatively selected, whilst T-cells with moderate self-recognition are 
positively selected. However T-cells have also been shown to mount immune 
responses against allogeneic peptide-MHC complexes, contrary to the tenet of 
MHC restricted presentation. Evidence for this observation suggests that T-cell 
allorecognition requires both peptide and MHC interactions akin to the 
cognate TCR-antigen recognition. The prevailing arguments for these 
observations are the ‘mistaken identity’ and the  hypotheses. Briefly, 
the ‘mistaken identity’ premise holds that it is possible for the conformational 
structure generated by alternative antigenic epitopes to demonstrate sufficient 
similarity as to enable an alternative binding solution for a TCR-peptide-MHC 
interaction, whereas the  hypothesis suggests that a slight variation in 
the architecture of an alternative TCR-peptide-MHC interaction could prove 
sufficiently similar to a previous activation signal as to be considered 
effectively identical59. Regardless of the mechanism involved, the 
allorecognition response has a precursor frequency 100 to 1000 times greater 
than any equivalent foreign peptide-MHC complex specificity60. Thus, in the 
absence of autologous or syngeneic donor cells, potential alloreactivity will 
always pose a risk.  
As therapeutic resolution of GvHD remains problematic, many experimental 
strategies remain under consideration designed to prevent development of, or 
progression to GvHD, including: selective depletion to exclude alloreactive T-
cells61, co-infusion of mesenchymal stem cells alongside haematopoietic stem 
cells54, low dose interleukin-2 (IL2) supplementation to enhance regulatory T-
cell (Treg) activity62, and infusion of Treg’s prior to HSCT infusion63. Cell 
processing strategies for therapeutic cell product to prevent the risk for 
alloreactivity of adoptive cells include: photodynamic or pharmacologic 
elimination of allospecific T-cells, regulatory T-cell enrichment of the infusion 
product and  anergisation of patient responsive T-cells64. However, as 
adoptive cell therapies already pose a high economic burden, the desire to 
reduce GvHD must be balanced against the potential effect additional handling 
would impose on the efficacy of the therapeutic product. 
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Therefore, allogeneic adoptive cell therapies face the challenge of opposing 
evolutionary adaptation of T-cell recognition of non-self MHC molecules. 
Hence, there remains a therapeutic need to enable strategic resolution of 
GvHD by selective deletion of the pathology-inducing population for adoptive 
cell therapies. 
 
As adoptive cellular therapies represent a broad and rapidly growing field, this 
discussion will focus on T-cell engineering as a strategy for cancer 
immunotherapy. Genetic modification of T-cells allows us opportunity to 
enhance, re-direct and engender T-cells with functionalities which can greatly 
enhance therapeutic potential beyond natural limitations. However, 
therapeutic benefit is accompanied by theoretical risk; thus gene transfer 
strategy, therapeutic protocol and transgenic cassette all present potential 
variables to be considered when generating cellular product. 
 
Implicit to T-cell effector function following target recognition is cellular 
proliferation. Correspondingly, consideration regarding T-cell genetic 
modification strategies must rely on integrating vectors to ensure effective 
sustained transgene expression by cellular progeny. Although a range of 
genetic modification strategies exist, discussion will focus on the three 
integrating vector strategies in current clinical application: retroviral vectors, 
lentiviral vectors and transposons. In the interest of brevity, discussion will 
focus on key variations between these strategies; namely transduction 
requirements and integration bias. 
 
The desired role of a retroviral vector is to achieve stable integration of a 
replication deficient provirus into chromosomal DNA. Due to the simple 
genomic architecture of gammaretroviruses combined with powerful 
constitutive promoters, vectors derived from the Moloney murine leukaemia 
virus (MLV) remain the most frequently employed strategy to achieve 
transgene integration for T-cell gene transfer65, 66. Three key stages must occur 
to achieve successful transduction: viral entry, reverse-transcription and 
proviral integration. Viral entry is mediated through either receptor mediated 
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endocytosis or viral envelope/plasma membrane fusion. Following entry, the 
retroviral plus-stranded RNA genome must then be modified and transported 
to the nucleus. Reverse transcriptase, supplied by the vector, converts the 
ssRNA genome into dsDNA. This is followed by formation of the pre-
integration complex (PIC) which combines the dsDNA genome along with viral 
and host proteins to mediate transport to the nucleus. However, as the PIC of 
gammaretroviruses such as MLV are relatively unstable, these are unable to 
cross the intact nuclear membrane of non-dividing cells33, 67. Therefore, a key 
limitation to retroviral transduction relates to the obligatory requirement for 
stimulation which has been shown to negatively impact antiviral immunity and 
alloreactivity and skew cellular phenotype68, 69. Further examination of 
stimulation imposed limitations necessary for retroviral transduction 
protocols suggest that increasing cellular dosage or depletion of Tregs prior to 
stimulation can enable retention of the desired cellular effector capacity70. 
 
In contrast to retroviral vectors, the PIC of lentiviruses such as HIV-1, is 
relatively stable allowing for transport across an intact nuclear membrane33. 
Hence, the capability to transduce quiescent cells attracted keen interest into 
application of lentiviral vectors as an alternative to retroviral mediated 
strategies. Discussion will focus on HIV-1 derived lentiviral vectors which 
compose the majority of lentiviral vectors in current application. 
A key advantage of LV transduction is the preservation of a less differentiated 
T-cell phenotype. Although stimulation is required to achieve effective 
retroviral transduction, mitogenic stimulation of T-cells via the T-cell receptor 
is associated with a loss of naïve T-cell subsets resulting in reductions in 
immune functionality, inversion of the CD4/8 ratio, and alterations to the TCR 
repertoire71. Although activation of T-cells from G
0
 to G
1b
 appears necessary to 
enable LV-mediated gene delivery, effective LV transduction efficiency has 
been demonstrated using IL7 cytokine stimulation ensuring retention of the 
phenotype, antiviral and allogeneic responsiveness69, 72. 
As the HIV-1 lentiviral genome is considerably more complex than 
gammaretroviral genomes, there has been progressive evolution of lentiviral 
vectors in the attempt to ensure biosafety from these gene transfer vehicles, 
with second or third generation LV composing the bulk of vectors in current 
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application with third generation LV offering the best safety profile. Third 
generation LV production only requires 3 of the original 9 HIV genes, whilst 
significant deletions to the viral LTR domains establish self-inactivating (SIN) 
vectors which demonstrate LTR independence from viral factors. Furthermore, 
separation of plasmids required for viral production ensure that three 
separate recombination events would be required to generate replication 
competent lentivirus (RCL). However, enhanced biosafety is achieved at the 
cost of reduction in viral titre, although the capacity for the VSVg envelope to 
withstand ultracentrifugation, and thereby enable concentration of viral 
particles, partially compensates for this limitation73. 
Perhaps an additional concern regarding the risk of application of LV as a 
vector is the increasing prevalence of HIV within the population. Presence of 
competent virus pre- or post-therapy offers the potential risk for RCL resulting 
from use of an integrating virus which may impose further limitations on the 
use of these vectors in gene transfer applications. 
 
The final integration strategy to be discussed involves use of transposons to 
introduce defined DNA sequences into genomic DNA. There are currently two 
transposon/transposase systems offering potential for T-cell gene transfer 
application: sleeping beauty74 and  75.  
DNA transposons are class II transposable elements offering a simple genomic 
organisation optimal for potential application for gene transfer. Excision and 
integration of the transposon element is mediated by the transposase enzyme, 
with the transposon element/cassette defined by internal terminal repeats 
containing the binding sites required to enable transposition. Safety of this 
system is achieved through simple separation of the transposase enzyme from 
the transposable DNA resulting in generation of a non-autonomous 
transposable element76. Hence, a key benefit of transposon delivery in contrast 
to viral vectors is the abrogation of risk from potential replication competent 
virus which imposes a significant financial burden into gene transfer 
protocols77. 
 
The second key variation between integration strategies involves integration 
bias demonstrated by the various vector strategies. 
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MLV derived vectors, such as SFG28, demonstrate non-random integration 
patterns within T-cells, showing clear site-specific preference for promoters 
and regulatory regions of genes which are transcriptionally active at the time 
of transduction. MLV site specific integration preference suggests a possible 
association between components of the RNA polymerase II transcriptional 
machinery and the MLV PIC, which further indicates that the risk from MLV-
mediated IM could vary dependent upon both the transcriptional activation 
status and target cell being transduced. Analysis of MLV T-cell integration 
sites, pre- and post-infusion, from patients enrolled in HSVtk/∆lNGFR clinical 
trials demonstrate clustering patterns for MLV integration events with genes 
targeted by MLV clusters showing association in functional networks involved 
in T-cell function. However, post infusion analysis of integration clusters 
showed little or no preference towards genes involved in signal transduction, 
cell proliferation or proto-oncogenes. Thus, in contrast to the perceived risk, 
this variation between pre- and post-infusion integration profile suggests a 
negative selective pressure on T-cells where integration events affect T-cell 
specific functions78. However, as the transgenes involved in this analysis confer 
no proliferative advantage, this promising absence of genotoxic risk may not 
be generally applicable to all MLV vector transgenes. 
Similarly, a retrospective analysis of HIV-1-based LV lentiviral vector 
integration in CD4 T-cells identified preferential integration within active 
transcription units. HIV-1 LV appears to favor integration into weakly 
conserved primary sequence, preferentially targeting gene rich chromosomes. 
Although there appeared to be no bias towards integration proximal to proto-
oncogenes, it was noted that integrations near 5’ ends of proto-oncogenes 
remained higher than anticipated occurring by chance alone79. Perhaps the best 
support for safety of LV integration is the single report citing HIV-mediated 
transformation into lymphoma despite extensive global HIV infection rates80. 
However, enhanced survival mediated by anti-retroviral therapy may increase 
observation of similar events. 
Evidence from sleeping beauty transposon integration patterns indicates no 
preference for integration within transcription units or proximal to 
transcription start sites81. Although T-cell integration analysis for the 
transposon indicated a non-random integration profile with a preference for 
transcriptional units,  integration within transcription start sites for 
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proto-oncogenes remained lower than frequencies identified for either RV or 
LV integration82. Following extensive examination of viral integration events, 
evidence suggests that despite observed frequencies for viral integration 
proximal to proto-oncogenes, oncogenic transformation remains restricted 
within a small subset of these integration events suggesting a requirement for 
subsequent ‘hits’ to incur uncontrolled cell proliferation77. 
Finally, the sleeping beauty transposon system offers a superior safety profile 
with respect to alternative integrating vector strategies although transgenic 
cargo capacity remains the key limitation. In this respect, a minimal sort-
suicide gene may offer the greatest potential for this application enabling 
maximum function alongside the safest integration strategy. 
 
Despite the improved safety profile, analysis of viral integration in 
haematopoietic progenitors highlights the possibility of SIN LV integration into 
genomic regions which can result in proto-oncogene upregulation and 
therefore the risk for insertional mutagenesis mediated toxicity remains83. 
Overall risk may vary dependent upon many factors which may prove additive 
in combination, including: target cell for modification, transgene and presence 
of co-stimulation, or integration risk combined with associated therapeutic 
genotoxicity, thereby excluding broad general extrapolations. Limited extended 
follow-up involving second and third generation CAR trials may have 
overestimated safety of CAR co-stimulation. Perhaps CD19-CAR clinical trials 
will offer defining insight into optimal gene transfer strategies for T-cells as all 
three integration strategies discussed are in current application in clinical 
trials84. Therefore, integration strategy selection may ultimately depend upon a 
range of factors including cellular target, transgenic cassette and therapeutic 
aim with no single strategy proving optimal for all scenarios. 
As a final note, research into alternative strategies remains ongoing; hence, 
mRNA electroporation85 has been proposed as an alternative approach for gene 
transfer to address toxicity and risk posed by integrating vectors. Although 
this strategy achieves rapid gene expression, detectable as early as thirty 
minutes post transfection, gene expression remains transient only lasting up 
to seven days. 
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However, coincident with desired anti-tumour efficacy, manipulation of the 
immune response may result in unforeseen and undesirable toxicities. Four 
primary safety concerns regarding T-cell therapy have been identified: 
insertional mutagenesis: toxicity resulting from the introduction of genetic 
material; on-target, off-tumour toxicity (OTOT): aberrant deletion of non-
tumorous tissue; immunological toxicity following therapeutic infusion such 
as GvHD resulting from an allogeneic response or autonomous proliferation 
independent of antigen/target binding, and finally, therapeutic toxicities 
resulting from concomitant therapy parallel to ACT, such as toxicity resulting 
from the preconditioning regimen, or sustained immunosuppression84. 
 
As any alteration to the genome is mutagenic, risks resulting from genetic 
modification can only ever be predicted. Furthermore, integrating vectors may 
impose mutagenic toxicity through a range of mechanisms. As the retroviral 
LTR can function as an efficient promoter/enhancer sequence, the primary risk 
from LTR-mediated gene expression is the potential impact upon cellular gene 
expression. Interaction between cellular transcription factors and the 
integrated viral LTR can result in activation of adjacent cellular proto-
oncogenes. Although this is most readily apparent through aberrant growth 
associated with oncogenesis, impacts such as transcriptional read-through 
may impair cellular functions without obvious phenotypic effect. As observed 
from the SCID trial52, this risk may reflect an additive impact resulting from 
both the transgenic cassette and the integration site. Alternatively, direct 
vector insertion within coding sequences may cause deletion or abnormal 
truncation of cellular transcripts86. Further, vector enhancer sequences have 
been demonstrated to mediate dysregulation of endogenous gene expression 
of genes located hundreds of kilobases from the viral integration site87. 
Additionally, vector insertion may cause genomic disruption through impacts 
upon genetic regulatory domains resulting in altered splicing or 
polyadenylation88 or by alterations to microRNA cistrons, thereby impairing 
the internal cellular regulatory machinery89. Finally, even application of SIN-
lentiviral vectors doesn’t preclude potential for phenotoxicity resulting from 
non-physiological activation of adjacent loci to vector insertion sites, such as 
 activation as observed in the β-thallassaemia trial90. 
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Recent reports of leukaemic risk from insertional mutagenesis from the X-
SCID clinical trials demonstrated a clear risk from gene marking, thus 
terminating further gene marking studies due to the absence of clinical 
benefit91. However substantial research suggests that the degree of risk 
appears dependent upon multiple factors including the cellular target for 
genetic modification and the transgene involved. Perhaps to put the risk from 
retroviral modification into perspective, it has been proposed that between 4-
10% of the vertebrate genome is composed of retroviral remnants92. Moreover, 
this fraction is greater than that corresponding to gene encoding sequences. 
Viewed in this light, perhaps the nature of the transgenic cassette coding 
sequence presents a far greater risk than the genetic modification strategy. To 
date, despite over a decade of T-cell engineering clinical trials, there remains 
to be a single incidence of clonal proliferation resulting from T-cell 
modification25. This may reflect a reduced sensitivity for transformation 
present in T-cells compared with haematopoietic stem cells93. 
 
Immunotherapy requires the presence of an antigenic target to enable 
identification of the cancer cell. These tumour associated antigens (TAAs) can 
be segregated into five categories94: i) tumour specific antigens, such as 
characteristic mutated antigens which remain truly tumour specific such as 
the BCR-Abl ‘Philadelphia chromosome’95, ii) overexpressed antigens where 
expression of a normal cellular protein may be significantly upregulated by a 
tumour, such as tyrosinase in malignant melanoma96, iii) oncofoetal antigens; 
antigens expressed during foetal development but are rarely expressed in 
adult tissue, such as alpha fetoprotein97 and carcinoembryonic antigen (CEA)98, 
iv) differentiation or lineage antigens such as CD19 in B-cell leukaemia and 
lymphomas, and finally v) testis antigens shared by spermatocytes and tumour 
cells, such as MAGE antigens99. Thus, apart from rare cases such as viral 
proteins or characteristic mutations, expression of most tumour antigens is 
not exclusive to the tumour target.  
As a result, targeted immunotherapy may also result in OTOT. In some cases, 
collateral damage resulting from therapeutic deletion of 'expendable' tissue 
may be readily resolved such as with CD19, where depletion of the B-cell 
compartment can be compensated with gamma globulin replacement therapy. 
Although CAR's are based on antibody technology which can enable binding 
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affinities extending beyond the affinity which can be achieved through T-cell 
isolation, OTOT can result from either CAR or TCR redirected T-cells. 
Furthermore, although pre-clinical animal modelling experiments may offer 
insight into the capacity for T-cell targeting efficacy, these models can never 
fully reflect the scenario within a human patient. Therefore, despite much 
promise, there have been a number of adverse events resulting from T-cell 
cancer immunotherapy as summarised by Table 2. Examples include: when T-
cells were directed against minor-histocompatibility antigens to treat 
leukaemic relapse, severe toxicity resulted from target antigen expression on 
lung tissue100; during a recent clinical trial involving transgenic T-cells specific 
for ERBB2, low level expression of the target antigen on lung epithelium 
resulted in a lethal cytokine storm20; therapeutic application of modified T-
cells against MART-1 in melanoma therapy was associated with toxicity to 
melanin-expressing cells in the inner ear and the retina101. In a trial against 
metastatic colorectal cancer involving TCR retargeted autologous cells against 
the CEA antigen, a dose limiting toxicity of severe transient inflammatory 
colitis was observed102. CAR re-targeted T-cells against the renal carcinoma 
target, carbonic anhydrase IX (CAIX), resulted in liver toxicity due to target 
antigen expression on bile duct epithelium103; and finally, TCR retargeted T-
cells against the MAGE-A3 antigen resulted in neural toxicity with two patients 
eventually succumbing from the neural insult104.  
Further, the risk of potential TCR mis-pairing raises the spectre for generation 
of novel specificities of unknown toxicity generated by the inadvertent cross-
pairing of transgenic and endogenous TCRs. Experiments in rodent models 
have demonstrated that this raises the risk for autoimmunity and GvHD46. 
Therefore TCR-mediated re-targeting strategies commonly employ a hybrid 
TCR domain including murine regions to exclude risk for cross-pairing. 
Although application of this strategy improves safety, it may also limit efficacy 
due to potential immunogenicity of the transgenic TCR14.  
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(Adapted from Shi et al
105
.) 
 
CAR CAIX Liver toxicity103 
CAR ERBB2 Lung toxicity, cytokine 
storm20 
CAR CD19/CD20 B-cell aplasia, tumour 
lysis syndrome, cytokine 
release syndrome, 
macrophage activation 
syndrome106 
 expanded T-cells Minor histocompatibility 
antigens 
Pulmonary toxicity100 
TCR MAGE-A3 Neurological toxicity104 
Cardiac toxicity107 
TCR CEA CEA expressed in 
normal colonic 
mucosa102 
TCR MART-1 Melanocytes in skin, eye 
and ear101 
TCR mis-pairing Self-antigens GvHD / autoimmunity 
Proposed toxicity 
identified from  
modelling experiments46 
 
 
A further risk associated with genetically engineered T-cell include 
immunological toxicities such as GvHD resulting from TCR cross-pairing or 
alloreactivity as previously addressed, . 
Also, supraphysiological stimulation and/or signal leakage from later 
generation CAR’s can theoretically result in cellular proliferation in the 
absence of cognate antigen recognition. Further, combination of possible 
insertional mutagenesis coupled with potential selective advantage mediated 
by co-stimulation domains could pose an untenable risk of 
lymphoproliferation in the absence of a regulatory control mechanism such as 
a suicide gene. However it should be noted that in the event of an acute 
immunological toxicity such as a cytokine storm, it is unlikely that by the time 
toxicity has been identified, that the physiological impact could be resolved by 
any suicide-gene strategy alone. 
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Therapeutic toxicities resulting from lymphodepleting regimens such as post-
transplant lymphoproliferative disease108 may also arise, however as these 
require alternative strategies for resolution separate to application of suicide 
gene machinery, these will not be discussed further. 
 
Despite significant clinical success, T-cell cancer immunotherapy remains in 
its infancy with many lessons yet to be learned. Research into further 
alternative T-cell modification strategies remain under development; 
retargeting achieved by transient gene expression following electroporation 
with mRNA offers transient gene expression thereby avoiding risk for 
insertional mutagenesis. Alternatively, selective modification of γδ T-cells may 
offer a strategy to reduce the risk from supraphysiological stimulation from 
later generation CAR’s as therapeutic administration of aminobiphosphonate 
can mediate selective proliferation of this population post infusion potentially 
reviving potential for first generation CAR therapy84. With a view towards 
stream-lining gene therapy for improved accessibility, various groups are 
investigating strategies designed to achieve ‘universal T-cells’109 such as 
through deletions of the endogenous TCR through genomic editing strategies 
which may offer therapeutic transfer across MHC barriers, by selective 
modification and differentiation of HSC’s or otherwise84. 
As research into better targets remains ongoing, perhaps improved specificity 
can be achieved in the future through further engineering; however, the risk of 
OTOT will likely remain to be established for every individual TAA. Therefore, 
inclusion of a suicide gene to offer a degree of protection from some of the 
risks posed by T-cell cancer immunotherapy remains a pressing need. 
 
A marker gene encodes for a protein absent from unmodified cells, which can 
enable selective identification and selection of genetically modified cells. 
 
Excellent reviews by Barese110 and Tey91 explore the historical progression of 
gene marking within cell and gene therapy. As it was the outcome of early 
pioneering efforts which established the foundations for subsequent gene 
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transfer applications and protocols, some of the key advances which have 
resulted from gene marking studies will be summarised as follows. 
At the advent of gene therapy research, genetic transfer efficiency was 
insufficient to enable therapeutic application, thus the first approved gene 
transfer protocols involved gene marking studies with an informative aim 
rather than therapeutic intent111-113. Gene marking demonstrated that bone 
marrow transfer could contribute to long term haematological reconstitution, 
that residual tumour present in autologous bone marrow transplants could 
contribute to subsequent relapse, that  manipulation of cells could 
impair their subsequent  efficacy whilst lymphodepletion could enhance 
 expansion of adoptive cells. Thus, gene marking research was critical to 
understanding and defining subsequent gene transfer protocols. Gene marking 
also demonstrated evidence supporting the role for gene modified cells in 
targeted adoptive cell therapies by illustrating the contribution of adoptively 
transferred tumour infiltrating lymphocytes to the anti-tumour effect through 
evidence of functional immune surveillance of adoptive cells in the absence of 
observable disease, and enabling tumour specific trafficking of adoptive cells.  
Finally, gene marking studies have highlighted risks and challenges associated 
with these new technologies. Gene marking identified the first evidence for an 
immune response against immunogenic proteins present within a vector 
cassette114. Also, despite the impressive safety profile from gene marking 
studies spanning years of research, including both modified bone marrow and 
T-cells, no observed clonal proliferation has been observed91. This is in sharp 
contrast to observations of insertional mutagenesis resulting from severe 
combined immunodeficiency (SCID) trials where leukaemogenesis was 
observed in five patients resulting from insertional mutagenesis out of a 
combined total of twenty patients from separate gene therapy trials115. Two 
arguments were cited to explain the variation between the scenarios. First, the 
observation that due to poor transduction efficiency from early gene marking 
studies, a smaller number of transduced cells were present which contained 
fewer integration events. Secondly, and notably, a growth promoting capacity 
was absent from these gene marking studies91; an observation which may 
prove important in consideration of ongoing cancer gene therapy strategies, 
. 
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The inclusion of a marker gene which could facilitate clinical-grade sorting of 
transduced cells would enable cellular purification and ensure consistency in 
the therapeutic product. Furthermore, marker genes also enable verification of 
transduction success, essential for expression of intracellular proteins such as 
calcineurin116 resistance or the p47phox protein employed in chronic 
granulomatous disease gene therapy117, as well as membrane bound proteins 
which may prove difficult to identify by antibody staining such as CD8-stalk 
bound CARs21. Finally, , marker genes offer potential for assessing 
cellular engraftment. 
 
Integral to assessing gene transfer efficiency, marker genes have evolved 
parallel with gene transfer technology, with three primary tangential strategies 
having developed. Visual reporters along with metabolic and cell surface 
selection markers each offer an alternative mechanism for measurement of 
gene transfer. Visual reporter genes, such as luciferases and fluorescent 
proteins, are probably the most frequently employed enabling ready detection 
of gene transfer through bioluminescence imaging, fluorescence microscopy or 
flow cytometry analysis. Although convenience and clarity make these obvious 
choices for  research and  modelling, the xenogeneic origins of 
these proteins preclude clinical application owing to inherent immunogenicity 
and toxicity. Thus, metabolic selection and cell surface selection markers 
define the primary competing strategies for clinical marker genes. 
 
Like GFP, early metabolic selection markers were derived from non-human 
enzymes enabling antibiotic selection such as neomycin, puromycin and 
hygromycin resistance genes. Although these proteins offer effective exclusion 
of non-transduced cells, immunogenicity resulting from their xenogeneic 
origin limits their application to highly immunosuppressed contexts. 
Furthermore, off-target functional activity from these enzymes may impose 
unpredictable impact upon cellular behaviour, such as impaired growth of 
HL60 cells observed to result from expression of the neomycin resistance 
marker118. However, significant illumination into the impact of tumour relapse 
and cellular tracking has been achieved following gene marking studies using 
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neomycin. An additional observation of interest from neomycin application 
was that prolonged  culture required to enable effective selection 
resulted in impaired T-cell function. Furthermore, expression of proteins of 
microbial origin could impose metabolic alteration upon genetically modified 
cells even in the absence of a prodrug68. Furthermore, G418 also imposes a 
degree of toxicity to primary cells imposing further impact on cellular 
function. The evolutionary product following  selection marker genes 
were the  selectable marker genes designed to increase engraftment 
mediated by therapeutic administration of drugs which are toxic to 
unmodified cells within the graft. Such marker genes include: multi-drug 
resistance (MDR-1), dihydrofolate reductase (DHFR) and O6-methylguanine-
DNA methyltransferase (MGMT)110. However, although these strategies also 
suffer from limited efficiency and/or drug toxicity, they paved the way for 
later modular drug resistance cassettes conferring selective advantage 
concurrent with therapeutic administration, such as calcineurin or Inosine 5’ 
monophosphate dehydrogenase (IMPDH) mutants offering tacrolimus and 
cyclosporin or mycophenolate resistance, respectively. Thus Ouaselect119, an 
ouabain resistance gene, was developed to address the short-comings 
highlighted by earlier metabolic marker genes. Ouaselect is based on a 
mutation in the ubiquitously expressed Na/K/ATPase. Two point mutations in 
this protein; Q118R and N129D, mediate a 2-log increase in the ouabain 
resistance. Furthermore, a long history of cardiac glycosides in clinical 
application supports a safe history for clinical application of the prodrug, 
which induces a rapid induction of cell death resulting in 99% purity of 
modified cells within 48 hours. However, a critical application of marker genes 
is co-expression with a suicide gene to enable cellular deletion in case of 
toxicity. As Ouaselect only offers the marker gene moiety for this role, at 
1023aa in length, this imposes a considerable transcriptional burden. 
Furthermore, as an intracellular protein, identification of marked cells is 
limited to intracellular flow cytometry or selection culture limiting the 
capability for functional assessment to  application. 
 
Cell surface marker proteins represent the alternative strategy; cell surface 
expression enables facile detection through the use of antibodies thereby 
allowing for swift detection of genetically modified samples by flow cytometry. 
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A similar evolution of cell surface proteins has occurred with a range of 
proteins having been considered as putative marker genes. Initial studies using 
murine CD24120 and a truncated form of murine CD4ζ121 were supplanted by 
the human derived CD4122 and Thy-1123 proteins. These, in turn were 
subsequently excluded due to expression on alternative haematopoietic 
lineages. A recent proposal for ∆EGFR, a truncated form of the human 
epidermal growth factor receptor (EGFR)124, as a putative marker gene, covers 
two functions, enabling both selection and cetuximab-mediated deletion. 
However, despite deletion of both the epidermal growth factor binding 
domains from the ectodomain and truncation of the signalling endodomain, 
proposed to ablate biological function, this marker-suicide gene remains a 
considerable 624 amino acids in length. Magnetic bead selection is achieved 
through a two-step process involving initial binding mediated by user-
generated biotin-conjugated cetuximab, followed by anti-biotin selection. 
Further, as cetuximab is a chimeric antibody, this strategy imposes the 
potential for a possible human anti-chimeric antibody (HACA) priming 
response from therapeutic infusion of cetuximab-selected cells due to residual 
cetuximab bound to cells following selection124. Most recently, ∆CD19125, 
∆lNGFR126 and ∆CD34127 have all shown promise as effective cell surface 
marker genes with all three in current clinical application. Although all three 
have demonstrated functional efficacy, long coding domains impose 
significant transcriptional burden. ΔlNGFR is the shortest of the three at 277aa 
in length, followed by ΔCD19 and ΔCD34 at 332 and 323aa residues, 
respectively. ∆CD19 allows for clear identification, although expression 
profiles of CD19 impose a requirement for additional co-staining to allow for 
exclusion of the B-cell population from clinical samples. ∆lNGFR is a 277aa 
marker gene which has the longest history of clinical application. An early 
report128, suggesting leukaemic risk resulting from ectopic expression and 
residual signalling capacity from ∆lNGFR gene marking, appears to have been 
tempered by subsequent research129, 130 indicating insertional mutagenesis as 
the cause of leukaemogenesis. However, the risk of unknown metabolic 
perturbations resulting from residual signalling capacity remains. Hence, of 
the marker genes in current clinical application, the 323aa ∆CD34 appears to 
represent the superior cell surface marker gene as CD34 expression is 
excluded from haematopoietic lineages apart from stem cells, and thus far no 
evidence has been presented suggesting metabolic perturbation resulting from 
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∆CD34 expression. Furthermore,  assays using modified and selected T-
cells including the ∆CD34 marker gene, the enriched T-cells demonstrated a 5-
6x increase in anti-tumour activity suggesting that the selection process also 
enhances the functional capacity of the therapeutic population131. Finally, 
similar to ∆lNGFR, despite early concerns regarding aberrant homing of CD34 
marked cells132, ∆CD34 appears to offer promise as an effective marker gene; 
however, a comprehensive interpretation of potential risk can only be achieved 
through long term follow-up study. 
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Luciferases133 Good signal to noise ratio 
Transgenic animals 
available 
Xenogeneic & immunogenic 
Fluorescent 
proteins134, 135 
Simple to detect 
Enables FACS selection 
Transgenic animals 
available 
Xenogeneic & immunogenic 
High expression can be toxic 
  
Blasticidin/ 
Hygromycin/ 
Neomycin/ 
Puromycin/ Zeocin 
resistance genes136 
Most data suggest no 
impact on cell function 
Selection is time consuming 
Prolonged culture can 
impair cellular function 
Xenogeneic & immunogenic 
Ouaselect119 Rapid selection (48hr) Long transcript size 
Intracellular localisation 
limits cell detection 
  
MDR-1 / DHFR / 
MGMT110 
 selection resolves 
impact imposed by 
prolonged  
selection 
Intracellular localisation 
limits cell detection  
Limited by toxicity & 
efficacy 
Calcineurin116 / 
IMPDH mutants 
Offers selective advantage 
concurrent with therapy 
Intracellular localisation 
limits cell detection 
  
mCD24120, mCD4121 Cell surface expression 
enables simple detection 
by flow cytometry analysis 
Xenogeneic & immunogenic 
hCD4122, hThy-1123 
(CD90) 
Enables simple detection 
by flow cytometry analysis 
Discrimination confounded 
by presence of marker on 
other haematopoietic 
lineages 
∆EGFR124 Offers both marker & 
suicide gene capabilities 
Selection reagents require 
in-house generation 
Limited experience 
∆CD19125 Enables clinical grade 
selection & flow cytometry 
detection 
Discrimination confounded 
by presence of marker on 
other haematopoietic 
lineages 
∆lNGFR126 Enables clinical grade 
selection & flow cytometry 
detection 
Concern for residual 
signalling capacity128 
tCD34127 Enables clinical grade 
selection & flow cytometry 
detection 
Concerns regarding homing 
& differentiation of 
transduced cells132 
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The premise of gene marking is to imprint a readily identifiable marker during 
genetic modification that enables facile discrimination between modified and 
unmodified cells. Although the exact criteria desired may vary dependent 
upon application, characteristics which define an ideal marker gene include: 
human derivation to avoid immune rejection; stable cell surface expression 
limited to engineered cells; acute sensitivity to allow for clear detection by 
flow cytometry analysis; compatible with current technology to enable clinical 
grade selection; composed from a compact coding sequence whilst remaining 
biologically inert. Western blot analysis and immunohistochemistry represent 
further characteristics which may also be desired. 
 
For this purpose, we have generated a minimal marker gene based upon the 
CD34 epitope which is bound by the monoclonal antibody QBEnd10 clone 
utilised by the Miltenyi CliniMACS systems. 
 
A suicide gene encodes for a protein, absent from unmodified cells that 
enables selective destruction of transgenic cells following exposure to a 
therapeutic agent such as an antibody or small molecule drug. 
 
A suicide gene encodes for a protein which can enable selective destruction of 
administered cells in the face of unacceptable toxicity. Thus, inclusion of a 
suicide gene engenders a safety strategy to enable targeted deletion of 
engineered cells in case of GvHD, IM, OTOT or other adverse therapeutic 
events. Further, the efficacy of this strategy has been demonstrated by 
resolution of GvHD in a number of clinical trials involving engineered T-cells 
which include a suicide gene137-143. 
The ideal suicide gene would: impose no basal toxicity, be non-immunogenic, 
be inducible with a readily available pharmaceutical and would enable 
complete cellular deletion. 
Inclusion of a suicide gene during donor lymphocyte infusion to control 
alloreactivity following allogeneic HSCT represents one of the widest 
applications for T-cell based gene transfer. The underlying principle behind 
Chapter One 
59 
 
this strategy follows from the observation that the clinical efficacy mediated 
by HSCT against malignancy is dependent upon the GvL effect, which is 
concurrent with the risk for GvHD. Resolution of GvHD can prove to be 
challenging, requiring non-specific immunosuppressive drugs such as steroids 
thereby imposing additional risk of infection to the patient. Thus, inclusion of 
a suicide gene allows for specific deletion of the pathology inducing 
population with minimal impact on overall immune constitution. Thus, in the 
case of post allogeneic HSCT GvHD, application of the inducing drug should 
selectively eliminate the genetically modified lymphocytes thereby resolving 
the GvHD pathology without interfering with the natural process of immune 
reconstitution that follows HSCT. 
Also, as the high costs associated with HSCT often reflect the requirement for 
additional treatment to resolve subsequent complications such as GvHD, 
infections and disease relapse, application of a suicide gene in DLI protocols 
can offer resolution of GvHD without impairing immune reconstitution. Thus 
the cost of inclusion of the suicide gene may prove favourable to the cost of 
therapy for post-transplant complications144. 
Early putative suicide genes including: D-amino acid oxidase, purine nucleotide 
phosphorylase, cytosine deaminase and herpes simplex thymidine kinase 
(HSVtk) were all derived from microbial components. Whilst offering 
specificity due to novel molecular circuitry, the immunogenic nature of these 
proteins has restricted application of all but HSVtk to direct targeted cancer 
gene therapy145. Therefore these early proteins will not be discussed further 
and the remaining discussion will focus on suicide genes which offer potential 
for therapeutic application. 
As with marker genes, suicide genes have evolved substantially from the initial 
concept, and similarly can be loosely segregated into categories dependent 
upon the induction strategy, which I will define as metabolic or indirect. 
However, in all cases it should be noted that induction of the suicide gene 
machinery is achieved through application of an exogenous therapeutic agent.  
Metabolic strategies can be further subdivided into non-toxic pro-drug and 
small molecule strategies. In metabolic strategies, the functional effect 
resulting from application of the inducing drug is mediated by intrinsic 
cellular pathways. As quiescence or mutation represent potential escape 
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mechanisms for these strategies, induction of suicide gene machinery imposes 
a selection advantage for cells able to escape deletion through functional 
escape from suicide gene mediated machinery. In contrast, indirect induction 
strategies rely on extrinsic cellular machinery to mediate deletion thereby 
reducing the potential for cellular escape. In all cases, low, or down-regulated 
gene expression may offer potential for target cells to escape selection 
through sub-threshold gene expression. If absolute deletion is essential, 
combination of suicide gene strategies may prove appropriate.  
Finally, although marker genes offer independent utility, implicit to the 
strategy of a suicide gene is the requirement for co-expression with a 
compatible marker gene. Thus, the impact of inclusion of a suicide gene 
regulatory component must consider the combined impact for both the 
marker and suicide moieties, in addition to any additional transgenes which 
may be desired. 
 
There is a long history of HSVtk in clinical trials which has demonstrated a 
clear efficacy in resolving GvHD when required supporting the initial premise 
behind the strategy, . 
HSVtk was the first transgene expressed by retroviral technology146 and 
remains in clinical application. Many advances in GT protocols have followed 
from HSVtk research including; optimisation of transduction protocols, 
revision of vector strategies, marker gene evolution and suicide gene re-
engineering. Some key advances as reviewed by Bonini .144, are briefly 
detailed below.  
 
Initial genetic modification protocols employed a CD3 monoclonal antibody to 
mediate the required T-cell stimulation to enable retroviral gene transfer. 
However, subsequent observations identified that T-cell stimulation in the 
absence of co-stimulation preferentially activates mature lymphocytes 
resulting in the production of a predominantly effector phenotype population 
with low alloreactive potential, thus impairing the GvL effect. Further, this 
transduction protocol, along with culture and selection strategies, was 
demonstrated to preferentially exclude T-cell precursors with EBV-specificity68, 
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147 impairing EBV immune reconstitution. Revision of T-cell transduction 
protocols to include two-signal stimulation was subsequently demonstrated to 
ensure both retention of alloreactive potential and transduction of a broad T-
cell repertoire with no evidence of clonal selection nine years post infusion144. 
 
Due to observations regarding vector mediated toxicity resulting from 
integration site analysis, lentiviral vectors were considered to offer a safer 
alternative strategy in light of observations regarding variation in the 
preferred integration sites between Moloney based retroviral vectors and 
lentiviral vectors, with third generation lentiviral vectors demonstrating an 
optimal safety profile for both viral production and T-cell transduction 
protocols. Furthermore, lentiviral vectors can transduce non-dividing cells 
through active transport of the pre-integration complex into the nucleus. 
Although LV cannot transduce quiescent cells in G
o
, low dose gamma chain 
cytokine incubation has been demonstrated to promote cell cycle progression 
from G
o
 to G
1
b which is sufficient to enable LV transduction144. 
 
Due to the imperative requirement for co-expression of a marker gene 
alongside a suicide gene, there has been a parallel evolution in clinical marker 
genes. Neomycin resistance was the first marker gene used in conjunction with 
a suicide gene; however, evolution to cell surface markers intended to resolve 
culture and G418-selection mediated impairment of EBV immunity resulted in 
∆lNGFR becoming the first cell surface marker gene to be used in a clinical 
trial. Subsequently, ∆CD34 evolved to become the second cell surface marker 
gene to enter clinical application148, with ∆CD19125 and ∆EGFR124 representing 
the most recent additions to clinical marker genes. 
 
Finally, therapeutic application of HSVtk has also suffered from a number of 
critical failures. Identification of an alternative splice variant generated from 
the wild-type (wt) HSVtk gene was shown to result in production of an inactive 
form of the enzyme. Retention of cryptic donor and acceptor splice sites from 
the wt HSVtk gene resulted with inclusion of an inactive form of the enzyme 
present in approximately 10% of retroviral particles and, correspondingly, 
approximately 10% of genetically modified cells149. Resolution of alternative 
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splicing was achieved through a conservative point mutation which was 
subsequently demonstrated to preclude production of undesired splice 
variants. However, despite the genetic correction, a subsequent report 
highlighted further ganciclovir resistant forms of HSVtk resulting from partial 
transgene deletions and post-translational proteolytic events resulting from a 
∆CD34/HSVtk fusion protein150. TK.007 represents the current evolution of 
therapeutic HSVtk, a codon-optimised construct containing a point mutation 
conferring enhanced GCV sensitivity and reduced nonspecific toxicity151. 
However, despite these limitations and failings, HSVtk has clearly 
demonstrated a proof of principle in that suicide gene therapy can offer 
resolution of GvHD. 
 
Existing suicide genes include Herpes simplex virus thymidine kinase 
(HSVtk)142, inducible caspase9125, 152, inducible FAS (iFas)153, CD20154, ∆c-myc155, 
∆EGFR124 and human thymidylate kinase (TMPK2)156, 157 with the former two 
currently in clinical use. 
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HSVtk142 Clear history of 
clinical efficacy 
Limited to application under 
profound immunosuppression. 
e.g. Haploidentical transfer 
Potential for escape through 
cellular quiescence 
TMPK2 
(TmpkF105Y)156, 157 
Human derivation Limited efficiency, delay in 
deletion, AZT toxicity 
Potential for escape through 
cellular quiescence 
iCaspase9125, 152 Human derivation 
Clear resolution of 
GvHD demonstrated 
from initial clinical 
trial 
 
Restrictive access to inducing 
drug 
Limited experience for 
potential small molecule 
toxicity 
Residual population may 
possess reduced sensitivity 
Tamoxifen inducible 
caspase158 
Human derivation Limited experience; current 
application limited to 
developmental biology research 
iFas153 Human derivation Target upstream of apoptosis 
inhibitors presents risk for 
escape 
  
CD20154, 159 Human derivation Possible residual signalling 
capacity 
Long coding sequence 
Requires co-expression with a 
separate marker gene 
∆c-myc155 Human derivation 
Small size 
Potential to function 
as both marker & 
suicide gene 
Lack of clinical c-myc antibody 
Experience limited to TCR GT 
∆EGFR124 Human derivation 
Potential to function 
as both marker & 
suicide gene 
Limited lytic capacity of 
cetuximab 
 
 
The HSVtk system involves selective phosphorylation of the non-toxic prodrug 
ganciclovir by the HSV-TK enzyme generating GCV-triphosphate. Incorporation 
of this metabolite into DNA results in chain termination and single strand 
breaks in dividing cells160. However, due to the viral origin, a key limitation to 
clinical application of HSVtk is the inherent immunogenicity of the protein. 
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Observations from clinical application demonstrate that the immunogenicity 
of the HSVtk protein depends upon the level immune constitution of the 
patient at time of infusion. Immunosuppressed patients do not generate a 
response against HSVtk unless they receive a subsequent infusion at a time 
point where they have achieved a degree of immune reconstitution. This 
suggests that the HSVtk protein remains largely ignored by the immune 
system144. However, this immunogenic limitation effectively restricts 
application of HSVtk to scenarios involving profound immunosuppression 
such as haploidentical transplant therapy. Furthermore, cytomegalovirus 
(CMV) reactivation following transplant related immunosuppression is a 
potential complication following cell therapy and ganciclovir therapy required 
to resolve CMV reactivation would also delete the HSV-TK transgenic cells. 
Finally, HSVtk represents a metabolic strategy with deletion efficacy 
dependent on enzymatic function. Thus deletion is non-immediate, whilst 
cellular quiescence offers protection from ganciclovir-mediated deletion. 
 
The iCaspase9 system remains the primary alternative to HSVtk, utilising a 
synthetic fusion gene construct derived from the human caspase9 activation 
domain fused to a synthetic FKBP12 binding domain152. Induction of suicide-
gene machinery is mediated through therapeutic administration of AP1903, a 
lipid-permeable, non-toxic analogue of the FDA-approved dimerising drug 
FK506. In a recent clinical trial125, a single dose of AP1903 achieved effective 
resolution of GvHD symptoms in all patients treated, with 90% of transgenic 
cells deleted within 30 minutes following therapeutic administration. Where 
subsequent therapeutic administration was employed to resolve resurgence 
from the residual adoptive cellular population, approximately 85% deletion 
was achieved. Furthermore, following transduction and selection in the clinical 
trial, cellular purity ranged between 90-93%, indicating that as much as 10% of 
the infusion sample excluded the suicide-gene machinery. It remains unclear 
whether this decrease in efficacy of deletion indicates a growing presence of a 
sub-threshold population, or possibly indicates the potential resurgence of 
unmodified cells. As secondary therapeutic administration has already been 
employed to resolve adoptive cell resurgence, concerns regarding potential 
resistance and/or presence of unmodified cells present within the cellular 
infusion remain, however initial results appear promising. 
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As with HSVtk, iCaspase9 offers only the suicide-inducing capacity and 
thereby requires additional co-expression of a suitable marker gene. At 402aa 
in length, this suicide-gene moiety alone imposes a significant payload for a 
transgenic cassette. Furthermore, iCaspase9 represents a metabolic suicide 
gene strategy. Cellular deletion is dependent upon apoptosis mediated via 
cellular machinery including apoptotic protease activating factor 1 (Apaf-1). 
Association of a splice variant of Apaf-1 in prostate cancer suggests a possible 
escape mechanism for this suicide-gene strategy161. The therapeutic drug 
represents a further concern regarding this strategy as increasing observation 
of HLA-linked hypersensitivities involving small-molecule drugs, such as 
abacavir hypersensitivity syndrome and Stevens-Johnson syndrome, raise 
concern regarding therapeutic safety of small-molecule drugs with limited 
clinical experience162. Finally, accessibility of the inducing drug is limited by 
exclusive licensing by the US pharmaceutical company necessitating further 
regulatory research to broaden potential clinical application. 
 
A variation from the iCaspase9 strategy involves tamoxifen inducible caspase 
constructs with dimerization achieved via synthetic fusion of a mutant 
estrogen receptor ligand binding domain to caspase8 or caspase9 domains.158. 
In theory tamoxifen offers potential for clinical application, hence inclusion 
within this list, although to date application of this strategy appears limited to 
developmental biology research. 
 
Effectively a precursor to iCaspase9, inducible-Fas (iFas) is a fusion construct 
composed of the FKBP12 binding domain fused to Fas-associated death 
domain containing protein (FADD)153. Although killing efficacy proved 
promising, selection of a target upstream of apoptosis inhibitors may result in 
variation of killing efficacy dependent upon cell type. Furthermore, limitations 
in the observed killing efficiency were thought to pose an untenable risk for 
cellular escape160. As a result, this strategy was supplanted by iCaspase9 as a 
putative suicide-gene strategy. 
 
CD20 initially appeared to offer the perfect choice as a putative marker-suicide 
gene, offering both clinical grade selection using Miltenyi magnetic sorting 
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beads and depletion mediated by rituximab, a well characterised therapeutic 
monoclonal antibody154, 159.  
Despite initial promise, evolution of this strategy has resulted in the 
generation of a bicistronic construct containing ∆CD34 as the marker gene, 
suggesting limitations for the application of CD20 as a marker gene for 
transgenic T-cells. This corresponds with our own observations of toxicity 
resulting from CD20 based bead-selection of transgenic T-cells (data not 
shown). As the biological role for CD20 in B-cells remains unclear, it is difficult 
to demonstrate the lack of a biological role of ectopic CD20 expression in T-
cells although bead selection based toxicity does suggest that residual 
signalling capacity remains, and raises further concern as to what impact this 
may pose in genetically modified cells. Furthermore, although codon 
optimisation appears to have resolved earlier limitations in transgene 
expression, the large size of the construct remains disappointing as transgene 
length is known to negatively impact upon viral titre and transduction 
efficiency119, 163. Finally, consideration for application of CD20 as a putative 
suicide gene for CD19 targeted CAR T-cell based therapies precludes 
application of rituximab/ofatumumab in the preconditioning regimen due to 
the prolonged half-life of these therapeutic antibodies. 
 
Consideration of ∆c-myc155 as a putative suicide-gene follows from previous 
strategies designed to combine marker-suicide gene capacity within a single 
construct. Selection of a 10a.a. tag derived from the human c-myc protein 
offers both minimal size and human derivation for this construct. However, to 
achieve effective expression enabling the desired functional capacity, a double-
myc tag construct localised to the amino-terminus of the variable region of the 
TCR alpha chain was required. In addition to limiting this strategy to TCR-
based gene therapy, inherent variation of TCR variable regions questions the 
generalisability for this strategy even within TCR-based gene therapy, likely 
imposing additional functional testing to ensure effective marker, suicide and 
TCR functionality in all cases. Furthermore, localisation of the c-myc binding 
to the TCR amino-terminus suggests the possibility of potential signalling 
resulting from antibody binding raising the risk for inducing a cytokine storm 
during therapeutic depletion. Finally, the lack of a current c-myc therapeutic 
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effectively restricts this strategy to research application for the foreseeable 
future. 
 
Further to potential as a proposed marker gene, a 336 residue ∆EGFR 
construct has also been proposed as a putative suicide gene with deletion 
mediated through cetuximab therapy124. Cetuximab is a chimeric monoclonal 
antibody which recognises a conformational epitope in the third domain of 
EGFR. Antitumour activity of cetuximab is indicated as resulting from 
inhibition of tyrosine kinase signalling and EGFR signalling blockade leading to 
induction of pro-apoptotic pathways164.  
Suicide-gene strategies based on transgenic expression of a binding target for 
a therapeutic antibody have been proposed124, 155, 165, 166 with the cetuximab based 
system124 being the closest to the strategy which we are proposing. Here, 
∆EGFR is expressed on a T-cell with depletion effected by the anti-EGFR 
therapeutic mAb cetuximab. Although the human derivation offers a low risk 
for immunogenicity, the choice of cetuximab as the therapeutic agent imposes 
some limitations. Cetuximab therapy is accompanied by acneiform follicular 
skin exanthema in more than 80 % of patients. Severe exanthema (grade III/IV) 
develops in about 9-19 % of patients with the necessity of cetuximab dose 
reduction or cessation167, which certainly poses some concern for a putative 
suicide gene strategy. In contrast, rituximab monotherapy is well tolerated by 
the majority of patients with little increase in opportunistic infection168, 169, no 
maximally tolerated dose165 and a solid reputation as a lymphodepleting agent 
in human subjects170, 171. 
 
TMPK2 is a mutant thymidylate kinase of human derivation which employs a 
similar strategy to HSVtk involving selective enzymatic conversion of a non-
toxic prodrug azidothymidine (AZT) into a toxic metabolite. Limited efficacy 
from an earlier enzyme156 has resulted in the directed evolution of 
TmpkF105Y157, a modified TMPK enzyme with increased catalytic capacity for 
AZT. Cellular deletion mediated by this enzyme is proposed to progress by 
two alternative mechanisms; incorporation of phosphorylated AZT into DNA 
during replication results in premature chain termination, whilst activated AZT 
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can damage mitochondrial membrane potentials resulting in caspase-3 
mediated apoptosis.  
However, as with HSVtk, primary concerns regarding metabolic suicide gene 
strategies remain. Notably, as cellular deletion is dependent upon the activity 
of the target enzyme, adoptive cells can escape deletion through quiescence. 
Furthermore, the therapeutic window required to achieve deletion may prove 
too prolonged to achieve effective resolution dependent on the nature of the 
ACT-based toxicity causing concern. Finally, reports of genomic toxicity and 
promotion of genomic instability mediated by AZT raise concerns for general 
application of this strategy as a suicide gene for ACT, particularly for cancer 
therapies where the potential of promoting genomic instability seems 
especially risky172. 
 
Despite the array of alternative suicide genes which have been considered, 
only HSVtk and iCaspase9 have been validated through clinical application 
with trial results pending for ∆EGFR. From an  comparison of HSVtk, 
iCaspase9, CD20 and TMPK2, equivalent deletion was observed for iCaspase9, 
CD20 and HSVtk although HSVtk requiring four days to achieve equivalent 
depletion as observed for iCaspase9 and CD20. Although the profile of TMPK2-
mediated deletion proved similar to that observed for HSVtk, a maximum 
efficacy of approximately 70% would likely preclude clinical application173. 
Metabolic and antibody-mediated suicide gene strategies each possess both 
advantages and limitations and the ultimate decision to consider a single, 
multiple or no suicide gene strategy should be balanced with the threat 
associated with the therapeutic application. 
 
Following upon the premise of using CD20 as a suicide gene, we have 
generated a suicide gene based upon the R3-C mimotope described by Perosa 
174 which is bound by the common therapeutic monoclonal antibody 
rituximab. Due to the minimal size of this antibody-binding epitope domain, it 
is optimal for co-expression alongside our QBEnd10 binding marker gene. 
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Antibodies compose the humoral arm of the adaptive immune response. In the 
membrane bound form, these act as the B-cell receptor mediating target 
recognition analogous to the T-cell receptor. In the soluble form, they mediate 
the effector functions of the humoral response. There are five classes of 
antibodies defined by heavy chain constant regions: IgM, IgG, IgA, IgE and IgD. 
As most therapeutic antibodies are based on the IgG isotype, these will form 
the basis for further discussion. 
The initial concept for a therapeutic application for antibodies was proposed 
by Paul Erlich late in the nineteenth century175, however it wasn't until the 
advent of hybridoma technology in 1975176 that monoclonal antibody 
technology became a reality. Monoclonal antibody therapy is a natural 
evolution from immunoglobulin replacement therapy dating from the 1970s 
with early monoclonal antibodies derived from antibodies raised in mice. 
However, the immunogenic capacity of murine-derived antibodies identified 
one of the first challenges in applying monoclonal antibody technology to 
clinical application. In addition to being immunogenic, early murine-derived 
antibodies also suffered from poor efficacy due to limited recruitment of 
immunological effector functions. Thus began progressive evolution of 
antibody engineering. To address the immunogenic potential, antibodies were 
re-engineered to be first chimeric, then humanised and finally fully humanised 
in an attempt to exclude the immunogenic impact of non-self-origin.  
 
(Adapted from Brekke et al. 2003177) Initial antibody technology employed murine antibodies 
obtained directly from hybridomas but which subsequently were established to be 
immunogenic. This elicited three major advances in antibody engineering to achieve fully 
humanised antibodies. By 1984 molecular biology enabled formation of chimeric antibodies by 
fusing human Fc to a murine Fab domain. Chimeric antibodies remain 1/3 murine and 2/3 
human in derivation. By 1986, further reductions from the parental murine sequence enabled 
exclusive transfer of only the CDR domains required to confer antigen specificity. A final 
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evolution using CDR grafting or veneering techniques developed in 1989 enabled generation of 
fully human antibodies which retain the desired antigen binding capacity178. 
Abbreviations: Fab –antibody binding fragment, Fc –constant fragment, CDR – complementary 
determining region 
 
Therapeutic antibodies mediate biological activity through one of three 
primary mechanisms: indirectly via effector-mediated lysis, following 
complement activation and/or effector cell recruitment (e.g. 
rituximab/alemtuzumab); cytotoxicity mediated through a toxic/radio-labelled 
conjugate moiety (e.g. mylotarg/epratuzumab); and through neutralising 
behaviours, (e.g.infliximab/basiliximab/ipilimumab)179. Further, the capacity for 
biological activity can be modulated where desired. The anti-CD20 therapeutic 
antibody ofatumumab was selected for enhanced complement-mediated lytic 
capacity premised to result from an alternative binding location against 
CD20180. In contrast, antibody-engineering of the anti-GD2 ch14.18 antibody 
involved inclusion of a point mutation in the Fc domain, designed to reduce 
complement fixation, with a view to attenuate therapy-related allodynia 
observed during therapy against neuroblastoma181. 
Antibodies can be subdivided into distinct functional units: the antigen 
binding (Fab) fragment, and the constant (Fc) fragment. The Fab is the variable 
region of the antibody, with variability primarily restricted to three 
complementary determining regions (CDR's) which define the antigen 
recognition specificity of the antibody. The constant Fc domain defines the 
isotype of the antibody as indicated above, and mediates the effector functions 
of the immune response (CDC/ADCC) as well as facilitating antibody stability, 
further mediated by FcRn receptors. A further role for the Fc domain is 
physiological stability; the prolonged serum half-life of antibodies results from 
interaction of IgG with the neonatal Fc receptor (FcRn). FcRn receptors present 
on vascular endothelium can reversibly bind serum IgG allowing for return to 
the circulation and preventing lysosomal catabolism en route to the 
lymphatics179. 
Humans and mice differ in their ability to recruit effector mechanisms based 
on antibody isotype, therefore definition of equivalent counterparts are based 
on similarity in functional behaviour with mouse IgG2a and IgG2b 
demonstrating similar complement-mediated functional capacity as human 
IgG1 and IgG3, respectively182. From animal models using CD20 depleting 
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antibodies, B-cell depletion efficacy was observed to perform relative to 
antibody subclass as follows: IgG2a>IgG1>IgG2b>IgG3183. In humans, 
complement mediated sensitivity shows a similar antibody subclass defined 
pattern: IgG1>IgG3>IgG2>IgG4184. 
 
Rituximab is a clinical success story; originating as a CD20 targeted chimeric 
antibody developed by IDEC pharmaceuticals under the name IDEC-C2B8, in 
1997 rituximab became the first FDA approved antibody drug for the 
treatment of malignancy. Initially approved for use against chemotherapy 
refractory non-Hodgkins lymphoma, rituximab has subsequently been 
approved for clinical application in chronic lymphocytic leukaemia, 
rheumatoid arthritis, Wegener’s granulomatosis and microscopic polyangiitis 
with further off-label applications, including myasthenia gravis, systemic lupus 
erythematosus (SLE), immune thromocytopenic purpura, type I diabetes and 
multiple sclerosis, currently under investigation185. Despite the clear efficacy 
demonstrated by rituximab, definitive attributions for the various mechanisms 
involved in the therapeutic effect remains in dispute. Although, direct 
signaling, sensitization to chemotherapeutic drugs, CDC and ADCC all appear 
to be involved in the therapeutic effect186, 187; from both  and  
data, it has been suggested that the relative importance of different 
mechanisms may vary dependent on the therapeutic and physiological 
scenario involved. 
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Adapted from Taylor et al188. Rituximab mediated deletion has been proposed to result from 3 
separate mechanisms: direct toxicity imposed by signalling resulting from antibody-mediated 
cross-linking of CD20, complement dependent cellular cytotoxicity (CDC) resulting from 
activation of the complement system and antibody dependent cellular cytotoxicity (ADCC) 
mediated by cellular effectors. 
 
Evidence for the role of direct signaling mediated toxicity are primarily derived 
from  assays involving cross-linking of rituximab with secondary 
antibodies. As the secondary antibodies usually possess a greater affinity for 
rituximab than rituximab has for the Fc receptors, these results may reflect 
artificial amplification of the signal thus raising doubt for the potential clinical 
relevance of direct signaling as a cytotoxic mechanism. Despite these 
limitations, this evidence suggests that rituximab-mediated restructuring of 
cellular CD20 molecules into lipid rafts mediates inhibitory cellular signaling 
through p38 MAPK, NFκB, ERK 1/2 and AKT survival pathways. 
Evidence for CDC-mediated toxicity of rituximab reflects both  assays 
and  observations.  assays have demonstrated expression of 
complement inhibitory molecules CD55 and CD59 on targets which correlates 
with the CDC-mediated efficacy of rituximab. While CDC has been shown to be 
a primary mechanism for rituximab-mediated deletion in some animal models, 
what remains contentious is the clinical relevance of CDC-mediated deletion, 
and to what degree this might occur outside of the intravascular compartment. 
A clinical observation suggestive for the role of CDC in patients relates to 
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residual chronic lymphocytic leukaemia (CLL) cells present following rituximab 
therapy, having been shown to express elevated levels of CD59 when 
compared against pre-therapy samples187. Further clinical evidence for the role 
of CDC in rituximab efficacy is indicated by enhanced therapeutic efficacy 
against CLL following plasma infusion to replenish plasma complement 
levels189. Finally, the role of CDC-mediated deletion in rituximab efficacy has 
been considered sufficiently crucial as to merit future CD20 antibody 
engineering to enhance the complement fixation effect. Ofatumumab, a new 
therapeutic CD20 mAb which binds to the small membrane-proximal 
extracellular loop of CD20 was selected based upon enhanced ability to 
mediate CDC-mediated lysis180. 
ADCC represents the third proposed primary mechanism for rituximab-
mediated efficacy. Most research exploring rituximab-mediated ADCC has 
examined the role of natural killer (NK) cell FcγRIIIa (CD16) in ADCC mediated 
lysis. However this strategy may distort the physiological setting as NK cells 
are unique as effectors of ADCC in that expression of the inhibitory FcγRIIb 
(CD32) is absent, therefore FcR cross-linking mediated activation proceeds 
uninhibited. ADCC can be mediated by a range of effector cells including 
granulocytes, macrophages and NK-cells, and apart from NK cells, the 
resulting activation decision reflects the combination of activating and 
inhibitory signals received by the cell. However, as high affinity CD64 FcγRIa 
(CD64) expression can be upregulated on granulocytes by IFNγ, and as NK cells 
are a source of IFNγ, it could be postulated that NK-cell CD16 may play a 
primary activating role in the process of ADCC-mediated deletion. The role of 
NK cells in ADCC is discussed further in Chapter five. 
As only CDC and ADCC mechanisms are relevant in the mechanism for 
deletion of our construct, we have used CDC assays using baby rabbit 
complement, and ADCC assays using donor derived,  expanded NK cells 
as effectors. 
 
To generate a minimal epitope-based, selection and suicide gene cassette, 
engineered for solid tumour chimeric antigen receptor immunotherapy. 
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 To epitope map the QBEnd10 binding epitope from the CD34 antigen 
 To establish a minimal marker gene expression construct using the 
QBEnd10 epitope which enables Miltenyi MACS selection of transgenic 
cells 
 To identify and establish a minimal rituximab binding epitope construct 
 To establish an effective co-expression construct for both minimal 
epitope binding domains 
 To establish flow-cytometry based  CDC deletion assays 
sufficient to enable effective comparative assessment of complement 
mediated deletion between similar epitope expression constructs 
 To establish flow-cytometry based  ADCC deletion assays 
sufficient to enable effective comparative assessment of effector 
mediated depletion between similar epitope expression constructs 
 To demonstrate a modular capacity of the marker suicide gene 
construct in conjunction with standard T-cell engineering components 
 To demonstrate functional efficacy of the marker-suicide gene construct 
through  adoptive transfer modelling using a murine model 
We have engineered RQR8 as a putative suicide gene for adoptive cell therapy. 
Although design and validation of RQR8 function has been with a view for 
application for cancer immunotherapy, it seems reasonable to premise that the 
functional capacity RQR8 could extend to general ACT application. 
T-cell gene therapy remains a young and rapidly developing field. Whilst many 
lessons have learned through clinical trials, therapeutic triumphs have been 
accompanied by tragedy. However, so long as risk of therapeutic toxicities 
exist, inclusion of effective safety mechanisms remains as crucial to ensuring 
general acceptance for ACT as therapeutic success. 
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Acetic acid (glacial)  BDH     10001CU 
Agarose   Bioline    BIO-41025 
Agarose (Cell culture) Lonza Seaprep agarose  50302 
Bovine Serum Albumin Sigma-Aldrich   A7906 
Boric acid   VWR International   20185.360 
Bromophenol blue  Sigma-Aldrich   B3269 
CaCl 2-hydrate  BDH Chemicals   437053L 
Carbenicillin   VWR International   69101-3 
Cellstor pot (10% NBF) Cellpath    BAF-6000-08A 
51Chromium radionuclide Perkin Elmer    NEZ030001MC 
Citric acid monohydrate Sigma-Aldrich   27491 
Coomassie R-250 dye Thermo Scientific   20278 
ECL prime   GE Healthcare Life sciences  RPN2232 
EDTA Disodium salt VWR International   20302.260 
Ethidium bromide  BDH Chemicals   443922U 
Glycerol   Sigma-Aldrich    G5516   
Laemmli sample buffer Sigma-Aldrich   S3401 
Luria-Bertani (LB) Medium MP Biomedicals LLC   3002-031 
LB-Agar Medium  MP Biomedicals LLC   3002-231 
Marvel skim milk powder 
Neutral buffered formalin Genta Medical   BFN010 
PBS tablets   Oxoid     BR0014G 
PFA 4% in PBS  Insight Biotechnology Ltd  sc-281692 
pH indicator strips  VWR International   1.09542.0001 
Propidium iodide  Sigma-Aldrich   P4170 
Sodium Chloride  BDH Chemicals   27810-364 
Sodium phosphate heptahydrate 
    Sigma-Aldrich   S9390 
Sodium phosphate monobasic 
    Sigma-Aldrich   S0751 
Sodium citrate  Sigma-Aldrich   S4641 
Terrific broth (TB)  Merck Chemicals Ltd  1.01629.0500 
Trisodium citrate  Sigma-Aldrich   C8532 
Tris base   Fisher Scientific UK   BPE152-5 
Trypan Blue solution Sigma-Aldrich   T8154 
X-gal    Sigma-Aldrich   B4252 
X-ray film (18x24)  Amersham    28906844 
 
 
Restriction enzymes New England Biolabs UK Ltd Various 
Hyperladder DNA ladder Bioline Limited   BIO-33026 
Phusion DNA polymerase New England Biolabs UK Ltd M0530L 
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Platinum PCR SuperMix Invitrogen    12532-016 
TOPO TA cloning kit Invitrogen    45-0641 
Murine GAPDH primer Qiagen    QT01658692 
M-MLV reverse transcriptase Ambion   AM2044 
Oligo primers  IDT DNA 
 
 
NEB 5-α Competent  (Subcloning Efficiency) C2988  
    New England Biolabs UK Ltd  C2988J  
NEB 5-α Competent  (High Efficiency) C2987 
    New England Biolabs UK Ltd C2987H 
 
 
Cryogenic vial internal thread Corning   430488 
Flask Ez Nunclon 175Cm  Thermo Electron  159910 
Flask Ez Nunclon 75Cm  Thermo Electron  156499 
Flask Ez Nunclon 25Cm  Thermo Electron  156367 
100mm TC dishes   Corning   430167 
6 Well plate TC treated  Corning   3506 
12 Well plate TC treated  Corning   3513 
24 Well plate TC treated  Corning   3524 
24 Well plate non-TC treated BD Biosciences  351147 
48 Well plate TC treated  Corning   3548 
96 Well plate flat bottom  Corning   3596 
96 Well plate V-bottom  Greiner Bio-One  650-180 
96 Well plate round-bottom Corning   3799 
15ml Centrifuge tubes  Corning    430791 
50ml Centrifuge tubes  Corning   430829 
250ml centrifuge tubes  Corning   430776 
0.2μM pore syringe filter  Sartorius   16532K 
0.45μM pore syringe filter  Sartorius   16537K 
 
 
2-Mercaptoethanol  Sigma-Aldrich   M7522 
ACK Lysing buffer  Lonza Sales AG   10-548E 
Baby rabbit complement AbD Serotec    C12CA 
CD34 microbeads (human) Miltenyi Biotec   130-046-702 
CD56 microbeads (human) Miltenyi Biotec   130-050-401 
Cell dissociation medium Sigma-Aldrich   C5914 
CellTRACE violet  Invitrogen Life Technologies C34557 
Concanavalin A   Sigma-Aldrich   C5275 
Counting beads  Beckman Coulter   6605359 
Cryopreservation Medium Lonza Bio Science Ltd  US12-132A 
DMSO    Sigma-Aldrich   D2650 
DPBS solution  Invitrogen Life Technologies 14190169 
EDTA solution (0.5M) Sigma-Aldrich   E7889 
FBS, Ultra-Low IgG  Invitrogen Life Technologies 16250-086 
FBS, IgG stripped  Biosera    S1811 
FCS    Biosera    S1900/500 
Ficoll-Paque   GE Healthcare Life sciences 17-1440-03 
Genejuice   Merck Chemicals Ltd  70967-3 
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GlutaMAX   Invitrogen Life Technologies 35050087 
HBSS 10x   Sigma     H1641 
Heparin sodium  Leo Laboratories Ltd  PL 0043/0149 
HEPES solution (1M) Sigma-Aldrich   H0887 
Horse serum   Life technologies   16050130 
IL-2 Recombinant human Genscript    Z00368 
IL-2 Recombinant mouse Invitrogen Life Technologies PMC0021 
IL7 Recombinant mouse PeproTech EC Ltd   217-17 
IMDM    Lonza Bio Science Ltd  BE12-726F 
IMDM L-Glut+, Phenol Red- Invitrogen Life Technologies 21056-023 
Normocin   InvivoGen    ant-nr-1
PHA    Sigma-Aldrich   L9017 
Polybrene   Millipore    TR-1003-G 
Retronectin   Lonza Bio Science Ltd  T100B 
RPMI     Lonza Bio Science Ltd  BE12-167F 
Sfm4Transfx-293  Fisher Scientific UK   HYC-014-020V 
Trypsin-EDTA solution Sigma-Aldrich   T4049 
 
 
Dissecting Scissors 115mm SLS    INS4800 
Forceps 115mm, fine tip curved Onecall   D00834 
Forceps straight with blunt tips Fisher Scientific UK  DKC-510-G 
Haemocytometer   Hirschmann Laborgeraete GmbH 8100103 
Histosette cassettes   Simport scientific Inc M490-2 
LS Columns    Miltenyi Biotec  130-042-401 
MS Columns    Miltenyi Biotec  130-042-201 
Nalgene® Mr. Frosty®   Thermo Scientific  5100-0001 
Parafilm    VWR International  291-1212 
Pellicon XL Biomax 50 TFF  Millipore   PXB050A50 
Portable Pipet-Aid XP  Drummond Scientific 4-000-101 
Vacuum filter unit   Corning   431097 
 
 
Qiagen Gel extraction kit Qiagen    28706 
Qiagen Miniprep kit  Qiagen    27106 
Quick Ligation kit  New England Biolabs UK Ltd M2200L 
Nucleospin Miniprep kit Thermo Scientific Abgene  NZ740588250 
Nucleobond Midiprep kit Thermo Scientific Abgene  NZ74041050 
BD Mouse IgG2a ELISA set BD Biosciences   552576 
BD OptEIA Reagent Set B BD Biosciences   550534 
 
 
Unless otherwise indicated, buffers and solutions were prepared in deionised 
reverse osmosis filtered laboratory grade water and either autoclave sterilised 
at 121oC for 15 minutes, or sterile filtered by vacuum filtration through a 
0.22μM filter. 
Composition of buffer solutions is detailed as follows:  
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Annexin V buffer 
[150mM NaCl, 10mM HEPES, 
10mM CaCl] 
8.71g of sodium chloride, 10ml 1M Hepes 
solution (Sigma) and 1.47g of Calcium chloride 
diluted into 1L of deionised water. 
Propidium iodide (PI) stock 
solution 
25mg PI (sigma) was suspended into 10ml of 
deionised laboratory grade water to establish a 
2.5mg/ml stock solution 
20mM sodium phosphate 
(pH7) 
3.27g sodium phosphate heptahydrate and 
0.94g sodium phosphate monobasic diluted 
into 1L of deionised water pH balanced to 
pH7.0 with concentrated HCl solution 
0.1M citric acid 21.01 g of citric acid monohydrate dissolved 
into 1L of deionised water 
0.1M trisodium citrate 29.41g trisodium citrate dehydrate dissolved 
into 1L of deionised water 
0.1M sodium citrate (pH3.6) Composite solution composed of 68.5ml of 
0.1M citric acid and 31.5ml of 0.1M trisodium 
citrate as indicated by Sigma.  
[http://www.sigmaaldrich.com/life-
science/core-bioreagents/biological-
buffers/learning-center/buffer-reference-
center.html] 
Tris-HCl buffer (pH9) 1M solution (121.14g diluted into 1L deionised 
water), pH adjusted with concentrated HCl 
solution. 
MACS/FACS buffer 1% FCS in PBS 
0.25% Coomassie stain 
[50% methanol, 10% acetic 
acid, 40% water] 
2.5g Coomassie R-250 dissolved in 500ml 
methanol, 100ml Glacial acetic acid and 400ml 
deionised water 
Coomassie de-stain 
[25% methanol, 7% acetic 
acid, 68% water] 
250ml methanol, 70ml Glacial acetic acid and 
680ml deionised water 
RIPA buffer 
Radio immunoprecipitation 
assay buffer 
150mM NaCl, 10mM Tris, pH 7.2, 0.1% SDS, 
1.0% Triton-X-100, 1% Deoxycholate, 5mM 
EDTA 
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TBE 
(Tris, Boric Acid, EDTA) 
108g Tris, 55g Boric acid, 108g Tris base, 
diluted into 1L of de-ionised laboratory grade 
water to establish a 10x solution, subsequently 
further diluted with an additional 9L of de-
ionised laboratory grade water. 
 
 
OneComp eBeads  eBioscience    01-1111-42 
Note: regarding antibody staining: for flow cytometry typically 1-2µl of 
antibody was used to stain 1x106 cells for both preconjugated and secondary 
antibodies. Therapeutic antibodies were diluted to 1mg/ml in PBS, with 1µl of 
antibody used as the primary antibody per 1x106 cells. For Western blotting, 
antibodies were diluted according to manufacturer’s instructions. 
 
Annexin V-APC  BD Biosciences    550474 
Streptavidin-APC  AbD Serotec    STAR119 
Streptavidin-PerCP  BD Biosciences    554064 
Anti-Flag M2   Sigma     F3165 
Anti-nuclear matrix protein p84 AbCam   ab487  
Anti myc-tag biotin  AbD Serotec    MCA2200B 
Anti PI3Kinase p85  Merck Millipore   06-497 
Anti HA tag biotin  AbCam    ab26228 
Anti OLLAS tag  Novus Biologicals   NBP1-06713 
Anti V5 tag biotin  Bioss     bs2109R 
Anti V5 tag APC  AbCam    ab72560 
Anti T7 tag biotin  Bioss     bs2107R 
 
CD3-PE   Beckman Coulter   PN IM1282 
CD16-PE   BD Pharmingen   555516 
CD20-PE   Dako UK    R7013 
CD34-(581)-APC  BD Biosciences   555824 
CD34-(QBEnd10)-Biotin AbD Serotec    MCA547B 
CD34-(QBEnd10)-PC5 Beckman Coulter   IM2650U 
CD34-(QBEnd10)-AF700 Exbio     A7-566-T100  
CD34-(QBEnd10)  Dako UK    M7165 
CD56-FITC   BD Biosciences   345811 
Anti-human IL15  Sigma-Aldrich   WH0003600M1 
Anti-human 4-1BB Ligand  Biolegend    311502 
Goat-anti-human-Fc Cy5 Jackson ImmunoResearch   109-175-098 
Goat-anti-hFc DyLight488  Jackson ImmunoResearch  109-485-098 
Goat-anti-hFc DyLight649  Jackson ImmunoResearch  109-496-127 
WT1-TCR Dextramer-PE Pro-Immune (NLVPMVATV) dextramer 
Rituximab   MAbThera (UCL pharmacy) 
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Ofatumumab   (UCL pharmacy) 
 
CD4 PE   eBioscience     
CD4 PE-Cy7   eBioscience    25-0041-82 
CD4 FITC   eBioscience    11-0042-85 
CD8a eFluor 450  eBioscience    48-0081-82 
CD90.1 (Thy1.1)  eBioscience    25-0900-82 
MHC Class I (H-2Kb) FITC eBioscience    11-5958-82 
MHC Class I (H-2Kd) PE eBioscience    12-5957-82 
Goat anti-mouse Fc-DL649 Jackson ImmunoResearch  115-495-071 
Goat anti-mouse Fc-APC  BD Biosciences   550826 
 
 
HEK293T    Human embryonic kidney cell line 
K562     Human chronic myeloid leukaemia 
Jurkat     Human acute lymphoblastic leukaemia 
Raji     Human Burkitt’s lymphoma 
SupT1     Human acute lymphoblastic leukaemia 
LinXE     Ecotropic envelope packaging cell line 
IDEC2B8 Hybridoma  Murine Rituximab Hybridoma HB-11388 
2.4G2 hybridoma    Murine 2.4G2 Hybridoma  HB-197 
 
 
Complete RPMI 
(Lonza) 
10% FCS (Biosera), 1% GlutaMAX (Invitrogen) 
Complete IMDM 
(Lonza) 
10% FCS (Biosera), 1% GlutaMAX (Invitrogen) 
mRtx-IgG2a IMDM 
Phenol red negative 
(Invitrogen) 
2.5% IgG stripped FCS (Biosera/Invitrogen), 
1% GlutaMAX (Invitrogen) 
Splenocyte media Complete RPMI + 1% 1M HEPES solution (Sigma) + β 
mercaptoethanol (BME) at a final concentration of 0.1mM 
PBMC assay 
medium 
Complete RPMI as above supplemented with 50i.u. of 
recombinant human IL2 
2.4G2 hybridoma 
medium 
IMDM (Lonza) supplemented with 5% horse serum (Life 
technologies), 5% FCS (Biosera), 1% GlutaMAX (Invitrogen) 
Cryopreservation 
medium (Lonza) 
18ml of FCS was added to Lonza cryopreservation 
medium to generate a solution containing 15% FCS and 
13% DMSO 
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β mercaptoethanol 
working stock 
50μl of 14.3M BME (Sigma) was added to 7.05ml of 
molecular biology grade water to generate a 1000x 
working stock at 0.1M concentration. This was stored at 
4oC for up to one month. BME supplementation was 
performed immediately prior to experimental 
application. 
 
 
Geneflow Limited   NGene transilluminator 
Clare Chemical research  Dark reader DR89X transilluminator 
Olympus IX70    Inverted fluorescence microscope 
Beckman Coulter    CyAn ADP flow cytometer 
BD Biosciences    LSR Fortessa cell analyser 
Nanodrop®     ND-1000 Spectrophotometer 
AGO HS MP 1    X ray irradiator
GE Healthcare life sciences  ÄKTAprime plus 
Millipore Labscale    Tangential flow filtration (TFF) system 
Invitrogen Surelock™   XCell blot module   
LKB Wallac     1282 Compugamma Gamma Counter 
Vacuum filter dryer   SG200 Savant integrated gel dryer 
Heidolph polymax horizontal wave shaker 1040 
 
 
HiTrap rProtein A FF GE Healthcare Life sciences 17-5080-01 
Vacuum filter unit  Nalgene Labware   450-0020 
SnakeSkin Dialysis Tubing, 10,000 MWCO    
Thermo Fisher Scientific Inc. 68100 
Pellicon XL 50 Ultrafiltration Cassettes      
Millipore    PXB050A50 
 
 
Summit    Beckman Coulter Inc 
Flowjo    Treestar data Inc 
Clone manager   Sci-Ed software 
 
 
 
 
Expression plasmid transgene cassettes were generated using splicing by 
overlap extension PCR (SOE-PCR). Putative epitope binding fragments were 
generated in two fragments; with the N-terminal fragment containing NcoI site 
and the signal sequence and the C-terminal fragment containing the CD8 stalk, 
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anchor and MluI restriction site. The target site under interrogation was 
defined by the overlapping internal oligonucleotide primers complimentary to 
both the flanking sequences and the desired modification. The primary PCR 
fragments were generated by PCR: (35) cycles of amplification were performed 
using the following conditions: Melting temperature: 98oC for 120s, Annealing 
temperature 65oC for 42s and extension temperature 72oC using Phusion 
polymerase (Extension duration defined by amplicon length; approximately 70 
seconds per 1000 base pairs of sequence to be amplified). Following PCR 
amplification, products were separated by gel electrophoresis and purified 
using Qiaquick PCR clean-up columns.  Primary PCR products were combined 
using a secondary fusion PCR reaction using the same conditions as above. 
Following verification of successful amplification, the PCR product was then 
cleaned up, again using Qiaquick PCR clean-up columns digested using NcoI 
and MluI restriction enzymes and subcloned into a suitably digested 
SFG.I2.eGFP destination vector. Sequence integrity of epitope expression 
mutants were confirmed by capillary sequencing performed in-house by 
Scientific Support Services. Further details regarding cloning strategies are 
addressed in Appendix 1. 
 
Cloning screening scale DNA preparation (miniprep) DNA was prepared as 
follows: Following bacterial transformation, single colonies were picked from 
an agar plate and grown overnight in 4ml LB supplemented with 100µg/ml 
carbenicillin. Following overnight culture, the Qiagen miniprep kit was used to 
isolate plasmid DNA according to manufacturer’s instructions. Constructs 
were verified by restriction digest and/or DNA sequencing. 
 
Generation of DNA for  and/or  modelling (midiprep) DNA was 
prepared as follows: 50ml of TB were inoculated with 250-500µl of bacterial 
culture and cultured for 16-18 hours in a bacterial shaking incubator; 220 RPM 
at 37oC. The Macherey Nagel midiprep kit was used to isolate plasmid DNA as 
per manufacturer’s instructions. Midiprep DNA was verified by separate 
restriction digests cutting in the vector backbone, retroviral LTR and transgene 
insert respectively. 
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DNA concentration reflects the property of DNA absorbance of light at 
wavelength 260nm, while the ratio of absorbance at 260nm:280nm can be 
used to establish purity. An A260nm:A280nm ratio of 1.8 indicates a high 
degree of DNA purity with little RNA or protein contamination. Purity and 
concentration of plasmid DNA was assessed using a nanodrop ND-1000 
spectrophotometer. 
 
Restriction digests were performed according to manufacturer’s instructions 
(NEB) to establish cloning fragments of DNA with ‘sticky’ ends to facilitate 
DNA ligation. For inserts derived by PCR, the entire sample was digested. To 
generate vector backbone, or vector derived insert fragments, 5µg of plasmid 
vector DNA was used. In either occasion, the reaction volume was adjusted 
with molecular grade water such that the final reaction volume was 100µl. 
Buffer selection and addition of BSA was defined by the manufacturer, with a 
final enzyme concentration of 5% v/v of the final reaction volume. Where 
buffers were incompatible, double digestions were performed serially with the 
digestion sample prepared between the reactions using the Qiagen QIAquick 
clean-up kit. 
 
DNA fragment size verification of restriction digests for molecular cloning 
plasmids and PCR product DNA was accomplished by DNA separation using 
agarose gel electrophoresis. 1% Agarose gels were prepared in 1x TBE buffer 
with agarose solubilisation achieved by microwave heating of the solution. 
Once solubilisation had been achieved, the agarose was then cooled and 
infused with 0.5-1μg/ml of ethidium bromide to enable UV visualisation of the 
DNA. Samples were mixed with loading buffer at a ratio 10:1 prior to loading 
into the gel to enable visualisation of the sample progression within the gel. 
Agarose gels were electrophoresed at 110V in 1xTBE buffer until appropriate 
separation was achieved. DNA visualisation was then achieved using an Ngene 
transilluminator (dark reader blue light box). 
 
Following separation of DNA fragments by agarose gel electrophoresis, bands 
were visualised using a dark reader blue light box to prevent UV-mediated 
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mutagenesis and excised from the gel with a clean scalpel. Gel extraction of 
DNA was then accomplished using Qiagen QIAquick or Macherey Nagel gel 
extraction kits, according to manufacturer’s instructions. 
 
Following fusion PCR reactions and where it was necessary to perform serial 
restriction digests due to buffer incompatibility, the Qiagen QIAquick kit was 
used according to manufacturer’s instructions to remove contaminants from 
the sample prior to downstream processing. 
 
Following gel extraction of the digested vector and insert fragments, DNA 
ligations were performed using Quick Ligase (NEB) according to the 
manufacturer’s instructions with a vector:insert molar ratio between 1:3-1:6. 
Following 5 minute incubation at room temperature, 2µl of the resulting 
ligation mix was used for bacterial transformation of high efficiency C2987 
(NEB) chemically competent  bacteria. 
 
The gammaretroviral vector SFG28 was used for all constructs examined during 
this course of research. SFG is based on the Moloney MLV, with the transgene 
start codon located at the start site of the deleted viral envelope gene. 
Bicistronic transgene expression was achieved by one of two strategies: in 
constructs indicated with ‘I2’, the primary transgene was followed by inclusion 
of the encephalomyocarditis internal ribosomal entry site (IRES) allowing 
expression of the downstream reporter gene eGFP. In constructs including ‘2A’ 
within the name, the dual construct was translated as a single peptide, with 
separation of the separate components achieved by the self-cleaving activity 
mediated by the TaV (  virus) 2A sequence resulting in equimolar 
expression of both transgenes. Constructs denoted SFGmR also include a 
scaffold attachment region to enhance transgene expression. 
Please see Appendix 1 for further details regarding vector design and modular 
cloning. 
 
Codon optimisation/gene synthesis of novel DNA was designed using pMol 
software written by Dr Martin Pulé. This software is designed to raise the GC 
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content to 70%, eliminate local sequence repeats, hairpins, cryptic splice sites 
and to code for preferential codons to enhance gene expression. Overlapping 
oligonucleotides were designed such that short sections of DNA sequence 
would be defined by the sequence overlap as illustrated by Figure 6. Using the 
overlapping oligos as template, two rounds of DNA amplification were 
performed; the first reaction resulted in short sections of synthetic DNA, with 
amplification of the desired sequence achieved during the second reaction as 
defined by the two terminal primers. 
 
Gene synthesis is achieved through application of overlapping oligonucleotides employed to 
establish a template DNA sequence following a primary PCR reaction. This template sequence 
is then amplified through a secondary PCR reaction facilitated by primers binding to terminal 
sequences which contain engineered restriction sites to facilitate facile restriction-digest 
mediated cloning. Further detail regarding this cloning is illustrated by Figure 61, p207. 
 
 
5x106 peripheral primary human blood monocytes isolated by ficoll extraction 
were resuspended in 1 ml of Trizol® reagent, with pipette agitation to achieve 
generation of single cell suspension to ensure effective cellular lysis. Cells 
were incubated in Trizol® for 5 minutes at room temperature. Trizol®-cell 
suspension was then transferred to a sterile eppendorf tube. 200µl of 
chloroform was added to the Trizol lysate. This suspension was then 
vigorously vortexed for 15 seconds, incubated at room temperature for 3 
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minutes then centrifuged at 11500G for 15 minutes. The upper/clear aqueous 
phase was carefully aspirated and transferred to a fresh sterile eppendorf 
tube. 500µl of isopropanol was added to this sample which was then inverted 
twice and incubated at room temperature for 10 minutes. This sample was 
centrifuged at 11,000G for 10 minutes at 4oC. The supernatant was aspirated 
by pipette, and the pellet was then washed twice with 1ml of 75% ethanol, each 
time the sample was re-pelleted by centrifugation at 7000G for 5 minutes at 
4oC. Following the second wash, the ethanol supernatant was aspirated by 
pipette and the eppendorf tube was dried in a sterile hood for 20 minutes. The 
RNA sample was then resuspended in 40µl of molecular biology grade water 
and the RNA concentration was assessed by spectrophotometric measurement 
by nanodrop prior to cDNA generation. 
 
cDNA was generated from RNA through a two-step process: In the first step, a 
20µl reaction mixture composed of 1µg of RNA, 2µl of Random Decamers, 4µl 
of 2mM dNTP’s, with molecular biology grade water composing the remainder 
of the sample, was heated at 70oC for 3 minutes then transferred to ice for 1 
minute. 2µl of 10x reverse transcriptase buffer was then added to the above 
reaction mixture followed by 1µl of RNasin and 1µl of reverse transcriptase. 
This second reaction mixture was then incubated for 1 hour at 42oC, followed 
by 5 minute incubation at 95oC to deactivate the polymerase enzyme. 
Confirmation of successful cDNA generation was achieved by amplification of 
the GAPDH housekeeping gene. Forward and reverse primers for the human 
GAPDH sequence (GCCGAGCCACATCGCTCAGA, 
GAGGCATTGCTGATGATCTTG respectively) were kindly supplied by Prof. 
Rosemary Gale. Primers for murine GAPDH amplification (Qiagen) were 
generously supplied by Dr. Jenny McIntosh. 
 
Hybridoma RNA extraction and successful cDNA generation were confirmed by 
amplification of the murine GAPDH housekeeping gene using primers supplied 
by Qiagen. Primers for heavy and light chain amplification were obtained from 
IDT according to the protocol by Dübel 190 and amplified using the 
platinum PCR SuperMix high fidelity kit (Invitrogen) which employs  
polymerase for amplification, selected to facilitate subsequent TOPO-TA 
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cloning. Successful amplicons were TOPO-TA cloned as per manufacturer’s 
instructions (Invitrogen). 
 
To facilitate facile screening of putative hybridoma cDNA amplicons, we 
employed a TOPO-TA (Invitrogen) cloning strategy to identify successful 
isolates. Briefly, the supplied TOPO plasmid vector is supplied in a linearized 
format possessing a single 3’-thymidine (T) overhang with the Topoisomerase I 
enzyme covalently linked to the vector. As the  polymerase demonstrates a 
non-template-dependent terminal transferase activity, -enzyme PCR 
amplicons possess a 3’-terminal deoxyadenosine (A) overhang. The presence of 
the corresponding T-A overhangs and the Topoisomerase I enzyme facilitates 
efficient ligation of -amplified PCR products into the linearized vector as 
illustrated by Figure 7. Following ligation, high-efficiency  (NEB) were 
transformed with the TOPO vector and plated onto Carbenicillin infused agar 
plates pre-coated with X-gal. Further discrimination of successful vector 
integrants is achieved through the chromogenic identification facilitated by 
deletion of galactosidase enzyme activity. X-gal is a lactose analogue which will 
form an indigo pigmented substrate due to dimerization of 5-bromo-4-chloro-
3-hydroxyindole following galactosidase-mediated cleavage. Where the 
galactosidase enzyme sequence of the TOPO vector is interrupted by PCR 
ligation, enzymatic activity is ablated and resultant colonies will appear white 
on the agar plate. Following overnight culture, white colonies located proximal 
to indigo colonies were isolated for further analysis. 
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Illustration from TOPO-TA cloning manual (Invitrogen). 
 
 
DH5α  bacteria were grown in liquid Luria-Bertani (LB) or terrific broth 
(TB) media (for mini-prep or midi-prep culture respectively) supplemented 
with 100µg/ml carbenicillin and cultured at 37oC with  agitation at 220rpm or 
on LB-agar infused with 100µg/ml carbenicillin in a static or shaking 37oC 
incubator as required. 
 
Chemically competent DH5α  bacteria were transformed by a heat shock 
protocol detailed as follows: 25µl of bacteria were thawed on wet ice. 2µl of 
ligation mix (for PCR based cloning into C2987 ), or 1µl of mini-prep 
DNA (for retransformation into C2988 ) was added to the bacteria and 
incubated on ice for 30-45 minutes. Bacteria were transiently heat-shocked by 
incubation in a 42oC water bath for 35 seconds, followed by incubation on ice 
for 5 minutes. Bacteria were transferred to 250µl of SOC media and allowed to 
recover for 30 minutes on a shaking incubator (37oC, 220 RPM). Following 
recovery, bacteria were streaked onto an LB-agar plate infused with 
Carbenicillin (100µg/ml) and incubated at 37oC overnight in an inverted 
orientation. 
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The adherent cell lines HEK293T and LinXE were cultured in complete IMDM in 
175cm2 tissue culture coated flasks at 37oC with a 5% CO
2
 atmosphere. Cellular 
passage was performed, biweekly, once 80-90% confluency was reached. Cells 
were washed with 1x PBS, incubated for 5 minutes at 37oC with 5ml 
trypsin/EDTA. Cells were harvested by washing the flask with 20ml of 
complete IMDM. During maintenance culture, LinXE cells were cultured under 
hygromycin selection (50µg/ml), but LinXE cells were passaged once in the 
absence of hygromycin prior to supernatant production. 
 
The non-adherent cell lines; Jurkat and SupT1 cells were cultured in complete 
RPMI while K562 cells, were cultured in IMDM, in 80cm2 tissue culture coated 
flasks placed in vertical orientation at 37oC with a 5% CO
2
 atmosphere.  Cell 
culture densities were maintained approximately between 0.2 and 1x106/ml, by 
1:8-1:20 dilution with fresh medium as determined by discolouration of 
phenol red indicator dye contained within the medium. 
 
For applications where a highly stable cell line was required, single cell cloning 
was performed to identify a stable isolate. Single cell isolation was achieved by 
limiting dilution. From a sample of cells previously verified for successful 
transgene expression and FACS sorted for purity, we performed multiple cell 
counts using a Haemocytometer to ensure the count was accurate. Cells were 
diluted appropriately to ensure that on average, 1 cell would be isolated into 
every third well of a flat bottom 96 well plate. Cellular isolates were cultured 
until a clear population had been established, which were subsequently 
screened for transgene expression and culture stability. 
 
As required, transgenic cell lines were cryopreserved for long term storage as 
follows: Cells to be cryopreserved were harvested whilst in optimal growth 
conditions. Following centrifugation, cells were resuspended at 5x106 cells/ml 
in chilled cryopreservation medium (Lonza) and aliquoted into 1ml aliquots 
into cryovials (Corning). Cryovials were placed into a ‘freezy’ tub which was 
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then transferred to a -80oC freezer. The isopropanol bath of the freezy tub 
ensures a controlled cooling rate of 1oC/minute. The following day, frozen 
cells were then transferred to a liquid nitrogen storage dewar for long term 
storage. 
 
As the DMSO cryoprotectant is toxic to actively metabolising cells at the 
concentration present in cryopreservation medium, it is imperative to 
minimise DMSO exposure during cellular recovery. Vials of cryopreserved cells 
were thawed by suspension in a 37oC water bath. Once thawed, cells were 
immediately washed in 25ml of the respective pre-warmed complete media, 
followed by resuspension in appropriate media and transfer to a 37oC 
incubator. 
 
 
PBMCs were sourced from a departmental donor pool of consenting 
individuals who had signed an institutional consent form. Whole blood was 
obtained by venesection into 50 ml syringes prepared with appropriate 0.5M 
EDTA solution to achieve a final concentration of 5mM EDTA to serve as an 
anti-coagulant. Whole blood was diluted 1:1 with unsupplemented RPMI with 
each 25ml of blood solution layered onto 10ml Ficoll-Paque in 50ml centrifuge 
tubes. Tubes were centrifuged at 750 RCF for 40 minutes at room temperature 
applying minimum acceleration and without brake. Following centrifugation, 
the buffy coat layer, localised to the Ficoll:plasma interface, was removed by 
pastette aspiration. PBMC’s were washed twice: once with unsupplemented 
RPMI and once with complete RPMI prior to final resuspension into a volume 
of complete RPMI matching the volume of the initial blood donation. 
 
PBMCs were cultured in 24-well, TC-treated plates at a density of 2 x 106 
cells/well. PBMCs were stimulated with PHA on the day of isolation. 24 hours 
later, PBMC’s were stimulated with 100u of IL2 with transductions performed 
24 hours following IL2 stimulation. 
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PBMC’s isolated by ficoll extraction as detailed in 2.2.2.2.1, were cultured in a 
T175cm2 flask overnight in horizontal orientation without stimulation. The 
following day, the suspension cells were aspirated and the adherent cell 
fraction was detached by incubation with 5ml of cell dissociation solution for 
10 minutes at room temperature. Cells were harvested by washing the flask 
with 10 of chilled sterile PBS into a 50ml centrifuge tube. Cells were 
enumerated and pelleted by centrifugation (400 RCF x 5 minutes) pending RNA 
extraction. 
 
K562.A5 cells (established as detailed by 2.2.2.1.3 and 0) cultured in complete 
IMDM were harvested and resuspended in complete RPMI at 1x106 cells/ml. 
1ml of this cell suspension was placed into each well of a tissue-culture 
treated 24-well plate. This plate was then irradiated with 120 gray of X-ray 
irradiation using an AGO HS MP-1 X-ray irradiator. Following irradiation, cells 
were returned to a 37oC incubator during preparation of PBMC’s. Sufficient 
PBMC’s (isolation as described 2.2.2.2.1) were isolated to provide for both the 
required NK-cell proliferation co-culture and for transduction of cellular 
targets. PBMC’s for NK-cell proliferation co-culture were re-suspended in 
complete RPMI supplemented with 80u IL2/ml, with 1ml of this cellular 
suspension added to each well of the irradiated K562 cells detailed above, 
thereby diluting the Il2 supplementation to a final concentration of 40u/ml. 
Partial media changes were performed as required dependent on media 
discolouration as indicated by the phenol-red indicator dye. Cellular co-
cultures were mixed as required by pipette agitation to maintain cellular 
interactions. Additional media supplied during partial media changes was 
supplement with 40u IL2. Following one week of cellular co-culture and one 
day prior to commencement of each ADCC assay, the entire PBMC-K562 co-
culture was harvested by pipette aspiration and harvested by centrifugation 
(400 RCF x 5 minutes). Cells were washed once with chilled PBS prior to 
Miltenyi bead separation using CD56 MACS beads. Following MACS separation, 
purified NK cells were resuspended in complete RPMI supplemented with IL2 
(40u/ml) at 1-1.5x106 cells/ml in 24 well tissue culture treated plates. MACS 
sorted NK cells were used for  assays within 24 hours of MACS 
selection. Validation of the purity and cellular phenotype of bead selected NK 
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cells was achieved by flow cytometry following antibody staining of the sample 
against CD56 and CD16. 
 
 
Following sacrifice of the donor animal by terminal CO
2
 narcosis, confirmed by 
cervical dislocation, the fur and implements were liberally sprayed with 70% 
IMS to prevent contamination. Using forceps, the abdominal wall was tented 
and cut with scissors to enable access to the abdominal cavity. Gentle pressure 
was applied to the spleen by tweezers located below the organ to identify the 
vascular pedicle points which were then cut with scissors to release the organ. 
This was then transferred to a bijou tube pre-filled with sterile PBS and placed 
on ice until splenocyte extraction could be performed in a sterile tissue culture 
hood.  
 
A cell strainer was placed into a 10cm tissue culture dish. Using sterile 
surgical implements, the spleen was then cut in half. 1ml of ACK lysing buffer 
was then pipetted over the spleen which was then mashed through the strainer 
using the blunt end of a 1ml sterile syringe. Once tissue chunks could no 
longer be reduced by maceration, the cellular suspension was incubated with 
ACK lysing buffer (Lonza) for 3-5 minutes. Next, the cell strainer was 
transferred to a 50ml centrifuge tube and 2ml of splenocyte medium was 
added to the sample to terminate lysis prior to transfer of the cell suspension 
through the 0.4µm strainer into the centrifuge tube. The tissue culture dish 
was then washed with an additional 5ml of splenocyte media [RPMI + 10% FCS 
+ 1% Glutamax + [BME]]. Cells were then pelleted by centrifugation (400 RCF 
for 5 minutes) prior to resuspension at 1-1.5 x 106 cells/ml stimulated with 
Concanavalin A (2µg/ml) and murine IL7 (1ng/ml), plated in 24 well tissue 
culture plates. 
 
 
Non-tissue culture treated 24-well plates were prepared by pre-coating plates 
with 500μl of PBS supplemented with 8μl of retronectin/ml at least 24 hours 
prior to suspension cell transduction, with plates wrapped in parafilm and 
Chapter Two 
93 
 
stored at 4oC until required. Retronectin supplemented PBS was reused twice 
by direct transfer to fresh plates and stored as above until required. 
 
Transient transfections were performed in multiwell TC-treated dishes or 
plates as defined by experimental requirements with volumes of media, 
genejuice and DNA as indicated by Table 6 
100mm dish 30µl 470µl 12.5µg 
6-well plate 5µl 95µl 2µg 
12-well plate 2.5µl 47.5µl 1µl 
24-well plate 1.25µl 23.75µl 0.5µg 
 
2 x 106 HEK293T cells were plated into 6-well plates, 2ml cell culture/well, 24 
hours prior to transfection. Cellular confluence was assessed by microscopic 
examination to ensure optimal density prior to transfection. For transient 
transfection experiments, cellular confluence between 50-70% proved suitable 
to achieve consistent clear results. 
A bulk transfection mixture was prepared where 5µl of genejuice (Merck) was 
added to 95µl of plain RPMI for each transfection condition to be tested. 
Genejuice is a lipid-based transfection reagent that complexes with DNA to 
mediate transport of DNA into cells during transfection. Following a 5 minute 
incubation to allow formation of genejuice-micelles, 100µl of the transfection 
mixture was transferred to a separate well of a round-bottomed 96-well plate. 
2µg of plasmid DNA was used for each separate condition to be tested. 
Following a 15 minute incubation of DNA, transfection was performed by 
dropwise addition of the transfection mixture over the HEK293T culture. 
 
Variations in retroviral supernatant production protocols were necessary due 
to variation in cellular targets and experimental scale required for 
transduction; alternative protocols are indicated below. 
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2.25 x 106 HEK293T cells were plated into 10cm tissue culture treated dishes 
24 hours prior to transfection. Cellular confluence was assessed by 
microscopic examination to ensure an optimal density of 50-60% confluence 
prior to transfection. 
A transfection mastermix was prepared as indicated by Table 6. Following five 
minute incubation at room temperature, a total volume of 12.5µg of DNA was 
added for each plate to be transfected. For triple transfections, the following 
ratios were used to establish the respective volume of plasmid DNA required: 
3/8 Gagpol, 2/8 Envelope and 3/8 retroviral vector plasmid. Following 
addition of plasmid DNA, the mixture was incubated for a further fifteen 
minutes at room temperature prior to dropwise addition to the HEK293T cell 
culture. Plates were gently agitated following transfection. Supernatant 
harvested at 48 hours was stored at 4oC, and then combined with the 72 hour 
harvest prior to aliquoting and storage at -80oC. 
 
The LinXE cell line is an ecotropic envelope retroviral producer line selected 
for constitutive expression of gagpol and ecotropic envelope proteins. This 
enables the entire 12.5µg capacity of genejuice to be exploited for transfection 
of the retroviral expression plasmid of interest. 
 
 
Retronectin coated wells were aspirated and pre-coated with 250µl of 
retroviral supernatant and maintained at 4oC during the cellular harvest 
process. 
 
Cells were harvested, counted and resuspended at a concentration of 6x105 
cells/ml. 500µl of this cell suspension was transferred to each well of the 
retronectin coated plate 1.5ml of retroviral supernatant was added to each 
well, with cells spin transduced at 1000 RCF for 40 minutes prior to return to 
the incubator for 2 days. 
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Retronectin was aspirated from the precoated non-tissue culture plates and 
wells were incubated with 250µl of retroviral supernatant whilst PBMC’s were 
prepared. Primary human PBMCs, isolated and stimulated as described by 
2.2.2.2.1 and 2.2.2.2.2 respectively, were harvested, counted and resuspended 
at a concentration of 6x105 cells/ml. The PBMC suspension was supplemented 
with 400i.u./ml of IL2 pending dilution with viral supernatant, resulting in a 
final transduction IL2 concentration of 100u/ml. Following removal of the 
retroviral supernatant, 500µl of the PBMC suspension was transferred to each 
well to be transduced. 1.5ml of retroviral supernatant was added to each well, 
with cells spin transduced by spinoculation at 1000 RCF for 40 minutes at 37oc 
prior to return to a 37oC/5%CO
2
 incubator for 2 days. 
 
Stimulated splenocytes were harvested by pastette aspiration into a 50ml 
centrifuge tube followed by centrifugation (400 RCF for 5 minutes). Cells were 
resuspended in complete splenocyte media to enable enumeration. 
Splenocytes were then repelleted, and resuspended in neat supernatant at 1-
1.5 x 106/ml supplemented with BME but without additional stimulation, and 
plated onto pre-treated retronectin coated 24 well plates – 1ml/well. 
Splenocytes were then transferred to a centrifuge and centrifuged at 1000 RCF, 
at ambient temperature for 90 minutes without application of the centrifugal 
brake. At completion of the centrifugation, the splenocytes were transferred to 
an incubator overnight. 24 hours following transduction, splenocytes were 
then aspirated from the retronectin plate, washed with complete splenocyte 
RPMI then resuspended in complete RPMI supplemented with IL2 and plated at 
1-1.5 x 106 cells/ml into 24 well tissue culture plates.24 hours following IL2 
stimulation, splenocyte transduction efficiency was measured by flow 
cytometry analysis prior to progression with downstream experimentation. 
 
HEK293T cells were transduced as follows: Cells were plated at 1 x 106 cells/6-
well plate, with 2ml of medium plated per well. The following day, plates were 
observed for confluence with the well selected for transduction based on 
confluence, growth and attachment profiles. Transduction was achieved by 
aspiration of cellular media which was replaced with 2ml of retroviral 
supernatant supplemented with 20µg of polybrene. Following media exchange, 
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cells were returned to the 37oC incubator overnight. The above transduction 
process was repeated daily until the HEK293T cells achieved confluence, when 
they were subcultured into a 175cm2 flask. 
 
Transduction efficiencies were assessed by flow cytometry based on marker 
gene expression as indicated by fluorescent protein expression and/or 
antibody staining. Where antibody staining was performed, the general 
protocol was performed with modifications performed as indicated. Flow 
cytometry was performed using Beckman Coulter CyAn ADP or BD LSR 
Fortessa instruments. 
 
24 hours post transduction recovery; transgenic cells were assessed for 
transduction efficiency. 3x105 cells were washed with PBS, stained with 
antibody, then washed and resuspended in FACS buffer and placed on ice 
pending analysis. Where multiple staining steps were required, samples were 
washed with PBS between individual staining steps. Isotype and/or non-
transduced controls were included as required to establish an appropriate 
benchmark for comparison. All staining steps were performed at room 
temperature in subdued lighting with 30 minute incubations per stain unless 
indicated otherwise. 
 
Samples were washed with 1% BSA-PBS prior to antibody staining. Samples 
were stained separately by 0.5µl/sample of Mabthera Rituximab followed by 
0.5µl/sample anti-human IgG as a secondary antibody with a PBS wash 
between stainings. 
 
Samples were blocked with 300µl of 2.4G2 hybridoma supernatant for 15-30 
minutes at room temperature prior to any antibody staining steps. Where anti-
human IgG was used for staining, this was applied as the primary stain, 
followed by QBEnd10 staining, with all remaining antibodies added collectively 
in the final staining step. 
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As calcium ions have been proposed to be involved in cellular attachment 
processes191, these ions are typically excluded from PBS buffers to reduce 
cellular aggregation. However as calcium is a required co-factor to achieve 
Annexin-V binding as indicated by the supplier (BD), preparation of a suitable 
calcium supplemented buffer is necessary when performing Annexin V 
staining as described, . 
Samples were washed with Annexin V buffer instead of PBS prior to staining. 
Annexin V staining was performed at room temperature for 15 minutes. PI 
staining was achieved by resuspending cells into Annexin V buffer 
supplemented with 5µl of PI stock per ml of buffer sample. Samples were 
retained on ice pending analysis. 
 
Where sample analysis was delayed overnight, following the final wash after 
antibody staining, samples were fixed by final resuspension into 0.4% PFA-PBS 
solution and stored at 4oC pending flow cytometry acquisition. 
 
Miltenyi CD56 bead purified NK cells were labelled with CellTRACE™ violet 
(Invitrogen) according to the manufacturer’s protocol immediately prior to 
inclusion into ADCC assay co-cultures. 
 
Where it was necessary to enable cellular enumeration within a sample, or to 
enable effective comparison between samples, samples were supplemented 
with a pre-determined quantity of fluorescent ‘counting beads’ as an internal 
control. Beckman Coulter Flow-Check™ fluorospheres are supplied at 1x106 
beads/ml in an aqueous solution containing preservative surfactant. To 
prevent toxicity to cellular samples, beads were washed once with PBS prior to 
addition to samples. Following centrifugation (400 RCF x 5 minutes), beads 
were resuspended in an equal volume of FACS buffer with 10µl of beads 
(10,000) added to each sample. 
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One of the proposed applications for RQR8 is to function as a marker gene to 
enable periodic engraftment assessment from clinical samples. To model this 
capacity, we premised that it would be necessary to mimic the clinical scenario 
as accurately as possible. Peripheral human blood PBMCs were transduced and 
MACS selected for purity. Following confirmation of purity by flow cytometry, 
transgenic and freshly isolated PBMCs solutions were prepared at 1 x 106 
cells/ml. MACS sorted PBMCs were mixed with autologous PBMCs freshly 
isolated from the same donor used to generate the transgenic cell product 
which were then combined in a 50:50 ratio generating the top dilution sample. 
Subsequent dilutions were achieved by serial dilutions of this sample into 
equal volumes of fresh PBMCs at 1 x 106 cells/ml. Efficacy of cellular marking 
was examined by flow cytometry assessing the ratio of QBEnd10+/CD3+ against 
QBEnd10-/CD3+ fractions. 
 
Miltenyi MACS reagents were used to facilitate both positive and negative 
selection of cells as required. Protocol was adapted from manufacturer’s 
instructions as indicated. In all cases, following cell harvest, cells were washed 
once in chilled MACS buffer prior to resuspension in 300µl of MACS buffer 
and incubation of MACS beads (volume of beads used as indicated). Incubation 
with magnetic beads was performed on ice for 25-30 minutes followed by a 
single wash with MACS buffer prior to column separation. 
 
Magnetic bead selections were performed for cell lines as well as both primary 
human T-cells and murine splenocytes. For cell lines, 20µl of beads were used 
to select <1.0x107 cells, separated using an MS column. For both human and 
murine primary T-cells, 100µl of beads were used to select <1.0x108 cells, 
separated using LS columns. Finally, to achieve effective separation of murine 
splenocytes, it was necessary to block Fcγ-receptors present in the cellular 
population to reduce background binding. This was achieved by incubation of 
each cellular sample in 1ml of 2.4G2 hybridoma supernatant for 15 minutes at 
room temperature. 1ml of conditioned medium was then added to the cells to 
ensure viability retention with cells incubated with 2.4G2 supernatant for an 
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additional 15 minutes at room temperature prior to a single wash with MACS 
buffer followed by magnetic bead incubation and separation as above. Where 
required, multiple separations were performed in tandem. 
 
Primary human NK cells were isolated from K562.A5:PBMC co-culture by CD56 
magnetic bead positive selection. As above, 100µl of beads were used to select 
<1.0x108 cells, separated using LS columns. Where required, multiple 
separations were performed in tandem. 
 
To exclude residual NK cells and potential lymphokine activated killer cells 
prior to chromium release assays, samples were depleted of CD56 expressing 
effector cells. For negative depletions, 20µl of beads were used to select 
<1.0x107 cells, separated using LD columns. Where required, multiple 
separations were performed in tandem. 
 
 
Cells were harvested, counted and resuspended at 1x106 cells/ml in RPMI 
supplemented with 50u of IL2/ml. 300µl of cellular suspension was 
transferred into each of 4 wells of  a 48-well TC plate. 100µl of complete 
media was added to the first well. 96µl of complete media and 4µl of Mabthera 
Rituximab was added to the second well. 100µl of freshly prepared baby rabbit 
complement was added to the third well and 96µl of baby rabbit complement 
and 4µl of Mabthera Rituximab was added to the fourth well. Plates were 
returned to the 37oC incubator for 2 hours. The assay was terminated by 
addition of 1ml of chilled Annexin V buffer and transfer of the sample into a 
pre-prepared FACS tube containing 3ml of Annexin V buffer. Samples were 
harvested by centrifugation, the supernatant was discarded and residual 
buffer was blotted on paper towelling. Samples were then stained with 1µl of 
Annexin V-APC, vortexed, and incubated in subdued lighting for 15 minutes. 
Samples were then washed with Annexin V buffer and resuspended in Annexin 
V buffer supplemented with 5µl of propidium iodide/ml buffer and placed on 
ice pending flow cytometry analysis performed immediately following final 
suspension. Procedural variations to the general protocol are indicated below. 
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Transgenic PBMCs were verified by antibody staining to establish 
approximately equivalent transduction efficiency prior to progression with the 
 CDC assay. 
 
Primary human PBMCs were transduced with SFG.Q8.I2.eBFP2 as an internal 
negative control compared against epitope constructs as indicated, but always 
and SFG.RQR8.I2.eGFP. Following transduction, transgenic PBMC’s were 
positive sorted with CD34 Miltenyi magnetic beads and recovered for 1-2 days 
prior to CDC assay. Cells were counted and then mixed together such that an 
approximate 50:50 mix of the two populations was achieved. Sample mixture 
was confirmed by flow cytometry analysis prior to progression to CDC assay 
where the target population was exposed to rituximab (100µg/ml) in the 
presence (CDC), or absence (control) of baby rabbit complement for 4 hours. 
Following 4 hour incubation, cells were Annexin V / PI stained and analysed by 
flow cytometry to assess the deletion of the eGFP expressing target 
population. 
 
Sample preparation protocol was as described by 2.2.5.6.3 above, with 
analyses extended to additional assay durations of: 1, 5, 10, 30, 60 and 120 
minutes and alternative rituximab concentrations of 12.5, 25, 50 and 
100μg/ml. 
 
 
Effector cells were harvested and resuspended at 6.4x106 cells/ml in assay 
media. Appropriate effector target ratios were achieved by serial dilution of 
the effector stock solution resulting in the final effector:target ratios: 16:1, 8:1, 
4:1 and 2:1. Target cells were harvested and resuspended at 1x106 cells/ml in 
assay media. Wells of a 48 well plate were prepopulated with 400µl of assay 
media. 100µl of target cell suspension was added to each well to be tested. 
10µl of rituximab stock sample was then added to each well. Finally, 500µl of 
the effector cell suspension was added to the respective wells. A control well 
to identify background killing was established by combining effectors and 
targets in the absence of rituximab. Assay duration was defined by the window 
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between additions of the effector population to the harvest of the assay 
suspension into chilled Annexin V buffer. Procedural variations to the general 
protocol are indicated below. 
 
To optimise ADCC assay conditions, the efficacy of alternative effector 
populations was compared. Effector cells considered were NK cells purified by 
Miltenyi CD56 positive selection (2.2.5.4), or freshly ficolled PBMCs. In either 
condition, the effector cell population was derived from the same donor as the 
transgenic cellular targets. 
 
NK cell effectors were stained with CellTRACE™ reagent (Invitrogen) 
immediately prior to preparation for the assay (2.2.4.1.5). 
 
All targets and effectors were Miltenyi MACS sorted 24 hours prior to assay. 
Target population was composed of an approximate 50:50 mix of Q8.I2.eBFP2 
transgenic PBMC’s mixed with an equal ratio of the desired target in question. 
Sample composition was assessed by flow cytometry to ensure optimal profile 
was achieved. 
Cellular killing was assessed by comparison of the ‘initial ratio’ (IR) against the 
‘final ratio’ (FR) based on the fluorescently labelled target populations 
according to the following equation: Killing %=100*[eGFP:eBFP2 (IR) – 
eGFP:eBFP2 (FR)]. The IR was defined by the ratio between fluorescently 
labelled eGFP targets compared to the eBFP2 labelled controls from the 
effector:target condition cultured in the absence of rituximab. 
 
Chromium release assays remain the gold standard for assessing cellular 
cytotoxicity. Briefly: target cells are ‘loaded’ with radiolabelled sodium 
chromate, which becomes retained within target cells due to binding of 
chromium to cellular proteins. In co-culture assays, cellular lysis resulting 
from cytotoxicity can be assessed by release of radiolabelled 51Cr into the 
cellular supernatant. As chromium loading varies between cell types and there 
can be spontaneous release of chromium from the target cells, it is necessary 
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to include minimum (background release) and maximum release (achieved 
through Triton-X-100 mediated target lysis) controls to establish the 
parameters for the assay.  
Functional demonstration of the modular capability of RQR8, and the 
abrogation of functional activity was measured by chromium release assays 
performed against SupT1 target cells transgenic for GD2. 
Chromium release was calculated as follows: 
Chromium release = [(Experimental release – background release)*100] / 
(Maximum release – background release) 
 
Approximately 1x106 target cells were isolated for each target to be assessed. 
Cells were harvested by centrifugation, the supernatant was discarded and the 
residual cell pellet was gently flick re-suspended. 3.7 MBq of 51Cr as sodium-
chromate was added to each tube of targets. Target cells were gently agitated 
every 15 minutes during the one-hour 51Cr loading step. Following chromium 
loading, residual chromium was removed by 5 complete media washes, prior 
to resuspension of the target cells for enumeration. 
 
Donor PBMC’s were transduced with the RQR8.2A.GD2-CARpvaa construct. 
Following transduction, cells were purified by CD34 Miltenyi bead positive 
selection. Purified cells were then combined with non-transduced PBMC’s from 
the same donor such that the resulting population was approximately equal in 
distribution for transduced and non-transduced cells. This cellular mixture 
was then divided in half and subjected to a complement lysis assay in which 
only one sample was exposed to Rituximab although both samples were 
incubated with complement. Following 2-hour incubation, cellular samples 
were recovered and cultured for 2-3 days prior to inclusion into the 51Cr 
release assay. Cytotoxic capacity of the cellular populations was compared 
against a non-transduced control effector assay against the same cellular 
targets. 
 
In an attempt to enable immunohistochemistry (IHC) using cells expanded 
through  culture, we performed the following protocol to embed a cell 
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pellet within agarose. Briefly, cell pellets were composed of approximately 
10x106 cells with the following compositions: (a) NT PBMC:Raji pellet - 1.85x106 
non-transduced PBMCs and 7x106 wt Raji cells, (b) NT/RQR8 PBMC:Raji pellet 
3.6x106 non-transduced PBMCs, 1.85x106 RQR8 transduced and MACS sorted 
PBMCs and 4.5x106 wt Raji cells. Once the cell compositions had been 
generated, cells were pelleted by centrifugation and resuspended in 3ml of 
neutral buffered formalin and fixed overnight at room temperature. The 
following day, a 2% agarose gel was generated using cell culture grade agarose 
prepared in deionised laboratory grade water. This was then cooled to 60 oC 
using a water bath. 500μl of the 2% agarose was transferred to a 1.5ml 
eppendorf tube and allowed to set. The fixed cell compositions were then 
pelleted by centrifugation and the NBF supernatant was discarded. Cells were 
briefly warmed in the 60oC water bath, then resuspended using 750μl of the 2% 
agarose and transferred to the eppendorf containing the set agarose base then 
briefly centrifuged at 7000 RCF for 15 seconds to establish a cellular layer 
within the agarose matrix. Following agarose solidification, the pellet was 
extruded from the eppendorf tube in preparation for sectioning and IHC. 
Sectioning and IHC was performed by Jennifer Patterson and Teresa Marafioti. 
 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) is a 
common technique used to separate proteins based upon molecular weight. 
SDS is an amphipathic detergent comprising an anionic headgroup and a 
lipophilic tail. SDS binds non-covalently to proteins conferring a negative 
charge thereby masking the intrinsic charge of the native protein resulting in 
proteins within a sample to possess similar mass-charge ratios. Thus PAGE of 
SDS-labelled proteins results in 2-dimensional protein separation essentially 
based upon molecular weight. Following protein transfer to a nitrocellulose 
membrane, separated proteins can be visualised by protein staining dyes such 
as Coomassie R-250 or through enhanced chemiluminescence (ECL) involving 
chemical reactions between hydrogen peroxide, horseradish-peroxidase and a 
luminol substrate. Protein binding by Coomassie R dyes is thought to be 
analogous to SDS binding as both molecules are amphipathic containing both a 
negative charge and hydrophobic moieties192. 
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Carboxy-terminal flag-tagged derivative constructs of the CD8 stalk-bound 
constructs: Q8 and RQR8, were compared against a similar CD8 stalk construct 
lacking an epitope Jurkat cell populations transduced with the respective 
constructs were harvested by centrifugation. Supernatant was discarded and 
the pellet was freeze fractured through three cycles of freeze-thaw cycling 
using a dry ice ethanol bath to freeze cells and a 37oC water bath for rapid 
thawing. Finally, the sample was thawed by addition of 1ml of radio 
immunoprecipitation assay (RIPA) buffer supplemented with 40µl of protease 
inhibitor cocktail. Samples were then placed onto a pre-chilled shaking 
incubator at 4oC for 1 hour to degrade the membrane fraction. Following 
cellular lysis, the protein sample was then centrifuged to pellet the cellular 
debris; protein supernatant was gently aspirated by pipette, aliquoted into 
Eppendorf tubes and stored at -80oC until required for Western blotting. 
 
Western blotting was performed by Clare Shepherd with staining details as 
indicated in figures. 
 
 
Protein samples were diluted with water as required with the final sample 
diluted by1/2 with Laemmli sample buffer prior to separation. 
 
Protein samples were separated using a 7.5% acrylamide gel. Post-separation, 
the gel was transferred to a staining tray, covered with 0.25% Coomassie R-250 
stain solution and stained for 30 minutes assisted with gentle agitation 
supplied by a rotating plate shaker. Staining solution was decanted and the gel 
was destained with a Coomassie destain solution, again with gentle agitation 
with paper towelling added to the tray to mop up the Coomassie stain. Further 
destain solution was added as required until the protein bands became clearly 
visible. Finally, the protein gel was transferred onto a matching size piece of 
Whatman filter paper, covered with cling film and dried with a vacuum filter 
dryer for 30 minutes. 
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Murine rituximab (mRtx-IgG2a) production was achieved by batch culture of 
the K562.A7 producer line. For each production run, a fresh sample of the 
cryopreserved producer line bank was thawed and recovered for one passage, 
cultured in standard IMDM medium, prior to generation of the seed culture for 
a batch production run. Once sufficient producer cells had been generated, 
cells were harvested and washed once with PBS prior to transfer to the 
antibody production media. A seed sample of 5-10 x 106 producer cells was 
transferred to 100ml of culture medium in T175cm culture flasks placed in 
horizontal orientation. Flasks were gently agitated once daily to ensure sample 
mixing. K562.A7 culture was allowed to progress for approximately 7 days or 
until a toxic density had been reached indicated by reduction in cellular 
viability. Batch culture was harvested into 250ml centrifuge tubes with cells 
pelleted by centrifugation (10 minutes at 400 RCF). The cellular supernatant 
was transferred to Duran bottles with a sample isolated for a test titration 
against transgenic targets to confirm presence of protein prior to downstream 
processing. 
 
Protein supernatant samples were vacuum filtered through a 0.22µm filter 
prior to concentration using a Millipore Labscale tangential flow filtration (TFF) 
system. A ten-fold concentration was achieved with each litre of cellular 
supernatant concentrated to a final volume of 100ml. Samples were taken at 
intervals for subsequent analysis to ensure sample concentration had been 
successful prior to antibody harvest. 
 
Following concentration, the concentrated protein sample was transferred into 
snakeskin tubing and dialysed overnight into the column loading buffer: 
20mM Sodium phosphate pH 7.0, at 4oC with gentle agitation mediated by 
magnetic stirrer to ensure effective buffer transfer. 
 
Antibody harvest was achieved by Protein A purification using an ÄKTAprime 
plus system with each 100ml of concentrated sample purified separately.  
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The protein A column was prepared as per manufacturer instructions prior to 
sample loading. Sample was loaded at 1ml/min with 5 volumes of loading 
buffer washed through the column following sample loading, or until the 
loading profile reflected an absence of sample. Target eppendorf tubes pre-
filled with 100µl of pH 9.0 Tris-HCl buffer were prepared for the elution 
fractions and antibody was eluted with pH 3.5 sodium citrate elution buffer 
into 1ml fractions. Dilute elution fractions were combined and concentrated 
using Microcon columns, then pooled with peak elution fractions. The pH of 
the concentrated antibody product was assessed using pH indicator strips and 
balanced to pH7 with pH9 Tris-HCl. 
 
Antibody product was then syringe filtered with a 0.22µm syringe filter for 
sterility with protein concentration assessed by A280 spectrophotometry and 
confirmed by ELISA. Functional activity of the product was verified by  
CDC and indirect staining assays. 
 
Following  development of the RQR8 marker-suicide gene, functional 
efficacy of cellular deletion afforded by this putative suicide gene was 
examined  with respect of intended clinical application. The use of 
animal models in research is generally considered acceptable when  
investigation cannot adequately mimic the wider biological environment and 
where suitable animal models exist. As the complex interplay between effector 
mechanisms mediating deletion in the face of antigenic challenge cannot be 
fully investigated , we believe it is justified to use animal models to 
examine efficacy of RQR8-mediated deletion.  modelling was performed 
under a UK home-office approved project license and in accordance with 
institutional policies. Experiments employed female Balb/c, C57BL/6 or CB6F1 
mice aged between 6-10 weeks, as indicated in experimental designs. Mice 
were housed in individually ventilated cages. 
 
Transgenic splenocytes prepared by the five-day protocol (0) were maintained 
in optimum culture conditions until immediately prior to transfer when they 
were washed once with PBS, then resuspended into a minimal volume of 
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chilled plain RPMI supplemented with 1% HEPES such that each 200µl would 
contain the desired dosage. 
 
Therapeutic doses of mRtx-IgG2a were prepared by dilution of the stock 
sample with PBS such that each 200µl of injection sample contained 150µg of 
mRtx-IgG2a. Control recipients were infused with an equal volume of sterile 
PBS. 
 
Experimental animals were transferred to a warming chamber set at 39-42oC to 
facilitate peripheral vasodilation prior to I.V. injections. 
 
Following animal euthanasia by CO
2
 narcosis and confirmed by cervical 
dislocation, the right femur was removed and transferred to PBS pending 
cellular harvest. The ends of the bone were removed by scissors with the 
contents of the bone PBS flushed using a 25G needle into a 50ml centrifuge 
tube. Cells were pelleted by centrifugation. Bone marrow samples were then 
resuspended into 1ml of ACK lysis buffer, vortexed, then incubated for 5 
minutes to lyse residual RBCs; termination of lysis was achieved through 10x 
dilution with PBS followed by filtration through a 70µm filter, centrifugation 
and final resuspension into PBS followed by transfer to a 96-well U-bottom 
plate for antibody staining. 
 
Animals were heated in a warming box to 39oC prior to blood collection to 
assist tail vein identification. 1ml syringes with 27G needles were prepared 
with 10µl of Heparin sulphate solution (1000IU/ml)/100µl of blood to be 
collected. Following collection, blood was transferred to a 1.5ml eppendorf 
tube and placed on ice pending further handling. Red blood cell lysis was 
achieved by osmotic shock as follows: 4.5ml of deionised distilled water was 
transferred into a 15ml centrifuge tube. 1ml of water was aspirated by pastette 
and used to wash the peripheral blood sample from the eppendorf tube. The 
blood was then mixed 3x in the water sample before being osmotically 
stabilised by addition of 500ml of 10x HBSS buffer solution. Samples were 
then harvested by centrifugation prior to subsequent staining. 
Chapter Two 
108 
 
 
At the conclusion of GvHD modelling experiments, samples of tissue were 
obtained for immunohistochemistry (IHC) analysis in addition to those 
obtained for flow cytometry analysis. To enable effectively isolation of all 
tissues required, samples were obtained in the order detailed below: 
Following CO
2
 sacrifice confirmed by cervical dislocation, mice were placed on 
tissue paper and liberally sprayed with ethanol. The skin from the nape of the 
neck was tented up by tweezers and excised by scissors and placed in a 
flattened orientation in the IHC chamber. Next, the lymph nodes then spleen 
were extracted and transferred to PBS. Then a section of liver tissue was taken 
for IHC analysis. The diaphragm was then perforated to enable access to the 
lungs with a section of lung tissue also taken for IHC analysis. Next the 
intestines were moved to once side to enable identification of the large bowel 
working back from the anus. A 1-2cm section of bowel was excised and 
perfused with sterile PBS by syringe to extrude faecal matter. Then the bowel 
was cut by scissors and opened outward to form a sheet and transferred to the 
IHC chamber. Finally, the right hind limb was removed and the femur and tibia 
were extracted and transferred to PBS to enable bone marrow analysis. 
Tissue samples for IHC were placed into plastic histosette cassettes prepared 
with PBS moistened paper towelling to prevent desiccation during sample 
preparation. Following isolation, chambers were secured and transferred to 
PFA pots pending wax embedding and sectioning. Samples for flow cytometry 
were placed into bijou tubes prepared with PBS and maintained on ice pending 
further handling. 
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An epitope represents the minimal antigenic determinant required to mediate 
specific identification by an antibody. Reduction of the requirement for 
expression of an entire cell surface antigen to the minimal epitope sufficient to 
enable antibody-mediated identification could significantly reduce the 
molecular footprint required to achieve transgene expression for gene marking 
or an antibody-mediated suicide gene strategy. 
 
 To identify and epitope map the QBEnd10 binding domain from the 
CD34 antigen 
 To establish an optimal expression mechanism to test putative epitope 
expression 
 To demonstrate effective MACS sorting of QBEnd10 binding epitope 
construct in transgenic PBMC’s 
 To identify a minimal rituximab binding epitope 
 To establish a dual expression construct demonstrating good binding 
capacity for both target monoclonal antibodies 
 
 
Features of an ideal marker gene include: cell surface expression limited to 
engineered cells without significant leakage of antigen, of human derivation so 
as to be non-immunogenic, should not interfere with cellular metabolism and 
should enable clinical grade selection compatible with current technology127. 
As the CD34 antigen meets all the criteria for a suitable marker gene, it is 
unsurprising that it was identified as a putative marker gene by Fehse 127. 
However, recognising that only the QBEnd10 epitope is required to enable this 
functional capacity, we propose an elegant refinement to previous work to 
achieve this effect without imposing the full transcriptional burden into an 
expression cassette. 
The CD34 antigen is a 115 kDa, 385 amino acid heavily glycosylated type I 
transmembrane sialomucin. The large molecular mass of this antigen is 
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primarily attributed to extensive O and N-linked glycosylation, with the 
predicted mass of the native protein sequence alone approximated to be only 
40 kDa. Research into the CD34 antigen largely followed from the 
identification of CD34 as a stem cell antigen, with isolated CD34+ cells proving 
capable of reconstituting all haematopoietic lineages. In addition to 
haematopoietic stem cells, CD34 is also expressed on a range of other tissues, 
including small vessel endothelial cells, fibroblasts and some leukaemias193, 194. 
Despite significant research into the CD34 antigen, a definitive biological role 
remains to be established. Although no ligands have been identified for the 
stem cell isoform of the CD34 antigen, when expressed on high endothelial 
venules variant glycosylation of the CD34 antigen enables tethering and 
transmigration of leukocytes mediated by L-selectin-CD34 interactions195, 196. 
Early reports suggesting a potential role for CD34 as an adhesion molecule 
conflict with more recent evidence implying a role for CD34 and similar family 
members as anti-adhesion molecules. However, as indicated in the early 
literature, the absence of a defined ligand for CD34 might indicate an indirect 
role in adhesion by which CD34-mediated activation could result in 
upregulation of alternative adhesion molecules thus potentially explaining this 
observation197, 198.  
A naturally occurring 323 amino acid splice variant of CD34 also exists 
resulting from introduction of a translational stop codon193. Some evidence 
suggesting variant regulation in cellular differentiation patterns resulting from 
expression of the full-length versus truncated isoform may suggest a role for 
the CD34 antigen199. This alteration in signalling behaviour might reflect the 
lack of protein kinase C interaction domains from the endodomain in the 
truncation variant.  
CD34 antibodies have been separated into three classes based upon epitope 
properties; type I antibody epitope are sensitive to both neuraminidase and O-
sialoglycoprotein endopeptidase (OSGE) treatment, type II antibody epitopes 
such as QBEnd10 are neuraminidase resistant but remain sensitive to OSGE, 
whilst class III antibody epitopes are resistant to treatment with both 
enzymes193, 194. The QBEnd10 is the monoclonal antibody utilised by Miltenyi in 
their CD34 CliniMACS reagents. 
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The CD20 antigen, (Bp35), is a 33-37 kDa, 297 amino acid, non-glycosylated 
phosphoprotein with expression restricted to the B-lymphocyte lineage. CD20 
expression is further restricted within specific B-cell development stages 
between the pre-B cell stages through to mature B-cells whilst remaining 
mostly absent from pro-B-cells and plasma cells as illustrated by Figure 8. 
 
Tedder, 2009200. As illustrated by this cartoon, CD20 expression remains primarily restricted to 
mature B-cells excluding early B-cell precursors and plasma cells. As a result, although 
rituximab-mediated depletion of the B-cell compartment may impose B-cell aplasia, humoral 
immunity remains largely intact due to immunoglobulin stability and retention of the plasma 
cell compartment. 
Thus, transient therapeutic ablation of the B-cell compartment does not 
significantly impair immunoglobulin production, nor does it harm the 
development of new B-cells. Furthermore, B-cells represent a disposable tissue 
in that antibodies, the B-cell product of adaptive immunity, can be readily 
supplemented through immunoglobulin infusion therapy as required. The 
tetraspan structure of the CD20 antigen results in the formation of two 
extracellular loops; one minor, and one major loop with the rituximab epitope 
localised to the major loop201. Despite significant research, no natural ligand 
for CD20 has yet been identified and as CD20 knockout mice retain a near 
normal phenotype, current understanding of the function of CD20 has been 
inferred from antibody-ligation signalling experiments186, 201. CD20 appears to 
be involved in regulating cellular calcium levels following B-cell receptor (BCR) 
ligation by acting as a store operated calcium channel. Further, following BCR 
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ligation this CD20-BCR association is lost with CD20 subsequently associating 
with calmodulin-binding and phosphoproteins implying a role in signal 
transduction. Overall, evidence suggests a role for CD20 in amplifying the 
signal mediated by the BCR in immature and mature B-cells202. Treatment of 
CD20 bearing target cells by some anti-CD20 antibodies results in the 
segregation of CD20 molecules into lipid rafts and this behaviour appears to 
correlate with the ability of the antibody to mediate complement mediated 
cytotoxicity201. 
CD20 was identified as an attractive target for monoclonal antibody therapy 
for multiple reasons; it is neither shed into the circulation nor internalised 
following antibody binding, it is not present in soluble form in the circulation, 
it possesses a favourable expression profile demonstrating a relatively high 
level of expression and the extracellular epitopes are located proximal to the 
cell surface allowing localisation of bound antibody close to the target cell 
thereby enabling effective engagement of Fc-dependent effector mechanisms186, 
202. The characteristics, which make CD20 an ideal target for non-Hodgkins 
lymphoma (NHL) remain equally valid for the argument to establish CD20, as a 
putative suicide gene. 
Due to cell surface localisation of CD20 and the existence of both therapeutic 
and CliniMACS reagents, in theory CD20 could offer dual functionality posing 
as both sort and suicide gene moieties. Moreover, rare instances of CD20 
positive lymphomas and leukaemias suggest potential for CD20 expression on 
T-cells203. However, reports of toxicity resulting from CD20-mediated selection 
have necessitated the co-expression of a marker gene to enable cellular 
selection for CD20 suicide gene constructs154. Whatever the mechanism 
imposing this toxicity, this observation suggests potential retention of 
signalling capacity which poses concern given the limited understanding of the 
biological function of CD20. Given this concern, it seems logical to consider 
truncation of the CD20 endodomain to delete the functional capacity of the 
antigen. However in our hands deletion of the signalling endodomain further 
impairs CD20 expression. Further, despite multiple groups attempting to 
establish CD20 as a suicide gene, the lack of truncated forms of CD20 cited in 
the literature suggest other researchers may have noted similar observations. 
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Lastly, mimotopes are short peptide sequences, identified by phage display, 
which mimic the epitope recognised by a therapeutic antibody. Having a 
smaller size than the native antigen, mimotopes can be readily synthesized 
and manipulated for applications such as antibody research or vaccination to 
induce immune responses against the native antigen204. For our purposes, 
theoretically they offer pre-mapped epitope binding alternatives. 
 
Experimental aim: to epitope map the QBEnd10 epitope from the CD34 antigen 
to establish an effective cell surface presentation strategy for this epitope.  
The CD34 cell-surface antigen is a highly glycosylated sialomucin widely used 
for identification of haematopoietic stem cells. Previous work with the CD34 
protein suggested that the QBEnd10 binding epitope of the CD34 antigen is 
localised to the amino terminus of the molecule193. To minimize the QBEnd10 
epitope from the CD34 antigen, a retroviral library of overlapping PCR 
fragments was generated from a collection of overlapping primers amplifying 
a portion of the amino terminus as illustrated by Figure 9. 
 
Figure adapted from Sutherland et al205. The cell surface antigen CD34 is heavily glycosylated 
containing multiple O- and N-linked glycosylation sites, which in addition to the globular 
domains, are proposed to mediate projection of this antigen away from the cellular surface. As 
the QBEnd10 epitope has been proposed as a linear epitope localised to the amino terminus of 
the CD34 antigen, a library of overlapping sequences was established by PCR amplification 
with the aim to identify only the critical residues which are required to facilitate QBEnd10 
binding. This work was performed by Dr. Martin Pulé. 
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PCR products were then cloned into a retroviral expression vector and 
subcloned into NcoI/MluI sites of the retroviral vector SFG.I2.eGFP upstream of 
the internal ribosomal entry site (IRES) to enable co-expression of eGFP as a 
reporter gene. As the native conformation of the QBEnd10 epitope is localised 
to the extreme amino terminus of a large heavily glycosylated protein, we 
postulated that physical access to this epitope when localised proximal to the 
cell surface might limit antibody binding. To address this potential 
impediment, we considered use of a molecular spacer which could project the 
epitope away from the cell surface. As the biological role of the 49 amino-acid 
residue heavily glycosylated stalk is to project the apical domain of CD8 the 
required 2.6 Å to reach down to the constant region of MHC I on the opposite 
cell206, we selected the CD8α stalk, a commonly used molecular spacer, to 
perform this role. Finally, as antigen-antibody binding occasionally requires a 
particular orientation, we also considered a construct where the putative 
QBEnd10 epitope was separated from the CD8 stalk by a flexible serine-glycine 
(S-G-G-G-S) linker sequence. From this work, we isolated the QBEnd10 binding 
fragment from the extreme amino terminus of CD34. Binding of QBEnd10 to 
this epitope when cloned directly proximal to a transmembrane domain was 
considerably less efficient than to full length CD34, whereas approximately 
equivalent binding affinity compared to the native antigen appeared to be 
mediated by both CD8α stalk-bound constructs, with or without inclusion of 
an S-G-G-G-S linker sequence, as illustrated by Figure 10. [These steps were 
performed by Dr. Martin Pulé]. As the flexible linker sequence appeared 
superfluous to facilitating antibody binding, further minimisation constructs 
for the QBEnd10 epitope were presented on the CD8α stalk without a linker 
sequence. Molecular detail of the CD8 stalk presentation format from the final 
construct illustrated by Figure 29, p138, with sequence cited in supplementary 
data of Appendix 2, p319. 
Note regarding plasmids and vectors used within this project: plasmids used 
are listed in Appendix 1, p305, with sequences for key plasmids listed in 
supplementary data of the corresponding publication in Appendix 2, p319. 
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(a) Cartoon illustration of the bicistronic SFG retroviral vector expression cassette. Gene 
expression is facilitated by the Moloney retroviral promoter/enhancer sequences located in the 
LTR domain. Bicistronic expression of a putative QBEnd10 binding domain alongside the 
eGFP marker gene is mediated through inclusion of an internal ribosomal entry site located 
upstream of eGFP, with engineered NcoI and MluI sites flanking the transgene of interest 
allowing facile generation of alternative epitope presentation iterations. (b) Artistic model of the 
T-cell receptor CD8 interaction with the MHC-antigen complex illustrating the proposed 
molecular spacer capacity of the CD8 stalk as adapted from Leahy207 (c) Optimisation of 
epitope expression was achieved through presentation of putative QBEnd10 binding domains 
presented in three alternative formats: at the terminus of a truncated portion of the CD8 antigen, 
with or without an additional serine-glycine linker sequence to facilitate flexibility, contrasting 
with a shorter cell surface localised construct. As illustrated, presentation on the CD8 stalk 
enhanced QBEnd10 binding efficacy compared with the cell-surface localised iteration, with no 
clear benefit demonstrated by inclusion of the flexible linker sequence. This work was 
performed by Dr. Martin Pulé. 
 
Experimental aim: to achieve fine epitope mapping of the QBEnd10 epitope. 
Having approximately identified the region of CD34 to which QBEnd10 binds, 
further minimisation of the epitope was achieved using a sequential bi-
directional deletion strategy using PCR primers which progressively minimised 
the parental QBEnd10 epitope. Once both the carboxy and amino termini 
minimisation limits had been established, the amino terminal deletion series 
was combined with the minimal carboxy terminal construct to establish B2A0 
as the final minimal epitope domain composed of 16 residues as confirmed by 
flow cytometry analysis; illustrated by Figure 11. This domain is subsequently 
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referred to as ‘Q’. Details of deletion series sequences for the various epitope 
constructs examined are illustrated in Figure 110. 
 
Following optimisation of the QBEnd10 epitope presentation as illustrated by Figure 10, 
p115, further discrimination of the critical residues was achieved through a bi-directional 
deletion strategy. Commencing from the parental QBEnd10 binding fragment, further deletion 
iterations were screened by flow cytometry analysis of transfected HEK293T cells to identify 
the carboxy and amino terminal limits of the QBEnd10 epitope. Finally, these limits were 
combined to identify the minimal 16 residue QBEnd10 binding domain as demonstrated by the 
B2A0 construct. 
 
Experimental aim: to identify a minimal rituximab binding epitope. 
Previous research into the rituximab binding epitope of CD20 had localised the 
binding domain to the disulphide bond constrained large extracellular loop as 
illustrated by Figure 12208.  
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Figure adapted from Du et al209. As illustrated by this cartoon, crystallographic binding data201 
has identified the rituximab binding epitope is localised to the cysteine-constrained large 
extracellular loop and is discrete and independent to the epitope identified by the alternative 
CD20 therapeutic antibody ofatumumab. 
 
Similar to the QBEnd10 epitope mapping procedure employed previously, next 
we sought to express putative rituximab binding epitopes projected from the 
cell surface on a CD8 stalk. To this end, we designed two variant presentations 
of the disulphide bond constrained loop: a primary construct including five 
flanking residues extending beyond the cysteine residues delineating the 
extracellular loop and an alternative iteration expressing a tightly bounded 
loop constrained by the cysteine residues. However we were disappointed to 
observe that neither construct demonstrated binding affinity equivalent to 
that observed for the full length CD20 control with no rituximab binding 
observed against the more conservative alternative construct. In light of the 
likely conformational nature of the rituximab binding epitope, next we 
considered whether application of mimotopes might prove a more suitable 
strategy to achieve our desired aim. Mimotopes are antibody binding mimics 
derived from phage display libraries. Thus, next we selected linear (R5-L) and 
circular (R3-C) mimotopes from a report174 describing rituximab-binding 
mimotopes as an alternative epitope identification strategy which we 
compared against our initial CD20 antigen derived constructs. As illustrated 
by Figure 13, contrasting with the limited or absence of rituximab binding by 
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constructs derived directly from the CD20 antigen, the circular mimotope 
offered rituximab binding efficacy matching that demonstrated by full-length 
CD20 while the linear mimotope produced a curiously biphasic binding 
pattern. Therefore the circular R3-C mimotope was selected for further 
investigation. This initial design work was performed by Dr. Martin Pulé. 
 
Flow cytometry analysis of transfected HEK293T cells was performed to assess the 
comparative efficacy of putative rituximab epitope expression constructs. (a) Rituximab binding 
by the native CD20 antigen (b) Rituximab binding by the large extracellular loop of CD20 
including flanking residues (c) Rituximab binding by the large extracellular loop of CD20 with 
protein sequence tightly constrained to the cysteine bounded loop (d) rituximab binding by R3-
C circular mimotope construct (e) rituximab binding by R5-L linear mimotope construct. 
Circular and linear mimotopes as described by Perosa et al174. This work was performed by Dr. 
Martin Pulé. 
 
Experimental aim: to engineer a molecular co-expression cassette for cell-
surface expression of both the minimal QBEnd10 and rituximab binding 
epitopes. 
Having successfully identified antibody binding epitopes for both target 
antibodies, the next challenge we faced was to establish a combination 
construct presenting both the QBEnd10 and rituximab epitopes whilst 
retaining similar functional binding capacity as observed for each of the 
individual epitope expression constructs. Double epitope constructs 
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comprising both the QBEnd10 (designated subsequently as ‘Q’), and rituximab 
(designated ‘R’) binding epitopes were established in both orientations 
attached to the CD8 stalk (designated ‘8’) to establish which orientation would 
enable the optimal rituximab binding. As illustrated by Figure 14, both RQ8 
and QR8 iterations facilitate clear binding to both target antibodies; however 
superior rituximab binding demonstrated by the RQ8 construct compared to 
that observed for QR8 from flow cytometry assays led to selection of the RQ8 
construct for initial optimisation of  CDC assays. 
 
Putative dual QBEnd10 and rituximab binding epitope constructs were generated by PCR with 
epitopes presented in either order as indicated by cartoon illustrations at left-hand side. 
QBEnd10 and rituximab antibody binding of dual epitope constructs was confirmed by flow 
cytometry analysis of transduced primary human PBMCs (compared against native CD20 and 
CD34 antigen expression; (data not shown). Human PBMC transduction according to protocol 
2.2.3.6, p94, using retroviral supernatant generated according to protocol 2.2.3.3, p93. 
 
Lastly we sought to demonstrate the capacity for our QBEnd10 binding epitope 
marker gene constructs to enable CD34 magnetic bead selection using Miltenyi 
selection reagents as illustrated by Figure 15. 
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Primary human PBMCs were transduced with the Q8 (B2A0) QBEnd10 construct as identified 
by Figure 11, p116 and the RQ8 binding construct as illustrated by Figure 14, p119. Results 
illustrate the typical cellular purification result achieved following CD34 magnetic bead 
selection (Miltenyi) of primary human T-cells transduced with (a) SFG.Q8.I2.eGFP and (b) 
SFG.RQ8.I2.eGFP. Data reflects a typical result from more than 10 replicates. 
 
From our epitope mapping work of the QBEnd10 epitope from the CD34 
antigen, we have confirmed that this is a linear epitope localised to the amino 
terminus of CD34. Further, we have established that presentation of the 16a.a. 
QBEnd10 epitope on the CD8 stalk offers sufficient access for antibody 
binding without requirement of a flexible linker sequence as to enable 
approximately equivalent antibody binding as demonstrated by the full-length 
antigen. This may reflect that the extensive glycosylation of the CD8 stalk 
results in a similar projection of the QBEnd10 epitope as occurs in the 
conformation of the native antigen projected at the terminus of the highly 
glycosylated CD34 antigen.  
In contrast, the conformational nature of the rituximab epitope proved 
incompatible to our simplistic reduction strategy requiring utilisation of the 
R3-C mimotope to achieve effective binding from a minimal a.a. sequence.  
Although previously proposed as a discontinuous epitope comprised of the 
170ANPS173 and 182YCYSI186 residues from the large extracellular loop of CD20 
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when brought into proximity by a disulphide bond formed between cysteine 
residues 167 and 183208 (Figure 12), recent crystallographic data has 
established that the complementarity determining region (CDR) loops of 
rituximab appear to interact primarily with the ANPS motif201. Further, 
observations suggesting that biochemical disruption of the disulphide bond 
ablates rituximab binding and cytotoxicity supports evidence indicating that 
the rituximab binding epitope is conformational rather than linear208, 210. 
Combined, this may suggest that previous observations regarding a role for 
the YCYSI domain as a secondary component of a discontinuous epitope may 
in fact reflect a role for this domain to establish and stabilize the 
conformation of the critical ANPS epitope to enable effective rituximab-
mediated recognition. Further, from the crystallographic binding data, it was 
noted that the ANPS motif remains deeply buried within the binding pocket 
formed by the CDR loops such that the binding cavity remains too deep to 
accommodate alternative residues other than serine in exchange for 
170alanine201. Notably, the R3-C mimotope retains the critical NPS motif and 
contains a serine residue in place of the aforementioned alanine174.  
We have succeeded in establishing dual minimal epitope expression constructs 
that demonstrate clear binding affinity for both monoclonal antibodies 
QBEnd10 and rituximab when presented in either orientation. The linear 
QBEnd10 binding epitope comprised of 16 residues compares favourably to 
the 385 present in the native antigen. Similarly, the 11 residue R3-C mimotope 
compares favourably against the 297 residue CD20 parent antigen. Further, 
presentation of the QBEnd10 epitope in this manner retains the functional 
capacity to enable Miltenyi CD34 magnetic bead selection of transgene 
expressing PBMC’s.  
 
 We have identified a 16 amino acid residue QBEnd10 binding epitope 
from the native sequence of the CD34 antigen which, when presented 
on a CD8α stalk, demonstrates approximately equivalent binding 
affinity for the QBEnd10 monoclonal antibody as the native CD34 
antigen as assessed by flow cytometry assays 
 We have established a CD8α stalk-bound rituximab binding construct 
containing the 11 residue R3-C mimotope, which demonstrates 
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approximately equivalent binding affinity for rituximab as the native 
CD20 antigen as assessed by flow cytometry assays 
 Combination QBEnd10 and rituximab epitope binding constructs 
facilitate orientation independent antibody binding for both target 
monoclonal antibodies 
 Both Q8 and RQ8 transgenic PBMCs retain the functional capacity to 
facilitate QBEnd10-mediated Miltenyi CD34 magnetic bead selection 
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As illustrated by Figure 5, rituximab is proposed to mediate cellular deletion 
through three mechanisms: CDC, ADCC and direct toxicity via apoptosis211. 
Due to the epitope binding capacity of our construct,  CDC and ADCC 
assays were considered to model the efficacy of rituximab-mediated deletion 
of our constructs. This chapter describes our work in establishing protocols to 
enable sensitive  flow cytometry based CDC assays sufficient to enable 
discrimination between similar epitope expression constructs. 
 
 To establish and optimise an effective flow cytometry based CDC assay 
 To demonstrate CDC-mediated deletion of transgenic PBMCs 
 To assess the efficacy of CDC-mediated deletion of epitope constructs 
through comparative sensitivity, specificity and titration assays  
 To identify and establish a sort-suicide gene construct which 
demonstrates equivalent sensitivity to CDC-mediated lysis as current 
technology 
 
The complement cascade of innate immunity was first discovered over a 
century ago, identified as a first line mechanism of anti-microbial immunity. 
Since then, it has become clear that the range and breadth of complement 
mediated immune regulation extends far beyond this capacity. In addition to 
the defensive role, complement also performs immune surveillance behaviour 
discriminating between healthy tissue, cellular debris and apoptotic cells. 
Further less obvious roles for complement include involvement in 
angiogenesis, mobilisation of stem cell progenitors, tissue regeneration and 
lipid metabolism. With such a broad spectrum of activity, tight regulation of 
complement activation is critical to maintain homeostasis. Correspondingly, 
dysregulation of complement activation has been associated in the 
pathogenesis of infectious conditions such as sepsis and anaphylaxis; also in a 
wide array of pathogenic inflammatory processes and diseases including 
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paroxysmal nocturnal hemoglobinuria (PNH), myocardial infarction, 
myasthenia gravis, systemic lupus erthematosus, and multiple sclerosis212, 213.  
The complement activation cascade can be initiated through three separate 
mechanisms; the classical pathway, following antibody binding, as well as the 
alternative and lectin pathways. All stages of the complement cascade are 
strictly controlled by multiple regulators and inhibitors, and regardless of 
initiating trigger, converge into a uniform pathway through assembly of the C3 
convertase. In humans, only IgM and IgG are effective at mediating 
complement activation, with two molecules of the monomeric IgG required to 
induce activation as illustrated by Figure 18. Host cells are protected from 
aberrant complement-mediated deletion through expression of membrane-
bound complement regulator proteins including CD21, CD46, CD55, CD59 and 
CRIg. Notably, both CD55 and CD59 are glycophosphatidylinositol (GPI) anchor 
linked membrane receptors. Mutations in the  gene resulting in non-
functional GPI anchor synthesis preventing expression of these inhibitors 
results in the pathology PNH, illustrate how small perturbations in 
complement regulation can result in pathology214, 215. 
In consideration of intended application in T-cell engineering, we premised it 
would be necessary to use transduced PBMC’s as target cells in our  
assays to best assess the functional sensitivity to CDC-mediated deletion as 
conferred by our rituximab binding constructs. 
 
Experimental aim: to establish an  assay capable of assessing variation 
in sensitivity to complement mediated cytoxicity (CDC) for transgenic human 
PBMCs in the presence of rituximab. 
Having previously demonstrated effective rituximab binding by dual-epitope 
binding constructs, we proceeded to test the functional rituximab-mediated 
deletion of RQ8 through  CDC assays. Referring to CDC assay 
conditions reported from the literature159, 216, we performed an initial CDC assay 
incubating target populations with 100μg/ml rituximab and 25% baby rabbit 
complement (BRC) for two, four and twenty-four hour durations to establish 
whether we could identify any indication of CDC-mediated deletion. As 
illustrated by Figure 16, although CDC-mediated deletion was observed at all 
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time-points, there was suggestion of non-specific complement-mediated 
toxicity from the twenty-four hour timepoint condition. Further, as the four-
hour incubation results appeared to offer superior consistency, this incubation 
duration was chosen for subsequent assays.  
 
Peripheral human PBMCs were transduced with constructs as indicated. Following FACS 
verification of successful transduction (data not shown), samples were assessed for sensitivity 
to CDC-mediated deletion according to the protocol as described (2.2.5.6.2, p100) variant 
dependent on incubation time. Data for the 2, 4 and 24 hours illustrate results from two, three 
and single donors respectively. Black lines indicate the mean values. 
 
From these assays we were disappointed to find that CDC-mediated deletion of 
RQ8 was considerably less effective than what was observed for the CD20 
positive control. Moreover, as illustrated by Figure 17, deletion appeared to be 
limited to the high expressing population, suggesting a density-dependent 
limitation to CDC-mediated deletion. As CD20 expression has been observed 
to become localised to lipid rafts following antibody binding204 this might in 
part explain the enhanced sensitivity of the CD20 positive control despite 
suggestions of similar binding efficacy between CD20 and the RQ8 construct. 
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Transduced peripheral human PBMCs were subjected to a CDC assay as described (2.2.5.6.2, 
p100). Efficacy of cellular deletion was assessed by flow cytometry with the residual live 
population identified as the Annexin V and PI negative fraction, subsequently gated onto an 
eGFP histogram to identify the residual transgenic fraction. As illustrated for the RQ8 target, 
although some killing was observed, sensitivity to CDC-mediated deletion appeared to be 
primarily restricted to the high-expressing population. Due to assessment of deletion by flow 
cytometry, indirect assessment of killing by identification of the live population was necessary 
to exclude confounding ‘noise’ imposed by autofluorescence from cellular proteins.  
 
Experimental aim: To engineer alternative molecular iterations of our epitope 
expression constructs to establish whether sensitivity to rituximab mediated 
deletion may be affected by the epitope expression format. 
From the classical pathway of complement activation, reduction of off-target 
toxicity is achieved through the requirement for C1q cross-linking of two 
molecules of IgG immunoglobulin prior to activation of the complement 
cascade as illustrated by Figure 18. 
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Adapted from figure 10.29 Murphy et al217. 
Complement-mediated toxicity is prevented by the requirement of the complement protein C1q 
to bind two separate bound antibodies to induce activation of the complement cascade. 
Following antibody binding of cognate antigen (a), two separate arms of C1q are required to 
engage bound antibody prior to initiation of the complement cascade (b). Thus, the natural 
process of complement activation is inherently density dependent, supporting the observation of 
density-dependent deletion as illustrated by Figure 17, p126. 
 
As both CDC and ADCC-mediated killing are constrained by the degree of 
cross-linking by the respective receptors, we premised that a strategy that 
could increase the epitope valency of the constructs might therefore increase 
the sensitivity of low expressers. Following from this logical reasoning and in 
an attempt to improve killing, we generated a series of alternative constructs 
to further examine the functional roles that the presentation motif and/or 
binding moiety might play in defining the sensitivity to CDC-mediated deletion 
illustrated by Figure 19. These modifications included a membrane-proximal 
construct to consider whether membrane localisation might enhance 
complement mediated toxicity (R') , bivalent constructs (RRQ8, RQR8) with a 
view to increase valency, and a monomeric construct (RQR4) to compare 
against dimeric RQ8 and R-HCH2CH3 constructs. Alternative stalk-based 
constructs included: a minimal flush construct (R') with the rituximab epitope 
localised proximal to the cell membrane without any stalk-based projection, an 
alternative presentation strategy whereby the rituximab epitope was localised 
to the apical terminus of the human IgG1 antibody constant domain on a rigid 
homodimeric stalk (R-HCH2CH3) and finally, a monomeric CD4 stalk-bound 
construct (RQR4) to establish whether projection from the cell surface was 
required and what role alternative binding orientations might present 
regarding rituximab-mediated CDC sensitivity. We also considered increased 
valency constructs where CD8-stalk bound versions of the rituximab binding 
epitopes were presented either in series preceding (RRQ8), or flanking the 
QBEnd10 binding epitope (RQR8) compared against both of the original dual 
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epitope variants (RQ8, QR8). The QBEnd10 binding epitope on the CD8 stalk 
was included as a negative control and a full-length expression construct for 
CD20 in conjunction with truncated CD34 was included as a positive control. 
To prevent homologous recombination of the multi-valent constructs: RRQ8, 
RQR8 and RQR4 during retroviral synthesis, the DNA sequence for the 
rituximab-binding domain was ‘wobbled’ by the use of alternative codons as 
illustrated by Figure 29. 
 
In an attempt resolve the density dependent limitation to rituximab-mediated deletion, further 
epitope constructs were engineered to address potential hypothesised limitations: R', R-
HCH2CH3 and RQR4 were designed to assess the potential role of projection from the cell-
surface with respect to complement activation with RQR4, RRQ8 and RQR8 all engineered to 
increase epitope valency. In construct nomenclature: Q indicates the QBEnd10 binding epitope, 
R indicates the rituximab binding epitope, 8 indicates the CD8α stalk domain, 4 denotes the 
CD4 stalk domain whilst CH2CH3 indicate the respective constant domains from the human 
IgG1 antibody. 
 
Following from our initial CDC assay strategy and epitope construct 
engineering; we proceeded to examine the efficacy of deletion through a range 
of CDC assays as illustrated by Figure 20. 
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All CDC assays were performed using transduced primary human PBMC targets. Sensitivity 
assays as described (2.2.5.6.2, p100) were performed using transduced but unsorted PBMC 
targets which were assessed by flow cytometry to confirm equivalent transduction efficiencies 
prior to assay progression. Specificity assays as described (2.2.5.6.3, p100): PBMCs were 
transduced with SFG.RQR8.IRES.eGFP and SFG.Q8.IRES.eBFP2, purified by CD34 magnetic 
bead selection and combined at equal concentration to establish the target population. 
 
In total, three separate CDC assays were considered: 1) Sensitivity assays 
which employed unsorted target cells to assess the comparative sensitivity of 
several similar epitope expression constructs to complement mediated lysis, 2) 
Specificity assays designed to demonstrate the stringent efficacy of 
complement mediated lysis of our optimal construct when compared against a 
nearly identical target population, and 3) Time-course / dose titration CDC 
assays, which formed a derivative of the specificity CDC assay, designed to 
further investigate the reaction kinetics of complement-mediated sensitivity. 
 
Experimental aim: To assess the variation in sensitivity to rituximab mediated 
CDC for our panel of alternative epitope expression constructs. 
From CDC assays using transduced but unsorted PBMC’s from three separate 
donors, the flush and CD4 stalk-bound constructs showed sensitivity barely 
above that of the negative control. The IgG1 homodimeric stalk-bound 
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construct performed similarly to the monovalent parental constructs, whilst 
the multivalent constructs demonstrated the greatest sensitivity with the 
RQR8 construct clearly demonstrating acute sensitivity to CDC-mediated 
killing equivalent to that demonstrated by the CD20 expressing positive 
control construct as illustrated by Figure 21. 
 
Human PBMCs were transduced with alternative epitope construct iterations and assessed in 
parallel for their comparative sensitivity to CDC mediated deletion through in vitro assays as 
previously described (2.2.5.6.2, p100). Results as illustrated reflect the level of deletion 
observed following independent assays from three separate donors. Error bars reflect SEM. 
 
 
Experimental aim: To demonstrate sensitivity to rituximab mediated deletion 
remains restricted to rituximab-binding epitope expression constructs. 
As our initial demonstration of the retention for magnetic bead selection 
function was assessed with Q8 and RQ8 (illustrated by Figure 15), it was 
necessary to confirm that RQR8 retains this capacity to enable specificity CDC 
assays as demonstrated by Figure 22. 
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Peripheral human PBMCs were transduced with RQR8.I2.eGFP, resulting in the heterogeneous 
population as illustrated in the 'transduced' histogram. From this mixed population, a pure 
population of RQR8 positive cells, typically of greater than 95% purity, can be readily attained 
following a single CD34 magnetic-bead selection (Miltenyi). Successful selection was 
confirmed by flow cytometry 24 hours following MACS selection. Plots represent a typical 
result from more than a dozen independent replicates. 
 
Next we sought to demonstrate the specificity of CDC-mediated deletion 
against RQR8 expressing targets. The minimal size of RQR8 is designed to 
enable functional modular capacity alongside other T-cell engineering 
components such as re-targeting moieties. In this capacity, the marker gene 
would enable clinical grade purification using Miltenyi cliniMACS reagents 
prior to ACT to ensure consistency of the therapeutic cell product. 
Furthermore, inclusion of a suicide gene is designed for a pure product to 
ensure ablation of the adoptive population in the event of toxicity. Thus 
sensitivity assays were designed to assess the  rituximab-mediated 
sensitivity of RQR8 which would best match that anticipated for potential 
therapeutic cellular product. To demonstrate the acute sensitivity of RQR8, we 
generated the Q8.I2.eBFP2 construct to act as an internal control. Briefly, this 
construct is identical to Q8.I2.eGFP, variant only by the co-expressed 
fluorescent protein. Cloning of this construct was achieved by ‘cut and paste’ 
cloning as described by (13.1.2, p306) in Appendix 1. Inclusion of the QBEnd10 
epitope in this construct enables cliniMACS selection while the eBFP2 
Chapter Four 
132 
 
fluorescent marker protein allows for separate identification in flow cytometry 
based CDC assays. Finally, as these cells would have been subjected to the 
identical handling as the RQR8-transgenic cellular targets they most accurately 
reflect the acute specificity afforded by RQR8 for deletion. Inclusion of the Q8 
internal control in a 1:1 ratio with RQR8 targets allows for clear demonstration 
of the specificity and efficacy of RQR8 mediated deletion against a virtually 
identical control population. Similar to the sensitivity assays, successful 
progression through multiple steps were required prior to progression with 
the specificity assays as illustrated by Figure 20 and Figure 23.  
 
Successful cell preparation for CDC specificity assays was achieved through a progressive 
series of handling steps requiring multiple critical checkpoints to be met prior to assay 
progression. (a) Transduction: Human PBMCs were transduced with RQR8.I2.eGFP, 
Q8.I2.eGFP, or Q8.I2.eBFP2. Confirmation of successful transduction was achieved by flow 
cytometry. (b) Selection: Transduced cell populations were purified by CD34 magnetic bead 
selection (Miltenyi) with successful selection confirmed by flow cytometry. Note: selection 
result only illustrated for the RQR8.I2.eGFP target population. (c) Target preparation and 
validation: Purified RQR8.I2.eGFP or Q8.I2.eGFP target populations were mixed with an equal 
proportion of Q8.I2.eBFP2 transduced and purified cells to act as an internal control. Sample 
mixtures were confirmed by flow cytometry prior to progression with specificity CDC assays, 
full protocol as detailed by 2.2.5.6.3, p100. 
 
From specificity assays performed from multiple donors, it is clear that 
despite the target population being reduced to background noise, the control 
population remains seemingly untouched. Figure 24 illustrates a typical result 
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from a CDC specificity assay. Further illustrations of specificity CDC assay 
efficacy are illustrated by Figure 28, Figure 42, Figure 49, Figure 53 and Figure 
69. 
 
Human PBMCs were separately transduced with target constructs: RQR8.I2.eGFP or 
Q8.I2.eGFP as well as Q8.I2.eBFP2 included as an internal control. Following transduction, all 
samples were purified by MACS-selection. To demonstrate specificity of CDC-mediated 
deletion, RQR8.I2.eGFP or Q8.I2.eGFP targets were combined in equal concentration with 
Q8.I2.eBFP2 internal control targets and subjected to a CDC assay as described (2.2.5.6.3, 
p100). At lower left, the histograms illustrate how the control target condition retains the 
original sample following CDC assay illustrating both target (eGFP) and control (eBFP2) 
populations whilst at right the RQR8 expressing targets are deleted leaving only the internal 
control population remaining. Illustration reflects a typical result from 6 separate assays taken 
from separate donors. 
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Specificity CDC assays examining rituximab-mediated deletion of peripheral human PBMCs 
was performed according to protocol as described 2.2.5.6.3, p100. Despite MACS selection, 
efficacy of deletion of RQ8 transgenic PBMCs remained inconsistent, albeit considerably 
higher than what was observed from sensitivity assays, whereas the degree of RQR8 deletion 
was consistently in excess of 96%. Results as illustrated reflect the level of deletion observed 
following independent assays from three separate donors. Error bars reflect the standard error of 
the mean. 
 
Experimental aim: To review the CDC assay conditions to more 
accurately assess the sensitivity of RQR8 to rituximab mediated CDC.  
As our initial CDC assay protocol had been established with a view to facilitate 
CDC-mediated deletion of our epitope constructs, we next examined whether it 
would be possible to titrate the observed sensitivity through variation of the 
primary assay parameters as assessed through a time-course and dose 
titration assay, as illustrated by Figure 26. Although maximum CDC-mediated 
deletion was observed at the 100µg/ml concentration, similar efficacy of 
deletion was observed even from the 12.5µg/ml concentration illustrating the 
acute sensitivity of RQR8 to rituximab-mediated CDC which appears to occur 
with approximately equivalent efficacy at all concentrations of rituximab 
observed. Based on maximum serum measurements of rituximab taken during 
administration at the 375mg/m2 dosage as indicated for NHL which range 
between 118.9µg/ml to 663.9µg/ml171, it seems clear from these assays 
performed in two donors that the rituximab mediated sensitivity is readily 
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achieved at levels well below the physiological levels associated with 
therapeutic administration. 
 
Having demonstrated effective deletion of RQR8 targets, assay conditions were reviewed 
through a time-course/dose-titration assay to consider whether similar levels of deletion could 
be achieved using lower doses of rituximab and/or shorter durations of incubation. Human 
PBMCs were separately transduced with the target construct RQR8.I2.eGFP and the internal 
control Q8.I2.eBFP2, purified by MACS-selection following transduction, then combined in 
equal proportions prior to inclusion into a CDC assay as described (2.2.5.6.3, p100). As 
illustrated, similar levels of deletion were achieved at significantly lower doses and durations of 
incubation. Results illustrated reflect average depletion from two separate assays from two 
separate donors. 
 
 
Experimental aim: To demonstrate absence of RQR8 sensitivity to ofatumumab 
demonstrating the capacity for coincident therapeutic administration. 
The acute sensitivity of RQR8 to rituximab-mediated depletion even at dilute 
concentration contrasting with the prolonged serum residence of rituximab 
ranging between 25-30 days218, clearly precludes rituximab chemotherapy prior 
to RQR8 ACT. However, ofatumumab offers an alternative anti-CD20 
therapeutic antibody which could theoretically be employed in conjunction 
with RQR8. To consider the potential for concurrent chemotherapeutic and 
cellular therapy regimes, a panel of alternative CD20 antibodies were assessed 
for their capacity to bind to RQR8 as illustrated by Human PBMCs were separately 
transduced with target constructs: RQR8.I2.eGFP, Q8.I2.eGFP or CD20opt.I2.eGFP as well as 
Q8.I2.eBFP2 functioning as an internal control. Following transduction verification, assay 
target populations were supplemented with Q8.I2.eBFP2-transduced PBMCs such that all 
cellular target populations contained an equal proportion of epitope-targets and Q8.I2.eBFP2 
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expressing controls. Cellular populations were subjected to an in vitro CDC assay as described 
(2.2.5.6.3, p100). Results illustrate efficacy of deletion observed from a single experiment. 
 
Table 7 (Binding assay kindly performed by Prof. Mark Cragg). Lack of binding 
to RQR8 by ofatumumab, and by extension theoretical resistance to 
ofatumumab-mediated CDC deletion, could demonstrate that ACT with RQR8 
could function in conjunction with ofatumumab therapy. To verify the lack of 
ofatumumab binding, we performed binding assays comparing QBEnd10, 
rituximab and ofatumumab against a 50:50 mixed population of non-
transduced and transduced Jurkat T-cells modified with Q8.I2.eGFP, 
RQR8.I2.eGFP and CD20opt.I2.eGFP respectively as illustrated in Figure 27. 
 
Binding assay to demonstrate absence of ofatumumab binding against RQR8-expressing 
targets: separately purified populations of SFG.Q8.I2.eGFP, SFG.RQR8.I2.eGFP and 
SFG.CD20opt.I2.eGFP transduced Jurkat T-cells were mixed with equal quantities of non-
transduced Jurkat T-cells as an internal control then stained with QBEnd10, rituximab or 
ofatumumab to enable assessment of comparative binding efficacy by flow cytometry. 
Therapeutic antibody binding was assessed indirectly through secondary anti-human Fc 
staining; QBEnd10-biotin binding was assessed using APC-conjugated streptavidin as the 
secondary stain. Clear binding of QBEnd10 was observed against both Q8 and RQR8; clear 
binding of rituximab was demonstrated by both RQR8 and CD20opt, however only CD20opt 
demonstrated any appreciable binding of ofatumumab. 
 
Having demonstrated no appreciable binding of ofatumumab by RQR8, we 
proceeded to demonstrate the lack of functional activity of ofatumumab 
Chapter Four 
137 
 
through a specificity CDC assay against similar mixtures of transduced PBMC’s 
as illustrated by Figure 28. 
 
Human PBMCs were separately transduced with target constructs: RQR8.I2.eGFP, Q8.I2.eGFP 
or CD20opt.I2.eGFP as well as Q8.I2.eBFP2 functioning as an internal control. Following 
transduction verification, assay target populations were supplemented with Q8.I2.eBFP2-
transduced PBMCs such that all cellular target populations contained an equal proportion of 
epitope-targets and Q8.I2.eBFP2 expressing controls. Cellular populations were subjected to an 
in vitro CDC assay as described (2.2.5.6.3, p100). Results illustrate efficacy of deletion 
observed from a single experiment. 
 
Jurkat T-cells transgenic for RQR8 were assessed for binding of alternative CD20 monoclonal 
antibodies; alternative CD20 antibody staining kindly performed by Prof. Mark Cragg. 
 
Rituximab ++ 
Ofatumumab - 
GA101 - 
1F5 ++ 
NKI-B20 ++ 
B9E9 + 
AT20 + 
 
 
As illustrated by Figure 29, Q8 and RQR8 are highly similar in structure 
whereby the CD8α stalk presentation strategy is achieved through the 
generation of fusion constructs comprising our epitope domains located 
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within the architecture of the CD8α protein. The extensive glycosylation and 
rigid stability afforded by the dimeric CD8alpha stalk appears to mimic the 
native presentation format of the QBEnd10 epitope in the CD34 antigen. As 
the presence of repetitive sequences was required to facilitate duplicate 
expression of the rituximab binding domain, ‘codon wobbling’ was employed 
to preclude homologous recombination. This was achieved through use of 
alternative codons to encode for the identical protein sequence afforded by 
the degeneracy of the genetic code. 
 
Epitope expression constructs are composed of modular components as indicated: a signal 
sequence to facilitate cell surface expression, an epitope domain and a portion of the CD8α 
stalk functioning as a molecular spacer, including the extracellular, transmembrane and 
intracellular anchor domains. To prevent potential homologous recombination resulting from 
sequence duplication of the rituximab binding domain in the bivalent RQR8 construct, codon-
wobbling was employed through the use of alternative codons thereby imposing sequence 
variation despite the identical protein sequence. 
 
Experimental aim: To model the functional capacity of RQR8 to serve as a 
marker gene for clinical application. 
In light of the desired functional capacity to function as a marker gene to 
enable cellular tracking , we sought to assess the sensitivity of cellular 
marking using a representative sample composition. As illustrated by Figure 
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30, this assay demonstrates the sensitive marking potential afforded by RQR8 
to enable detection of transgenic cells from primary samples even when 
present at low levels. The consistent indication of cellular detection exceeding 
numbers of transgenic cells which were anticipated to be present in this assay 
may reflect a counting error during assay set-up. 
 
To model the proposed sensitivity of RQR8 gene marking as might be observed when assessing 
primary patient samples, the following assay was performed. Peripheral human blood PBMCs 
were transduced with RQR8.I2.eGFP then purified by MACS selection. Following confirmation 
of purity by flow cytometry, sorted PBMCs were mixed with freshly isolated PBMCs derived 
from the same donor in a 50:50 ratio. Subsequently, this parental sample was serially diluted 
into pure populations of freshly isolated PBMCs establishing dilutions as indicated. Efficacy of 
cellular marking was assessed by flow cytometry to compare the level of marking observed 
against what was anticipated. Data presented reflects a result from a single donor; assay 
performed by Eva Kokalaki. 
 
 
Experimental aim: To demonstrate QBEnd10 marker gene capacity is retained 
even in the presence of saturating rituximab antibody as would be present 
during clinical application. 
Demonstration of co-staining of RQR8 with both QBEnd10 and rituximab: 
following from successful demonstration of the sensitivity afforded by RQR8 
gene marking, we next sought to confirm the proposed ability to detect the 
presence of residual cells through QBEnd10 gene marking in the presence of 
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saturating levels of rituximab. Due to the minimal size of the RQR8 protein, we 
postulated that steric hindrance due to the presence of bound rituximab might 
preclude effective QBEnd10 staining which could result in overestimation in 
the efficacy of cellular clearance following therapeutic administration. To 
investigate this line of reasoning, we assessed the ability to identify target cells 
by QBEnd10 staining in the presence or absence of rituximab antibody. As 
illustrated by Figure 31, the RQR8 transgenic population can be clearly 
identified through QBEnd10 staining despite pre-staining with 200µg of 
rituximab; however there does appear to be an approximately ½ log 
attenuation of the signal suggestive of some steric hindrance of the QBEnd10 
antibody binding. 
 
To establish whether marker gene capacity would be retained in the presence of saturating 
antibody, purified Jurkat T-cell populations transgenic for Q8 or RQR8 were combined with 
non-transduced Jurkat T-cells in an equal ratio. Samples were indirectly stained with 200µg of 
rituximab, with anti-human Fc Dylight 450 employed as the secondary antibody prior to 
QBEnd10 staining. Results illustrated are from a single experiment. 
 
 
Experimental aim: To assess the potential immunogenicity of RQR8  to 
predict the potential for immunological rejection by therapeutic recipients. 
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As with all non-native genes used for T-cell engineering, immunogenicity 
presents a potential limitation of RQR8. E.g. Chimeric antigen receptors, 
commonly derived from murine antibodies, often retaining the parental 
murine derived Fab domain, are typically presented in a format which may 
leave junctional and linker sequences exposed; both factors risk presentation 
of potentially novel immunogenic epitopes. Similarly, RQR8 has novel and 
junctional sequences which may prove to be immunogenic. A bioinformatics 
analysis of B- and T-cell immunogenicity of RQR8 is presented in Figure 32, 
identifying 6 T-cell and 24 B-cell epitopes as assessed using the LBtope219 linear 
B-cell epitope prediction server and the NetCTL 1.2220 servers respectively. 
However, in light of the proposed application of RQR8 in conjunction with re-
targeted T-cell therapies, it should be noted that current CAR and TCR 
adoptive immunotherapy protocols typically employ profoundly 
lymphodepleting preparatory regimens resulting in profound 
immunosuppression at the time of T-cell administration. This may reduce the 
occurrence of, and may prevent development of an immune response. Notably, 
with respect to T-cell epitopes, RQR8 immunogenicity is only predicted for 
four MHC supertypes, conspicuously excluding the MHC supertype A2, which 
represents the most common serotype for almost all ethnic groups221. 
Ultimately, only clinical studies can determine the practical consequences of 
immunogenicity of any particular T-cell engineering component. Further 
discussion regarding immunogenicity of RQR8 is considered in 12.3. 
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Bioinformatics analysis of B- and T-cell immunogenicity of RQR8 as assessed using the 
LBtope219 linear B-cell epitope prediction server and the NetCTL 1.2220 servers respectively. 
 
 
Experimental aim: To confirm the approximate molecular mass of the RQR8 
protein corresponds with that predicted by  algorithms and to establish 
whether cell-surface localised RQR8 is present in monomeric or dimeric 
format. 
Assessment of protein size was achieved through Western blotting. Initial 
attempts at Western blotting using the QBEnd10 antibody resulted with an 
indistinct smear pattern suggestive of extensive glycosylation (data not 
shown). However, this result was not unexpected as both the CD8 stalk207 and 
the CD34 antigen193 are known to be heavily glycosylated and a bioinformatics 
analysis of putative glycosylation of epitope constructs using the NetOGlyc222 
and NetNGlyc223 servers respectively, identified both N- and O-glycosylation 
sites as indicated by Figure 33. Due to the minimal fragment of the CD34 
antigen present within the QBEnd10 binding domain, the majority of proposed 
glycosylation sites appear to be localised to the CD8 stalk region. In order to 
confirm that glycosylation predominantly results from sites localised to the 
CD8 stalk domain and to enable approximate assessment of the predicted 
molecular mass of Q8 and RQR8 as indicated by Table 8, we generated 
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carboxy-terminal FLAG-tagged versions of both the Q8 and RQR8 constructs, 
compared against a ‘headless’ iteration presenting the CD8 stalk domain 
lacking an amino terminal epitope domain as illustrated by Figure 33. 
Subsequently, Western blotting analysis of FLAG-tagged epitope proteins were 
performed with or without inclusion of the reducing agent dithiothreitol 
(DTT), from transgenic Jurkat T-cell samples. Additionally, the RQR8-FLAG 
protein was assessed from Jurkat T-cell samples, cultured in the presence or 
absence of an O-glycosylation inhibitor, and one condition where protein 
samples derived from cells grown in the presence of an O-glycosylation 
inhibitor were also treated with PNGase to remove N-glycosylation. Western 
blotting results are indicated by Figure 34.  
Bioinformatics prediction of protein mass224. Values in brackets indicate proposed mass of the 
dimeric structure. 
Headless-FLAG 11.96 (23.92) 
Q8-FLAG 14.23 (28.46) 
RQR8-FLAG 17.04 (34.08) 
 
Comparison of protein samples separated under reducing or non-reducing 
conditions illustrated by Figure 34a, suggests that the CD8 stalk is likely 
present as a dimer which becomes separated into monomers under reducing 
conditions resulting in protein bands approximately ½ the mass under 
reducing conditions as the non-reducing counterparts. Notably, the presence 
of multiple bands may reflect protein shearing resulting either, from sample 
preparation or protein degradation. Following initial failure to obtain protein 
samples for Western blotting from lysis buffer incubation alone, a freeze-
fracturing strategy was employed to damage the membrane before incubation 
in the lysis buffer. Although this strategy proved successful for generating 
protein supernatants, the generation of multiple fragments may reflect the 
presence of natural breaking points within the proteins under examination. 
Figure 34b illustrates the comparison between RQR8 samples separated under 
reducing and non-reducing conditions, as well as when samples were grown in 
the presence of an O-glycosylation inhibitor and subsequently treated to 
remove N-glycosylation. Although no difference was observed when comparing 
the samples grown in the presence or absence of the O-glycosylation inhibitor 
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which may reflect loss of function of the inhibitor during the extended culture 
duration required, a reduction in the observed protein mass of larger 
fragments following PNGase treatment to remove N-glycosylation supports the 
predicted presence of N-glycosylation at amino-terminal residues. Further, the 
consistent presence of approximately 12-14 kDa protein fragments between 
epitope samples remains unclear, but again, may reflect protein shearing 
resulting from the severe conditions required to achieve effective separation of 
protein from the plasma membrane. Notably, as indicated by the monomeric 
mass of the headless FLAG-tagged iteration, these consistent bands might 
identify CD8 stalk monomers which have been stripped of the epitope 
domains during processing possibly highlighting structural stability of the 
CD8 stalk with the epitope junction posing as a natural ‘break-point’ when the 
protein is subjected to profound shearing forces, such as were required to 
extract protein from cellular samples. 
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(a) To enable demonstration that glycosylation evidenced from initial Western blots resulted 
from the CD8 stalk (data not shown), it was necessary to establish FLAG-tag marked CD8 
stalk-bound constructs. Three constructs were generated as indicated: a control construct 
expressing no epitope, denoted as ‘headless’, Q8 and RQR8 respectively. (b) Putative 
glycosylated residues for each protein sequence are identified as indicated. As highlighted by 
the top row which details the 'headless' CD8 stalk, residues which might possess O-
glycosylation appear localised to both the epitope and CD8 stalk domains whilst the lower 
sequences illustrate that proposed residues containing N-glycosylation are exclusively 
associated with the epitope domains.
222, 223
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Jurkat T-cells were transduced with FLAG-tagged derivatives of Q8, RQR8 as well as a 
'headless' iteration presenting the CD8 stalk without an additional epitope domain (Cartoon 
illustration of epitope constructs presented by figure 33). Transduced cell populations were 
FACS sorted based on equivalent eGFP expression in an attempt to establish roughly 
comparable transduction efficiencies. (a) 'Headless’, Q8 and RQR8 protein samples were 
separated by Western blotting in the presence or absence of 50mM DTT reducing agent. As 
indicated by protein samples exposed to DTT, the reduction of the 20kDa band into a 10kDa 
band suggests that the CD8 stalk is likely present as a dimer on the cell-surface. (b) RQR8 
protein samples were prepared with or without protocols to exclude O- or N-glycosylation as 
described (2.2.5.10.1.1, p104). The presence of reduced bands present in the sample modified to 
exclude N-glycosylation suggests that some residues within RQR8 contain this modification. 
Absence of reduction in protein sizes despite culture in the presence of an O-glycosylation 
inhibitor may be inconclusive due to loss of function of the inhibitor due to extended cell 
culture duration which was required to generate sufficient cell product to enable protein sample 
generation. 
 
Although rituximab binding by the R3-C mimotope facilitates clear binding of 
rituximab, sensitivity to complement mediated deletion appears to occur in a 
density dependent manner. Thus, further engineering was required to fully 
achieve a level of efficacy matching that of the positive control. Following 
further examination considering a range of alternative iterations, RQR8, a 
136aa construct composed of 2 rituximab binding mimotopes flanking the 
QBEnd10 binding sequence was identified which appears to offer at least 
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equivalent sensitivity to CDC-mediated deletion as afforded by the full length 
CD20 control construct. Furthermore, in addition to demonstrating acute 
sensitivity to CDC-mediated deletion, the sensitivity afforded by RQR8 appears 
to be highly specific with no killing observed against Q8 expressing control 
targets and only limited killing demonstrated against the highly similar RQ8 
expressing target as illustrated by Figure 25. Finally, as verified by timecourse 
and dose-titration assays, CDC-mediated deletion occurs both rapidly and well 
within therapeutic dosages. 
Following the clear demonstration of acute sensitivity to CDC-mediated 
deletion, further examination was considered to identify the potential 
mechanism involved. As indicated by Figure 18, C1q cross-linking is required 
to initiate complement activation. Premising that the increased sensitivity 
might result from bi-valent binding of rituximab by the RQR8 construct, this 
would result in any surface expression of RQR8 offering potential for cross-
linking of C1q provided rituximab was present at sufficient concentration. To 
interrogate this possibility,  assessment of the molecular span 
separating the rituximab-CD20 interactions was assessed by Rasmol, 
measuring the binding pockets from the protein data bank reference 2OSL, 
derived from crystallographic binding data as identified by Du 201. Having 
selected the threonine residue located in the centre of the cluster of residues 
involved in the rituximab-CD20 interaction as a reference point, we predicted a 
molecular distance of 76.57Å separating the threonine 58 residue in antibody 
chain A from the equivalent threnonine residue within antibody chain H, as 
measured using the Swiss protein data viewer (SPDV). Next we sought to 
approximate the molecular distance separating the alpha carbon atoms from 
adjacent amino acid residues from a linear peptide sequence. Again using 
SPDV, we approximated this distance to be 14.19Å, or 2.84Å per amino acid 
residue. As we predict that the 30 residues separating the rituximab binding 
domains within RQR8 compose a linear sequence derived from the QBEnd10 
binding domain, the SGGGS linker sequence and a fragment of the CD8 stalk, 
this suggests a molecular separation between the rituximab binding motifs of 
>85Å which exceeds the 76.57Å span separating the rituximab binding 
domains predicted by  modelling as illustrated by Figure 35. Further 
examination of this interaction would require crystallographic binding analysis 
which exceeds the bounds of this project; however this approximation 
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suggests that RQR8 possesses the capacity for bi-valent binding of rituximab 
which might explain the enhanced sensitivity to CDC-mediated deletion as 
observed through  CDC assays. 
 
In silico modelling was considered in an attempt to identify whether RQR8 might truly offer a 
bivalent epitope expression format. (a) The distance separating the threonine residues identified 
in the centre of the rituximab-CD20 interaction were measured as 76.57Å using the Swiss 
protein data viewer (SPDV). (b) From a known linear peptide sequence, the distance separating 
alpha-carbon residues within protein sequences was approximated to be 2.84(Angstrom units) 
as assessed using SPDV. (Data not shown). Therefore, considering the approximately 30 amino 
acids, present in what we premise as a linear sequence, separating the two rituximab-binding 
domains; the molecular distance between rituximab binding epitopes within RQR8 was 
approximated to exceed 85Å which is greater than the span of rituximab. Generation of in silico 
modelling illustration and analysis was achieved with the kind assistance of Dr. Amit Jathoul. 
 
 
 CDC-mediated deletion can be clearly achieved following incubation of 
transduced PBMCs with 25% BRC and 100μg/ml rituximab without any 
apparent impact upon control target viability 
 Inclusion of eGFP & eBFP2 marker genes alongside Annexin V – APC and 
PI staining enable flow cytometry assessment of cellular deletion 
resulting from  CDC assays 
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 Although the R3-C mimotope facilitates clear binding of rituximab, 
CDC-mediated deletion appears to occur in a density dependent manner 
from monovalent constructs 
 Following re-engineering, a bivalent construct: RQR8, was identified 
which demonstrated equivalent CDC-mediated sensitivity as the full-
length CD20 positive control 
 CDC-mediated deletion facilitated by RQR8 appears to be sensitive, 
specific, rapid and occurs well within physiological levels following 
therapeutic rituximab administration 
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 To establish a more reflective CD20 positive control through codon 
optimisation 
 To generate an IL15/4-1BBL K562 cell line clone as per Imai . 
 To achieve effective  NK cell amplification sufficient to enable 
ADCC modelling 
 To demonstrate  expanded NK cells represent a suitable effector 
population 
 To demonstrate  mediated ADCC deletion resulting from a 
primary effector cell population 
 To establish and optimise a flow cytometry based ADCC assay 
 To assess the comparative sensitivity and specificity of rituximab-
mediated target deletion through  ADCC assays 
 
As mentioned previously, rituximab mediated deletion occurs through a 
number of mechanisms including antibody dependent cellular cytotoxicity 
(ADCC)186, 187. Thus following from successful demonstration of CDC-mediated 
deletion of RQR8, we next sought to assess the potential role and efficacy of 
ADCC-mediated deletion of our epitope constructs. However prior to 
progression with ADCC assays, we identified a number of factors which 
required further consideration in preparation for this research tangent 
including: review of the capacity of our positive control to accurately reflect 
cellular deletion, the choice of effector population to be used within our ADCC 
assays and how to establish a consistent effector population to ensure 
experimental consistency.  
 
Owing to degeneracy of the genetic code, individual species demonstrate 
codon bias suggesting species selective advantages to individual codon 
selection. Whilst many levels of control mechanisms are involved in the 
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regulation of gene expression, codon optimisation has been shown to improve 
levels of gene expression of genes in human cells226. 
Although the inclusion of a CD20 positive control construct is clearly required 
to establish the comparative efficacy of rituximab mediated deletion between 
RQR8 and the native CD20 antigen, we were concerned regarding potential 
limitations of our experimental strategy which might overestimate the efficacy 
of deletion of the positive control unfavourably skewing assay results. In our 
experimental design, we employed the eGFP and eBFP2 fluorescent proteins as 
marker genes to identify the target populations with the view that these would 
represent a consistent control. However, we had noted a trend for attenuated 
fluorescent marking from constructs possessing a longer primary transgene 
which corresponds with a report citing lower gene expression following an 
IRES227. Although we could consistently observe clear separation between eGFP 
expression levels with epitope expressing targets compared against non-
transduced PBMCs, this separation remained less distinct for the CD20 
positive control as illustrated by Figure 36. Furthermore, from observations 
suggesting poor T-cell viability when transgenic for CD20, we premised that 
codon optimisation of CD20 might boost transgene expression similar with 
previous observations from work with other transgenes by Dr. Simon Thomas, 
and correspondingly might result in enhanced IRES mediated eGFP expression. 
Results for codon optimisation of CD20 are described in section 5.3, p158. 
 
Antibody dependent cellular cytotoxicity (ADCC) reflects the capacity of an 
effector population to selectively destroy a cellular target through non-
phagocytic processes. ADCC can be mediated directly through release of 
cytotoxic granules or reactive oxygen intermediates, or indirectly through 
induction of cellular apoptotic machinery via expression of cell-death inducing 
molecules. Efficacy of ADCC depends upon multiple variables including 
antigen density on the target cell surface, antibody affinity for the target 
antigen and the Fc-receptor (FcR) affinity for the respective antibody 
subclass228. ADCC effector populations are derived from both myeloid and 
lymphocyte lineages and include NK cells, macrophages, monocytes, 
neutrophils, dendritic cells and γδ-T-cells228, 229. 
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The lack of non-specific activation of effector cells despite high levels of 
monomeric antibody molecules present in serum was initially premised to 
result primarily from the low affinity of most FcγR proteins for 
immunoglobulin Fc domains. However, similar to CDC, NK cell effector 
activation is contingent upon molecular cross-linking of FcγR’s. The molecular 
explanation for requirement of FcγR cross-linking was established following 
elucidation of the crystal structure of FcγR-Fc interactions. This interaction 
results in formation of an asymmetrical contact between the FcγR and the 
immunoglobulin Fc domain which sterically precludes binding of a subsequent 
FcγR to the same Fc fragment. Thus innate effector cell activation depends 
upon binding of multiple antibody-Fc fragments which is only achieved at 
sufficient density as occurring within immune complexes. A secondary level of 
regulation results from the requirement of adapter molecules, as with the 
exception of FcγRIIa and FcγRIIc, activating FcγRs are unable to transmit 
activation signals without association with a signal transducing adapter 
molecule containing a cytoplasmic ITAM domain. Furthermore, variation of 
adapter molecules between effectors represents an additional layer of 
regulation within the ADCC-mediated response. Finally, pro-inflammatory 
mediators such as TNFα, IFNγ and LPS have been shown to mediate 
upregulation of FcγR expression. Upregulation of FcR expression mediated by 
the late components of the complement pathway, such as C5a, also highlight 
potential synergism between humoral mediated immunological pathways. 
However, despite variation between mechanisms involved in generation of an 
activating signal, resultant signalling pathways remain similar for all FcγRs230. 
Furthermore, the presence of multiple subclasses of Fcγ-receptors (FcγR’s) 
containing activating or inhibitory endodomains (possessing either an ITAM or 
ITIM motif respectively), offer an additional layer of complexity to ADCC 
efficacy whereby the decision to impose a cytotoxic or inhibitory response 
against the target cell depends upon the composite signalling input from all of 
the respective FcγR’s by the effector cell. Correspondingly, alterations in FcγR 
functionality due to aberrant expression or allelic variation have been 
associated with pathologies such as arthritis and systemic lupus 
erythematosus231.  
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Note: due to variation between human and murine NK-cell biology, this 
discussion is restricted to human NK cells. 
Natural killer (NK) cells, first described in 1975232, 233, are relatively short-lived 
granular lymphocytes, distinct from both B and T-cells. NK cells represent a 
minority lymphoid subset, typically composing between 2-18% of the 
peripheral blood lymphocyte population234. NK cells perform three primary 
functions: cytotoxicity, cytokine and chemokine secretion and lastly contact 
dependent cell co-stimulation facilitating a bridge between innate and adaptive 
immunity235.  
 
As most research into the ADCC-mediated efficacy of rituximab has been 
derived from NK cell interactions, further discussion regarding ADCC will 
focus on the role of NK-cells187. NK cells can be broadly sub-divided into two 
subsets which demonstrate variation in homing and functional capacity234: 
CD56bright NK cells appear to function in a primarily immunoregulatory capacity 
producing IFNγ >16 hours following activation and tend to localise to the 
tonsils and lymph nodes, whereas the CD56dim/CD16+ NK-cell subset, primarily 
responsible for NK cell mediated cytotoxicity, release IFNγ rapidly following 
activation and account for 90% of the NK cells located in the spleen and 
peripheral blood235, 236. NK cells are capable of killing target cells without prior 
activation, sensitisation or MHC restriction; however the kill/spare decision 
remains dependent upon the balance between activating and inhibitory signals 
which the cell receives235. Due to the extensive repertoire of potential activating 
and inhibitory signalling receptors which may be present237, deconvolution of 
NK cell signalling can prove quite complicated, however a minimalistic view 
can separate the decision for NK cell killing primarily to the presence of an 
activating signal, such as bound antibody on a target cell, or the absence of an 
inhibitory signal, such as MHC-I typically present on the surface of virtually all 
cells, with ‘missing self’, ‘altered self’ and ‘stress-induced self’ describing three 
models by which NK-cell mediated killing results from the lack of an inhibitory 
signal.  
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Once the decision for a cytotoxic response has been established, NK cell killing 
can be mediated through a number of mechanisms235: 
i. Release of cytotoxic granules (Perforin/granzymes) 
Cytotoxic granule release results in target cell apoptosis through both 
caspase-dependent and independent mechanisms. 
ii. Death receptor mediated apoptosis 
Induced expression of FasL or TNF-related apoptosis inducing ligand 
(TRAIL) on the NK-cell surface interact with the cognate ligands, Fas or 
TRAILR respectively, on the target cell to induce apoptosis 
Activated NK cells can also secrete TNFα inducing target cell apoptosis 
following binding to TNFR1/2 
iii. Secretion of effector molecules 
a. Activated NK cells secrete IFNγ which may exert cytotoxicity 
through a range of mechanisms including stimulation of adaptive 
immunity 
b. Cytokine activation of NK cells may also result in cytotoxicity 
mediated by reactive oxygen and/or nitrogen intermediates 
While the presence of preformed perforin/granzyme granules facilitate the 
characteristic rapid cytotoxicity of the NK cell response, other mechanisms 
such as induced expression of death receptors require a longer kinetic to 
achieve maximal efficacy. 
 
Cytokine and chemokine secretion by NK cells, including IL3, GM-CSF, TNFα 
and IFNγ, facilitates the capacity to recruit and moderate responses from both 
the innate and adaptive immune compartments in addition to mediating 
cytotoxicity235. 
Furthermore, recent research suggests kinetic variation in the capacity of NK-
cell subset cytokine secretion relevant to proposed immunological roles. Rapid 
IFNγ secretion by the CD56dim/CD16+ NK-cell subset, as rapidly as 2 hours 
following activation, but terminating before 16 hours post activation was 
proposed to correlate with the primary role of NK cells to mediate a rapid 
innate immunological response. In contrast, the IFNγ secretion mediated by 
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the CD56bright subset demonstrates a delayed response typically commencing 16 
hours following an activating stimulus. This was proposed to be consistent 
with an immunoregulatory role236. Although obviously the net result following 
IFNγ secretion remains the same, the variation in the kinetics of the reactions 
reflects the capacity of NK cells to mediate both short and sustained 
immunological responses. 
 
Finally, NK cells can mediate contact dependent cell costimulation. As NK cells 
express T and B cell co-stimulatory ligands such as CD40L and OX40L, they 
can act as a bridge between the innate and adaptive immune responses. NK 
cells express a range of surface receptors known as inhibitors and activators. 
Current models for NK cell activation predict that the particular response of 
an NK cell is dependent on the composite balance between the activating and 
inhibitory signals which the cell receives. E.g. Self MHC class I molecules 
deliver an inhibitory signal to prevent unchecked autoimmunity. However, 
down-regulation of self MHC-I results in unopposed activation signals 
delivered to the NK cell due to ‘missing self-recognition’238. 
 
The binding ratio between IgG subtypes against the inhibitory FcγRIIb and the 
various activating FcγR’s define the ADCC activation threshold of effector 
cells. However, as indicated by Table 9, due to the lack of expression of the 
inhibitory FcγRIIb, NK cells possess significant potential to impose unchecked 
toxicity if alternative protective mechanisms remained absent. Hence evolution 
has provided the related NK-cell licensing and MHC-I mediated inhibition 
‘missing-self’ mechanisms as alternative protective strategies.  
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γ
Indicative FcγR binding affinities adapted from Beutler et al and Smith et al33, 231. 
Effector populations: NK – Natural killer cells, MO – Monocytes, MA – Macrophages, N – 
Neutrophils, DC - Dendritic cells, M – Mast cells, E – Eosinophils, B – Basophils, P – Platelets 
 
γ
FcγRI (CD64) Activating 
FcγRIIa (CD32) Activating 
FcγRIIb (CD32) Inhibitory 
FcγRIIc (CD32) Activating 
FcγRIIIa (CD16) Activating 
FcγRIIIb (CD16) Activating 
 
 
The missing-self hypothesis239 describes a mechanism of self-protection 
against autoaggression mediated by inhibitory interactions between killer cell 
immunoglobulin like receptor (KIR) interactions with MHC-I. Since virtually all 
normal cells express MHC-I, reduced or absence of expression of MHC-I 
attenuates the inhibitory signal of NK-cell KIR’s, thereby reducing or removing 
the block preventing cytotoxicity240. Correspondingly, due to the crucial role of 
KIR’s, a secondary mechanism of control is necessary to ensure the NK-cell 
compartment is capable of identifying self-MHC prior to enabling the capacity 
for cytotoxicity; this is achieved through a process known as NK-cell licensing. 
 
The KIR genes comprise of a multigene family containing both activating and 
inhibitory receptors demonstrating significant inter-individual variation such 
that individuals may express between 7-14 separate KIR genes. The potential 
for NK-cells to express a KIR lacking a cognate HLA ligand, arises from the fact 
that the KIR locus and the corresponding HLA genes are encoded by separate 
chromosomes. Furthermore, there can be significant intra-individual NK-cell 
clonal variation resulting from differential patterns of KIR expression238, 241. 
Hence, the process of NK cell licensing, which can be viewed as an analogous 
system to tolerance induction processes occurring during T and B cell 
ontogeny is required. 
As the ‘missing-self’ hypothesis describes the importance for the role of 
inhibitory KIRs in preventing autoaggression in the lack of an activating signal, 
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‘NK-cell licensing’ ensures that capacity for NK-cell cytotoxicity is restricted to 
those cells which have demonstrated the ability to identify self-MHC. As a 
result of the NK-cell licensing process, two populations of self-tolerant NK 
cells result: one population which possess self-tolerance mediated by the self-
MHC molecule by which it became licenced, and a second population which 
remains tolerant due to cellular anergy resulting from a failure to become 
licenced240. 
 
NK-cells remain under constitutive inhibition as defined by the ‘missing-self’ 
hypothesis, which requires a sufficient activation signal to be overcome238. As 
NK-cells lack expression of the inhibitory FcγRIIb, an additional layer of NK-
cell regulation is achieved through restriction of FcγR expression to the low 
affinity FcγRIIIa (CD16) and FcγRIIc (CD32) subclasses, which unable to bind 
monomeric IgG, are limited to binding IgG when associated in an immune 
complex231. Finally, NK-cell licensing imposes tolerance toward self-HLA 
limiting NK-cell mediated autoimmunity240. 
Having selected NK-cells as our effector population for ADCC assays, it was 
necessary to establish a strategy to ensure consistent production of an effector 
population which could enable effective assessment of ADCC-mediated 
cytotoxicity detailed further in section 5.6. As ADCC-mediated deletion 
comprises both rapid and sustained components,  assay design should 
consider both phases to ensure a fully reflective result is obtained. 
Rituximab is a chimeric antibody composed of the murine derived antibody-
binding Fab domain and the human IgG1 Fc constant domain. Although we 
selected NK-cells as the effector population for ADCC modelling experiments, 
as illustrated by Table 9 and Table 10, as all FcγR’s can demonstrate binding to 
the IgG1 subclass, ADCC is not restricted to NK cells. Thus  NK-cell 
ADCC assays confirm or preclude whether ADCC is involved in depletion of 
epitope expressing targets, but due to the exclusion of effector populations 
expressing the high affinity FcγR’s, these assays do not fully model the 
potential depletion which could be achieved.  
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γ
Indicative immunoglobulin binding affinities adapted from Beutler et al and Smith et al33, 231. 
 
    
Complement fixation 
ADCC 
FcγRI (CD64) 
FcγRIIa (CD32) [Variant H131] 
FcγRIIb (CD32) 
FcγRIIc (CD32) 
FcγRIIIa (CD16) [Variant V158] 
FcγRIIIb (CD16) [GPI anchored] 
 
 
Experimental aim: To improve functional expression of full-length CD20 
through codon optimisation of the coding sequence. 
During  CDC assay experiments, we observed a trend of typically poor 
expression of the CD20 antigen on T-cells when coded by the native cDNA 
sequence. Moreover, expression of the downstream eGFP marker gene 
presented a limiting factor for discrimination of cellular deletion as assessed 
by flow cytometry analysis with co-culture assays where the signal to noise 
ratio is impaired by a high effector to target ratio. This results in skewing the 
deletion as assessed by  assays in favour of the positive control. 
Premising that codon optimisation might result in enhanced expression levels, 
we designed a codon optimised version of CD20 for this purpose. Codon 
optimisation of the CD20 sequence was achieved using pMol software using an 
algorithm written by Dr. Martin Pulé. This algorithm is designed to 
preferentially select codons based on the most common tRNAs present in 
human cells. In addition, hairpins, literal repeats, and cryptic splice sites were 
removed, whilst the GC content was raised to 70%. This coding sequence was 
then generated by gene synthesis using overlapping oligos and subcloned as 
an NcoI-MluI fragment into SFG.I2.eGFP. Correct clones were identified by 
restriction digest followed by DNA sequencing. Comparison of the original 
CD20 wild-type construct compared with the codon-optimised CD20opt 
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construct was assessed by flow cytometry staining of retrovirally transduced 
PBMC’s as illustrated by Figure 36. 
 
(a) Primary human PBMCs were transduced with SFG.CD20.I2.eGFP and 
SFG.CD20opt.I2.eGFP. CD20 expression was assessed by flow cytometry shown by the top 
row, whilst the bottom row illustrates enhanced co-expression of the eGFP marker gene 
employed to measure cytotoxicity through in vitro assays. (b) An exaggerated extrapolation of 
the fluorescence bleed by the eGFP marker into the non-transduced fraction is indicated in the 
lower panel to highlight potential for over-interpretation of the sensitivity to CDC-mediated 
deletion of the CD20 positive control construct. This limitation is notable given the clarity of 
the eGFP marker expression afforded by epitope constructs under interrogation which are 
illustrated by Figure 45, comparative analysis of transduction efficiency, page ]. Flow 
cytometry data illustrates a representative sample from more than five donors. 
 
Although the effect of codon-optimisation was modest regarding improving 
eGFP expression by the bicistronic vector, Figure 36 clearly illustrates 
enhanced CD20 expression between samples with comparable eGFP 
expression. However we did observe a consistent improvement in the level of 
transduction which was achieved by the codon-optimised construct typically 
achieving 35-50% transduction efficiencies compared with 20-35% which had 
been achieved from the CD20wt construct. Figure 36a illustrates typical 
histogram profiles from transduced PBMC’s, with Figure 36b modified to 
suggest potential improvement in the capacity of CD20opt.I2.eGFP construct 
to accurately reflect cellular deletion from ADCC assays. We proceeded with 
ADCC modelling using the CD20opt.I2.eGFP construct recognising that limited 
efficacy of the CD20 positive control to fully represent ADCC mediated 
deletion might result in under-representation of the efficacy of our epitope 
constructs. 
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Experimental aim: To generate a functional molecular cassette to mediate cell 
surface expression of IL15 and 4-1BBL. 
Following from our decision to employ NK cells as the effector population for
 ADCC assays, we faced the challenge of how to consistently establish a 
sufficient population to enable effective modelling. Each assay as described in 
2.2.5.7.3, required almost 3x107 NK cells; as this would require between 140ml-
1.4L of peripheral blood per donor based on typical NK-cell composition 
within peripheral blood, it was essential to identify an alternative strategy to 
establish the effector cell population. Ideally, we desired a strategy which 
would enable consistent generation of a functional NK cell effector population 
which could be established concurrent with transduction, and selection where 
required, of the target population, all derived from the same donor to preclude 
NK-cell ‘missing-self’ activation and preferably from a single peripheral blood 
draw of reasonable volume. 
Previous work by Imai 225 has demonstrated the ability to amplify NK cells 
 through co-culture with the MHC-I negative K562 cell line242, modified 
to express cell-surface localised IL15 and the 4-1BB ligand. Using this strategy, 
this group demonstrated NK cell proliferation through ectopic expression of 
IL15 and the 4-1BB ligand on modified K562 cells resulting in a 1000-fold 
amplification of NK cells following 3-week co-culture of PBMC’s with modified 
K562 cells225. Briefly, it was known that the K562 myeloid leukaemia line243 
demonstrates acute sensitivity to lymphocyte mediated cytotoxicity244 and co-
culture of NK cells with irradiated K562 cells can substitute for ionomycin as a 
mitogenic signal although it was premised that optimal NK cell proliferation 
would require additional co-stimulation245. Relative to our research, IL15 has 
been identified as a potent activator of NK cell effector function promoting 
both NK-cell development and NK cell survival225, 234, IL2 promotes NK-cell 
proliferation and cytotoxicity234 and the 4-1BBL was observed to enhance NK-
cell activation and production of IFNγ and GM-CSF cytokines225.  
As we were unable to obtain this modified K562 cell line, we recapitulated this 
research to generate our own NK-cell amplifying K562 clone. As an expression 
plasmid encoding the 4-1BBL had already been generated by Dr. Martin Pulé, 
only the coding sequence for the IL15 cytokine was required. The coding 
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sequence for IL15 was sourced from monocyte cDNA, achieved by Trizol-based 
RNA extraction from monocytes as described (2.2.1.1.12), followed by cDNA 
generation using an Ambion reverse transcriptase kit. Successful generation of 
cDNA was confirmed by PCR amplification of the GAPDH housekeeping gene 
from the cDNA sample prior to progression with IL-15 amplification using 
monocyte derived cDNA as template.  
Premising that IL15 presentation format might affect NK cell expansion, we 
generated two alternative IL15 / 4-1BBL expression constructs variant for the 
size of the CD8 molecular spacer presenting the IL15 cytokine. Both constructs 
present the IL15 cytokine upstream of a TaV 2A sequence followed by the 4-
1BBL transgene were sub-cloned into a similarly digested SFG.I2.eBFP2 vector 
as AgeI-MluI to generate the expression constructs. As indicated by Figure 37, 
MP6930 utilises the same CD8 stalk as the QBEnd10 epitope presentation 
strategy whereas the membrane-proximal construct MP6891 contains only the 
transmembrane and anchor domains derived from the CD8 stalk. Successful 
cloning was verified by restriction digest followed by DNA sequencing. Finally, 
functional verification of IL15 and 4-1BBL expression by the alternative 
constructs was confirmed by indirect flow cytometry (data not shown). 
 
To facilitate ectopic cell-surface localised IL15 cytokine presentation, it was necessary to 
engineer a signal sequence, molecular spacer and anchoring domain into the expression 
cassette. Equimolar bi-cistronic expression of 4-1BBL was achieved through deletion of the 5' 
transgenic STOP codon and inclusion of the self-cleaving TaV 2A peptide sequence localised 
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between the separate transgenes. Modular design of the engineered protein through inclusion of 
the separate protein domains as indicated. The IL15 / 4-1BBL cassette was sub-cloned into the 
SFG.I2.eBFP2 vector as an AgeI-MluI fragment. 
 
Experimental aim: To generate a stable K562 clone expressing high level cell-
surface localised IL15 and 4-1BBL, as a platform to mediate  NK-cell 
expansion. 
To ensure consistent NK cell proliferation, we premised that it would be 
necessary to establish a single cell clone expressing the IL15/4-1BBL construct. 
To this end, we generated RD114 pseudotyped retroviral supernatant for both 
constructs. Following a single round of retroviral transduction, transduction 
efficiencies over 90% were achieved for both constructs. Successful surface 
expression of both IL15 and 4-1BBL was confirmed by flow cytometry through 
indirect staining illustrated by Figure 38. 
 
K562 cells were separately transduced with both iterations of the IL15 / 4-1BBL expression 
cassette. The eBFP2 fluorescent protein marker identified transgenic cells thereby enabling 
confirmation of successful expression of the desired surface antigens achieved through indirect 
antibody staining. Successful binding by the murine anti-IL15 or anti-4-1BBL primary 
antibodies was achieved by secondary staining using an anti-mouse APC secondary antibody 
with binding efficacy assessed by flow cytometry. Although both constructs demonstrated 
similar levels of 4-1BBL expression, the CD8-stalk bound presentation format appeared to offer 
superior presentation for the IL15 cytokine as illustrated by the MP6930 construct. 
Next we isolated high expressing K562 populations for each construct by flow 
cytometry using a Beckman Coulter MoFlo cell sorter based on the eBFP2 
fluorescent protein marker; cell sorting performed by Arnold Pizzey. Finally 
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single cell clones isolated by limiting dilution (2.2.2.1.3), were screened based 
on expression levels of the respective protein targets compared against the 
internal eBFP2 fluorescent marker as illustrated by Figure 39. For the MP6930 
construct, the A5 clone demonstrated the highest level of transgene 
expression combined with an optimal growth profile. For the MP6931 
construct, both the E1 and E5 clones were selected as they demonstrated 
equivalent expression profiles. Cell banks for the identified clones were 
cryopreserved with fresh aliquots thawed and transiently passaged as 
required. 
 
To reduce potential experimental variation between in vitro NK-cell expansions, transgenic 
K562 populations were single cell cloned to enable consistent IL15/4-1BBL expression and 
therefore theoretically equivalent IL15/4-1BBL stimulation. Single cell isolates were stratified 
based upon the mean fluorescence intensity of antibody binding against both the IL15 and the 
4-1BBL protein targets as compared against eBFP2 fluorescent protein marker gene expression. 
As illustrated, for the MP6930 series the A5 clone demonstrated clearly superior expression for 
both targets. In contrast, the MP6931 clones demonstrated a consistent and reduced expression 
than what was observed for the MP6930 series, and both the E1 and E5 clones were retained for 
subsequent consideration. 
 
Experimental aim: To demonstrate consistent and sufficient  NK-cell 
expansion as to enable downstream ADCC assays using NK-cells as the 
effector population. 
Having established stable modified K562 cells, we next sought to confirm 
efficacy of NK-cell proliferation following PBMC:K562 co-culture. From a series 
of co-culture expansions with separate donors, we observed clear evidence of 
NK-cell expansion in all instances (more than 6 donors, data not shown). As 
successful amplification was consistently achieved in all donors following co-
culture with the K562.A5 clone, contrasting with typically more modest 
expansion resulting from the K562.E1 co-culture, the K562.A5 clone was 
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selected for expansion of NK-cell effectors for all subsequent ADCC assay 
experiments (data not shown). In our hands, following a 7 day co-culture with 
the K562.A5 clone typically, 0.5-1.0 x 106 NK cells can be isolated for each 1.0 
x 106 PBMC’s supplied in the initial PBMC:K562 co-culture. NK-cells were 
isolated by CD56 positive selection following seven days of co-culture. NK-cell 
phenotype was confirmed by flow cytometry analysis following overnight 
recovery post-MACS selection, with ADCC assays initiated within 24 hours of 
NK cell selection. An example of NK-cell profile following MACS selection is 
illustrated by Figure 40. 
 
Primary human PBMC’s were expanded in vitro for 7 days as described (2.2.2.2.4, p91). 
Following a 7-day in vitro expansion, NK-cells were positively selected by CD56 magnetic 
bead selection, recovered overnight then assessed by flow cytometry for confirmation of purity 
and phenotype confirmation prior to inclusion into ADCC assays. As illustrated at far right, 
NK-cell effectors for the sensitivity assay were identified (and excluded) based upon 
CellTRACE violet staining. For both assays, as indicated by the middle samples, NK-cell 
effectors were confirmed as possessing a CD56dim/CD16+ phenotype prior to assay progression. 
Successful NK cell proliferation can be predicted based on alterations to the 
co-culture profile by microscopic analysis over time as illustrated by Figure 41. 
At the start of cellular co-culture, the larger K562 cells clearly dominate the 
culture sample; following extended co-culture, K562 cells are progressively 
cleared by the developing NK cell populations ultimately becoming the clearly 
dominant population. 
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Primary human PBMCs were co-cultured with irradiated K562.A5 cells according to protocol 
as described 2.2.2.2.4, p91 to mediate ex vivo NK cell expansion. Successful amplification of 
NK cells could be predicted by visualisation of progressive deletion of the larger K562 cells 
concurrent with expansion of the smaller lymphocyte population as indicated. Image at 40x 
magnification. 
 
Experimental aim: To establish a flow-cytometry based  ADCC assay 
capable of discriminating sensitivity to ADCC-mediated deletion between 
closely related molecular targets. 
Having successfully established a strategy to generate our chosen effector 
population, we next sought to demonstrate ADCC-mediated deletion through a 
flow cytometry based assay to correspond with our previous CDC deletion 
assays. Failings identified from an initial series of ADCC assays directed 
modifications required to optimise flow-cytometry assay protocols allowing 
assessment of both sensitivity and specificity of ADCC-mediated target 
depletion. Modifications included: functional confirmation of ADCC by the NK-
cell effector population, optimisation of staining strategies to enable cellular 
discrimination within the assays, and altering of the duration of effector:target 
incubation to enhance assay sensitivities. 
 
In our preliminary ADCC assays, we reprised the strategy employed for 
Specificity CDC assays, utilising Q8.I2.eBFP2 as an internal control, 
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RQR8.I2.eGFP as the specific target, using Annexin V-APC/PI staining for 
viability discrimination. From this initial series of assays, we observed modest 
ADCC mediated deletion of RQR8 expressing targets. Although technical 
problems precluded full and complete assessment of the efficacy of deletion 
as illustrated by Figure 42, the level of ADCC mediated deletion appeared 
clearly inferior to what had been observed from CDC mediated deletion. This 
in part likely reflects an exaggerated indication of the efficacy of CDC-
mediated deletion due our choice of baby rabbit complement for CDC assays. 
As early monoclonal antibodies demonstrated a poor ability to activate 
complement, historically rabbit serum was chosen as an alternative to human 
complement to enhance CDC efficacy due to the inability of cell surface 
complement inhibitors, such as CD35, CD46, CD55 and CD59, to inactivate the 
heterologous complement cascade246. From these initial ADCC assays, we 
observed an average level of ADCC-mediated deletion of approximately ten 
percent. 
 
Primary human PBMCs were transduced with RQ8.I2.eGFP, RQR8.I2.eGFP or Q8.I2.eBFP2, 
with each sample separately purified by CD34 magnetic bead selection (Miltenyi). 
Subsequently, the RQ8.I2.eGFP and RQR8.I2.eGFP populations were independently combined 
with the Q8.I2.eBFP2 population to establish a 50:50 assay target suspensions. These target 
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populations were then incubated for 4 hours with NK-cell effectors derived from the same 
donor at an effector:target ratio of 8:1 with or without rituximab at 100µg/ml. RQ8 assay reflect 
the result from a single donor; RQR8 assay illustrations reflect results from three separate 
donors. Note: For donors 1 and 2, the Q8.I2.eBFP2 population appears absent due to problems 
with the violet laser on the Cyan cytometer precluding effective detection. 
During consideration regarding how best to proceed with subsequent assays, 
we premised that it remained plausible the modest level of ADCC-mediated 
killing observed might reflect an accurate illustration of the level of deletion 
which could be expected. However, we remained concerned that, the degree of 
depletion observed might alternatively reflect an impaired capacity of NK-cells 
resulting from  manipulation and/or impaired functional capacity 
resulting from the CD56 positive selection purification strategy (personal 
communication with Anthony Allen, Miltenyi Biotec). Additionally, the limited 
four-hour assay duration might under-represent effector mediated cytotoxicity 
through exclusion of the more prolonged mechanisms. Lastly, in consideration 
of a report describing impaired NK-cell mediated ADCC in combination assays 
including complement due to steric hindrance resulting from proximity of the 
C3b and the FcγRIIIa (CD16) receptor epitope on IgG1247, we elected to assess 
CDC and ADCC efficacy independently in subsequent assays. 
 
Although 51Cr release assays remain the gold standard for cytotoxicity assays, 
spontaneous release can restrict the maximum duration for these assays 
thereby excluding some of the slower effector mechanisms of ADCC248. 
Further, a recent report by Veeramani .249, attempting to shed insight on 
the contentious issue regarding the role of FcγR polymorphisms in rituximab 
mediated deletion as identified by Cartron .250, suggests that the variation 
in efficacy of ADCC -mediated deletion due to FcγR polymorphisms might 
result from an experimental artefact whereby FcγR polymorphisms impose a 
delay in the rate of the ADCC mediated response rather than an impaired 
capacity to mediated a response, thus implying that extended incubation 
durations may improve reflective accuracy. 
Further, to address the possibility that  manipulation of NK cells may 
impair functional capacity, we considered an alternative ADCC assay whereby 
freshly ficolled PBMC’s were employed as the source for our effector 
population again responding against MACS sorted target populations. 
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Furthermore, in consideration of the absence of  stimulation of the 
PBMC effectors, we also considered whether a prolonged assay duration might 
enhance sensitivity, we measured ADCC-mediated efficacy following 2, 4, 8 
and 24 hours of co-culture incubation as illustrated by Figure 43a. Results 
from a single donor at the 2, 4 and 8 hour timepoints appeared to match the 
10% level of depletion observed from our preliminary 4 hour ADCC assays, 
whereas the degree of depletion indicated at the 24 hour timepoint appeared 
to be in excess of 20%. Buoyed by this result but concerned regarding potential 
for significant variation resulting from application of freshly ficolled PBMC’s 
as effectors, we performed a final optimisation experiment comparing efficacy 
of PBMC effectors against expanded NK cells, assessing ADCC-
mediated depletion following 24, 48 and 72 hours of incubation as illustrated 
by Figure 43b. From this assay, NK-effectors appeared to consistently offer 
superior depletion compared with PBMC effectors, demonstrating the greatest 
degree of depletion following 48 hour co-culture. As our ultimate intention 
was to assess comparative sensitivity for a range of similar constructs, we 
premised that the optimum assay conditions would be required to ensure 
effective discrimination between highly similar targets. Therefore, we selected 
the 48 hour assay duration, employing NK cell effectors to ensure consistency, 
to assess the comparative sensitivity of ADCC-mediated deletion of our 
epitope constructs.  
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Primary human PBMCs were transduced with RQR8.I2.eGFP or Q8.I2.eBFP2, with each 
sample separately purified by CD34 magnetic bead selection (Miltenyi). Subsequently, the 
RQR8.I2.eGFP and Q8.I2.eBFP2 populations were combined to establish an equal 50:50 assay 
target suspension. Target populations were then incubated with effector populations at 
effector:target ratios as indicated, in the presence (query) or absence (control) of rituximab at 
100ug/ml. (a) Freshly isolated PBMC’s from the same donor as the RQR8.I2.eGFP expressing 
targets were assessed for their capacity to mediate ADCC at timepoints as indicated. (b) Freshly 
isolated PBMC’s from the same donor as the RQR8.I2.eGFP expressing targets were compared 
for their capacity to mediate ADCC assessed against ex vivo expanded NK cells as an 
alternative effector population. As illustrated, optimal clarity of ADCC-mediated killing was 
observed following 48 hours of effector:target co-culture when NK-cells were employed as the 
effector population. 
 
 
Optimisation assays also identified the further challenge of achieving effective 
cellular discrimination by flow cytometry, due to autofluorescence noise 
imposed by the high cellular volume involved. Following unsuccessful 
attempts to identify the NK-cell effector population and thereby enable gating 
exclusion through anti-CD56 antibody staining, we next considered a strategy 
whereby we marked the effector population using a membrane staining dye. 
For this purpose, we employed the CellTRACE violet dye to mark the NK-cell 
effector population. Even following 48 hour co-culture, the intensity of the 
CellTRACE stain remained sufficient to clearly identify and exclude the NK cell 
effectors, without any notably observation of fluorescent-bleed between 
cellular populations, thereby facilitating clear exclusion of the majority 
effector fraction to facilitate clear focus on the target population of interest. 
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Following ADCC assay optimisation, we successfully established a protocol 
whereby we could generate sufficient populations of both NK-cell effectors 
and transgenic targets from a single peripheral blood draw of 60ml, enabling 
assay initiation 8 days following PBMC isolation and allowing for both flow-
cytometry based sensitivity and specificity assessments consistent with 
previous CDC assays. Both ADCC assays required confirmation of successful 
progression at multiple checkpoints prior to assay initiation; these are 
reflected by Figure 44 which illustrates an assay flowchart to highlight 
commonality and procedural divergence between the assays.  
 
CDC and ADCC represent the two primary mechanisms of effector mediated deletion available 
for the RQR8 construct. As with CDC-mediated deletion previously, separate protocols were 
established to assess both sensitivity (2.2.5.7.3, p101) and specificity (2.2.5.7.4, p101) of 
ADCC mediated deletion. Briefly: human PBMCs were separated into two populations and 
expanded ex vivo to establish both target and effector populations. Successful NK cell 
expansion and T-cell transduction of all constructs under interrogation were defined as essential 
criteria prior to assay progression. For all ADCC assays, NK cells were CD56 magnetic bead 
selected the day prior to ADCC assay set-up with selection confirmed by flow cytometry. To 
enable exclusion of the NK-cell effector population in sensitivity assays, NK-cells were labelled 
with CellTRACE violet according to manufacturer’s instructions (Invitrogen). For specificity 
assays, a heterogenous target population was employed including an eBFP2 marked control 
leaving NK cells remaining unstained. 
 
Experimental aim: To stratify the sensitivity of alternative rituximab-epitope 
expression constructs to  ADCC-mediated deletion. 
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Note regarding experimental variation: Following a parallel research tangent 
considering the generalizability for cell-surface epitope expression discussed 
further in Chapter eleven, we had concurrently generated a GPI-anchored RQR-
motif expression construct at the point when we had completed ADCC assay 
optimisation. As we had previously established that the QR8 target was 
inferior to RQ8, and faced with a limited population of NK-cell effectors, we 
elected to replace the QR8 target with RQR-GPI in ADCC assays. 
As illustrated by Figure 44, the ADCC sensitivity protocol required 
identification of effective progression at several checkpoints prior to assay 
initiation, including: validation of sufficient NK-cell expansion, successful 
CD56 selection, confirmation of effector phenotype and effective CellTRACE 
labelling concurrent with successful transduction of all target populations; all 
derived from the same donor to exclude ‘missing-self’ activation. Transduction 
verification of target populations was assessed by antibody staining to ensure 
approximately equivalent transduction efficiencies were achieved and to 
enable comparative binding efficacy for the various targets for the respective 
antibodies, as illustrated by Figure 45. Similarly, NK cell effector populations 
were verified by antibody staining to ensure the effector profile remained 
consistent between donors.  
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Primary human PBMCs were transduced with epitope constructs under consideration. Prior to 
progression with ADCC assay modelling, transduction verification was assessed by flow 
cytometry of QBEnd10 or rituximab antibody stained transgenic samples to confirm successful 
transduction and to ensure approximately equivalent levels of transduction were achieved for all 
constructs. Staining as illustrated reflects a typical transduction result from three separate 
experiments derived from separate donors. 
 
Transduced, but unsorted target populations were assessed for their 
sensitivity to ADCC mediated deletion through a range of effector:target ratios 
(16:1, 8:1, 4:1 and 2:1) with killing efficacy compared against a control sample 
containing 8:1 ratio of NK cell effectors in the absence of rituximab. ADCC 
sensitivity assay results displaying the 8:1 effector:target ratio from three 
separate donors are illustrated by Figure 47. From sensitivity ADCC assays, 
RQR8 demonstrated superior sensitivity to ADCC-mediated deletion proving 
even more sensitive than the codon optimised CD20 positive control. Notably, 
as indicated by the comparative antibody binding efficacy inset within Figure 
47, excluding the CD20 positive control, rituximab binding capacity for the 
various constructs appears to correspond with the level of ADCC mediated 
depletion achieved. Typical histogram profiles illustrating ADCC-mediated 
depletion are illustrated by Figure 46. 
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Primary human PBMCs were transduced with epitope constructs under consideration and 
assessed for sensitivity to ADCC-mediated deletion mediated by NK cells through in vitro 
assays. Assessment of depletion achieved was identified through the residual eGFP-expressing 
population. Results from a typical donor are illustrated with results from 3 separate donors 
summarised in Figure 47. 
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Primary human PBMCs were transduced with epitope constructs under consideration and 
assessed for their sensitivity to ADCC-mediated deletion mediated by NK cells as assessed 
through in vitro assays. Excluding the CD20 positive control, comparative antibody binding 
results for the various targets (inset), appear to approximately correlate with the level of 
deletion which was achieved. Results illustrate comparative sensitivity from three separate 
donors. Error bars reflect standard error of the mean 
 
 
Experimental aim: To demonstrate that when challenged with a heterogenous 
target population, ADCC-mediated deletion remains specific to the rituximab-
epitope expressing fraction. 
Having assessed the comparative sensitivities for the various epitope 
constructs, next we investigated the specificity of ADCC mediated depletion. 
As cellular therapies which require suicide gene protection would be purified 
prior to infusion, we aimed to obtain an indication for the level of depletion 
which might be anticipated against putative RQR8 expressing cellular product. 
Specificity of ADCC mediated depletion was assessed by incubation of NK-cell 
effectors against an equally mixed composite target population composed of 
MACS selected RQR8.I2.eGFP and Q8.I2.eBFP2 transgenic targets. Similar with 
Chapter Five 
175 
 
CDC assays previously, ADCC-mediated depletion was demonstrated to be 
acutely specific against the target population, with selection appearing to 
approximately double the sensitivity of RQR8 expressing targets to ADCC 
mediated deletion as compared with efficacy against unselected targets. ADCC 
specificity results are indicated by Figure 48. 
Finally, in consideration of the minimal size of the RQR-GPI construct which 
had demonstrated similar efficacy as the RQ8 construct in sensitivity ADCC 
assays, we compared the efficacy of RQR8 compared against RQR-GPI in a 
specificity ADCC assay. Despite the identical epitope, variant only in the 
format of the molecular spacer, experimental results as illustrated by Figure 
48b, appear to suggest increased sensitivity of the RQR-GPI expressing target 
to ADCC-mediated deletion when compared against RQR8. However, as 
demonstrated by PNH, a simple mutation facilitating deletion of GPI anchor 
expression represents an untenable risk for escape, thereby excluding RQR-GPI 
as a serious option for a putative suicide gene construct. Hence this data only 
reflects the result from a single donor with further investigation into this 
anomaly deemed beyond the scope of this project.  
 
(a) Primary human PBMCs were transduced with either RQR8.I2.eGFP or Q8.I2.eBFP2 and 
were CD34 magnetic bead selected prior to ADCC assay incubation. Following selection, 
purified cells were combined to establish an approximately 50:50 mixture of control and assay 
targets. Results illustrate average ADCC-mediated deletion from 2 separate donors. (b) Primary 
human PBMCs were transduced with RQR8.I2.eGFP or the RQR-GPI.I2.eGFP assay targets, as 
well as the Q8.I2.eBFP2 control target. Following transduction, cells were CD34 magnetic bead 
selected, then combined to establish target mixtures prior to ADCC assay incubation. Results 
illustrate ADCC-mediated deletion from a single donor. 
Finally, although the RQR-GPI construct was engineered following completion 
of the CDC sensitivity assays it was examined within 
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, addressing the sensitivity of epitope constructs to the alternative 
mechanism of effector mediated deletion, namely ADCC. 
 
Primary human PBMCs were transduced with either RQR8.I2.eGFP or RQR-GPI.I2.eGFP and 
assessed for efficacy of CDC-mediated deletion through a CDC sensitivity assay as described 
(2.2.5.6.2, p100). Results from a single experiment are illustrated. 
 
Despite clear improvement in facilitating ectopic cell-surface expression of the 
CD20 antigen, codon optimisation of CD20 appears to have only conferred a 
modest increase in the expression level of the co-expressed fluorescent marker 
protein. In this endeavour, our aim was to boost expression of the eGFP 
marker to enable better clarification of the level of deletion achieved for the 
CD20 positive control population. However despite our efforts, there remains 
a degree of overlap between the non-transduced and the transduced 
populations for the positive control target which remains typically less 
pronounced for our epitope expressing target populations. Thus, potential 
over-representation of the sensitivity of the CD20 positive control may result 
with under-estimation of the comparative killing efficacy of our rituximab 
binding targets through  killing assays. 
Recapitulating work by Imai .225, following generation of a modified K562 
stimulator line, we have successfully demonstrated  amplification of 
NK-cells sufficient to enable ADCC assay modelling experiments. From our 
Chapter Five 
177 
 
results, we have established a 7-day protocol whereby PBMC:K562.A5 co-
culture maintained with 40iu IL2 and maintained with partial media changes 
as required, can generate approximately 0.5-1.0 x 106 NK cells for each 1.0 x 
106 PBMCs included in the initial co-culture. NK-cells can be successfully 
purified using CD56 magnetic bead selection to establish a consistent and 
purified effector population for  ADCC assays. 
Observations of attenuated deletion of transgenic epitope expressing targets 
through  ADCC assays as compared with efficacy observed from CDC 
assays led us to interrogate our choice of an effector population for  
ADCC assays. Following optimisation comparing NK cells versus freshly 
isolated PBMCs as the effector population alongside assay duration, identified 
an  ADCC assay protocol employing NK cell effectors and 48 hour assay 
duration to be highly effective for discrimination of sensitivity to ADCC 
mediated deletion between similar target populations.  
Following assessment of the comparative sensitivity of our epitope constructs 
in transgenic PBMCs, we have demonstrated that ADCC-mediated depletion of 
RQR8 appears at least equivalent, if not more sensitive than what was 
observed for the full-length CD20 expressing positive control. Further, results 
from specificity assays suggest that cellular selection, as would be required to 
establish therapeutic product, enhances sensitivity of RQR8 expressing targets 
to ADCC-mediated deletion, whilst highlighting that deletion remains acutely 
specific to the target population. As demonstrated in Chapter four, RQR8 
demonstrates superior sensitivity to CDC-mediated deletion potentially 
resulting from bivalent binding of rituximab which could resolve the density 
dependent limitation of CDC against monovalent epitope expressing 
constructs. Fortuitously this pattern of enhanced sensitivity of RQR8 also 
appears to extend to ADCC-mediated deletion, which might reflect increased 
FcγR cross-linking due to greater clustering of rituximab molecules. At face 
value, our data might be construed to suggest that CDC plays a primary role in 
the cellular deletion mediated by RQR8. However efficacy of CDC is likely over-
represented by our choice of BRC as the source of complement, thus further 
consideration into the roles of the separate effector mechanisms will be 
revisited in Chapter nine and Chapter ten, which investigate rituximab deletion 
through  modelling. 
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Despite extensive similarity between epitope constructs, RQ8 appears more 
sensitive to ADCC-mediated deletion whereas RRQ8 appears more sensitive to 
CDC, highlighting a target-dependent variation in the sensitivity to effector 
mediated deletion as illustrated by Figure 50. Although the RQR-GPI construct 
was excluded from the CDC assay datasets due to delayed construction, we did 
assess efficacy of CDC-mediated deletion of this construct from a single donor 
as illustrated by Figure 48. In light of the variation in efficacy of deletion 
between RQ8 and RRQ8 when comparing CDC versus ADCC assays, it is 
interesting to observe a similar discrepancy between RQR-GPI and RQR8, 
illustrated by Figure 49 and Figure 50. Although these results are intriguing 
regarding suggestions for role of the antigenic target in facilitating sensitivity 
to antibody mediated deletion, further examination of this tangent remains 
beyond this project. 
 
Due to variation between constructs examined for sensitivity to CDC and ADCC mediated 
deletion, this figure only reflects constructs which offer comparative data. 
 (From CDC sensitivity data, illustrated by Figure 21, (p130) and ADCC sensitivity illustrated 
by Figure 47, p174), this figure highlights the level of deletion achieved for epitope constructs 
which were assessed through both CDC and ADCC assays. These results appear to indicate that 
stratification of epitope sensitivity to CDC or ADCC-mediated deletion is not uniform with 
some constructs demonstrating enhanced sensitivity to CDC mediated deletion (eg.RRQ8) 
whilst others appear to mediate enhanced sensitivity to ADCC-mediated deletion (eg.RQ8). 
 
 
 Codon optimised CD20 enhances transgene and eGFP marker gene 
expression demonstrating a more effective positive control for  
ADCC assay modelling 
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 The K562.A5 clone demonstrates good expression of both IL15 and 4-
1BBL antigens as assessed through antibody binding MFI by flow 
cytometry 
 Co-culture of PBMC’s with the K562.A5 cell line in a 1:1 ratio result in 
profound NK cell expansion following 7 days of culture 
 Following CD56 selection,  expanded NK cells demonstrate an 
effector CD56dim/CD16+ phenotype 
 We have demonstrated that RQR8 expression renders transgenic PBMCs 
sensitive to ADCC-mediated deletion in the presence of rituximab and 
an appropriate effector population. 
 This sensitivity is specific to RQR8 expressing targets and appears to be 
enhanced when a Miltenyi selected population of targets is considered. 
 Indication of potential variation in the sensitivity of the similar RQR-GPI 
construct with respect to CDC versus ADCC mediated deletion 
highlights a curious observation suggesting the presentation motif of an 
epitope target may affect the sensitivity of this target to effector-
mediated deletion. 
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As illustrated by Figure 1, successful clinical application of adoptive cellular 
therapies has resulted in an ever-expanding array of potential functional 
modifications for T-cell engineering. Therefore, apart from haploidentical 
HSCT, inclusion of a suicide gene may largely represent an additional feature 
alongside a primary functional modification such as a re-targeting moiety. 
Thus it is essential that we demonstrate the capacity for RQR8 to retain 
functional efficacy when co-expressed alongside common T-cell engineering 
components. 
 
 To demonstrate the modular capacity of RQR8 to enable co-expression 
alongside common T-cell engineering components 
 To demonstrate functional retention of all separate components when 
RQR8 is co-expressed with the GD2-CAR as verified by: 
o Miltenyi CD34 magnetic bead selection (QBEnd10 epitope) 
o  deletion defined by CDC-assay (Rituximab epitope) 
o Cytotoxicity against GD2 expressing cellular targets (GD2-CAR) 
 To demonstrate that following CDC-mediated deletion, the cytotoxic 
capacity of the effector population returns to non-transduced effector 
baseline activity as assessed by 51Cr release assays 
 
T-cell engineering offers the opportunity to engender T-cells with additional 
and/or novel functional capabilities, such as: molecular re-targeting mediated 
by inclusion of a TCR or a CAR moiety, drug resistance capability such as 
calcineurin or mycophenolate resistance, ability to secrete cytokines to 
enhance a desired immune response, enhanced proliferative capacity and/or 
survival, and obviously inclusion of marker genes for identification and suicide 
genes for resolution of therapeutic toxicity. 
However each modification presents novels risks; each TAA target presents 
opportunity for unforeseen OTOT, signalling modifications designed to 
overcome toxic tumour microenvironments present risk for unpredicted 
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metabolic perturbations, whilst insertional mutagenesis implicit with 
integrating genetic engineering modalities, imposes risk for potential 
leukaemagenesis, which although yet to be observed from T-cell cancer 
immunotherapy, nevertheless remains a hypothetical possibility. 
Further, as toxicity assessments based on  and animal modelling are of 
limited predictive value, risk can never be fully excluded. Thus inclusion of a 
marker-suicide gene moiety within a transgenic cassette represents a 
functional mechanism or molecular safety switch to enable opportunity to 
resolve adverse events which might arise . Thus, following from our 
previous work, we wanted to demonstrate the modular capacity of RQR8 to 
function alongside other T-cell engineering components. As the two primary 
strategies for T-cell retargeting involve genetic modification of T-cells to 
include either a CAR or a TCR moiety, we decided to demonstrate effective co-
expression of RQR8 separately with both a TCR and a CAR. Subsequently, 
using  assays we examined the functional capacity for the separate 
modular components using a RQR8.2A.CAR construct re-targeted against the 
GD2 ganglioside. 
 
Experimental aim: To generate a molecular expression cassette to facilitate 
functional co-expression of RQR8 alongside either a chimeric antigen receptor 
or an engineered T-cell receptor. 
To illustrate the capacity of RQR8 to function alongside T-cell engineering 
components, it was necessary to establish appropriate expression vectors to 
facilitate experimentation. For this purpose, we used the Wilms tumour 
antigen-1 (WT1) TCR and the anti-GD2 ganglioside CAR. 
WT1 is an attractive target for cancer immunotherapy due to upregulation of 
the WT1 transcription factor identified as a TAA in haematological 
malignancies including AML, CML and myelodysplastic syndromes as well as 
solid tumours including breast, colon and ovarian cancers. Previous work by 
the Hans Stauss lab have identified a high avidity TCR specific for the WT1 
derived peptide pWT126 when presented in the context of HLA-A2251. As a 
safety feature to preclude mis-pairing with the native TCR, murine sequences 
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were exchanged for the human constant domain252. The WT1-TCR expression 
vector template was a kind gift from Prof. Hans Stauss. 
Selection of the GD2-CAR was a natural choice for co-expression assays due to 
previous research by Dr. Martin Pulé5. The GD2-CAR targets the GD2 
ganglioside which is the most common antigen expressed in neuroblastoma. 
Neuroblastoma is the most common extracranial solid tumour, emanating 
from sympathetic nerve cells derived from the neural crest. Neuroblastoma is 
a widely heterogenous disease, but one which can demonstrate a highly 
therapy-resistant aggressive phenotype highlighting a need for alternative 
therapeutic strategies such as ACT253. Template for the GD2-CAR construct was 
derived from a second generation anti-GD2 CAR previously generated by Dr. 
Martin Pulé, containing CD28 and CD3ζ signalling domains. 
To establish our expression vectors, our first step was to identify an 
appropriate modular bicistronic vector format to generate functional co-
expression constructs. To achieve functional co-expression, we premised that 
it would be necessary to employ the TaV-2A sequence to establish equimolar 
co-expression of the transgene rather than employing an IRES-based strategy 
which results with increased expression levels from the primary cistron, 
potentially imposing either attenuated retargeting moiety expression or risk 
from cellular escape dependent upon transgene orientation. Further, use of the 
self-cleaving TaV-2A sequence results with addition of a residual 19a.a. suffix 
to the primary cistron and a single proline prefix added to the secondary 
cistron. Premising that the residual suffix might impair functional activity of 
the signalling domains if the CAR or TCR sequences were located upstream of 
the TaV-2A sequence, our molecular design located the RQR8 sequence 
upstream of the CAR or TCR domains separated by the TaV-2A sequence. 
Further, to assist facile generation of subsequent constructs, we opted for a 
modular cloning design whereby an NcoI site was localised at the terminal 
junction of the TaV-2A sequence and the primary methionine of the secondary 
transgene to allow subsequent CAR/TCR constructs to be subcloned as NcoI-
MluI fragments in keeping with previous work from our lab. Lastly, as longer 
transcripts impose additional burden onto the transcriptional machinery, 
impacting on both viral titre and transgene expression119, we premised 
inclusion of a S/MAR domain might be required to ensure stable sustained 
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transgene expression due to the longer transcript length of the CAR/TCR 
domains. Functional benefit of inclusion of a S/MAR domain within a vector is 
described in further detail in Appendix 1 (13.3.3, p315). However, briefly it has 
been observed that transgene expression in retrovirally transduced T-cells is 
decreased in mitotically quiescent cells. However, this effect can be offset by 
orientation specific incorporation of the human beta inteferon S/MAR region 
into Moloney murine leukaemia virus based vectors which has been 
demonstrated to improve transgene expression in primary human T-cells254. 
Having established appropriate vector backbones with or without the human 
beta-interferon S/MAR domain in reverse orientation, located 3' of the 
transgenic coding sequence and upstream of the 3' terminal LTR, subsequent 
CAR/TCR amplicons were subcloned as NcoI-MluI fragments into suitably 
digested vectors, with final sequence integrity confirmed by DNA sequencing. 
Further, as this work coincided with ongoing preparations toward a pending 
clinical trial, a derivative construct based on the GD2-CAR described above was 
also established. A common molecular feature of CARs is the molecular spacer 
domain separating the scFv binding region from the transmembrane domain 
and which has been shown necessary to achieve stable and functional CAR 
expression for a number of CAR constructs. Although the dimeric IgG1 derived 
CH2-CH3 molecular spacer commonly employed in CAR constructs was 
premised to be minimally immunogenic due to the human derivation, it was 
reported that undesired FcγR binding of the IgG-Fc domain could result in bi-
directional activation whereby T-cells become activated against innate effector 
targets independent of CAR-target antigen recognition. Correspondingly, the 
reverse innate immune response against transgenic T-cells was also observed 
resulting in cytolysis and cytokine secretion of pro-inflammatory cytokines255. 
Responding to this report and in preparation for a pending neuroblastoma 
clinical trial resulted with the generation of a CAR spacer domain variant 
designed to minimise FcγR recognition whilst retaining CAR expression and 
functionality; henceforth indicated by the ‘pvaa’ suffix noted on modified GD2-
CAR constructs. Cloning of the GD2-CAR pvaa variant was performed by Alicia 
Kopec, with functional validation of the resolution of toxicity performed by 
Eva Kokalaki. The GD2-CAR pvaa variant vector backbone included a S/MAR 
domain for improved transgene expression. 
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Initial expression assays illustrated by Figure 51 reflect the initial constructs 
whilst all subsequent work involving co-expression of RQR8 with the GD2-CAR 
employed the aGD2-pvaa derivative CAR construct. 
 
Experimental aim: To demonstrate cell-surface co-expression of RQR8 
alongside either a chimeric antigen receptor or a T-cell receptor. 
The first experimental question to be addressed was to confirm whether we 
could achieve effective co-expression of both RQR8 and the CAR/TCR moieties 
from our bicistronic vectors. Secondly, would the additional burden and 
therefore potential reduction in viral titre due to inclusion of the S/MAR 
domain in the vector, be sufficiently offset by increased transgene expression? 
In this experiment, we transduced primary PBMCs with supernatants generated 
for the separate constructs and assessed CAR/TCR expression compared 
against QBEnd10 staining. The IgG1-Fc molecular spacer for the GD2-CAR 
enabled simple indirect detection achieved by anti-human IgG antibody 
staining. However, as the TCR recognises specific MHC-peptide complexes, a 
more specific reagent was required to assess expression of the WT1 construct. 
MHC-multimers are reagents composed of multiple MHC-peptide complexes. 
Resulting from the capacity to bind to multiples TCR's on a single cell thereby 
amplifying the signal, MHC-multimers achieve a more stable binding than 
monomeric equivalents. To assess WT1 expression, fluorescence staining was 
achieved using a custom labelled MHC-WT1 peptide dextramer produced by 
Pro-immune and generously supplied by Prof. Hans Stauss. As illustrated by 
Figure 51, RQR8 co-expression with the GD2-CAR resulted in identification of a 
clear double positive population from both samples. Although the result 
remains less-clear for the WT1-TCR transgenic PBMCs, there was also evidence 
of WT1-dextramer staining for both samples. Further, from parallel 
transductions in PBMCs demonstrating similar levels of transduction 
efficiency, a modest but apparent increase in transgene expression appeared 
to be observed for both S/MAR containing constructs matching with previous 
work from our group. 
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Primary human PBMCs were transduced with RQR8 co-expressed with either the GD2-CAR or 
the WT1-TCR, with equimolar expression facilitated by the TaV 2A sequence, with or without 
the presence of a S/MAR domain within the vector. The left-hand column illustrates the non-
transduced staining control; the middle and right-hand columns illustrate staining without and 
with the inclusion of a S/MAR domain illustrating the enhanced expression afforded by 
inclusion of the S/MAR domain. Data illustrated represent a typical result from three 
experiments. MFI – mean fluorescence intensity. 
 
Experimental aim: To demonstrate that when co-expressed with a CAR or TCR, 
the cell-surface expression level of RQR8 remains sufficient to facilitate CD34 
magnetic bead selection. 
The remaining work in this chapter employed the RQR8.2A.aGD2-pvaa 
derivative CAR construct. As this vector contains three separate functional 
components, functional validation required serial examination of all three 
separate functional capacities: marker gene, suicide gene and the aGD2-CAR, 
in the relevant sequential order: selection, deletion and cytotoxicity. As 
illustrated by Figure 52, a clear double positive population can be observed 
following a single round of transduction in primary PBMCs. Following 
magnetic bead selection, RQR8+ purity >98% could be consistently achieved. 
Results shown reflect a typical result from a single donor. 
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Primary human PBMCs were transduced with SFGmR.RQR8.2A.GD2-CAR. Transduced cells 
were purified by CD34 magnetic bead selection (Miltenyi), with the resulting cell product 
assessed for purity as compared against a residual fraction of the unsorted population. As 
illustrated, following a single round of cell selection, greater than 95% purity is achieved. Data 
as illustrated reflects a typical result from 7 separate experiments. 
 
Experimental aim: To demonstrate that when co-expressed with a CAR or TCR, 
the cell-surface expression level of RQR8 remains sufficient to facilitate 
rituximab-mediated CDC. 
CDC assays were performed in preparation for 51Cr release assay, whereby we 
sought to demonstrate both retention of specific cytotoxic potential from CAR+ 
PBMCs as well as ablation of cytolytic toxicity following targeted complement 
mediated deletion. Thus, following purification, samples were combined with 
non-transduced PBMCs derived from the same donor in a 50:50 ratio to ensure 
presence of a residual population of cells remaining following CDC-mediated 
depletion of the sample which would then be used to establish the effector 
population for subsequent cytotoxicity assays. Verification of retention of the 
capacity for CDC-mediated deletion was performed as previously with the 
following modifications: CDC assay duration was limited to two hour 
incubation to reduce potential complement mediated toxicity. Following 
deletion, cells were recovered into complete RPMI supplemented with 40u IL2 
for two days prior to progression with 51Cr release assays. In both cases, 
samples were incubated with 25% BRC, in the absence (no CDC) or presence 
(CDC) of rituximab (100µg/ml). As illustrated by Figure 53, clear depletion 
could be observed from the sample exposed to rituximab in the presence of 
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BRC, whilst no depletion was observed in the sample exposed to BRC in the 
absence of rituximab. 
 
(a) Primary human PBMCs were transduced with SFGmR.RQR8.2A.GD2-CAR, purified by 
CD34 magnetic bead selection (Miltenyi), and then combined with non-transduced PBMCs 
from the same donor in a 50:50 ratio as confirmed by FACS analysis. (b) Sample mixtures were 
then separated into two fractions and incubated for 2 hours with 25% baby rabbit complement 
in the absence (no CDC) or presence (CDC) of rituximab (100µg/ml). Data reflects a typical 
result from 6 replicates from separate donors. 
 
Experimental aim: To demonstrate that when co-expressed with RQR8, the 
GD2-CAR retains functional capacity to mediate target specific cytotoxicity. 
Further, to demonstrate that the functional potential of RQR8 to serve as a 
suicide gene enables resolution of the effector potential from a mixed 
transgenic population when challenged with the CAR defined antigenic target. 
Finally we examined the functional capacity of CAR-mediated cellular 
cytotoxicity. As indicated above, this final stage presented a two-part assay 
whereby we were attempting to confirm both retention and ablation of CAR-
mediated cellular cytotoxicity. Reflecting the potential risk of OTOT posed by 
retargeting T-cells against TAAs, it remains imperative that induction of the 
suicide gene machinery would achieve ablation of cellular cytotoxicity. To this 
end, we employed 51Cr release assays to assess the capacity for cellular 
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cytotoxicity. Three populations of effectors: non-transduced PBMCs as well as 
both sample mixtures, illustrated by Figure 53, were incubated for 4 hours 
with GD2-transgenic SupT1 target cells at three effector target ratios with 
cytotoxicity assessed by 51Cr release. Results illustrated by Figure 54 reflect 
cytotoxicity assays from three separate donors, clearly demonstrating a 
reduction in cytotoxicity from the sample mixture exposed to CDC back to the 
baseline level established by the non-transduced effector population.  
(a) Selection: Primary human PBMCs were transduced with SFGmR.RQR8.2A.GD2-CAR,  
purified by CD34 magnetic bead selection (Miltenyi), then combined with non-transduced 
PBMCs from the same donor in a 50:50 ratio as confirmed by FACS analysis. (b) Deletion: 
Sample mixtures from (a) were separated into two fractions and incubated for 2 hours with 25% 
baby rabbit complement in the absence (no CDC) or presence (CDC) of rituximab (100µg/ml). 
(c) Cytotoxicity: Following CDC-mediated deletion, assay fractions from (b) were recovered 
for 2 days prior to inclusion into chromium release cytotoxicity assays employed as effectors 
against GD2-transgenic SupT1 target cells at effector:target ratios as indicated. As 
demonstrated, the RQR8.2A.GD2-CAR cassette enables independent functional capacity of all 
modular components in transgenic PBMCs. Data reflects typical results from 6 replicates from 
separate donors. 
 
Progressive advances in molecular engineering offer increasing potential for 
modification of T-cell function, extending far beyond simple retargeting. Thus 
far, our research has focussed on the functional capacity of the marker and 
suicide moieties. However, there are many potential applications where the 
marker/suicide capacity may prove secondary to a primary engineering 
modification. Viewed from this perspective, to validate the potential for RQR8 
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to act as an effective T-cell engineering cassette, it was essential to 
demonstrate functional retention of the marker and suicide gene capacities in 
conjunction with confirmation of the functional capacity for a standard T-cell 
engineering component such as a CAR or a TCR. 
As illustrated by Figure 51, we have demonstrated functional co-expression of 
the GD2-CAR or the WT1-TCR alongside RQR8, mediated by the TaV-2A 
sequence and as confirmed by antibody staining for the QBEnd10 marker gene 
and the retargeting moiety. However, validation of the functional retention for 
all three components required a multi-stage assay as illustrated by Figure 54. 
In addition to establishing purity of the cellular product, selection also 
excludes low expressing cells which results in a more consistent therapeutic 
product and has been observed to enhance functional capacity131. Functional 
co-expression of RQR8 clearly retains QBEnd10 and rituximab binding 
capacities enabling both cellular sorting mediated by magnetic bead selection 
and retention of the capacity for CDC-mediated cellular deletion afforded by 
rituximab and complement. Crucially, the efficacy of the functional capacity 
for CAR-transgenic T-cells to mediate cellular cytotoxicity is retained 
suggesting RQR8 expression does not impede basal T-cell functionality. 
 
 Modular design of RQR8 enables co-expression alongside common T-
cell re-targeting moieties such as CARs or TCRs 
 Functional retention of marker gene, suicide gene and CAR components 
were each separately confirmed through  assays using PBMCs 
transgenic for co-expression constructs 
  modelling demonstrates ablation of cytotoxic capacity of re-
targeted cells following CDC-mediated deletion 
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Progression toward  modelling required two major modifications to 
previous research methodologies: alteration of experimental protocols to 
reflect variation in cellular origin and adjustment of experimental scale to 
address the increased requirements. 
 
 To successfully demonstrate effective and consistent transduction of 
murine splenocytes 
 To confirm that murine splenocytes can effectively express epitope 
binding constructs 
 To demonstrate effective Miltenyi CD34 magnetic bead selection of 
transduced splenocytes 
 To establish and optimise a protocol for effective splenocyte 
transduction and purification sufficient to enable  GvHD 
modelling experiments 
 
This chapter focuses upon the modification to transduction and tissue culture 
protocols which were required to enable  murine modelling 
experiments, whilst the following two chapters will present modelling 
results. 
Having successfully demonstrated functional efficacy of RQR8 through 
carefully controlled  assays, the next phase of the project focussed on 
functional efficacy of RQR8 in more complex biological settings. With a view 
towards future clinical application we next sought to assess efficacy of RQR8 
depletion . As work to this point had utilised human derived cell culture 
for small scale experiments, it was necessary to revise experimental scale 
sufficiently to enable effective  experimentation using murine models. 
This experimental tangent raised multiple questions which were addressed in 
sequence. 
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In contrast with previous chapters, the work in this chapter focussed on 
establishing protocols designed to enable subsequent research rather than 
specifically investigating RQR8. Thus, acting as a means to an end many 
experiments recapitulated previous work but in primary murine T-cells as 
opposed to human cells with most questions binary in nature; e.g. could we 
generate RV supernatant which would enable effective and consistent 
expression of our constructs in murine splenocytes using the SFG vector; 
would splenocytes demonstrate successful expression of our epitope 
constructs to enable antibody binding; could we generate sufficient viable 
transgenic T-cell product through splenocyte culture to enable  
modelling experiments? Hence, experiments typically progressed in a linear 
manner as we addressed these questions in sequence; ultimately resulting in 
generation of a 5-day protocol which offered a minimal timeframe for  
manipulation whilst allowing for confirmation of cellular profile and ensuring 
optimal viability. 
Strategies for splenocyte culture and transduction were adapted from the 
Schumacher, Stauss and Anderson laboratory protocols.  
 
An obvious impact resulting from the alteration in cellular target results from 
challenges imposed by splenocyte culture. Although Roswell Park Memorial 
Institute (RPMI) medium is traditionally chosen for splenocyte culture, it was 
originally optimised for human lymphocyte culture256. As there does not 
appear to have been a similar effort employed to establish an analogous 
medium for splenocyte culture, it appears that limitations from this choice 
have been overcome through alternative stimulation strategies and use of 
supplemental additives, with further discussion restricted to the modifications 
chosen for this course of experimentation. 
 
The isolation strategy for murine T-cells is in stark contrast with that of 
primary human T-cells from peripheral blood. Ficoll-Paque extraction offers a 
facile strategy to exclude erthrocytes and granulocytes from peripheral blood 
by density gradient centrifugation resulting in a clearly visible buffy coat 
offering a rich source of lymphocytes alongside a minority population of 
monocytes33. Further, as T-cells typically compose 70-80% of the lymphocyte 
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fraction from peripheral blood, the sample starts as a highly enriched 
population257. In contrast, to resolve the restriction imposed due to the limited 
volume of blood available, the spleen is typically extracted as a source of 
lymphocytes for murine modelling experiments. As a peripheral lymphoid 
organ, the T-cell proportion of the lymphocyte population from the mouse 
spleen typically matches that of the B-cell fraction, with both populations 
present at approximately 30-35%258. Further, splenic macerates contain a 
significant proportion of stromal cells, primarily present to offer signal to 
sustain lymphocyte populations in the absence of an antigenic signal as well as 
red blood cells (RBCs) reflecting one of the primary roles of the spleen to 
cleanse the blood259. 
 
Key variations between human PBMC activation and splenocyte culture include 
RBC lysis, a stimulation/re-stimulation protocol, and media supplementation 
with β-mercaptoethanol. 
 
Traditionally, ammonium chloride potassium (ACK) lysis buffer is employed to 
selectively deplete RBC’s from single cell suspensions through selective 
osmostic lysis. Intrinsic to their role to facilitate CO
2
/O
2
 exchange, RBC’s 
possess a membrane Cl/HCO
3
 antiporter to facilitate rapid gas transfer260. In 
ACK lysis buffer, the combination of NH
3
 and Cl- ions prove lethal to RBCs by 
skewing cellular equilibrium. Increased Cl- uptake results in elevated carbonic 
anhydrase formation of HCO
3
- ions, imposing a deficit of OH- ions, regenerated 
through increased formation of NH
4
+, progressing until osmotic pressure 
imposes cellular lysis. As RBCs are acutely sensitive to this process, they can 
be selectively excluded from contaminated cultures using ACK lysis buffer. 
 
For cellular stimulation, we employed the Concanavalin A (ConA)/IL7 
stimulation/re-stimulation protocol described in all three laboratory protocols 
considered at the start of our splenocyte research which we observed offered a 
consistent and reproducible strategy to facilitate splenocyte stimulation and 
transduction. 
 
The role of the β-mercaptoethanol (BME) additive in splenocyte culture is 
premised to enhance membrane transport of cysteine to maintain intracellular 
glutathione levels required for optimal growth following mitogenic 
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stimulation, such as Concanavalin A stimulation261. β-mercaptoethanol was 
added to media immediately prior to use, at active concentration of 0.1mM. 
 
Lastly, due to the murine derivation of the QBEnd10 antibody, and the 
complex composition of tissue samples isolated during  modelling 
experiments, it was necessary to establish a blocking strategy to reduce 
background signal resulting from Fc-recognition of antibodies by murine 
FcγR’s. For this purpose, we used neat supernatant from the 2.4G2 hybridoma, 
which binds a non-polymorphic epitope present on murine FcγRII (CD32) and 
FcγRIII (CD16) receptors, which has been demonstrated to prevent non-specific 
IgG binding262.   
 
A cellular viral receptor represents the specific cell surface component which 
viral glycoproteins bind to, with viral entry into the cell representing the 
ultimate result following this binding event. However, binding alone does not 
necessarily mediate virus internalisation. Oligomeric surface domain (SU) 
glycoproteins are anchored to the viral membrane through transmembrane 
(TM) domains. Viral binding is proposed to confer a conformational change in 
the SU protein such that hydrophobic residues within the TM domain become 
exposed leading to a fusion event between the viral and cellular membranes. 
Hence, viral envelope glycoproteins define the tropism of the viral particle, and 
therefore the target range for retroviral vectors can be modified by alteration 
of the viral envelope through a process known as pseudotyping such that the 
novel viral particle expresses glycoproteins derived from enveloped viruses 
separate from the viral strain being packaged. In nature, altered tropism can 
occur naturally following coincident infection of a cell by separate enveloped 
viruses leading to formation of phenotypically mixed virions being produced. 
Observation that HIV-1 virions were able to extend their host range through 
incorporation of heterologous glycoproteins led to the design of pseudotyped 
HIV-1 based viral vectors263. The first demonstration of this principle involved 
generation of amphotropic murine leukaemia virus pseudotyped HIV-1 
particles produced following transient transfection of COS-7 cells264. The most 
commonly used glycoprotein for pseudotyping viral vectors remains the 
vesicular virus glycoprotein (VSV-G) due to the broad tropism and relative 
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stability of this glycoprotein. However duration of viral production is limited 
by the toxicity of this glycoprotein263.  The broad tropism of the VSV-G 
envelope reflects the ubiquitous low density lipoprotein (LDL) receptor or LDL-
receptor family members serving as cellular targets for this glycoprotein265. 
Further, additional cell surface components may influence the tropism of viral 
particles by stabilising virus-receptor interactions thereby facilitating 
membrane fusion events. Experiments using Tunicamycin, an inhibitor of N-
glycosylation, have demonstrated that although the HATBo receptor for the 
RD114 envelope glycoprotein is present on mouse cells, alternative 
glycosylation of this receptor abrogates receptor binding. It has also been 
shown that the efficiency of Eco-mediated infection does not correlate with 
expression levels of the Eco mCAT1 receptor suggesting that additional 
cellular interactions are involved in facilitating virion entry266. 
Production of retrovirus requires three separate elements: , the group-
specific antigen and polymerase genes which enable amplification of the LTR-
bounded retroviral genome, , the envelope required to package nascent 
viral particles and the retroviral RNA genome. Common practice for 
production of retrovirus is achieved through transient transfection. This 
strategy is designed as a safety feature as the components required for 
retroviral production are separated in trans orientation thereby reducing the 
probability for a potential recombination event. However the triple 
transfection strategy results in significant batch-to-batch variation. One 
solution to reduce inter-batch variation is achieved through the use of 
producer lines. Producer lines are stable cell lines modified to express the 
 and  proteins in trans, thereby offering the desired safety profile, 
with human derived cell lines preferred for producers due to the absence of 
endogenous murine retroviruses267. Thus, production of retrovirus from a 
stable cell line only requires transfection with a single plasmid expressing the 
retroviral cassette to be packaged. Producer lines are defined by the envelope 
protein of a producer line which they constitutively express. Although 
producer lines exist for both the RD114 and Eco envelopes, the toxicity of the 
VSV-G envelope precludes constitutive expression of this protein hence 
inducible expression strategies have been developed to accommodate this 
limitation when VSV-G envelope tropism is desired.  
Chapter Seven 
195 
 
 
Experimental aim: To demonstrate functional expression of RQR8 in murine 
splenocytes in preparation toward  modelling experiments. 
Note regarding variation in splenocyte strain between experiments: the model 
which we were preparing for was a C57BL/6 to Balb/c allogenic acute GvHD 
model previously established by the Chakraverty group at the Royal Free 
hospital, employing CD90.2 congenically marked C57BL/6 mice as the source 
for donor splenocytes, to be transferred into wild-type CD90.1 Balb/c recipient 
animals. As the CD90.2 C57BL/6 strain was a limited resource, preparatory 
experiments were mostly performed using Balb/c splenocytes with CD90.2 
C57BL/6 splenocytes used when available and where required. 
In our transition from human to murine culture, our first step was to confirm 
we could generate viral supernatant that would achieve effective transduction 
of splenocytes. Previous research had employed RD114 pseudotyped 
supernatant to facilitate retroviral transductions of human PBMC’s, using 
supernatant which had been generated by triple transfection of HEK293T cells. 
As both the Stauss and Anderson protocols employed ecotropic envelope 
producer lines for supernatant generation (Phoenix-Eco and LinXE 
respectively), we used the LinXE producer line268 for ecotropic supernatant 
generation. (LinXE cells were a kind gift from John Anderson). 
In our initial experiment, we generated Eco enveloped retroviral supernatant 
for the Q8.I2.eGFP construct to confirm successful transduction of 
splenocytes. As previously with epitope mapping research, co-expression of 
the eGFP marker protein was included to confirm identification of transgenic 
cells to account for the potential scenario whereby splenocytes might be 
limited in their capacity to successfully express the epitope on the cellular 
surface. As illustrated by Figure 55, we were able to successfully transduce 
both CD4 and CD8 T-cells in both Balb/c and C57BL/6 splenocytes, 
demonstrating effective expression of the Q8 epitope. Notably, following with 
anecdotal evidence by other researchers from the Royal Free hospital, there 
was a marked reduction in the transduction efficiency observed for the Balb/c 
cohort compared with the C57BL/6 cohort. Premising this might reflect a 
comparatively reduced expression of the mCAT1 receptor on C57BL/6 
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splenocytes, we compared transduction efficiency of a hybrid supernatant 
whereby we transfected LinXE producer cells with the VSV-G envelope in 
addition to the expression vector with a view to producing dual pseudotyped 
supernatant. However this strategy appeared to reduce the viral titre rather 
than offering potential benefit. Further, as our experimental aim necessitated 
cellular purification through MACS sorting subsequent to transduction, we 
considered that this limitation could be resolved by increasing the scale of 
splenocyte transduction. 
Having demonstrated successful splenocyte transduction and expression of 
the Q8 epitope, we next sought to similarly confirm successful expression of 
the RQR8 epitope, illustrated by Figure 55c.  
 
(a) Balb/c and C57BL/6 splenocytes were transduced with Q8.I2.eGFP supernatant with 
transduction efficiency assessed 48 hours following transduction, 24 hours following cellular 
recovery. (b) T-cell profile of splenocytes transduced from (a) were examined to confirm 
successful transduction of both CD4 and CD8 compartments (c) Balb/c splenocytes were 
transduced with RQR8.I2.eGFP supernatant to confirm transgenic splenocytes retain antibody 
binding capacity for both QBEnd10 and rituximab binding epitopes. As illustrated, ecotropic 
supernatant generated from the SFG vector enable effective and functional transduction of 
RQR8 in CD4 and CD8 Balb/c and C57BL/6 splenocytes. Data reflects a typical result from 
many experiments. 
 
Having successfully demonstrated supernatant generation, transduction and 
cell-surface epitope expression, our next experimental question addressed the 
stability of viral supernatant. Both the Stauss and Anderson laboratory 
protocols described application of fresh viral supernatant for transduction, 
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however in light of the experimental scale required, we questioned whether it 
might be possible to generate and validate batches of viral supernatant in 
advance, stored at -80oC until required, to reduce the cost imposed by 
experimental abortions. Lastly, further to research from Chapter seven, we 
also considered inclusion of a S/MAR domain in our construct with a view to 
enhancing transgene expression. Figure 56 illustrates the results from these 
experiments confirming that following a freeze-thaw cycle, both 48 and 72 
hour viral supernatant harvests retained infective capacity demonstrating 
successful transductions of Balb/c splenocytes. Further, we confirmed 
effective expression of both Q8 and RQR8 epitopes in the presence or absence 
of a S/MAR domain. Although increased transduction and expression was only 
apparent for the Q8 construct, as there was no reduction in expression 
observed with RQR8, the S/MAR containing construct was employed where 
indicated in subsequent research. 
 
  
Further Balb/c splenocyte transductions were performed to establish whether ecotropic 
enveloped supernatant could withstand a freeze-thaw cycle and to validate epitope expression 
constructs lacking a fluorescent protein marker. (a) Balb/c splenocytes were transduced with 
Q8, RQR8 and Q8.I2.eBFP2 supernatants snap frozen 48 hours and 72 hours post LinXE 
transfection to establish ability of Eco-enveloped supernatant to withstand a single freeze-thaw 
cycle with flow cytometry analysis performed 24 hours following splenocyte recovery. (b) 
Balb/c splenocytes were transduced with Q8 and RQR8 supernatants from constructs 
possessing or excluding a S/MAR domain in the retroviral vector construct. Data reflects the 
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result from a single experiment which assisted development of a protocol employed for 
subsequent experiments. 
 
Experimental aim: To demonstrate retention of CD34 magnetic bead selection 
of RQR8-transgenic murine splenocytes in preparation toward  
modelling experiments. 
We next sought to demonstrate effective MACS selection of transgenic 
splenocytes, which represented a critical milestone to enable successful 
transition to  modelling experiments. Illustrated by Figure 57, we 
observed clear efficacy from MACS selection when performed on a small scale 
but a reduced efficacy on increase of experimental scale. Further, following 
MACS selection, we observed a rapid and severe decline in splenocyte viability. 
 
Retrospective analysis of flow cytometry results assessing sample purify from separate 
experiments involving Q8.I2.eGFP transduction and CD34 magnetic bead selection of Balb/c 
splenocytes demonstrated variation between efficacies of purification dependent upon the scale 
of the transduction. Left - small scale transduction: 6 wells of a 24 well plate/12-18x10^6 
Balb/c splenocytes transduced. Right - large scale transduction: Twelve 24 well plates of 
splenocytes/48-60x10^6 splenocytes/plate transduced. As illustrated, an increased background 
of non-transduced splenocytes remaining following magnetic bead purification was observed 
when selection was performed at a larger scale. 
 
Having observed that the viability of splenocytes maintained in dense culture 
appeared to be higher than for those maintained in sparse conditions, we 
premised that the cocktail of cytokines secreted by stromal, myeloid and other 
populations may be in part responsible for this observation. Further, having 
observed that fresh RPMI supplemented with IL2 proved insufficient to 
mediate recovery of fragile splenocytes following MACS selection, we 
considered splenocyte recovery into the ‘conditioned’ medium from which 
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they had been harvested from. Illustrated by Figure 58, we observed a similar 
comparative viability between the non-transduced control sample and the 
MACS sorted cells two hours following selection, but demonstrating a 
profound enhancement in cellular viability following 24 hours of culture in 
conditioned medium for both Balb/c and C57BL/6 splenocytes; thereby 
resolving the limited viability previously observed and enabling improved 
cellular analysis prior to infusion. Note: recovery into fresh medium was not 
considered in this experiment having proven uniformly toxic through 
numerous previous experiments. 
 
Having observed poor splenocyte viability following magnetic bead selection, we assessed the 
viability of purified cell product when recovered in conditioned medium. 24-wells/48-60x10^6 
splenocytes of either Balb/c or C57BL/6 splenocytes were transduced with Q8.I2.eGFP, 
recovered overnight, then purified by CD34 magnetic bead selection. Following MACS sorting, 
splenocytes were recovered into 0.45µm filtered cellular supernatant from which they were 
derived with cellular viability of the recovered cells assessed at 2 and 24 hours following 
selection. Note: Non-transduced cells represent the viability control as these cells remained 
unhandled during the assessment timeframe to reflect typical progressive loss of splenocyte 
viability typically resulting from extended in vitro culture. 
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The reduction in sample purity observed from the MACS selection process 
when performed in large scale posed the next experimental challenge. As 
QBEnd10 is a murine antibody, we premised high background binding 
reflected FcγR binding of the QBEnd10 antibody by residual effector cells such 
as monocytes. Further, having established conditioned medium facilitated 
enhanced cellular viability, we opted to attempt a blocking strategy to exclude 
residual effectors at the selection stage rather than by increasing experimental 
cost through T-cell selection from the outset. We identified two strategies 
which might fulfil this function; Miltenyi murine IgG cocktail as a blocking 
reagent to saturate the FcγR’s, or use of the 2.4G2 hybridoma supernatant as 
an antibody-mediated blocking strategy. From our initial attempt illustrated by 
figure a, neither strategy appeared to demonstrate improved clarity of MACS 
selection following 30-minutes of blocking with 100µl of either reagent; 
however as purity and viability appeared improved following blocking with the 
2.4G2 hybridoma supernatant, further repeats were performed ultimately 
identifying a requirement for 1ml of 2.4G2 hybridoma supernatant per spleen 
to achieve the desired efficacy of FcγR-blocking. Results from this experiment 
are indicated by Figure 59. 
 
To resolve selection of FcyR expressing effectors which impair the level of purity which could 
be achieved from large scale magnetic bead selection of splenocytes, we assessed the effect of 
application of anti-mouse CD32 2.4G2 supernatant might have on magnetic bead selection 
efficacy. (a) 24-wells/48-60x10^6 of Balb/c splenocytes were transduced with Q8.I2.eGFP, 
then purified by CD34 magnetic bead selection following a 30 minute incubation in either 
100µl of Miltenyi murine IgG blocking reagent or 0.45µM filtered neat 2.4G2 hybridoma 
cellular supernatant. Sample purity and cellular viability was assessed by flow cytometry 24-
hours following MACS selection. (b) 24-wells/48-60x10^6 of C57BL/6 splenocytes were 
transduced with RQR8.I2.eGFP, then then purified by CD34 magnetic bead selection following 
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a 30 minute incubation in 1ml of 0.45µM filtered, neat 2.4G2 hybridoma cellular supernatant. 
Following selection, splenocytes were recovered into 0.45µm filtered cellular supernatant from 
which they were derived with sample purity and cellular viability assessed by flow cytometry 
24-hours following MACS selection. As illustrated, use of 2.4G2 supernatant as a blocking 
reagent improved sample purity whilst recovery into conditioned medium enhanced cellular 
viability. 
 
Experimental aim: To establish an experimental protocol to achieve consistent 
generation of sufficient viable transgenic murine splenocyte cellular product 
to enable  modelling experiments. 
Combining results from this preliminary series of investigations led to the 
generation of a 5-day protocol offering a minimal period of  handling 
required to facilitate consistent isolation, transduction, recovery, purification 
and confirmation of transgenic murine T-cell product prior to re-infusion into 
recipient animals, illustrated by Figure 60 and briefly summarised below: 
Day 1: splenocytes are isolated from donor animals and stimulated with 
ConA/IL7 (2µg/ml and 1ng/ml respectively). Day 2: Activated splenocytes are 
harvested and transduced in the absence of stimulation, in neat viral 
supernatant. Day 3: Restimulation: Transduced splenocytes were recovered 
into fresh RPMI supplemented with murine IL2 (50ng/ml). Day 4: Transduction 
efficiency was tentatively confirmed by flow cytometry and splenocytes were 
MACS-sorted following 2.4G2 blocking, and recovered back into 0.45µM 
filtered conditioned medium from which they originated. Day 5: Final 
assessment of purity for transgene expression and cellular CD4/CD8 profile 
was confirmed by flow cytometry prior to infusion of transgenic cell product 
into recipient animals. 
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A five day protocol was established as illustrated, which combined standard splenocyte 
transduction protocols with recovery in conditioned medium and blocking with 2.4G2 
supernatant prior to magnetic bead selection. This optimised protocol enables generation of 
5x106 purified transgenic cell product for each 24-wells/48-60x106 splenocytes which were 
transduced. 
 
In this chapter, we have demonstrated successful generation of ecotropic-
pseudotyped retrovirus facilitating transduction of C57BL/6 and Balb/c 
splenocytes, observing successful transduction for both murine CD4 and CD8 
T-cell subsets. The SFG viral integrant appears to mediate stable expression of 
all transgenic cassettes investigated, with successful binding observed for both 
QBEnd10 and rituximab antibodies against appropriately modified 
splenocytes. Further, ecotropic envelope has been shown to be sufficiently 
robust to tolerate freeze-thaw cycling thereby facilitating generation and 
validation of viral supernatant in advance of experimentation, assisting design 
and planning of large modelling experiments. 
Use of 2.4G2 hybridoma supernatant as a blocking reagent improves clarity of 
MACS selection of splenocytes despite the murine derivation of the QBEnd10 
antibody, whilst recovery into conditioned medium results in improved 
cellular viability following overnight recovery from MACS selection. In 
combination, employing our 5-day protocol we observed that we could 
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consistently generate 5x106 transduced purified viable splenocytes per donor 
spleen. 
 
 Ecotropic pseudotyped SFG retrovirus facilitates successful 
transduction of murine splenocytes 
 Transgenic splenocytes demonstrate epitope expression analogous to 
previous results achieved with primary human PBMCs 
 Use of the 2.4G2 hybridoma supernatant as a blocking reagent reduces 
cellular contamination of the transgenic cell population following 
Miltenyi bead selection 
 MACS selection of transgenic splenocytes enables consistent 
purification >90% 
 The optimised 5-day protocol demonstrates a consistent strategy to 
produce sufficient transgenic splenocytes for  modelling 
experiments 
 Use of conditioned medium enhances post-MACS selection recovery and 
ensures optimal cellular viability prior to infusion
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As the capacity for murine effector mechanisms to respond to the human IgG1 
domain of rituximab presented an uncontrolled variable, we premised it would 
be necessary to use an equivalent murine isotype as human IgG1 to achieve a 
more reflective result from  modelling experiments. 
 
 To reverse engineer rituximab to generate a murine IgG2a isotype 
 To confirm the binding domain of mRtx-IgG2a matches the sequence 
from the rituximab IDEC2B8 hybridoma 
 To establish a producer line to ensure stable production of mRtx-IgG2a 
 To achieve a production strategy to enable sufficient production of 
mRtx-IgG2a to enable  modelling 
 To confirm of retention of functional capacity of mRtx-IgG2a antibody 
product through  assays 
 
As rituximab is a chimeric antibody, we premised that the presence of the 
humanised constant domain may pose an uncontrolled variable limiting 
efficacy and possibly negatively impacting upon the therapeutic half-life in our 
proposed modelling experiments. In an effort to establish a more reflective 
model of human rituximab kinetics, we reverse engineered rituximab into the 
murine IgG2a isotype which offers analogous functional capacity with the 
human IgG1 format of rituximab based on B-cell depletion studies from animal 
models183, 184. Table 11 illustrates functional capabilities of alternative murine 
IgG isotypes. 
Note: ADCC activity refers to activity assessed for murine effectors 
CDC269 
ADCC270 
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As variation between the murine IgG2a allotypes has been identified as a 
confounding variable affecting ELISA quantification due to variation in 
antibody binding affinity for the separate allotypes, it was necessary to 
confirm the absolute identify of the IgG2a allotype employed in our Rtx-IgG2a 
engineering to ensure effective ELISA based quantification. 
IgG2a allotype gene conversion is proposed to result from improperly paired 
bases occurring during genetic recombination271. Following gene duplication of 
the mouse IgG2a / IgG2b gene ancestor, these genes readily diverged with the 
observed divergence between IgG2a alleles thought to be the result of gene 
conversion likely promoted by the short genetic distance separating the two 
loci. This has resulted in a high degree of divergence in the coding sequence of 
the murine IgG2a gene272. Although multiple alleles have been identified for 
each of the murine immunoglobulin isotypes, the IgG2a allele is the most 
polymorphic with 12 allelic forms characterised. The Balb/c and the C57BL/6 
strains are the prototypes for the IgG2aa and IgG2ab haplotypes, henceforth, 
allotypes, respectively273. 
Additionally, generation of sufficient therapy grade antibody required 
identification of a suitable protein production strategy. The main strategies for 
recombinant protein production are transient gene expression (TGE) or 
generation of a stable cell line for continuous production with both strategies 
offering benefits and limitations. Although TGE offers a strategy to achieve 
large-scale protein production, it can prove expensive due to the volume of 
DNA and transfection reagents required; further, TGE may demonstrate 
significant batch-to-batch variation and might require substantial post-
production steps. In contrast, generation of a stable producer cell line can 
resolve or reduce most of these limitations but imposes a longer lag-time 
before protein production can be achieved. Hence TGE is an optimal strategy 
where small-scale screening is required whilst generation of a producer line is 
better suited for bulk production. Finally, scalability imposes further limitation 
to the process. Currently HEK293 are the cell line most commonly employed 
for TGE of recombinant proteins although as of 2006, no recombinant protein 
produced by TGE had been approved for clinical application by the FDA274. In 
the interest of biosafety it is preferable to exclude animal derived components 
from protein production, thus identification of a simple strategy offering 
robust protein production in serum-free mammalian cell culture could be of 
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benefit to facilitate and reduce the cost of pre-clinical modelling. In this 
chapter we describe stable and consistent antibody production from a 
modified K562 cell line. 
 
Experimental aim: To generate a codon optimised expression cassette to 
express the antibody binding domain (Fab) of the therapeutic antibody 
rituximab. 
Having elected to reverse engineer rituximab, the first challenge we faced was 
to locate a reference sequence for the rituximab hybridoma which we could 
use as a template during our design for our gene synthesis cloning strategy. 
Locating the rituximab consensus sequence was confounded by identification 
of alternative sequences from the Alberta drug bank and the US patent 
5,843,439, both claiming to define the protein sequence for the variable 
domains of the rituximab IDEC2B8 hybridoma. Uncertain which sequence was 
correct; we generated constructs for both sequences, henceforth denoted as 
RtxC and RtxP, for the Canadian derived and patent derived sequences 
respectively. 
As with codon-optimisation for CD20opt generated previously, gene synthesis 
was again used to generate codon optimised rituximab scFv fragments using 
pMol software designed by Dr. Martin Pulé. This coding sequence was then 
generated by gene synthesis using overlapping oligos and subcloned in-frame 
as an NcoI-BamHI fragment into SFG.S-CEA_NA1-HCH2CH3-CD28OXZ.I2.eBFP2. 
Following BglII-NsiI restriction digest screening to identify putative correct 
clones, mini-preps were further screened by flow cytometry staining for the 
IgG1 stalk to exclude frame shift mutants, as illustrated by Figure 61. Finally, 
constructs which demonstrated surface expression of the scFv construct were 
verified by DNA sequencing. 
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Molecular cloning and functional screening of gene-synthesized rituximab-scFv. (a) PCR-based 
gene synthesis: Template PCR reaction containing overlapping oligonucleotide primers 
produced a smear of DNA fragments; these were subsequently focussed into clear product 
following a fusion PCR reaction combining the separate fragments through amplification of the 
desired sequence bounded by terminal oligonucleotide primers. (b) Restriction digest of 
destination vector and PCR-amplified inserts: Following PCR clean-up, fusion PCR products 
were digested as NcoI-BamHI fragments, then subcloned into a similarly digested target vector 
(MP5616) (c) Restriction digest screening: miniprep colonies were screened by BglII-NsiI 
restriction digest to identify transgene positive clones (d) Functional screening by flow-
cytometry: As the insert sequence was cloned in-frame into the open reading frame (ORF), 
mini-prep DNA transfected HEK293T cells were used to stain for functional expression of the 
scFv IgG1 immunoglobulin HCHG2CH3 domain confirming functional expression of protein 
product from the ORF to exclude frame-shift mutants. Non-transduced HEK293T included as 
staining control indicated at left. Note: dim eBFP2 expression was due to poor laser alignment 
of the violet laser. Lastly, following exclusion screening, one RtxC and two RtxP clones were 
confirmed by DNA sequencing. 
 
Experimental aim: To subclone the antibody binding domains of the anti-CD20 
scFv’s into secreted formats to validate binding efficacy against RQR8. 
Having generated putative rituximab binding fragments, we proceeded to 
subclone the scFv domain into a secreted format through ‘cut and paste’ 
cloning as an NcoI-BamHI insert into a secreted scFv construct previously 
generated by Dr. Simon Thomas. To enable functional validation of our 
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constructs, supernatant containing the putative scFv binding domains was 
generated by transient transfection of HEK293T cells. Validation of antibody 
binding was assessed through an indirect flow cytometry binding assay 
comparing binding of anti-human Fc following primary staining of Jurkat T-
cells using HEK293T produced scFv supernatant. As illustrated by Figure 62, 
although both scFv constructs bound to the CD20 positive control only the 
RtxP-scFv demonstrated clear binding against the RQR8 target likely 
representing the correct sequence for rituximab. 
 
Putative rituximab scFv constructs were subcloned into a secreted expression format, 
transfected into HEK293T cells and the resulting supernatant was used to assess binding 
efficacy by flow cytometry through indirect binding assays against transgenic Jurkat T-cell 
targets. Primary staining was performed using RtxP or RtxC scFv supernatant followed by 
secondary staining with an anti-human Fc-Cy5 conjugate. As illustrated, clear binding against 
the RQR8 target was observed from RtxP-scFv supernatant whereas the RtxC-scFc only bound 
the CD20 control. 
 
Experimental aim: To confirm that the antibody binding domain coding for our 
rituximab scFv (RtxP) as defined by the US patent 5,843,439, corresponds with 
the rituximab antibody sequence as identified from the IDEC-2B8 hybridoma. 
Having confirmed the functional capacity of our RtxP-scFv construct to bind 
the RQR8 target, and in light of concerns regarding the exact sequence of the 
rituximab antibody, lastly we aimed to conclusively establish that our RtxP-
scFv sequence was identical to that of the rituximab IDEC-2B8 hybridoma. 
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To this end, we obtained the rituximab IDEC-2B8 hybridoma from the 
American Type Culture Collection (ATCC). Following hybridoma recovery, we 
performed RNA extraction and cDNA generation as per protocols 2.2.1.1.12 
and 2.2.1.1.13 respectively, with successful cDNA generation confirmed by 
amplification of the GAPDH housekeeping gene using Qiagen oligonucleotide 
primers.  
Finally, amplification of the heavy and light chains from the hybridoma was 
performed using oligonucleotide primers (IDT) as detailed in the protocol by 
Dübel . Successful amplicons were subcloned by TOPO TA cloning 
(Invitrogen) with DNA sequencing performed by the scientific support core 
facility. 
Variable region allele analysis was performed through comparison of coding 
regions identified from hybridoma sequence traces against the mouse 
immunoglobulin set as assessed using IMGT/V-QUEST. Comparison of the 
heavy variable region analysed between the first nucleotide of the coding 
sequence to the second cysteine codon identified a productive rearranged IGH 
sequence demonstrating 93.75% homology with the murine IGHV1-12*01F 
allele. Further, analysis of the light chain variable region identified 96.01% 
homology with the murine IGKV4-72*01F allele. Having confirmed the 
identified sequence corresponded with the murine immunoglobulin coding 
sequence, we then compared a translation of the open reading frame identified 
from hybridoma sequence traces, aligned against the rituximab sequence 
which demonstrated regions of clear homology as illustrated by Figure 63, 
confirming our RtxP sequence matched that of the IDEC-2B8 hybridoma. 
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Heavy and light chain sequences for rituximab as defined by US patent 5,843,439 were 
compared against DNA sequence traces from cDNA derived from the rituximab hybridoma 
IDEC-2B8. As illustrated, the protein sequence used for the RtxP scFv matches the coding 
sequence from the rituximab hybridoma. 
 
Experimental aim: To reverse engineer rituximab back into a murine antibody 
by subcloning the rituximab scFv heavy and light antibody binding domains 
onto murine constant IgG2a heavy and kappa light chains. 
Having successfully cloned, functionally validated and confirmed the identity 
of the rituximab variable domain sequences, we proceeded to reverse engineer 
rituximab into a complete murine IgG2a isotype antibody. The genetic 
sequence for the murine IgG2a heavy and kappa light chains were sourced 
from Invivogen pFUSEss-CH1g-mG2A and pFUSE2ss-CLIg-mk plasmids 
respectively. Concerned that functional impairment of our antibody might 
result from the presence of residual TaV-2A sequence if the construct was 
expressed in a bicistronic format, we opted to separate the heavy and light 
chains into separate constructs each identified by a separate fluorescent 
protein marker. As previously, application of a SOE-PCR cloning strategy 
enabled inclusion of NcoI and MluI restriction sites facilitating facile cloning of 
the heavy and light chains into HA1-TCRbeta.I2.eGFP and HA1-
TCRbeta.I2.eBFP2 vectors respectively. Restriction digest screening of miniprep 
samples identified putative correct constructs which were confirmed by DNA 
sequencing. 
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Concerns regarding confounding variables such as limitations in cellular 
glycosylation capacity or aberrant protein folding could impact upon 
functional antibody production, next we sought to confirm that we could 
successfully generate functional antibody following co-expression of both 
heavy and light chain constructs in cell culture. Therefore, as a proof of 
principle experiment prior to generating supernatant and establishing stable 
cell lines, HEK293T cells were co-transfected with both heavy and light chain 
constructs and grown to confluence. Supernatant derived from this culture 
was then used to stain Jurkat T-cells as previously to confirm successful 
antibody production as illustrated by Figure 64. 
 
To confirm expression of our re-engineered heavy and light chains of rituximab would form a 
functional antibody we performed a staining assay using cellular supernatant derived from 
HEK293T cells co-transfected with Rtx-H-mIgG2a and Rtx-L-mKappa constructs; four days 
following transfection, cellular supernatant was harvested as employed as a primary stain 
against Q8, RQR8 or CD20 transgenic Jurkat T-cell targets. Functional binding was confirmed 
by flow cytometry analysis using an APC-conjugated anti-mouse Fc as the secondary antibody. 
As illustrated, mRtx-IgG2a binding was observed against both the CD20 and RQR8 transgenic 
targets. 
 
As illustrated by Figure 64, clear specific binding was demonstrated against 
both RQR8 and the CD20opt control constructs, with no binding observed 
against the Q8 target.  
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Experimental aim: To establish a stable eukaryotic producer line capable of 
producing sufficient mRtx-IgG2a antibody to enable  modelling 
experiments. 
Our next challenge was to establish a culture strategy which would 
demonstrate sufficient antibody production as to enable  modelling 
experiments. Based on modelling experiments for putative CD20 suicide gene 
constructs from the literature154, we premised that milligram quantities of 
mRtx-IgG2a would be required for each  modelling experiment. 
HEK293T cells are commonly employed for protein production. However, a 
limitation of HEK293T cells is restriction to 2-dimensional cell culture due to 
their adherent growth profile. Although we briefly considered 3-dimensional 
suspension culture of the 293SF serum-free adapted HEK293T cell derivative, 
these cells proved fragile and limiting in their potential application for our 
purposes. Next we considered K562 cells having previously proven easy to 
transduce and manipulate as an alternative suspension cell population. We 
multiply transduced both HEK293T and K562 cells with both heavy and light 
chain constructs. Following confirmation of successful transductions, 
transduced cell populations were subsequently MoFlo sorted based on high 
expression of both the eGFP and eBFP2 fluorescent marker genes. Finally we 
single cell cloned high expressing isolates which were examined for mRtx-
IgG2a production based on serial dilution titration assays as illustrated by 
Figure 65. High expressing clones producing protein supernatant 
demonstrating comparable rituximab binding capacity as the IDEC-2B8 
hybridoma supernatant were identified for both HEK293T and K562 cells. 
However, the K562 mRtx-IgG2a producer clone A7 was selected for subsequent 
mRtx-IgG2a production based on antibody titre, cellular growth profile and 
stable viability. 
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Cellular supernatants produced by putative K562 producer lines were screened for efficacy of 
mRtx-IgG2a protein production using serial dilution of cellular supernatants as assessed for 
RQR8 target binding by flow cytometry. (a) Equal numbers of Jurkat.RQR8.I2.eGFP 
expressing target cells were stained with serial dilutions of cellular supernatant but assessed 
using constant level of the DyLight-649 conjugated anti-mouse Fc secondary. MFI of mRtx-
IgG2a antibody binding was assessed against a stringent population of high expressing targets 
as illustrated. Results illustrate comparative binding efficacy of the K562.A7 clone compared 
against the IDEC-2B8 hybridoma. (b) Titration assay results from the top six single cell clones 
from both K562 and HEK293T mRtx-IgG2a producer lines. As illustrated, both K562 and 
HEK293T producer lines demonstrated similar levels of protein production. 
 
Experimental aim: To establish a protocol for bulk production and purification 
of mRtx-IgG2a antibody. 
Antibody production comprised a multi-stage process involving successful 
confirmation of protein production at crucial progression points. Observations 
from initial purification runs were modified to establish the final protocol as 
detailed in methods 2.1.7. 
Briefly, a fresh batch of K562.mRtx-IgG2a.A7 producer cells was recovered one 
week prior to antibody production. Following recovery, cells were grown in 
complete IMDM to establish a seed culture for bulk production. For 
production, cells were harvested by centrifugation, washed with PBS and 5-10 
million K562.mRtx-IgG2a.A7 cells were seeded into T175cm2 flasks pre-filled 
with 100ml of mRtx-IgG2a IMDM. Cell culture was allowed to progress for 
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approximately 1 week until terminal density was achieved defined by cell 
death observed in approximately 50% of cells as assessed by Trypan blue 
exclusion by haemocytometer analysis. At this point, antibody supernatant 
was harvested and prepared for purification briefly detailed as follows: 
Cell culture was harvested into 250ml centrifuge tubes and centrifuged at 
400G for 10 minutes to pellet cells.  Cellular supernatant was transferred to a 
Duran bottle with a sample taken to confirm presence of antibody through 
flow cytometry staining analysis. Cellular supernatant was then 0.22μm 
filtered by vacuum filtration to exclude cellular debris to prevent filter 
blockage during protein concentration. Next, protein supernatant was 
concentrated using a Millipore Pellicon tangential flow filter system fitted with 
a Pellicon XL Biomax 50 filter to enable exclusion of small proteins whilst 
retaining proteins of mass 50kDa±20kDa. Following tenfold concentration, 
supernatant was transferred to snakeskin dialysis tubing and dialysed into 
20mM sodium phosphate loading buffer solution at 4oC overnight, assisted by 
agitation mediated by magnetic stirrer. Samples obtained during protein 
concentration were assessed by indirect staining to demonstrate successful 
concentration and retention of antibody as illustrated by Figure 66.   
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(a) Samples of protein supernatant were assessed by flow cytometry against a 50:50 mixture of 
non-transduced or RQR8.I2.eGFP transgenic Jurkat T-cells for the presence of functional 
antibody. Concentration and elution discard fractions were also assessed for presence of 
residual antibody. (b) A280 measurements were made from samples obtained during 
concentration to verify successful sample enrichment. (c) Comparative MFI analysis assessed 
by flow cytometry of fractions taken during protein concentration further validate successful 
protein concentration. As illustrated, mRtx-IgG2a protein retained functional stability during 
tangential flow filtration concentration prior to purification. 
 
Following dialysis, the supernatant was again 0.22μm filtered by vacuum 
filtration prior to sample loading onto a protein A column using an 
ÄKTAprime plus system. Sample loading and elution profiles are illustrated by 
Figure 67. A280 measurements were taken to confirm elution samples match 
with profile. 
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(a) Sample fractions obtained during protein concentration were assessed by 
A280 spectrophotometric assessment to ensure successful concentration and protein retention. 
(b) During Protein A column loading, absorbance measurements on the ÄKTAprime plus 
allowed confirmation of presence of protein in the loading buffer and identified completion of 
sample loading. (c) Absorbance measurements of elution fractions indicated protein release 
from the column. (d) A280 spectrophotometric measurements of elution fractions were 
performed to confirm presence of concentrated protein. Functional confirmation of purified 
mRtx-IgG2a protein is illustrated by Figure 69  
Following the initial purification run, size confirmation of the mRtx-IgG2a 
product was assessed by Coomassie staining following SDS-PAGE. Mass 
approximations for the mRtx-IgG2a heavy and light chains, identified using the 
ExPASy275 bioinformatics research tool suggested predicted protein masses of 
51.8 and 25.5kDa for the mRtx-IgG2a heavy and light chains respectively. 
Purified mRtx-IgG2a protein was compared against reference samples of 
Mabthera rituximab as illustrated by Figure 68. Presence of a smaller heavy 
chain specific to the IMDM samples suggested residual contamination from 
FCS despite the reduced bovine IgG content indicated by the absence of this 
band from the sample generated from serum-free Hyclone medium. During 
initial mRtx-IgG2a production runs, IMDM medium was supplemented with 
10% IgG depleted FCS. However, as analysis of K562 cellular viability at 
reduced levels of FCS supplementation did not appear to impose any impact 
upon K562 cellular viability as assessed by Annexin V/PI staining, serum 
supplementation of culture media was reduced to 2.5% for subsequent 
purification runs to further reduce bovine IgG contamination. Due to the 
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desired functional application of mRtx-IgG2a, protein product validation 
following subsequent production runs was restricted to quantification and 
functional assays. 
 
To confirm the presence of putative mRtx-IgG2a protein, purified samples of mRtx-IgG2a 
protein from five separate production runs were separated by polyacrylamide gel 
electrophoresis and assessed for protein size by Coomassie staining; sample protein 
concentrations were established by A280 measurements. Serial dilutions of clinical-grade 
rituximab were included to enable visual comparison of intensity of protein staining and protein 
band size. 
 
Experimental aim: To confirm functional retention of both the antibody 
binding (Fab-domain) and mRtx-IgG2a mediated deletion (Fc-domain) following 
protein production, purification and downstream processing. 
Antibody stability varies widely dependent upon the protein sequence. 
Further, handling can impair functional behaviour of the protein. Following 
sterile filtration, mRtx-IgG2a was quantified by: A280 measurements and 
ELISA, with functionality verified by indirect staining and CDC assays. 
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(a) Binding: Samples of purified mRtx-IgG2a antibody were assessed by flow cytometry for 
retention of functional binding efficacy against a 50:50 mixture of non-transduced or 
RQR8.I2.eGFP expressing Jurkat T-cells for the presence of functional antibody. (b) Deletion: 
Peripheral human PBMCs were transduced with RQR8.I2.eGFP or Q8.I2.eBFP2, separately 
purified by CD34 magnetic bead selection then mixed together in an equal ratio to establish a 
target population which was then subjected to a specificity CDC assay employing purified 
mRtx-IgG2a as rituximab in this assay. As illustrated, final purified mRtx-IgG2a antibody 
product retained functional capacity of both Fab and Fc domains; antibody binding & CDC-
mediated deletion respectively. 
 
In conclusion, we have successfully identified and established variable domain 
binding fragments of rituximab. Further, following re-engineering into the 
murine IgG2a isotype, we have demonstrated that we can produce functional 
antibody in sufficient quantity to enable  modelling experiments. 
Through generation of a stable K562 producer cell line, we have established a 
three-dimensional culture strategy demonstrating robust and stable protein 
production. From a 2L large scale run, we produced 65mg of mRtx-IgG2a, 
suggesting a production rate of 32.5mg/L. Compared against transient gene 
expression (TGE) strategies for protein production which typically yield 1-
80mg/L274, this production level is well within the range for TGE expression 
strategies and offers the potential for consistent protein production for future 
production runs. Further, this follows from minimal optimisation achieving a 
stable production strategy avoiding inter-batch variation typical of TGE 
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strategies. Lastly, separate work performed by Ben Draper under my 
instruction has demonstrated that K562 cells can be readily adapted to culture 
in serum free medium, demonstrating a more robust growth profile than was 
observed for suspension HEK293 cells, adding support for the potential of 
general application of K562 cells as a protein production platform. 
 
 Through gene synthesis we have identified the binding domain of 
rituximab as cited in US patent 5,843,439, and verified against the DNA 
sequence isolated from the IDEC2B8 hybridoma 
 Following subcloning of the variable domains into murine IgG2a 
constant heavy and kappa light chains, we have demonstrated  
production of IgG2a isotyped rituximab following transient transfection 
of HEK293T cells 
 From comparison of antibody production between stably transduced 
HEK293T and K562 cells, we identified and established the high 
expressing and stable producer line: K562.A7  
 Following large scale antibody production, functional and qualitative 
assays verified that we had produced sufficient functional IgG2a 
isotyped rituximab to enable  modelling experiments 
Chapter Nine 
220 
 
 
As GvHD is neither vector nor target specific, we selected GvHD modelling as 
the simplest strategy to assess the  functional capacity of RQR8 to 
resolve therapeutic toxicity. 
 
 To successfully increase experimental scale sufficient to enable  
modelling experiments 
 To successfully achieve transgenic cellular engraftment in recipient 
animals 
 To establish a model of GvHD pathology mediated by activated, 
transduced and MACS sorted splenocytes 
 To demonstrate resolution of GvHD pathology through mRtx-IgG2a 
mediated cellular deletion 
 
GvHD remains a common co-morbidity following HSCT despite administration 
of immunosuppressive therapies. Correspondingly, a range of animal models 
have been established in order to obtain further insight into the molecular 
pathology of GvHD276, including description of a C57BL/6 to Balb/c acute GvHD 
MHC-I mismatch model as described by van Leeuwen 277. 
Reflecting the direct relevance of the observations by van Leeuwen 277  the 
following discussion will briefly summarise some of the key findings as they 
pertain to observations from our own research. Myeloablative preconditioning 
and bone marrow transfer was associated with a two-phase model of GvHD 
pathology with an initial phase characterised by weight loss followed by a 
second phase demonstrating symptoms characteristic with clinical GvHD. 
Although both syngeneic and allogeneic recipients demonstrated significant 
weight losses during the first week following irradiation, syngeneic recipients 
were observed to have recovered body mass 16 days post transfer whilst 
allogeneic recipients demonstrated sustained weight loss progressing until 
euthanasia became necessary. Animals which were irradiated without bone 
marrow recovery mirrored the initial weight loss of the syngeneic recipients, 
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and despite a brief weight recovery phase, rapidly progressed into terminal 
decline resulting from haematopoietic failure. Thus, although some weight 
loss could be attributed to a response to total body irradiation (TBI), additional 
weight loss was proposed to reflect an initial phase of GvHD progression. 
Furthermore, a profound depletion of the host MHC-II compartment was 
observed resulting in undetectable levels of host MHC-II cells from the spleen 
and bone marrow 7 days following the preconditioning irradiation contrasting 
with a progressive increase in the donor MHC-II compartment during this 
period. This variation in the MHC-II compartment was proposed to explain the 
transient recovery separating the two-phases of GvHD pathology. The authors 
propose that an initial phase of GvHD, progressing up to day 7 as evidenced by 
weight loss greater than that observed by syngeneic controls, might reflect 
direct recognition of host antigens presented by host APCs by the donor T-cell 
population, whilst the second phase commencing after 12 days post-transfer, 
was suggested to arise from indirect antigen presentation by donor-derived 
APC’s to donor T-cells. 
Reflecting our aim toward demonstration of GvHD resolution mediated by the 
suicide-gene capacity of RQR8, our primary intent was to establish a model of 
MHC-I mismatched GvHD which would offer a platform by which efficacy of 
RQR8-mediated deletion could be assessed .  
 
Experimental aim: To establish an  experimental model of GvHD 
pathology mediated by transgenic splenocytes. 
 
Our acute C57BL/6 to Balb/c GvHD model was based upon previous research 
Prof. Ronjon Chakraverty and Dr. Barry Flutter278. Following a report from the 
literature suggesting an impaired capacity for GvHD induction resulting from 
the  handling necessary to accomplish retroviral transduction and 
paramagnetic selection279, we commenced with an initial pilot experiment 
designed to confirm that  manipulated splenocytes would retain the 
capacity to induce a pathology consistent with classical symptoms of GvHD 
assessed by  modelling. The presence of a single nucleotide 
polymorphism in the murine allele for CD90, hereafter Thy1.1 and Thy1.2, 
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enables discrimination between donor and recipient lymphocyte populations 
by antibody staining and reflects current technology for cellular marking 
strategies employed within  modelling experiments. Briefly, our 
allogeneic GvHD induction model comprised transduction and purification of 
splenocytes from a (C57BL/6) Thy1.1 x Thy1.2 donor, which were subsequently 
transferred into a (Balb/c) Thy1.1 host. To enable MACS sorting and cellular 
identification, splenocytes were transduced with the Q8.I2.eGFP construct to 
enable cellular marking by QBEnd10, with further specific identification of the 
transgenic population mediated by the eGFP fluorescent marker. To prevent 
deletion of the transgenic cell infusion by host cells and to assist effective 
engraftment by the adoptive cells91, recipient mice were pre-conditioned with 8 
Gy X-ray TBI supplied in two equal 4 Gy doses supplied 48 and 4 hours 
respectively, prior to adoptive cell transfer. All recipient animals were supplied 
with 10 x 106 freshly isolated, T-cell depleted, bone marrow cells sourced from 
an identical donor population as used for preparation of transgenic T-cells, to 
preclude lethality from haematopoietic failure following TBI preconditioning.  
Due to poor transduction efficiency, difficulty with MACS selection and poor 
viability of the transgenic splenocytes, our pilot experiment resulted in only 
one Balb/c mouse being infused with 3 x 106 MACS sorted splenocytes in 
addition to supplemental bone marrow as described, which was assessed 
against two control Balb/c mice which were supplied with only the bone 
marrow infusion. Animals were assessed for evidence of GvHD pathology 
during the experiment by weight and GvHD scoring assessments. GvHD 
scoring parameters are indicated by . 
Animals were scored based on progressive weight loss and a range of subjective criteria as 
indicated. Further, indication of diarrhoea and/or weight loss greater than 10% each resulted in 
a score of 1. According to licence parameters, euthanasia was required when weight loss 
remained beyond 20% or if the cumulative GvHD score ≥4. 
Grooming 0-2 
Posture 0-2 
Activity 0-2 
Eyes 0-2 
Diarrhoea 0 or 1 
Weight loss 0 or 1 
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Although weight loss is typically observed following pre-conditioning 
irradiation, it is anticipated that with normal feeding behaviour weight will 
return to normal. This pattern of weight loss followed by recovery was 
observed for both control mice, whereas in the experimental mouse, the initial 
weight loss was more profound and despite a brief reduced recovery, the 
animal remained underweight for the duration of the experiment as illustrated 
by Figure 70.  
 
Balb/c recipient mice were weighed prior to adoptive transfer of Q8.I2.eGFP transgenic 
C57BL/6 CD90.1 splenocytes, then subsequently at regular intervals throughout the experiment 
to assess progression of GvHD pathology. As illustrated, all mice demonstrated weight loss 
following X-ray TBI. However, although control mice demonstrated rapid recovery to starting 
mass, the adoptive transfer recipient remained below starting mass throughout the experimental 
window. 
 
By day 26, noting that control animals had demonstrated weight recovery 
contrasting with sustained and progressive weight loss observed in the 
experimental animal, peripheral blood analysis was performed to establish 
whether a transgenic population could be identified. As illustrated by Figure 
71, there was clear evidence of the presence of a transgenic population of T-
cells as indicated by the presence of an QBEnd10-eGFP co-expressing 
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population. Furthermore, following from clear evidence indicating reduction of 
the Thy1.1 lymphocyte compartment suggestive of GvHD pathology, all 
animals were sacrificed three days later, twenty-nine days following cellular 
infusion. Spleen, bone marrow and lymph node compartments were analysed 
by flow cytometry analysis to assess the haematological chimerism present at 
experimental termination, with samples of large bowel, skin, liver and lung 
submitted for histological examination. 
 
To assess engraftment in our ACT C57BL/6 to Balb/c acute GvHD induction pilot, peripheral 
blood was assessed for presence of engraftment 26 days post ACT. Evidence of engraftment 
was observed as illustrated by the top row, whilst evidence of GvHD, as indicated by reduction 
in the host Thy1.1 compartment (bottom row). 
 
 
Observation of clear engraftment of a transgenic population was observed in 
all compartments demonstrating successful engraftment of donor cells. 
Evidence of engraftment from spleen and bone marrow are illustrated by 
Figure 72. 
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Following sacrifice of experimental animals, spleen and bone marrow samples were examined 
to assess engraftment from the C57BL/6 to Balb/c acute GvHD pilot experiment. As illustrated, 
we observed clear evidence of transgenic T-cell engraftment in both spleen and bone marrow as 
identified by co-expression of QBEnd10 and eGFP marker genes. 
 
 
Due to the non-myeloablative pre-conditioning irradiation, a residual 
population of host bone marrow cells would be predicted to be present within 
the observed haematological repopulation resulting in a chimeric population 
of CD4+/CD8+ T-cells derived from both donor and the host mouse.  However, 
during GvHD, donor CD8+ cytotoxic T-cells (CTL’s) target and lyse host tissues 
following recognition of minor histocompatibility antigens expressed on the 
host cells. Clear evidence of deletion of residual host CD4+/CD8+ cells was 
observed in all compartments, with only the lymph nodes demonstrating a 
significant reservoir of host T-cells illustrated by Figure 73. 
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Following sacrifice of experimental animals, spleen and bone marrow samples were examined 
for evidence of deletion of host lymphocytes which could be identified as the Thy1.1 positive 
population. Non-myeloablative conditioning results in haematopoietic chimerism post-transfer 
reflecting both donor and recipient populations following haematopoietic reconstitution. 
Depletion of the Thy1.1 compartment as evidenced by the Q8.I2.eGFP recipient is suggestive of 
GvHD pathology. 
 
Finally, we observed clear histological evidence of GvHD from the gut tissue 
sections as indicated by: ulceration and crypt abscess formation, Lamina 
propria infiltration and loss of villae structure in the section of recipient 
Balb/c gut when compared against an equivalent tissue section obtained from 
a control animal as illustrated by Figure 74. 
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Following sacrifice of experimental animals, tissue samples from skin, liver, lung and bowel 
were examined by H&E staining to identify evidence of GvHD. As illustrated, evidence of 
GvHD was identified from H&E stained sections of large bowel; GvHD is indicated by 
ulceration, crypt abscess formation, Lamina propria infiltration and loss of villae structure in the 
T-cell recipient when compared against a tissue section obtained from a PBS control recipient. 
This finding was supported by similar evidence from other tissues (not illustrated). Wax 
embedding, sectioning and H&E staining were performed by the Royal Free hospital pathology 
department. 
 
Experimental aim: To demonstrate rituximab-mediated resolution of GvHD 
pathology by  deletion of RQR8-transgenic splenocytes. 
 
Having successfully demonstrated GvHD induction through a C57BL/6 to 
Balb/c MHC mismatch model using activated, transduced and MACS-selected 
splenocytes, our next challenge was to increase the scale and efficiency of 
splenocyte transduction sufficient to achieve a model of sufficient size as to 
enable statistical confirmation of efficacy. Having generated sufficient 
validated supernatant in advance, the experimental model, illustrated by  
Figure 75, is briefly summarised as follows: splenocytes obtained from 12 
female C57BL/6 - Thy 1.1 x 1.2 donor mice were transduced with 
SFGmR.RQR8, a construct expressing RQR8 by the SFG LTR promoter, with 
expression enhanced by inclusion of the human beta interferon S/MAR domain 
to maintain sustained transgene expression using the 5-day protocol 
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illustrated by Figure 60. Recipient animals, (female Balb/c Thy 1.1), were 
prepared by a split-dose 8Gy X-ray TBI pre-conditioning regimen, 48 hours and 
4 hours prior to adoptive cell transfer i.v. by tail-vein injection. Engraftment 
was assessed by peripheral blood draws, obtained 7 and 14 days following T-
cell transfer, with mRtx-IgG2a therapy infused randomly into ½ of T-cell 
recipients following acquisition of the day 7 blood sample to enable a 
preliminary confirmation of progression of therapeutic activity. Disease 
progression was assessed by tri-weekly weight and GvHD scoring assessments 
as required by the project licence. Weight loss ≥ 20% of starting mass, or a 
cumulative GvHD score of 4, based upon grooming, hunching, activity, eyes 
and presence of diarrhoea necessitated euthanasia of the animal(s). Our 
therapeutic dosing regimen of 3 weekly infusions of 150µg mRtx-IgG2a 
injected i.p. was based from a report describing an analogous suicide gene 
strategy encompassing a co-expression construct expressing codon optimised 
CD20 as the suicide gene moiety and a truncated form of CD34 as the marker 
gene154. Although experimental termination had been planned for 37 days post 
T-cell transfer, a sharp progression of GvHD symptoms necessitated sacrifice 
of the entire PBS therapy cohort and one animal from the mRtx-IgG2a therapy 
cohort 29 days following T-cell transfer. Limited resources delayed sacrifice of 
the remaining animals until the original experimental endpoint as planned. 
Figure 76 illustrates the comparative depletion/progression of engraftment as 
assessed by peripheral blood assessments at days 7, 14 and at experimental 
termination. Figure 77 illustrates animal mass and GvHD scoring across the 
duration of the experiment. Figure 79 to Figure 82 illustrate RQR8 engraftment 
from the tissues assessed at experimental termination. Notably, although some 
PBS therapy controls appears to indicate comparatively poor engraftment, the 
presence of thin QBEnd10-/CD8- populations appear to indicate reduced 
engraftment resulting from loss of stromal support due to profound tissue 
damage suggestive of lethal GvHD, such as indicated by PBS controls 1, 4 and 6 
in Figure 79. 
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Primary murine splenocytes isolated from C57BL/6 donors were prepared according to the 5-
day protocol as detailed in 7.5 and infused into X-ray TBI pre-conditioned Balb/c recipients. 
Verification of effective engraftment was assessed by flow cytometry analysis of peripheral 
blood isolated 7 days post transfer. Mice were supplied with weekly doses of rituximab therapy, 
150ug i.p., or PBS carrier. Animals demonstrating poor health were euthanased 29 days post 
transfer; remaining animals were culled 37 days post transfer. 
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Peripheral blood samples were obtained at timepoints as indicated and assessed by flow 
cytometry for donor T-cell engraftment. As illustrated by the top row, PBS carrier recipients 
demonstrated progressive expansion whilst engraftment levels in mRtx-IgG2a therapy 
recipients appeared to remain stable 7 days following the initial therapeutic administration. 
Lower row: declining levels of T-cell engraftment was observed in both control and mRtx-
IgG2a therapy cohorts by the end of the experimental window although engraftment levels in 
mRtx-IgG2a therapy recipients remained substantially lower than what was observed from PBS 
therapy control recipients. Note: euthanasia imposed experimental termination for PBS therapy 
cohort occurred 29 days post transfer, whilst experimental end for the mRtx-IgG2a cohort was 
elective at 37 days post transfer. RQR8 engraftment was defined as a proportion of the entire T-
cell subset.  
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Following licence requirements, indirect assessments of disease progression were performed 
throughout the experimental window including animal mass as illustrated. Animals were 
euthanased where weight loss or GvHD scoring reached severity criteria. Although all animals 
appeared to demonstrate weight loss following X-ray TBI conditioning, control animals 
demonstrated rapid recovery. In contrast, PBS therapy recipients demonstrated progressive 
weight loss leading to euthanasia imposed experimental termination. In contrast mRtx-IgG2a 
therapy recipients appeared to demonstrate partial recovery with animal mass remaining greater 
than PBS control cohort but failing to achieve recovery demonstrated by bone marrow control 
recipients. 
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At experimental termination, peripheral blood, spleen, bone marrow and lymph node 
compartments were assessed for levels of T-cell engraftment. Evidence of mRtx-IgG2a 
mediated T-cell clearance was observed in all compartments as illustrated. Note: all PBS carrier 
controls and one mRtx-IgG2a therapy recipient were euthanased due to weight loss and GvHD 
scoring 29 days following T-cell infusion with all remaining animals culled 37 days following 
T-cell infusion. 
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At experimental termination, peripheral blood, spleen, bone marrow and lymph node 
compartments were assessed for levels of T-cell engraftment. As illustrated, primary data 
illustrates evidence of reduction of engraftment but without achieving clearance in mRtx-IgG2a 
therapy recipients. In contrast, PBS control recipients demonstrated substantial engraftment; 
where engraftment of controls appeared modest, there was a coincident reduction in the non-T-
cell fraction highlighting splenic destruction as observed during organ harvest. 
 
 
At experimental termination, peripheral blood, spleen, bone marrow and lymph node 
compartments were assessed for levels of T-cell engraftment. As with Figure 79 previously but 
even more evident, primary data illustrates evidence of reduction of engraftment but without 
achieving clearance in mRtx-IgG2a therapy recipients. In contrast, PBS control recipients’ 
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demonstrated consistent engraftment, with consistent evidence of a reduction in the non-T-cell 
fraction highlighting marrow destruction as observed during organ harvest. 
 
At experimental termination, peripheral blood, spleen, bone marrow and lymph node 
compartments were assessed for levels of T-cell engraftment. As with Figure 79 previously, 
primary data illustrates clear evidence of reduction of engraftment but without achieving 
clearance in mRtx-IgG2a therapy recipients. In contrast, PBS control recipients demonstrated 
consistent engraftment.  
 
  
At experimental termination, peripheral blood, spleen, bone marrow and lymph node 
compartments were assessed for levels of T-cell engraftment. As with Figure 79 previously, 
primary data illustrates clear evidence of reduction of engraftment but without achieving 
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clearance in mRtx-IgG2a therapy recipients. In contrast, PBS control recipients demonstrated 
consistent engraftment.  
 
Although there was significant evidence of efficacy as illustrated by our 
results, this model clearly failed to accomplish the desired aim of achieving 
therapeutic resolution of GvHD. Retrospective review of our research offered 
insight into limitations and opportunities from these results. Reflecting initial 
concern regarding the capacity for  manipulated splenocytes to induce 
GvHD, our experimental design offered excessive attention to the role of 
inducing disease but insufficient emphasis on the task of ensuring successful 
therapeutic resolution of pathology in the face of disease. The following points 
highlight primary factors premised to explain efficacy observed and 
therapeutic failings from this work. 
 
For the full-scale GvHD model we reprised the MHC mismatch model used in 
the GvHD induction pilot. Our choice of an acute GvHD model has been 
reported to induce lethal GvHD 10-21 days following transfer of naïve cells277, 
and which from our experience appears to demonstrate a slightly delayed 
progression when splenocytes are subjected to significant  
manipulation. Notably, this model contrasts sharply with the clinical scenario 
where primary focus is given to HLA-haplotype matching with the aim of 
achieving GvL benefit whilst ameliorating potential GvHD toxicity. Reflecting 
difficulties with alteration in scale during the pilot model in which our 
investigation was limited to a single animal, this precluded further 
interpretation regarding the rate of GvHD induction. However, observation of 
GvHD pathology evident from all experimental animals in the full-scale model 
despite therapeutic intervention highlights the severity of the model. As GvHD 
remains a potentially lethal complication following HSCT, it seems plausible 
that the severity of our model reflecting fulminant GvHD may preclude 
resolution despite therapeutic intervention. 
 
Compounding the T-cell priming potential mediated by MHC mismatch was the 
decision to employ a severe preconditioning regimen, which was necessary to 
prevent rejection but which also establishes a highly inflammatory 
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environment thereby ensuring presence of host antigens to mediate T-cell 
activation whilst further facilitating haematopoietic space to assist adoptive 
cellular expansion. However sustained immunodeficiency remains a primary 
risk associated with HSCT resulting from preconditioning regimens which 
profoundly impair the capacity to respond against infectious agents, and 
correspondingly likely results with impaired ADCC during the 
immunosuppressed window. Assessing cellular depletion following TBI in 
C57BL/6 mice, Hashimoto . report profound depletion of DC’s, NK-cells 
and neutrophils as well as T- and B-cells within 48 hours following TBI280. This 
observation potentially highlights a key limitation associated with an antibody-
mediated suicide gene strategy. As discussed previously, rituximab is 
proposed to mediate cellular deletion through three separate mechanisms. 
However, variant from the native antigen, RQR8 lacks the direct signalling 
sensitivity as observed with native CD20 reducing the rituximab-mediated 
mechanisms for deletion to CDC and ADCC. Thus, preconditioning regimens 
and immunosuppression maintenance strategies which negatively impact upon 
ADCC effector populations may significantly impair the potential for an 
antibody-mediated suicide gene strategy to achieve resolution of therapy-
related toxicities. Therefore, there might exist a recovery window, as defined 
by both the preconditioning regimen and the nature of the therapeutic toxicity 
which might preclude opportunity to attain therapeutic resolution mediated by 
an antibody-directed suicide-gene system. 
 
Although i.p. injection reflects a common therapeutic dosing strategy for 
modelling, there remains the potential for ‘off-target’ injection such as 
into the bowel. Further, as the gut remains a target organ for inflammation 
during GvHD, it remains plausible that much of the antibody therapy may have 
been mopped up by gut inflammation proximal to the site of injection 
impairing the systemic distribution of therapy. Although ip administration was 
employed in our GvHD modelling experiment, this revised to iv administration 
for subsequent haploidentical modelling experiments. 
 
As indicated, our dosing regimen was modelled on previous research from an 
analogous marker-suicide gene strategy154. Although the ∆CD34/CD20 marker-
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suicide gene strategy was similar, there were significant variations in the 
animal modelling strategy; notably transfer of C57BL/6.Ly5.1 donor cells into 
Rag-1-/- recipients on the C57BL/6 background in the absence of TBI reflects a 
profoundly less aggressive model of disease. This was further reflected by 
slow progression of disease with therapy in the reference paper commencing 
at a time-point when lethal GvHD had been observed in our model.  
As no maximum tolerated dose was identified following dose escalation 
experiments for rituximab165, there remains significant potential for increased 
therapeutic administration in the scenario that our experimental result might 
have reflected dose-limiting efficacy. Subsequent research employed more 
robust dosing regimens. 
 
As suggested previously, the efficacy of CDC-mediated depletion was likely 
over-represented through  CDC assays due to the choice of BRC as the 
source of complement. Clear evidence of depletion despite impaired ADCC 
likely reflects some degree of complement mediated deletion, although the 
respective role of CDC-mediated deletion  remains unclear. 
 
Our GvHD model was prematurely truncated due to a sharp progression of 
behavioural symptoms. Although the role of GvHD has been established, the 
acceleration might also reflect concurrent termination of antibiotic therapy. To 
reduce potential for infectious disease following TBI preconditioning, animals 
were supplemented with Baytril therapy commencing a few days prior to TBI, 
and maintained for the following 3 weeks. Thus, potential bacterial infection 
controlled by antibiotic therapy might have accelerated disease progression 
upon termination of maintenance therapy. 
Although our model failed to achieve therapeutic resolution of GvHD, there 
was clear evidence of efficacy resulting from mRtx-IgG2a therapy. 
Furthermore, therapeutic shortcomings likely reflect failings in model design 
which were addressed in subsequent  modelling experiments presented 
in . 
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 Using the 5-day protocol as detailed in chapter 7, we have achieved 
successful increase in scale of cellular production typically generating 5 
x 106 purified transgenic splenocytes per donor spleen 
 The C57BL/6 to Balb/c MHC-I mismatch model facilitates clear 
engraftment of transgenic splenocytes 
 Transduced and MACS selected splenocytes retain functional capacity 
to induce acute fulminant GvHD 
 Therapeutic administration of mRtx-IgG2a demonstrated clear 
reduction of RQR8 transgenic splenocytes  
 Acute toxicity associated with the C57BL/6 to Balb/c MHC-I mismatch 
model likely precludes mRtx-IgG2a mediated therapeutic resolution at 
the dosing regimen as initially considered 
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Despite generation of national and international donor registries, inability to 
locate a suitable HLA-matched donor remains a limitation to HSCT therapy for 
many patients. For these individuals, haploidentical stem cell transplantation 
from a half-matched parental donor presents an alternative approach for most 
cases but with greater risk for development of GvHD142.  
 
 To demonstrate effective engraftment of transgenic C57BL/6 donor 
splenocytes in (C57BL/6 x Balb/c) CB6F1 recipients 
 To confirm progressive engraftment of donor T-cells following adoptive 
transfer 
 To demonstrate deletion of adoptive cells mediated by therapeutic 
administration of mRtx-IgG2a  
 To assess the kinetic progression of mRtx-IgG2a mediated deletion 
 
 To demonstrate retention of the  capacity for RQR8-mediated 
depletion when co-expressed with a CAR 
 
Despite generation of national and international donor databases, donor 
availability remains a common limitation to allogeneic HSCT therapy. Thus 
haploidentical HSCT offers an attractive option for many patients lacking a 
suitable HLA-matched donor. However, haploidentical transplantation remains 
a high risk strategy due to the high risk of GvHD. Although threat of GvHD can 
be resolved through T-cell depletion, this effectively exchanges the risk from 
morbidity and mortality due to GvHD for that resulting from sustained 
immunodeficiency. Numerous strategies, designed to resolve or reduce the risk 
from GvHD through graft modification, have been identified, however none 
manage to also fully address the threat imposed by profound 
immunodeficiency which can only be resolved through transfer of a mature 
population of T-cells possessing a replete polyclonal repertoire142.  
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There exist two clinical paradigms for our experimental query, each involving 
suicide gene therapy employed in conjunction with haploidentical transfer; the 
TK007 trial142 and the iCasp9 trial125. Briefly, in the TK007 trial, patients 
presenting with high risk leukaemias were treated with T-cell depleted, 
haploidentical HSCT. Patients demonstrating successful engraftment were 
subsequently supplemented with monthly serial DLI infusions (as required), 
composed of purified T-cell product transgenic for HSVtk and the ∆lNGFR 
marker gene derived from the same donor as used for HSCT, and commencing 
28 days post HSCT. In this trial, 28 patients successfully progressed to receive 
DLI post HSCT with 22/28 demonstrating successful HSVtk+ T-cell 
engraftment. Following DLI, 11/22 patients developed GvHD; 10 acute and 1 
chronic. Where ganciclovir therapy was supplied in isolation, GvHD resolution 
was achieved within 14 days, with 5 patients requiring combination therapy 
(cyclosporine or prednisone), to achieve complete resolution of GvHD; notably 
all instances of GvHD were resolved in this trial142. Similarly, the iCasp9 trial 
recruited patients presenting with relapsed leukaemia which were initially 
treated with T-cell depleted, haploidentical HSCT. Following demonstration of 
successful engraftment, 5 patients were subsequently infused with purified T-
cell product transgenic for iCasp9 and the ∆CD19 marker gene derived from 
the same donor as used for HSCT. In this trial, 4/5 patients progressed to 
develop GvHD which was rapidly resolved in all cases following administration 
of a single dose of the dimeriser drug which was observed to eliminate >90% 
of T-cells within 30 minutes of therapeutic administration125. 
Thus, following from the clinical precedent of haploidentical modelling, we 
revised our  modelling strategy accordingly to assess the efficacy of 
RQR8-mediated deletion in a comparable experimental setting. 
 
When defining conditions for our haploidentical model, we adjusted a number 
of critical parameters which were premised to have been critical in limiting the 
efficacy of mRtx-IgG2a mediated depletion which was previously 
demonstrated; including the degree of TBI preconditioning, the experimental 
duration, the therapeutic dosing regimen, infusion strategy and finally the 
dosage of cellular product as indicated by Table 13. 
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TBI preconditioning 8 Gy 5Gy 
Experimental duration 37 days 14 days 
Cellular infusion dose 4 x 106/mouse 1.5 x 106/mouse 
Therapeutic dosing regiment 
150µg/mouse/week 
3 x 
150µg/mouse/week 
Route of therapy 
administration 
i.p. i.v. 
  
In the MHC-I mismatch model, high-dose TBI was necessary to prevent donor 
rejection by host effectors. However in the haploidentical setting, although 
donor cells will respond against host alloantigens, recipients remain tolerant 
for donor MHC antigens preventing donor rejection and thereby allowing for 
milder preconditioning regimens which would hopefully ensure greater 
retention of the ADCC effector compartment. As the CB6F1 mice typically 
demonstrate a higher radio-tolerance than Balb/c animals (personal 
communication with Dr. Sergio Quezada), we employed a preconditioning 
dosage of 5 Gy TBI. Premising that our initial rituximab dosage might have 
been limiting, we increased the dosage to three doses administered within one 
week, by i.v. administration to prevent potential of impaired uptake from 
enteric inflammation. Finally, we considered a shorter experimental window 
alongside a lower infusion dose, selected to avoid fulminant disease 
precluding therapeutic resolution. 
 
Experimental aim: To demonstrate  rituximab-mediated deletion of 
RQR8 transgenic splenocytes through haploidentical transfer experiments 
mimicking reported clinical application of current suicide genes125, 142. 
In light of limitations identified from previous GvHD modelling experiments, 
we initially sought to demonstrate effective rituximab mediated depletion of 
RQR8 transgenic splenocytes examined through a more clinically relevant 
haploidentical experimental model with all animals sacrificed in parallel at a 
single experimental termination point; data presented in 10.3.1. Having 
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identified clear efficacy of rituximab-mediated depletion 7-days following 
commencement of rituximab therapy, efficacy and progression of depletion 
was further scrutinised through an experimental time-course examining RQR8 
recipient subjects sacrificed at serial timepoints up to and including the 7-day 
time-point examined initially; data presented in 10.3.2. Finally, with respect to 
the future application of RQR8 in conjunction with CAR therapy, we examined 
the capacity for rituximab-mediated depletion of RQR8 expressing splenocytes 
co-expressing a CD19 CAR; data presented in 10.3.3.  
 
Experimental aim: To demonstrate effective mRtx-IgG2a mediated deletion of 
RQR8-transgenic splenocytes in a haploidentical transfer model contrasting 
with continued engraftment in the absence of therapeutic administration. 
 
CB6F1 (C57BL/6 x Balb/c) recipients were preconditioned with 5Gy X-ray TBI 4 hours prior 
to cellular infusion of CD34 magnetic bead purified RQR8 transgenic splenocytes derived from 
C57BL/6 donors. Engraftment was confirmed by peripheral blood analysis seven days post T-
cell transfer prior to progression with mRtx-IgG2a therapy. At sacrifice, peripheral blood, 
spleen, lymph nodes and bone marrow compartments were examined to confirm efficacy of 
mRtx-IgG2a mediated deletion. 
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Splenocytes isolated from 10 female C57BL/6 donor mice were transduced and 
purified for expression of SFGmR.RQR8 using the 5-day protocol. Female 
CB6F1 (C57BL/6 x Balb/c) recipient animals were preconditioned by 5 Gy 
single dose X-ray TBI 4 hours prior to adoptive cell transfer of 1.5 x 106 
SFGmR.RQR8 cells/mouse infused i.v. by tail-vein injection. Successful T-cell 
engraftment was confirmed by flow cytometry analysis from a peripheral 
blood draw obtained 7 days following T-cell transfer. Animals were separated 
into 2 cohorts receiving either mRtx-IgG2a therapy or PBS carrier, infused i.v. 
on days 7, 10 and 12. Fourteen days following T-cell transfer, all experimental 
animals were sacrificed with samples from blood, spleen, lymph nodes and 
bone marrow obtained and assessed by flow cytometry for evidence of 
depletion or progressive engraftment. Comparative engraftment/depletion in 
blood is illustrated by Figure 84, clarity of depletion from spleen samples by 
flow cytometry analysis illustrated by Figure 85, and efficacy of depletion 
across all compartments illustrated by Figure 86. 
Note regarding the staining strategy employed to assess engraftment at end of 
experiment: H2Kb is the MHC haplotype present on C56BL/6 splenocytes 
whilst H2Kd is the MHC haplotype present on Balb/c splenocytes. As CB6F1 
mice result from the cross of C57BL/6 and Balb/c parents, they will be positive 
for both H2Kd and H2Kb, whilst C57BL/6 donors remain single positive. Thus, 
inclusion of H2Kb and H2Kd antibodies within our staining panel serves as a 
strategy to facilitate donor cell marking thereby supporting our claim 
regarding the efficacy of rituximab-mediated RQR8 depletion which was 
achieved.  
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 1.5 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. Seven days post transfer engraftment 
was assessed by peripheral blood analysis. mRtx-IgG2a therapy commenced with 150ug doses 
at day 7, 10 & 12 by i.v. injection, or PBS carrier for the control cohort. Each cohort comprised 
5 mice with an additional 3 control mice irradiated but given neither T-cells nor mRtx-IgG2a. 
Animals were sacrificed at day 14 with engraftment assessed by considering the proportion of 
QBEnd10 positive T-cells as a proportion of the T-cell population. Intra-animal assessment of 
engraftment was achieved by comparison between peripheral blood engraftment 7 days post-T-
cell transfer prior to commencement of mRtx-IgG2a therapy and 7 days post therapy. As 
illustrated, PBS therapy recipients demonstrated progressive engraftment with time whilst 
mRtx-IgG2a therapy recipients achieved RQR8 clearance. 
C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 1.5 million cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral 
blood, spleen, bone marrow and lymph node compartments were assessed for levels of T-cell 
engraftment. As illustrated, primary data illustrates clear deletion of RQR8-transgenic T-cells 
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from the spleen in mRtx-IgG2a therapy recipients contrasting with profound engraftment 
observed in PBS therapy controls. 
 
 
C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 1.5 million cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral 
blood, spleen, bone marrow and lymph node compartments were assessed for levels of RQR8-
transgenic T-cell engraftment as a proportion of the entire T-cell subset. As illustrated, mRtx-
IgG2a therapy affords effective clearance from all compartments assessed contrasting with clear 
evidence of engraftment observed for all PBS therapy controls. 
 
 
Experimental aim: To assess the kinetics and progression of mRtx-IgG2a 
mediated deletion of RQR8-transgenic splenocytes in a haploidentical transfer 
model. 
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients with engraftment confirmed by 
peripheral blood analysis six days following T-cell transfer. Subjects were separated into 10 
cohorts based on engraftment levels with each pair of therapy/control cohorts sacrificed at serial 
timepoints as indicated. PBS or mRtx-IgG2a therapy commenced with 150ug doses at day 7, 10 
& 12 by i.v. injection. At experimental termination, peripheral blood, spleen, bone marrow and 
lymph node compartments were assessed for levels of RQR8-transgenic T-cell engraftment as a 
proportion of the entire T-cell subset. 
 
Splenocytes obtained from 24 female C57BL/6 donor mice were transduced 
and purified for expression of SFGmR.RQR8 using the 5-day protocol. Female 
CB6F1 (C57BL/6 x Balb/c) recipient animals were preconditioned by 5 Gy 
single dose X-ray TBI 4 hours prior to adoptive cell transfer of 2.0 x 106 
SFGmR.RQR8 cells/mouse infused i.v. by tail-vein injection. Successful T-cell 
engraftment was confirmed by flow cytometry analysis from a peripheral 
blood draw obtained 5 days following T-cell transfer. 
Subject animals were stratified based upon the proportion of RQR8-transgenic 
T-cell engraftment as a proportion of the entire T-cell subset and separated 
into 10 cohorts, each composed of 4 animals selected to establish an mRtx-
IgG2a and a PBS therapy cohort pair for all five pre-determined experimental 
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timepoints. Further, timepoint cohorts were selected such that subject animals 
would possess corresponding levels of RQR8 transgenic T-cell engraftment. 
Animals demonstrating enhanced engraftment were preferentially chosen for 
assessment at earlier timepoints with a view to minimise potential GvHD 
toxicity. Animals which received neither T-cells nor mRtx-IgG2a therapy posed 
as staining controls for flow cytometry analysis. Six days following T-cell 
transfer, 150µg of mRtx-IgG2a therapy was administered i.v. to therapy 
recipient animals with subsequent experimental terminations performed 6, 24 
and 48 hours following therapy. Nine and eleven days following T-cell transfer, 
(72 and 120 hours following initial therapy dosage respectively), therapy 
recipient animals were infused with further 150µg doses of mRtx-IgG2a 
therapy by i.v. where tail-vein integrity allowed or by i.p. if not, such that 
animals sacrificed at the 120 and 172 hour timepoints had received 2 and 3 
therapeutic doses respectively, matching the therapeutic dosing regimen as 
employed in 10.3.1 previously. Efficacy of depletion illustrated by  
 to Figure 94; please note that that flow cytometry plots illustrated 
by Figure 89 to Figure 92 reflect depletion at the 48 hour timepoint following a 
single therapeutic administration of rituximab. 
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. At experimental termination 
termination timepoints as indicated, peripheral blood, spleen, bone marrow and lymph node 
compartments were assessed for levels of RQR8-transgenic T-cell engraftment as a proportion 
of the entire T-cell subset. (a) PBS-therapy controls illustrating progression of cellular 
engraftment (b) mRtx-IgG2a therapy recipients demonstrating rapid and progressive depletion 
of RQR8 marked cells. 
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. 48 hours following mRtx-IgG2a or PBS 
carrier therapy, blood, spleen, bone marrow and lymph node compartments were assessed for 
levels of RQR8-transgenic T-cell engraftment as a proportion of the entire T-cell subset. As 
illustrated by primary data from spleen samples, we observed clear evidence of cellular 
depletion 48 hours after a single dose of mRtx-IgG2a therapy contrasting with profound T-cell 
engraftment as indicated by the PBS therapy cohort. 
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. 48 hours following mRtx-IgG2a or PBS 
carrier therapy, blood, spleen, bone marrow and lymph node compartments were assessed for 
levels of RQR8-transgenic T-cell engraftment as a proportion of the entire T-cell subset. As 
illustrated by primary data from bone marrow samples, mRtx-IgG2a therapy recipients were 
approaching cellular clearance 48 hours following a single dose of mRtx-IgG2a therapy, 
contrasting with profound T-cell engraftment as indicated by the PBS therapy cohort. 
 
C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. 48 hours following mRtx-IgG2a or PBS 
carrier therapy, blood, spleen, bone marrow and lymph node compartments were assessed for 
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levels of RQR8-transgenic T-cell engraftment as a proportion of the entire T-cell subset. As 
illustrated by primary data from peripheral blood samples, mRtx-IgG2a therapy recipients had 
virtually achieved cellular clearance 48 hours following a single dose of mRtx-IgG2a therapy, 
contrasting with significant T-cell engraftment as indicated by the PBS therapy cohort. 
 
 
C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. 48 hours following mRtx-IgG2a or PBS 
carrier therapy, blood, spleen, bone marrow and lymph node compartments were assessed for 
levels of RQR8-transgenic T-cell engraftment as a proportion of the entire T-cell subset. As 
illustrated by primary data from lymph node samples, we observed clear evidence of cellular 
depletion 48 hours after a single dose of mRtx-IgG2a therapy contrasting with profound T-cell 
engraftment as indicated by the PBS therapy cohort. 
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. 48 hours following mRtx-IgG2a or PBS 
carrier therapy, blood, spleen, bone marrow and lymph node compartments were assessed for 
levels of RQR8-transgenic T-cell engraftment as a proportion of the entire T-cell subset. As 
illustrated, 48 hours following a single infusion of mRtx-IgG2a therapy, a comparative 
reduction in the RQR8 engraftment of 96, 56, 80 and 60% for blood, spleen, bone marrow and 
lymph node compartments respectively, was observed. Error bars reflect the standard error of 
the mean. 
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C57BL/6 splenocytes were retrovirally transduced to express RQR8 and selected to >90% 
purity with Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. 48 hours following mRtx-IgG2a or PBS 
carrier therapy, blood, spleen, bone marrow and lymph node compartments were assessed for 
levels of RQR8-transgenic T-cell engraftment as a proportion of the entire T-cell subset. (a) 6 
hours following commencement of mRtx-IgG2a therapy, we observed depletion levels of 73%, 
54%, 67% and 18% of RQR8 transgenic T-cells from blood, spleen, bone marrow and lymph 
node compartments. (b) Intra-animal assessment of efficacy of mRtx-IgG2a mediated RQR8 
depletion was assessed by serial sacrifice of PBS and mRtx-IgG2a therapy cohorts at 6, 24, 48, 
120 and 168 hour timepoints following commencement of therapy. We observed progressive 
depletion or engraftment as illustrated, achieving 96%, 75%, 85% and 82% depletion in the 
blood, spleen, bone marrow and lymph node compartments respectively by the 168 hour 
timepoint. Error bars reflect the standard error of the mean. 
 
 
Experimental aim: To demonstrate effective mRtx-IgG2a mediated deletion of 
RQR8.2A.aCD19-CAR transgenic splenocytes in a haploidentical transfer model 
contrasting with continued engraftment in the absence of therapeutic 
administration. 
Note regarding the RQR8.2A.aCD19-CAR construct: This construct is a codon 
optimised expression cassette generated by Cellectis therapeutics based upon 
an optimised anti-CD19 scFv format validated by Gordon Cheung and Leila 
Mekkaoui. 
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C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients with engraftment confirmed by 
peripheral blood analysis six days following T-cell transfer prior to progression with mRtx-
IgG2a therapy. At sacrifice, peripheral blood, spleen, lymph nodes and bone marrow 
compartments were examined to confirm efficacy of mRtx-IgG2a mediated deletion. 
 
Splenocytes obtained from 12 female C57BL/6 donor mice were transduced 
and purified for expression of SFGmR.RQR8.2A.aCD19-4g7-CD8.41BBZ using 
the 5-day protocol. Female CB6F1 (C57BL/6 x Balb/c) recipient animals were 
preconditioned by 5 Gy single dose X-ray TBI 4 hours prior to adoptive cell 
transfer of 2.0 x 106 SFGmR.RQR8.2A.aCD19-4g7-CD8.41BBZ cells/mouse 
infused i.v. by tail-vein injection. Successful T-cell engraftment was confirmed 
by flow cytometry analysis from a peripheral blood draw obtained 6 days 
following T-cell transfer. Animals were separated into 2 cohorts receiving 
either mRtx-IgG2a therapy or PBS carrier, infused i.v. on days 7, 10 and 12. 
Fourteen days following T-cell transfer, all experimental animals were 
sacrificed with samples from blood, spleen, lymph nodes and bone marrow 
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obtained and assessed by flow cytometry for evidence of depletion or 
progressive engraftment. Efficacy of depletion was demonstrated to match 
with previous results from 10.3.1 which illustrates efficacy of clearance from 
monocistronic RQR8 expression; results illustrated by Figure 96-Figure 101. 
 
Intra-animal demonstration of progressive engraftment or deletion: Peripheral blood samples 
were taken at both mid and terminal time-points to examine intra-animal progression of 
engraftment or deletion. As illustrated, PBS therapy recipients demonstrated progressive 
engraftment contrasting with clear deletion observed for the mRtx-IgG2a therapy cohort. 
 
C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million of these cells were injected i.v. into 5Gy X-ray 
preconditioned C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral 
blood, spleen, bone marrow and lymph node compartments were assessed for levels of T-cell 
engraftment. As illustrated, primary data demonstrates clear deletion of RQR8-transgenic T-
cells from the spleen in mRtx-IgG2a therapy recipients contrasting with profound engraftment 
observed in PBS therapy controls. 
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C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray preconditioned 
C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral blood, spleen, 
bone marrow and lymph node compartments were assessed for levels of T-cell engraftment. As 
illustrated, primary data demonstrates clear deletion of RQR8-transgenic T-cells from the bone 
marrow in mRtx-IgG2a therapy recipients contrasting with profound engraftment observed in 
PBS therapy controls. 
 
C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray preconditioned 
C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral blood, spleen, 
bone marrow and lymph node compartments were assessed for levels of T-cell engraftment. As 
illustrated, primary data demonstrates clear deletion of RQR8-transgenic T-cells from the blood 
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in mRtx-IgG2a therapy recipients contrasting with profound engraftment observed in PBS 
therapy controls. 
 
C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray preconditioned 
C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral blood, spleen, 
bone marrow and lymph node compartments were assessed for levels of T-cell engraftment. As 
illustrated, primary data demonstrates clear deletion of RQR8-transgenic T-cells from the 
lymph nodes in mRtx-IgG2a therapy recipients contrasting with profound engraftment observed 
in PBS therapy controls. 
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C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray preconditioned 
C57BL/6 x Balb/c cross (F1) recipients. At experimental termination, peripheral blood, spleen, 
bone marrow and lymph node compartments were assessed for levels of T-cell engraftment. As 
illustrated, mRtx-IgG2a therapy affords effective clearance from all compartments assessed 
contrasting with clear evidence of engraftment observed for all PBS therapy controls. 
 
Responding to the limitations identified from initial GvHD modelling attempts, 
the haploidentical model presented a less severe and clinically more reflective 
representation of the physiological scenario. In our initial haploidentical 
depletion experiment (10.3.1), we reviewed the question whether therapeutic 
administration could facilitate cellular depletion  in the face of 
significant and sustained antigenic stimulation. Having presented the question 
in a binary manner, we assessed the efficacy of cellular deletion through an 
experimental snapshot seven days following commencement of rituximab 
therapy. In this model, blood remains the only compartment allowing for intra-
animal comparison at separate time-points. Comparing the intra-animal 
engraftment in the blood, the rituximab therapy cohort demonstrated 99% 
depletion, contrasting with an opposing 285% increase in engraftment 
observed in the control cohort. Further, from inter-animal comparisons we 
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observed consistent and profound depletion of RQR8 expressing target cells in 
all compartments assessed; achieving 99%, 96%, 99% and 95% depletion in 
blood, spleen, bone marrow and lymph nodes respectively, when compared 
against the mean engraftment identified from the PBS therapy control cohort. 
Evidence of progressive engraftment in the blood demonstrated by the control 
cohort, supported by substantial engraftment observed in spleen and bone 
marrow compartments suggests the inflammatory environment resulting from 
X-ray TBI in this model presents a sufficient antigenic stimulus to establish 
fulminant GvHD effectively modelling the clinical risk posed by allogenic 
transfer. Further, we demonstrate clear evidence of cellular depletion in all 
tissue compartments analysed following from the shorter and more 
substantial dosing regimen. 
Having successfully established an effective model by which to assess the 
efficacy of rituximab mediated deletion , we sought to examine the 
process of cellular depletion in further detail as described in 10.3.2 
(Haploidentical time-course). As intra-animal assessment of depletion is 
limited to the peripheral blood, to achieve this aim it was necessary to expand 
the scale of this experiment to allow for serial assessments of separate cohorts 
to enable inter-animal comparisons from the tissues to examine the 
progression of depletion over time, illustrated by Figure 94 and Figure 102. We 
observed clear evidence of depletion in all compartments 6 hours following 
mRtx-IgG2a therapy, most evident in the peripheral blood and bone marrow 
(73% and 67% respectively); compartments rich in ADCC effectors, with least 
depletion observed from the spleen and lymph nodes (45% and 18% 
respectively). Depletion progressed throughout the examination period with 
maximum depletion achieved at the 168 hour (7 day) endpoint. The spurious 
but notable reduction in the observed depletion in the peripheral blood 24 
hours following therapy might reflect cellular mobilisation from the spleen 
and bone marrow reservoirs, possibly resulting from the cytokine stimulation 
associated with ADCC effector mechanisms up to this point. 
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C57BL/6 splenocytes were retrovirally transduced to co-express RQR8 alongside a second-
generation anti-human CD19 chimeric antigen receptor and selected to >90% purity with 
Miltenyi CD34 beads. 2.0 million cells were injected i.v. into 5Gy X-ray preconditioned 
C57BL/6 x Balb/c cross (F1) recipients. Assessment of the progression of mRtx-IgG2a 
mediated RQR8 depletion over time was achieved by serial experimental terminations of 
separate cohorts 6, 24, 48, 120 and 168 hours following commencement of therapy. As 
illustrated, we observed a trend of increasing deletion of RQR8-transgenic cells with 
progression of time. 
 
Notably, in this experiment, efficacy of depletion achieved was inferior to that 
observed in 10.3.1and 0; proposed explanations for this observation are as 
follows: Due to the increased scale required for this experiment, purity 
following MACS selection was reduced compared against the alternative 
haploidentical models. As a result, a significant proportion of non-transduced, 
GvHD-responsive activated T-cells secreting IL2 may have assisted 
proliferation of the residual RQR8 positive fraction not depleted by the initial 
dose, resulting in the reduced efficacy which was observed. Further, a slightly 
increased cellular dose was employed with a view of achieving sufficient 
engraftment to enable commencement of therapy at an earlier time-point. 
Finally, the sheer scale of this experiment imposed a significant challenge 
which added many confounding variables into the analysis and which may 
have factored into the increased engraftment and reduced efficacy which was 
observed. In the initial experiment (10.3.1), engraftment in the peripheral 
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blood seven days following T-cell infusion ranged between 1.5-8.5% with a 
mean of 4.5%, contrasting with engraftment ranging between 10.9-37.0%, five 
days following T-cell infusion with a mean of 21.6% for the time-course 
experiment. Further, one animal from both the 120 and 168 control cohorts 
was excluded from analysis due to severe tissue damage in all compartments 
likely the result of profound GvHD. Despite a considerably more aggressive 
model, clear evidence of progressive RQR8 mediated depletion was observed 
for all compartments, achieving 96%, 75%, 85% and 82% depletion in the blood, 
spleen, bone marrow and lymph nodes respectively which likely would have 
resulted in complete clearance matching the previous result had the 
experimental duration been extended or had RQR8 transgenic engraftment 
proven as modest as observed in 10.3.1 (Haploidentical depletion model). 
Finally, reflecting the anticipated application of RQR8 alongside a CAR, our 
final model assessed the efficacy of rituximab mediated depletion of RQR8 
expressing targets co-expressing a CAR. We have observed enhanced 
proliferation of CAR-transduced T-cells  likely reflecting basal 
activation from the CAR co-stimulation domains. Thus, in this model, 
transgenic T-cells potentially receive stimulation from both MHC-mismatch via 
the TCR as well as an endogenous signal from the CAR. Similar to 10.3.2, an 
infusion dosage of 2.0 x 106 cells/animal was chosen due to the earlier time-
point chosen for peripheral blood analysis. Notably, despite day 6 engraftment 
ranging between 9.2-53.8% with a mean of 33.4%, the efficacy of depletion 
assessed matched results from 10.3.1 (Haploidentical depletion model) 
previously. 
Overall, our series of haploidentical modelling experiments demonstrate a 
consistent capacity of rituximab-mediated depletion of RQR8 expressing target 
cells . However, in addition to successful demonstration of efficacy, the 
time-course experiment also appears to highlight the primary limitation of an 
antibody-mediated suicide gene strategy imposed by limitations from effector 
mechanisms. As both intrinsic and extrinsic suicide gene strategies 
demonstrate potential but with limitations, it may be necessary to combine 
strategies where complete ablation is required. 
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 Clear engraftment was evident in all T-cell recipients in all 
haploidentical modelling experiments considered 
 Progressive T-cell expansion was observed in all T-cell control recipients 
 mRtx-IgG2a therapy mediated clear T-cell depletion from all 
compartments: peripheral blood, lymph nodes, spleen and bone marrow 
  modelling with RQR8 demonstrated clear deletion of modified 
cells in the haploidentical setting 
 mRtx-IgG2a mediated deletion of RQR8 transgenic targets occurs 
rapidly following therapeutic administration with clear evidence of 
deletion apparent 6 hours post-therapy 
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An epitope, also known as an antigenic determinant, is the component of an 
antigen which elicits an antigenic response. Although most B-cell epitopes are 
discontinuous conformational epitopes defined by the three-dimensional 
structure of the native protein, some antibodies recognise linear epitopes. 
Epitope tags are commonly short linear antigenic sequences, initially used for 
protein purification, which remain in common use in research to assist 
characterisation of novel proteins for which monoclonal antibodies have yet to 
be identified or are of low affinity limiting sensitivity of experimental 
applications. As mentioned previously, marker genes encode for proteins 
absent from unmodified cells, thereby enabling selective identification and 
selection of genetically modified cells. Following from our previous work 
demonstrating the ability to express antibody binding epitopes on molecular 
spacers such as the CD8 stalk and a GPI anchor, we sought to establish 
whether our molecular spacer presentation strategy could be applied to 
common epitope tags to establish a novel set of research tools. 
 
 To establish whether cellular GPI anchor machinery can be exploited to 
facilitate cell surface gene marking 
 To establish whether cell surface presentation of epitope tags can be 
exploited as a general strategy to achieve multi-gene marking 
 To demonstrate the generalizability of epitope tag presentation using 
either the GPI-anchor or the CD8 stalk to theoretically enable 
concurrent expression of multiple separate marker genes 
 To establish whether cell-surface presentation of epitope tags on a GPI 
anchor could facilitate magnetic bead selection of transgenic cells 
 To further reduce the size of the QBEnd10 binding epitope to isolate 
and establish the ‘smallest marker gene’ 
 
Alternative multi-gene marking strategies have been described and the 
following discussion will briefly introduce LeGO vectors and Brainbow which 
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represent the most relevant comparative mechanisms to this final research 
tangent. Although molecular strategies for lineage tracking analysis such as 
DNA bar coding281 represent the gold standard, these remain limited by 
retrospective analysis and won’t be further discussed.  
LeGO vectors136 combine fluorescent protein expression with a drug resistance 
cassette to enable cellular selection. Although this strategy does enable multi-
gene marking, options remain limited with only 10 pairings described. Further, 
spectral overlap of the fluorescent proteins would likely limit or preclude 
further protein antigen analysis by flow cytometry, compounding observations 
of limited transgene expression due to the large size of the transgenic cassette 
and toxicity resulting from the drug resistance component. Lastly, selection 
remains limited to flow cytometry or a more prolonged drug-mediated 
selection. Brainbow282 offers a more powerful alternative strategy to facilitate 
lineage tracking. In Brainbow-1, the authors describe a method employing Cre-
mediated excision between incompatible lox sites to achieve irreversible 
stochastic recombination events identified by alternative fluorescent protein 
expression. Evolution of this strategy resulted with Brainbow-2 which utilises 
reverse orientation of loxP sites to mediate inversion of DNA generating 
multiple outcomes. Due to combinatorial spectral overlap resulting from 
multiple integrants, a fluorescent mosaic effect was achieved facilitating 
identification of up to 90 separate distinguishable colours. This strategy is 
ideally suited for fluorescent analysis of  tissue sections, but would 
likely prove less effective for flow cytometry analysis from an ongoing 
experiment. Finally, both of these strategies employ fluorescent protein 
markers which in addition to immunogenicity, large protein size and spectral 
overlap, impose further limitations with respect to cell culture; high levels of 
fluorescent protein expression can result in aggregation imposing cellular 
toxicity, excitation of fluorescent proteins may generate toxic free radicals, 
and membrane damage imposed by fixation may result in fluorescent protein 
escape283.  
Epitope tagging refers to the molecular biology technique whereby a known 
antigenic epitope, for which a commercially available antibody is available, is 
fused to a recombinant protein to assist in characterisation and purification. 
FLAG, 6xHis and the glutathione-S-transferase (GST) tags, initially used for 
protein purification, were the first epitope-tags available commercially. 
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Application of this technique for research and characterisation of novel 
proteins resulted in a rapid increase in the epitope-tag/antibody pairs which 
were commercially available284. As discussed previously, following from clinical 
observations, progressive evolution of marker genes tended toward cell 
surface proteins derived from the same species but absent from the cell type 
under investigation, to preclude immunogenicity but enable cellular tracking. 
Hence, apart from fluorescent proteins, there is a limited range of options 
available to allow for identification of multiple separate marked cell 
populations. Further, the wide emission spectra of fluorescent proteins restrict 
the number of markers which can be included within a single cell limiting the 
number of research questions which can be addressed simultaneously. 
However, due to the preferable emission spectra of fluorochromes which can 
be conjugated to antibodies, theoretically this limitation could be extended 
through the use of antigenic epitopes as cellular markers.  
In cellular engineering, there remain many instances where multi-gene marking 
could prove beneficial to examine the impact resulting from expression of 
multiple transgenes; e.g. T-cell engineering, packaging cell lines, iPS cells. Thus 
to conclude this body of research, we examine the potential for GPI-anchor 
mediated expression to further reduce the size of the QBEnd10 marker gene to 
establish a minimal marker gene, as well as the potential to utilise epitope tags 
as putative marker genes to facilitate multi-gene marking. 
 
Glycosylphosphatidylinositol (GPI) anchored proteins can be viewed as an 
alternative cell surface protein expression strategy, variant to the type I-IV 
classifications of transmembrane proteins. Biosynthesis of GPI-anchors occurs 
in three stages: assembly of the GPI-anchored precursor protein in the ER 
membrane, attachment of newly synthesized protein within the lumen of the 
ER to the GPI-anchor, concurrent with cleavage of the GPI addition signal 
peptide and finally post-translational modification occurring in the ER and 
Golgi apparatus. GPI-anchors appear to be ubiquitously expressed across 
eukaryota with virtually all GPI-anchors sharing a common core structure. In 
mammals, alternative mRNA splicing may result in expression of 
transmembrane or GPI-anchored forms of the same protein285. Unsurprising 
given the evolutionarily highly conserved GPI-anchor strategy, defects in GPI-
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anchor biosynthesis and protein expression is associated with a range of 
pathologies including PNH and autosomal recessive GPI-anchor deficiency286. 
As GPI-anchor biosynthesis remains an endogenous process facilitating plasma 
membrane localisation, we premised that we could exploit GPI-anchoring as a 
generic strategy to achieve cell-surface epitope tag expression, requiring a 
minimal protein coding sequence, even shorter than our previous CD8 stalk 
based strategy, which would impose little or no immunogenicity. 
 
Although sufficient for monogenic therapy, advances in molecular engineering 
and increasing desires for additional applications are approaching or have 
already exceeded the packaging capacity for retroviral and lentiviral vectors. 
The sleeping beauty transposon strategy, used by the Laurence Cooper group 
at MD Anderson offers a favourable integration profile compared with 
retroviral and lentiviral vectors but with a limited packaging capacity that 
declines with increasing transgene size287. Similarly, adeno-associated viral 
(AAV) vectors, commonly used for gene therapy applications possess a limited 
transgene packaging capacity of approximately 2.3kb288. One obvious strategy 
to resolve limitations in vector packaging capacity is to reduce the size of the 
transgenic cassette thus any strategy which can achieve similar efficacy but 
with a reduced genetic footprint would be of considerable utility for gene 
therapy application. 
 
Experimental aim: To establish whether we could further reduce the coding 
sequence for our QBEnd10 binding epitope to establish an absolutely minimal 
marker gene cassette for gene marking research. 
Note: Gene marking and suicide gene generation represented parallel research 
tangents, hence previous mention of GPI anchor-mediated expression. 
At only 105 a.a. residues in length (post-processing), Q8 is already under one-
half the size of eGFP. However in consideration of vectors with stringent 
packaging capacities, we premised that exploitation of cellular GPI anchor 
presentation machinery would allow us to further reduce the size of our 
QBEnd10 binding marker gene to establish a truly minimal marker gene. As 
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previously, our initial constructs compared expression of the QBEnd10 binding 
domain, with or without a flexible SGGGS linker sequence compared against 
the parental Q8 construct. Although both GPI anchored versions demonstrated 
inferior marking to that observed for the Q8 construct, in this instance the 
linker did appear to mediate slightly superior antibody binding capacity, as 
identified through comparison between QBEnd10 binding MFI between 
equivalently transduced targets; antibody staining illustrated by Figure 103.  
 
HEK293T cells were transfected with QBEnd10 epitope expression constructs, with or without 
a flexible S-G-G-G-S linker sequence, presented on a GPI-anchor to establish whether this 
presentation strategy might enable further reduction of epitope expression constructs. As 
illustrated, both constructs demonstrate effective epitope expression although under 
examination of MFI of antibody binding suggests that inclusion of the linker sequence offers 
modest improvement in epitope presentation efficacy. 
Having demonstrated that GPI anchor machinery could be exploited as a 
generic presentation strategy for an antibody binding epitope, albeit with 
attenuated binding efficacy, next we proceeded with two separate lines of 
interrogation regarding GPI-anchored QBEnd10 epitope constructs as 
illustrated by Figure 104: Firstly, through further single residue deletions, 
could the aforementioned 16 a.a. residue QBEnd10 binding epitope tolerate 
any further reduction whilst retaining antibody binding efficiency [deletion 
series], and secondly, could we enhance GPI-anchored marking efficacy to 
match that previously observed for Q8 [insertion series]? 
For the insertion series, we considered 3 alternatives to boost binding efficacy 
of the GPI-anchored marker gene. Premising that limited projection of the 
epitope from the cellular surface might restrict antibody access resulting with 
impaired binding efficacy, we considered two alternative presentation motifs 
to extend this distance. MP12231 presents the QBEnd10 epitope, amino 
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terminal to the CD52 Campath epitope, exploiting the highly glycosylated 
native sequence from CD52 to increase the epitope projection away from the 
cellular surface. Similarly, MP12232 includes a fragment of the CD3ζ 
ectodomain also projecting the QBEnd10 epitope from the GPI anchor signal 
region; further, the presence of a cysteine residue within the CD3ζ domain 
might facilitate dimerization through disulphide bonding boosting the valency 
thereby hopefully matching the binding efficacy achieved by the dimeric CD8 
stalk strategy. Lastly MP12230 represents a minimalist version of MP12232 
through inclusion of a cysteine residue but lacking supplementary projection. 
As evidenced by both terminal deletion series, further reduction of the 
QBEnd10 epitope appeared to mediate a threshold binding effect whereby 
successful binding only results at high levels of epitope expression as 
indicated by the corresponding level of eGFP expression; most apparent with 
the amino terminal deletion series. This may reflect a progressive degradation 
of the binding affinity with the result that where expression levels remain low, 
the on/off rate of antibody binding is not discriminable from that of 
background binding only achieving an effective signal where expression levels 
remain high. Disappointingly, all reduction constructs demonstrated further 
reduction in QBEnd10 binding capability. In contrast, the insertion series 
proved more promising with inclusion of the CD3ζ ectodomain achieving 
improved QBEnd10 binding compared against the parental GPI-anchored 
construct MP11601, albeit still inferior to binding efficacy achieved by Q8. 
However the CD3ζ construct still facilitates a clear two-log shift in QBEnd10 
binding whilst only requiring a 234 base coding sequence, contrasting with the 
416 bases required for Q8, or the 719 bases as required for eGFP. 
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In an attempt to further reduce the genetic footprint required for our marker gene, further point 
mutation reductions of the QBEnd10 binding domain were presented on a GPI anchor 
compared against the CD8-stalk bound parent. (a) Protein sequences of epitope reduction 
constructs illustrate design variation to optimise antibody binding efficacy. As indicated, use of 
the GPI-anchor presentation strategy enables a further reduction of the molecular footprint 
required for gene marking by almost 50%. (b) SupT1 cells transgenic for the alternative epitope 
constructs were assessed by flow cytometry to assess the comparative MFI of QBEnd10 
antibody-binding. As illustrated, although clear functional efficacy was observed for multiple 
constructs with greatest binding demonstrated by the MP12232, QZL-GPI construct, none of 
the GPI-anchor iterations offered equivalent binding as mediated by the parental CD8-stalk 
bound construct. 
 
Experimental aim: To demonstrate that the CD8 or GPI-anchor molecular 
spacers can serve as a general expression format for common epitope tags. 
Having successfully demonstrated GPI-anchor mediated epitope expression, 
next we considered whether this capacity could be extended as a general 
strategy to alternative antibody binding domains such as epitope tags. To this 
end, we examined cell-surface expression of the HA, HSV, T7, c-myc, V5 and 
OLLAS epitope tags when presented on a GPI anchor. These constructs were 
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cloned by Emily Hardman under supervision. As illustrated by Figure 105, 
clear binding was demonstrated for the HA, c-myc and V5 tags, limited binding 
was achieved with the HSV tag with OLLAS and T7 epitopes demonstrating 
poor or no binding respectively.  
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To demonstrate the generalisability of epitope expression on GPI anchors to facilitate cellular 
marking, common epitope tags were presented on the CD52 GPI anchor sequence co-expressed 
with either eGFP or eBFP2 fluorescent protein marker genes to identify successful 
transfectants. Functional validation of this strategy was assessed by flow cytometry against 
epitope transfected HEK293T cells. (a) Cartoon illustration of CD8 and GPI-anchor epitope 
presentation strategies. Due to the limited commercial antibodies available for flow cytometry 
application, alternative straining strategies were employed to assess epitope presentation 
efficacy as follow: (b) Efficacy of c-myc and OLLAS epitope tag expression were assessed by 
an anti-secondary antibody against the primary antibody Fc domain as indicated. (c) and (d) 
Efficacy of HA and QBEnd10 or HSV and T7 epitope tags were all assessed through 2-layer 
Biotin, Streptavidin staining strategies with the former pair co-expressing eBFP2 and the latter 
pair eGFP. 
Further, to establish whether cell surface expression of our epitope-tag based 
markers could facilitate magnetic bead selection, we considered indirect 
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selection of HA-GPI transduced Raji cells using HA-biotin primary staining 
followed by streptavidin bead selection as illustrated by Figure 106. 
 
Raji lymphoma cells were transduced with the HA-GPI epitope tag. Miltenyi magnetic bead 
selection was achieved by two-step staining process whereby cells were labelled with an HA-
biotin primary stain then purified using Streptavidin-bead secondary staining step. Results 
illustrated reflect sample purity following a single cycle of magnetic bead selection. 
 
Having demonstrated the generalizability of this strategy, next we assessed the 
comparative binding capacity of the HA, c-myc and V5 tags compared against 
binding demonstrated by the GPI-anchored QBEnd10 marker in an attempt to 
establish a hierarchy of binding efficacy for the separate epitope tag 
constructs. To enable comparative analysis of binding efficacy between the 
various epitope constructs, we obtained biotin-conjugated antibodies in an 
attempt to control the variable posed by the fluorescence signal used to assess 
antibody binding through consistent application of a fluorescently labelled 
streptavidin conjugate. Further, following observations of reduced binding 
from GPI anchored marker, we established both GPI-anchored and CD8-stalk-
bound alternatives for each of the tags under interrogation to compare 
efficacy of the different formats. CD8 stalk-bound constructs were cloned by 
Dimitra Markantoni under supervision. As illustrated by Figure 107, from this 
analysis, a consistent pattern of superior staining was observed for CD8 stalk-
bound iterations of constructs as compared with the GPI-anchored equivalents. 
However, we were disappointed to observe poor binding efficacy by the myc 
and V5 epitope tag targets which had previously demonstrated promising 
staining efficacy. As most epitope tag antibodies are designed for Western 
blotting, our initial staining attempts were performed using the antibody 
Chapter Eleven 
273 
 
options which we were able to source from our laboratory and those of our 
colleagues. Further, none of the biotin-conjugates were validated for flow 
cytometry, and one of which was a bespoke reagent conjugated only by 
request. Thus, following the lack of clarity from the biotin-conjugate staining 
strategy, we reconsidered the variation in binding efficacy observed for the 
myc and V5 constructs between our initial experiment (Figure 105) and the 
comparison assay (Figure 107). As illustrated by Figure 108, we were able to 
demonstrate clear binding of GPI-anchored epitope tags using preconjugated 
antibodies. Although this result precludes a definitive answer to our query 
regarding the comparability of epitope tags efficacy, it does confirm that 
epitope tags can be exploited to function as cellular marker genes in either 
presentation format, with the CD8 stalk appearing to offer a superior 
presentation format, albeit at the cost of imposing a larger molecular 
footprint. 
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SupT1 cells were separately transduced with QBEnd10, RQR, HA, c-myc and V5 epitope tags 
in both GPI and CD8-stalk presentation formats. Efficacy of epitope presentation was compared 
by flow cytometry with targets stained with a biotin-conjugated primary antibody with 
functional efficacy assessed using equal volumes of the streptavidin secondary stain for all 
conditions. Although modest staining can be achieved for all three epitope tags in the CD8-stalk 
presentation format, however only the HA tag proved effective as a marker gene in the GPI 
anchored format.  
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SupT1 cells were separately transduced with QBEnd10, RQR, HA, c-myc and V5 epitope tags 
in both GPI and CD8-stalk presentation formats. Efficacy of epitope presentation was compared 
by flow cytometry with targets stained using preconjugated antibodies as indicated. Use of pre-
conjugated antibodies for the HA, c-myc and V5 epitope tags demonstrated clear functional 
efficacy for all three epitope tags in either GPI-anchor or CD8-stalk presentation formats 
although the CD8 stalk does appear to represent the superior presentation strategy  based on 
MFI. 
 
Although fluorescent proteins are commonly employed to facilitate multiple 
gene marking, their broad spectral emission profiles impose significant 
limitation to the number of channels which can be examined concurrently. 
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Through careful selection of compatible fluorochromes examined with an LSR 
Fortessa cell analyser, we have successfully established 14 colour panels 
facilitated through antibody staining. This contrasts with a maximum of five 
fluorescent proteins which can be compared in parallel accounting for all 
channels on the instrument due to spectral bleed. A further advantage of cell-
surface localised epitope constructs is the capacity to enable cellular 
purification through magnetic bead selection thereby reducing the risk for 
contamination associated with flow sorting as well as offering a more gentle 
strategy for selection, optimal for fragile cell populations. Finally, the minimal 
size of epitope based presentation formats offer a favourable genetic footprint 
to that required by a fluorescent protein, with GPI-anchored constructs and 
CD8 stalk-bound constructs approximately ⅓ and ½ the size respectively, of a 
fluorescent protein.  
Attempts to further reduce the QBEnd10 binding epitope proved unsuccessful, 
demonstrating that the absolute limit of the QBEnd10 epitope had already 
been accurately established. Furthermore, despite successful presentation of 
the QBEnd10 epitope on a GPI-anchor, we were unable to achieve equivalent 
binding efficacy as that previously achieved through the CD8 stalk 
presentation format despite attempts to resolve this limitation through further 
molecular engineering. Although neither increased projection, nor putative 
dimerization alone appeared to enhance the GPI-anchor presentation strategy; 
combination of both strategies, as with the CD3ζ ectodomain iteration, did 
appear to improve antibody binding efficacy, albeit still not to the level 
observed for the Q8 control construct. 
Furthermore, we have demonstrated that both the GPI-anchor and the CD8 
stalk can be exploited as a general molecular spacer strategy to facilitate 
presentation of common epitope tag sequences to function as cell-surface 
marker genes. However due to the primary application of epitope tags for 
Western blotting, it may be necessary to confirm functional verification for 
putative antibody and epitope tag pairings to ensure these can be suitable for 
flow cytometry application. Further to our observations assessing QBEnd10 
presentation, we note that CD8 stalk presentation consistently appears to 
facilitate superior cell-surface presentation of epitope tags when compared to 
GPI-anchored equivalents, however, despite this limitation, GPI- anchor 
presentation still offers potential for a two-log shift in MFI demonstrating that 
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GPI-anchor mediated presentation remains a viable alternative strategy. Due to 
the minimal degree of engineering involved with GPI-anchor presentation, this 
strategy offers potential for both multi-gene cellular marking and/or indirect 
magnetic bead selection from a minimal coding sequence which remains as 
minimally immunogenic as can be achieved. Further, due to the favourable 
fluorescence profile of fluorochromes as compared with fluorescent proteins, 
this strategy offers significant potential as a research tool for applications 
where multi-gene marking would prove informative. Thus, we report that both 
the GPI-anchor and the CD8 stalk can be utilised as general strategies for the 
presentation of common epitope tag sequences to function as marker genes. 
Lastly, the linear epitopes of QBEnd10 and similar epitope tags also offer 
multi-functional application as they additionally enable identification through 
primary applications of western blotting and IHC. 
 
 Despite further attempts to reduce the size of the QBEnd10 binding 
marker gene, reduction in size of the coding sequence was associated 
with reduction in binding efficacy. 
 Presentation of the QBEnd10 binding domain on a GPI anchor including 
additional projection mediated by the CD3ζ ectodomain achieved the 
best binding efficacy of GPI-anchored constructs from a transgene 
sequence only 234 bases in length, coding for a 57 a.a. protein. 
 Both GPI anchors and the CD8 stalk offer generalised strategies to 
function as molecular spacers to facilitate cell surface expression of 
epitope tags as putative marker genes. 
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Adoptive cell therapies represent a rapidly developing field of therapeutic 
application. The graft versus leukaemia effect following allogeneic stem cell 
transfer29, recent successes from CD19-CAR clinical trials21, 48, 289 and successful 
resolution of X-SCID from gene therapy trials51 highlight the promise from 
adoptive cellular therapies, and arising from each success, the potential for 
ACT to become potential first line therapy inches ever closer. However, 
panoply of risks including GvHD, IM, OTOT arise coincident with potential 
therapeutic benefit. Recent evidence demonstrating sustained engraftment 
potential arising from single cell transfer experiments illustrates both the 
potency of cellular transfer therapies whilst highlighting the possibility for 
residual toxicity290. Furthermore, improvements in therapeutic efficacy offering 
sustained survival raise potential for further identification of toxicities 
resulting from therapies previously perceived as ‘safe’. Hence, as the breadth 
of application for cellular therapies grows, the need for a universally effective 
control mechanism becomes ever more imperative.  
HSVtk64 and iCaspase9125 suicide gene strategies represent the mainstays of 
current technology with both currently in clinical application; however, both 
possess limitations. HSVtk has a long history of clinical application having 
proven highly effective in therapeutic administration following haploidentical 
stem cell transfer. Limitations identified from clinical trials have largely been 
resolved through progressive engineering. However, transgene immunogenicity 
remains the Achilles heel of this system restricting application to scenarios of 
profound immunosuppression. Hence, engineering of alternative suicide gene 
strategies focussed on identifying non-immunogenic alternatives with 
iCaspase9 proving the forerunner as a potential replacement for HSVtk. 
However, limited safety profiling of the dimeriser drug, a long transgene 
coding sequence comprising only the suicide gene moiety, restrictive access to 
clinical grade dimeriser and the intrinsic mechanism for deletion offering 
potential for escape all present limitations and concerns from this suicide 
gene strategy. 
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As cancer is a heterogenous disease, it seems likely that therapies will become 
increasingly personalised. Further, the risk for OTOT remains to be established 
for each individual retargeting moiety and TAA target. With the extensive 
range of variables involved, it seems implausible that risk could ever be 
excluded, hence the ever pressing need for a universal safety mechanism. 
Further, until vector packaging capacity limitations can be overcome, ever 
increasing options for T-cell engineering will continue to tax vector packaging 
capacity imposing cumulative pressure toward minimal modular transgenic 
cassettes.  
Hence, a minimal non-immunogenic combined selection/suicide gene system 
compatible with current technology demonstrating equivalent efficacy to 
current technology would offer significant potential as an engineering tool for 
general application in adoptive cell therapies. For this purpose, we propose 
RQR8 as a potential universal marker-suicide gene for adoptive cellular 
therapies. 
 
 
As the QBEnd10 binding epitope had been proposed to be a linear epitope 
localised to the amino-terminus of the CD34 antigen193, initial work performed 
by Dr. Martin Pulé optimised a presentation strategy for putative QBEnd10 
binding fragments projected from the cell surface on the CD8α stalk. Bi-
directional deletions from the parental construct resulted in generation of a 
final construct containing only 16aa residues from the 385 present in the 
parental antigen achieving a final construct composed of only 105aa yet 
offering binding affinity and magnetic selection capacity matching that of the 
parental antigen.  
In direct progression from successful epitope mapping of the QBEnd10 
binding domain, we next sought to identify an equivalent rituximab binding 
epitope to function as a putative suicide gene moiety. However, achieving this 
aim proved more arduous owing to the conformational rather than linear 
nature of this epitope; initial constructs composed from the rituximab binding 
epitope derived from the parental CD20 antigen, as identified by 
crystallographic binding data, proved inferior to binding demonstrated by the 
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parental antigen. Fortunately, this experimental avenue was rescued by 
rituximab binding mimotopes as identified by Perosa 174, with clear binding 
demonstrated by the R3-C mimotope when presented on the CD8α stalk. 
Furthermore, co-presentation of both epitope binding domains demonstrated 
clear retention of functional antibody binding by both target antibodies 
offering promise as a minimal marker-suicide gene system. 
 
Having confirmed the functional capacity for antibody binding and cellular 
selection of double-epitope expression constructs, next we sought to establish 
the potential for cellular deletion through  CDC and ADCC assays. 
Commencing with the less complex CDC assays, we report results from two 
alternative flow cytometry based CDC assays designed to interrogate the 
sensitivity and specificity of CDC-mediated deletion. Our initial CDC sensitivity 
assays examining RQ8 deletion proved disappointing despite clear rituximab 
binding capacity. However we observed that sensitivity to deletion was 
inconsistent across the target population with high expressers proving acutely 
sensitive whilst low expression appeared protective. Premising that molecular 
re-engineering of epitope constructs might enhance binding affinity, increase 
valency, or otherwise enhance sensitivity to CDC, we generated a panel of 
variant iterations for further examination. Comparison of CDC-mediated 
deletion of this panel of epitope expression constructs identified a hierarchy 
of sensitivity, with RQR8 proving acutely sensitive to complement mediated 
deletion even surpassing that demonstrated by the CD20 positive control. 
Following  analysis of RQR8 and the crystallographic structure of 
rituximab, it seems likely that the observed acute sensitivity reflects bivalent 
rituximab binding by RQR8 thereby resolving the density dependent limitation 
of CDC. However, absolute confirmation of this bivalent binding hypothesis 
would require crystallographic analysis which is beyond the scope of this 
project.  
Whereas sensitivity assays examined the comparative capacity for CDC-
mediated deletion across a panel of constructs, we also established specificity 
CDC assays to demonstrate the efficacy of deletion of a cellular population 
mimicking therapeutic product. From these assays we report typically >98% 
deletion of RQR8 expressing targets whilst analogous Q8 targets present 
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within the sample remain untouched. Finally, to ensure this capacity for 
rituximab-mediated deletion is physiologically relevant, we examined CDC-
mediated deletion of RQR8 targets through time-course and dose-titration 
assays, demonstrating that CDC-mediated deletion of RQR8 occurs both 
rapidly and within the therapeutic dose of rituximab171. 
As the CD20154 and ∆EGFR124 suicide genes represents analogous strategies to 
RQR8, it should be noted that efficacy of CDC-mediated deletion of these 
suicide genes would likely demonstrate a similar density dependent limitation 
as identified by our alternative epitope constructs, whilst also imposing 
expression limitation due to longer coding sequences. 
 
Having successfully demonstrated CDC-mediated deletion, we next sought to 
assess the sensitivity of our epitope constructs through ADCC-mediated 
deletion. From  ADCC modelling, we report generation of two separate 
flow cytometry based ADCC assays: a sensitivity assay which enables 
independent comparison between similar constructs and a specificity assay 
which demonstrates efficacy of ADCC-mediated deletion of a target population 
relative to a control population present within the same sample. Flow 
cytometry analysis enables direct observation of the cellular targets under 
interrogation, whilst the extended assay duration facilitates consideration of 
both rapid (perforin/granzyme) and prolonged (TRAIL/FASL) mechanisms of 
ADCC-mediated deletion. From these assays we demonstrated acute sensitivity 
of RQR8-expressing targets to ADCC-mediated deletion, superior to that 
observed for alternative epitope expression iterations and at least equal, if not 
superior to that observed by the CD20 expressing positive control. Further, 
this effect was specific to rituximab-binding targets with no deletion observed 
against the highly similar Q8 expressing controls as suggested by Q8 target 
proliferation despite the presence of both rituximab and NK-cell effectors.  
Contrasting with sensitivity assays, specificity assays, examined the efficacy of 
ADCC-mediated deletion of an analogous target as would be anticipated from 
a transduced and purified transgenic therapeutic product. Inclusion of an 
internal Q8 expressing control further highlighted specificity of deletion was 
restricted to the target population. 
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Finally, Alemtuzumab is a particularly lytic therapeutic antibody targeting the 
GPI anchored cellular antigen CD52. Premising high CD52 antigen density on 
T-cells might offer potential for similarly high expression levels of a GPI-
anchored target; we established an expression construct whereby the RQR 
motif was presented on a GPI anchor which we included in our ADCC assays. 
Curiously, from a specificity assay from a single donor comparing the efficacy 
of ADCC-mediated deletion between RQR8 and RQR-GPI, we observed superior 
deletion of the RQR-GPI construct. Whether this enhanced deletion resulted 
from potentially higher surface expression mediated by the GPI anchor 
expression strategy, or from localisation of GPI anchored RQR epitopes in lipid 
rafts, this observation of variation in sensitivity of the identical epitope 
presented in alternative formats suggests potential for the antigenic target to 
factor in the capacity for lytic antibody efficacy. However, despite promising 
deletion facilitated by the minimal RQR-GPI construct, we premised the single 
mutation required to ablate GPI anchored expression posed an untenable risk 
for cellular escape, inappropriate for a putative suicide gene so this 
observation was not examined further in this project. 
 
Beyond resolving potential GvHD as might manifest following haploidentical 
HSCT, marker-suicide genes largely offer a supplemental role rather than the 
primary objective of ACT, hence it remains essential that this component can 
function in a modular capacity alongside other common T-cell engineering 
components such as a CAR or TCR. We report functional retention of the 
marker gene capacity when RQR8 is co-expressed with either the GD2-CAR or 
the WT1-TCR. Further functional assessment examined RQR8 co-expression 
with the GD2-CAR where we report full functional retention of both marker 
and suicide gene capacities as well as retention of GD2-CAR mediated 
cytotoxicity demonstrating the clear modular capacity of RQR8 and supporting 
negligible impact from co-expression of this minimal cassette upon other 
engineering components. Concomitant therapeutic toxicities including OTOT101, 
102, 291, cytokine storms20, macrophage activation syndrome106, and both neural104 
and cardiac toxicities107 have all been reported even whilst CAR-mediated T-cell 
ACT remains its infancy. As further toxicities are likely to be identified as this 
technology develops, there remains both a pressing need and a growing 
requirement to include a suitable strategy to offer potential mitigation or 
Chapter Twelve 
283 
 
resolution of unwanted therapeutic complications. However, as all suicide 
genes have limitations, it may prove appropriate to consider the suicide gene 
strategy alongside anticipated toxicities to optimise potential to resolve 
prospective adverse events, bearing in mind that it is unlikely that any suicide 
gene strategy could facilitate recovery from an acute cytokine storm. Hence, 
successful application of suicide gene therapy will likely only result from 
appropriate matching of manifold factors such as gene transfer application, 
therapeutic regimen, suicide gene strategy and the health status of the patient 
at time of transfer. Although many lessons have been learned from ACT trials, 
many more likely remain outstanding. 
 
Premising the chimeric nature of rituximab and the potential for mouse anti-
chimeric antibody responses might represent uncontrolled variables impairing 
therapeutic efficacy of rituximab, we chose to employ a fully murine antibody 
for  modelling experiments. Due to the IgG1 format of the IDEC2B8 
hybridoma, it was necessary to re-engineer the rituximab antibody into a 
murine IgG2a format, analogous to the therapeutic antibody, to achieve 
optimal effector recruitment and activation. Having established suitable 
plasmids to facilitate protein production, it was necessary to establish a 
suitable strategy which could rapidly and consistently generate milligram 
quantities of functional product at minimal cost. Aiming for a suspension cell 
culture strategy to achieve this aim, we report stable production of antibody 
from transgenic K562 cell culture achieving protein production of 32.5mg/L, 
which is comparable with TGE strategies but at reduced cost and offering 
lower batch to batch variation. With optimisation, the three dimensional 
culture format and hardy nature of K562 cells might prove a promising 
alternative to protein production strategies currently in practice. 
 
Having established an effective acute GvHD model intended to confirm the 
 efficacy of RQR8, we were initially disappointed to observe limited 
efficacy and failure to resolve pathology. However, once the innate immune 
system has become fully activated, there may be limitations to the potential 
for resolution of fulminant disease mediated through suicide gene therapy 
strategy alone. This failing highlights a key limitation of an antibody-mediated 
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suicide gene strategy; although extrinsic deletion mechanisms reduce potential 
for cellular escape, conditions which impair effector activity similarly reduce 
levels of deletion which can be achieved. Further, our choice of model also 
represented an extreme scenario which is of limited clinical relevance. Our 
initial choice of an acute GvHD model resulted from reports from the 
literature279 and anecdotal evidence from research colleagues (personal 
communication with Barry Flutter and Angelika Holler) regarding limitations in 
the functional capacity of  manipulated splenocytes. However, 
contrasting with initial concerns, we observed fulminant disease in all animals 
and in all experiments considered, attesting to the severity of this model. 
Reconsidered from this perspective, we report significant capacity for 
rituximab-mediated RQR8 deletion despite profound impairment of effector 
mechanisms. Moreover, reports from the haploidentical TK.007 trial already 
offer clinical precedent where induction of the suicide gene machinery proved 
insufficient to resolve fulminant GvHD alone142. In this trial, 5/11 patients 
required supplemental steroid therapy in combination with ganciclovir 
treatment to achieve resolution of GvHD. In subsequent examination we 
considered the less aggressive and more clinically relevant haploidentical 
model, from which we report rituximab mediated deletion offers a consistent 
capacity to resolve fulminant disease. From examination of rituximab-
mediated deletion of RQR8-expressing targets, both in isolation and when co-
expressed alongside a CD19-CAR, we observed clearance from all 
compartments 7 days following commencement of rituximab therapy, 
contrasting with profound engraftment which was observed from all 
experimental control subjects. Subsequent examination of progressive  
deletion, we observed significant clearance from all compartments at the first 
time-point considered; 6 hours following therapeutic administration achieving 
73, 45, 67 and 18% clearance from the blood, spleen, bone marrow and lymph 
nodes respectively, progressing to 96, 75, 87 and 82% clearance from the 
blood, spleen, bone marrow and lymph nodes respectively following 7 days of 
therapy. Although the absolute efficacy of any suicide-gene strategy can only 
be fully assessed through clinical experience, this comprehensive dataset 
highlights the potential of RQR8 to effect effective cellular deletion under 
profoundly challenging  conditions. 
Chapter Twelve 
285 
 
 
Progressing from demonstration of successful presentation of antibody 
binding epitopes on cellular surfaces, we further describe the potential to 
extend this strategy to the common HA, myc and V5 epitope tags. Although 
epitope presentation was successfully demonstrated by both the CD8 stalk 
and GPI-anchored molecular spacer strategies, CD8 stalk presentation appears 
to offer a superior presentation format. This observation may be due to the 
dimeric presentation afforded by the CD8 stalk and/or superior cellular 
projection as compared with the GPI anchor strategy. Epitope identification 
mediated by chromophore-conjugated antibodies enable reduced spectral 
overlap compared with fluorescent protein marking strategies allowing for 
concurrent investigation such as immunophenotyping and can enable facile 
indirect magnetic bead selection for purification. Further, the minimal 
molecular footprint imposed by these tags, as short as 55a.a. with the HA-GPI 
marker tag should facilitate application in even the most restrictive vector 
packaging strategies. Thus we premise application of epitope tags in this 
manner facilitates facile multi-gene marking and offers significant potential as 
a research tool. 
 
A recent report by Marin 173, describes results from comparative 
assessment of the efficacy of the four main suicide gene strategies available at 
that time; namely HSVtk, iCaspase9, TMPK2 and CD20, which were all 
expressed in EBV-CTLs to facilitate transgene analysis following sustained 
culture. (Note: the ∆EGFR marker-suicide gene,  was excluded from 
this comparison due the research having commenced prior to publication of 
this system). In this report, none of the suicide genes assessed appeared to 
demonstrate notable impact upon the immunophenotype, proliferation or 
function of the EBV-CTLs suggesting a lack of basal toxicity following 40 days 
of continuous culture. However, a variation between alternative suicide gene 
strategies was demonstrated through efficiency of cellular deletion. Although 
both iCaspase9 and CD20 suicide genes demonstrate similar efficacy of 
cellular deletion as assessed at 1, 4 and 7 day time-points, HSVtk required 4 
days to achieve equivalent deletion whilst TMPK2 remained inferior at all 
timepoints observed. This demonstrates that an antibody-mediated strategy 
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for cellular deletion of putative suicide genes potentially offers similar efficacy 
to that demonstrated by iCaspase9, which currently represents the current 
gold-standard. 
As the merits and functional limitations of the alternative suicide gene 
strategies have already been extensively discussed, it seems helpful to 
consider the comparative biological distribution of the respective inducing 
drugs in achieving the desired aim of the corresponding suicide genes to 
enable further discrimination of the advantages and disadvantages separating 
the various strategies. RQR8 was initially engineered to address potential 
toxicity associated with solid-tumour ACT where potential therapeutic 
toxicities remain less defined as those which have been identified through 
anti-CD19 CAR therapies. Thus, discrepancy between the suicide gene systems 
might be most apparent when considering variation in the capacity for the 
respective inducing drugs to resolve potential ACT-mediated toxicity in a 
protected site such as the central nervous system104. Studies considering the 
biodistribution of Ganciclovir in non-human primates, clearly demonstrates 
the favourable bioavailability profile offered by this drug292; hence, for HSVtk, 
the primary limitation to this system remains the potential immunogenicity of 
the transgene due to the viral origin293. Thus, despite the substantial history of 
clinical application of HSVtk as a suicide gene, future use remains restricted to 
profoundly immunosuppressive environments such as haploidentical HSCT. 
Correspondingly, to address the limitation imposed by immunogenicity, 
iCaspase9 was engineered from human proteins to preclude immune rejection. 
However, in this instance, despite being a small molecule, some evidence 
suggests limited penetrance of the blood brain barrier by the FK506 dimerizer 
AP20187294. This is in addition to restrictive access to the clinical grade 
dimerizer imposed by Bellicum pharmaceuticals further restricting general 
application of this system for clinical application. Finally, both RQR8 and the 
∆EGFR suicide genes employ antibodies as the therapeutic agent. Extensive use 
of rituximab in clinical practice is testament to the lack of therapeutic toxicity 
from this agent. Furthermore, observation of CNS penetration supports a 
favourable biodistribution including immune-privileged sites such as the 
CNS295. Although similar evidence exists regarding cetuximab penetrance of the 
CNS296, in this instance, therapeutic toxicity remains a limiting factor (
. Furthermore, in instances where rituximab chemotherapy is indicated, 
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there remains the option to treat the patient with ofatumumab, thus 
application of rituximab to effect suicide-gene machinery does not preclude 
therapeutic potential for the patient. This contrasts with use of Ganciclovir to 
effect HSVtk-mediated deletion precluding application of Ganciclovir to 
resolve CMV reactivation. 
Antibody mediated suicide gene strategies offer an extrinsic mechanism for 
cellular deletion excluding opportunities for escape through mutation of 
cellular metabolic machinery, although potential down-regulation or loss of 
transgene expression remain a common potential escape risk from all suicide 
gene strategies. As transgene size has been correlated with expression levels119, 
163, a suicide gene system composed from a minimal coding sequence offers 
the maximum potential to preclude escape through low expression. Suicide-
gene strategies based on transgenic expression of a binding target for a 
therapeutic antibody have been proposed124, 154, 155, 165, 166 with the 
CD20/rituximab154 and ∆EGFR/cetuximab124 systems representing analogous 
strategies to RQR8. Reports from various groups proposing CD20 as a putative 
suicide gene strategy describe widely disparate results regarding efficacy of 
rituximab-mediated deletion of CD20 transgenic T-cells which remain difficult 
to interpret154, 166, 173, 297. In our hands, magnetic selection of ectopically expressed 
CD20 on T-cells resulted in cellular deletion precluding application of CD20 as 
a marker gene, whilst the long coding sequence impacted upon both viral titre 
and transgene expression levels. Further, as the biological function of CD20 
remains unknown, the impact of cellular expression of this transgene remains 
immeasurable. Notably, results of RQR8 efficacy have been readily 
recapitulated by research collaborators supporting the consistency of our 
findings. Alternatively, ∆EGFR has also been proposed as a putative suicide 
gene: here, ∆EGFR is expressed on the T-cell surface with depletion effected by 
the anti-EGFR therapeutic mAb cetuximab. Although this system is likely to be 
less immunogenic than RQR8, RQR8 retains some attractive advantages: 
firstly, RQR8 has an “off-the-shelf” clinical grade selection system available; 
secondly rituximab monotherapy is well tolerated by the majority of patients 
with little increase in opportunistic infection168, 169 and with no maximally 
tolerated dose. In contrast treatment with cetuximab is accompanied by 
acneiform follicular skin exanthema in more than 80 % of patients. Severe 
exanthema (grade III/IV) develops in about 9-19 % of patients imposing the 
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necessity for cetuximab dose reduction or cessation167. Thirdly, Rituximab’s 
property as a highly potent lymphodepleting agent in human subjects is well 
established; in contrast cetuximab offers reduced efficacy mediated by CDC 
compared with ADCC, with potential restriction in ADCC efficacy due to HLA-E 
expression298. Further, there remains potential for the development of 
cetuximab resistance due to the HACA response reflecting the chimeric nature 
of cetuximab increased by potential residual cetuximab antibody following 
cellular selection. As a modular engineering component, this limitation might 
restrict application of ∆EGFR as a suicide gene dependent on the therapeutic 
target of interest. In contrast, RQR8 remains less than half the size of either 
CD20 or ∆EGFR, reducing the impact upon packaging capacity and transgene 
expression. 
From a bioinformatics analysis of putative immunogenic epitopes assessed 
using the LBtope219 linear B-cell epitope prediction server and the NetCTL 1.2220 
servers respectively, we identified clear evidence of putative CTL and B-cell 
immunogenic epitopes present within RQR8. The impact of the B-cell epitopes 
present within RQR8 may become apparent through future clinical trials; 
proposed application of RQR8 in a GD2 CAR trial for neuroblastoma will 
present an informative contrast with proposed inclusion in CD19 CAR trials 
for CLL and lymphoma, to identify the risk of immunogenicity posed by the B-
cell epitopes identified. Similarly, these trials should prove informative 
regarding the small number of putative CTL epitopes which were identified, 
variant in number between MHC supertypes. Despite identification of 
potentially immunogenic epitopes, these remain fewer than what would be 
anticipated from larger CAR-constructs currently in clinical application. 
Further, as instances of sustained engraftment from neomycin resistance299 
and HSVtk300 transgenic cells have been reported, only clinical application will 
accurately assess the full impact of the potentially immunogenic epitopes 
identified.  
However, in addition to potential immunogenicity, there remain two further 
main limitations to application of RQR8: prolonged serum half-life of 
rituximab and potentially impaired effector mechanisms resulting from pre-
conditioning regimens. Although rituximab efficacy offers the critical 
advantage to the RQR8 strategy, it also imposes a key limitation. The 
prolonged serum half-life of rituximab, ranging between approximately 24-30 
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days for males and females respectively218, presents a limitation to application 
of RQR8 toward rituximab pre-treated patients. Through  dose-titration 
CDC assays, we observed only modest reduction in the efficacy of rituximab-
mediated deletion even at 12.5µg/ml rituximab, representing the lowest 
concentration examined. With a median rituximab serum level of 1.1µg/ml 
nine months following termination of rituximab therapy218, we cannot exclude 
potential for cellular deletion even nine months post rituximab therapy. A 
second main limitation to efficacy of an antibody-mediated suicide gene 
strategy results from impaired effector mechanisms. Resulting from profound 
immunosuppression following pre-conditioning regimens, there may be a lag-
phase required for regeneration of the effector compartment before full 
efficacy of the suicide-gene strategy can be restored. However it remains 
unclear as to how relevant this finding might be due to the artificial scenario 
imposed in our acute GvHD model. In this model, the direct mismatch, severe 
preconditioning and high infusion dose all factored into the observed toxicity. 
Additionally, therapeutic benefit was clearly observed in this model and it is 
likely that further rituximab therapy might have proved beneficial had further 
monitoring been possible to identify this requirement. Further, an acute 
cytokine storm represents the most probable early onset toxicity which likely 
precludes resolution through any suicide gene strategy.  
One further potential limitation which should be acknowledged might result 
from antigenic modulation or ‘epitope shaving’. Epitope shaving was identified 
following clinical observations in CLL of circulating B-cells stripped of the 
CD20 antigen following rituximab therapy. Subsequent investigation suggested 
that this observation was likely due to removal of rituximab-CD20 complexes 
mediated by the high affinity FcγRI present on monocytes and macrophages. 
Notably, loss of CD20 was not observed when B-cell burden was low. 
Additionally, a solution proposed to resolve the therapeutic limitation 
presented by epitope shaving involves lower and more frequent rituximab 
therapy infusions and/or FcγRI blocking as potential solutions301. 
Alternative marker/suicide gene strategies which have translated into clinical 
application have been reported (HSVtk/NGFR142, iCasp9/CD19125, 152, ∆EGFR124), 
each possessing unique limitations, all necessitating lengthy coding sequences 
for the suicide gene moiety alone (377, 402 and 336 amino acids respectively; 
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note: for ∆EGFR this sequence codes for both marker and suicide gene 
moieties) compared with 139 for both marker and suicide gene capacity of 
RQR8. Thus, directly compatible with Miltenyi CliniMACS reagents and the 
substantial safety profile demonstrated by rituximab therapy, we propose that 
RQR8 represents a significant advance as a putative marker/suicide gene for 
adoptive T-cell therapy. 
 
The impetus driving research toward establishing a novel marker-suicide gene 
developed from pressing clinical need. With HSVtk limited by immunogenicity 
and iCaspase9 restricted by access to clinical grade dimeriser, there was an 
urgent requirement for an alternative safety mechanism. So it is hardly 
surprising that development of the ∆EGFR suicide gene was established 
independently alongside our research into RQR8 with ∆EGFR currently in 
clinical trial and potential clinical application of RQR8 pending. Although this 
report has focussed upon discovery and validation of RQR8 functionality, 
there has been further concurrent pre-clinical preparation performed by 
myself and others including  tumour modelling experiments and full-
scale test production of cellular product respectively further confirming 
functional capacity of RQR8. At time of writing, RQR8 has been proposed for 
application in clinical CAR trials targeting GD2 in Neuroblastoma and CD19 in 
CLL and lymphoma. Should these applications be approved, the solid versus 
humoral nature of the target tumours in these trials offer great potential for 
achieving greater clarity regarding the risk presented by potential 
immunogenicity of RQR8. 
A curious observation identified from this project was the potential variation 
between CDC and ADCC mediated efficacy between GPI anchored and CD8 
stalk presentation strategies. Although the efficacy of CDC mediated deletion 
appeared superior for the CD8 construct compared with the GPI anchored 
alternative, the opposite was observed during ADCC mediated deletion assays. 
In light of the potential for cellular escape resulting from the GPI expression 
strategy, we premised this would prove inappropriate for a suicide gene 
system presenting an untenable potential for cellular escape under the 
selection pressures which would be involved. However, as an academic 
question, this observation offers intriguing insight into potential variation in 
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sensitivity to CDC and ADCC mediated deletion demonstrated by cellular 
epitopes dependent on presentation. Given the extensive budget afforded to 
research and development of therapeutic antibodies, research progressing 
along this tangent might offer significant insight into the suitability of cellular 
antigens as therapeutic targets with regard to optimising the most suitable 
strategy for targeting them. Similar observation is indicated between the 
sensitivity of deletion conferred by RQ8 versus RQR8. Although RQR8 is 
considerably more sensitive to CDC mediated deletion, the two constructs 
demonstrate very similar levels of deletion from ADCC mediated assays. 
Additionally, successes following from mRtx-IgG2a production have 
demonstrated the capacity of K562 cells as a protein production platform. 
Further work progressing from this research supports our initial observations 
and future work aims to demonstrate the generalizable potential of this 
strategy. 
As the complexity of  modelling experiments increases, concurrent and 
clear identification of multiple transgenic markers becomes increasingly 
important. Although fluorescent proteins have long been the mainstay of 
cellular marking, these impose limitations in marking capacity due to spectral 
overlap. For example, the 4 laser configuration of the LSR Fortessa instrument 
potentially offers 16 channels for multi-spectral analysis; in contrast, spectral 
bleed resulting from the broad emission profiles of fluorescent proteins 
restricts concurrent analysis to 5 channels when only fluorescent proteins are 
considered (paper in preparation). Hence, application of epitope-based targets 
to facilitate simultaneous marking for multiple separate targets in addition to 
cellular antigens represents a significant advance upon restrictions imposed 
by fluorescent proteins. Additionally, the surface expression of epitope tags 
offers potential for magnetic cellular selection reducing the risk for 
contamination resulting from flow cytometry based cellular sorting. Future 
work aims to demonstrate the generalizability of the marker gene strategy 
identified during the course of this project. 
 
In addition to facilitating MACS selection, the marker gene capability of RQR8 
also enables high sensitivity tracking by flow cytometry analysis to assess 
 persistence and expansion. Further, the marker gene capacity also enables 
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detection of engineered cells in fixed biopsy samples through IHC. The indirect 
suicide gene strategy limits the risk for cellular escape which might result 
from mutation or attenuated gene expression of intrinsic strategies. 
In summary, we have created a 136 amino acid epitope-based marker/suicide 
gene for T-cells. The translated protein is stably expressed on the cell surface 
following retroviral transduction. It binds QBEnd10 analogously to full-length 
CD34 allowing clinical-grade sorting with off-the-shelf reagents and offers 
clear  tracking. Further, the construct binds rituximab; the dual epitope 
design engenders highly effective CDC and ADCC and consequently renders T-
cells highly susceptible to  rituximab mediated depletion. Due to the 
small size of RQR8, it can easily be co-expressed with a wide range of T-cell 
engineering components. 
The ultimate measure of utility of RQR8 will be determined through clinical 
experience. At time of writing, RQR8 has been incorporated in several CAR 
cassettes destined for clinical application. I hope that the functional capacity 
of RQR8 will be of great practical utility to existing T-cell engineering 
components and will make ACT with engineered T-cells cheaper, safer and 
ultimately more efficacious. 
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Splicing by overlap extension PCR enables construction of novel genetic 
sequences through fusion of one or more PCR-amplified sequences. This is 
achieved through inclusion of terminal padding sequences containing the 
required restriction sites to facilitate restriction digest ligation of novel inserts 
into appropriately digested destination vectors. This strategy enables 
insertion, deletion and even ligation-mediated restriction site ablation to 
generate the desired expression product. When designing epitope constructs 
to be expressed on the cell surface, the 5' oligo primer was engineered to 
contain the NcoI restriction site (CCATGG) which contains the start codon. 
Although this limits the potential amino acid residues which might be encoded 
for by the second codon, use of online signal sequence detection algorithms 
enable the ability to predict whether the functional capacity of the signal 
sequence has been retained. However, as predicting the impact of sequence 
modifications to cytosolic or integral membrane proteins is less clear, cloning 
design exploited the unique BglII or AgeI restriction sites located upstream 
within the psi packaging signal domain, resulting in a longer 'padding' 
sequence in the PCR amplicon. Where unique restriction sites such as NcoI or 
MluI were present within the template coding sequence, use of alternative 
codons in the cloning design enabled restriction site ablation to ensure 
subsequent constructs correspond with the modular cloning strategy. 
PCR amplification of novel sequences was typically achieved through a 2-part 
process; an initial template PCR to amplify separate template fragments which 
were subsequently used as templates for a second and final PCR reaction when 
these fragments annealed based on homologous sequences established in the 
cloning design. In this manner, many separate fragments can be strung 
together to generate a completely novel template such as with gene synthesis 
employing overlapping oligo nucleotide primers, however typically, cloning 
designs were composed of two or three separate fragments. Amplicons 
generated by the primary template PCR reaction were separated by agarose gel 
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electrophoresis with the bands extracted and cleaned up according to 
manufacturer’s instructions (Qiagen) prior to inclusion in the final fusion PCR 
reaction which contained only the terminal primers for the desired amplicon 
with annealing of the separate fragments facilitating generation of the desired 
extended template sequence. 
Due to limited proof-reading ability of the polymerase enzyme compared with 
the full complement of proof-reading present within bacteria, all PCR-based 
cloning products were screened using a 2-part strategy with initial verification 
achieved through restriction digest followed by absolute confirmation by DNA 
sequencing. 
 
The modular strategy of the laboratory vectors enables facile subcloning of 
subsequent constructs in alternative iterations simply by cut and paste cloning 
facilitated by compatible restriction digests. Due to the reduced likelihood of 
errors resulting from this cloning strategy, construct validation from cut and 
paste cloning was by restriction digest and functional validation. 
 
pEQ-Pam3-E -  expression plasmid Elio Vanin 
RDF RD114 envelope expression 
plasmid 
Francois Cosset & 
Mary Collins 
pMono.Eco Ecotropic envelope expression 
plasmid 
Gianpietro Dotti 
 
SFGm_SAR.eGFP Vector backbone for 
constructs containing S/MAR 
domain 
Martin Pule 
SFG.HA1betaTCR.I2.eG
FP 
Vector backbone for IRES.eGFP Martin Pule 
SFG.HA1betaTCR.I2.eBF
P2 
Vector backbone for 
IRES.eBFP2 
Martin Pule 
SFG.CD34-L-8.I2.eGFP Parental QBEnd10 epitope 
construct with linker 
 
Martin Pule 
SFG.CD34-8.I2.eGFP Parental QBEnd10 epitope Martin Pule 
Appendix 1 
307 
 
construct without linker 
SFG.CD34min8.I2.eGFP QBEnd10 epitope - carboxy 
terminal mutant 1 
Martin Pule 
SFG.CD34epA1-
CD8STK.I2.eGFP 
QBEnd10 epitope - carboxy 
terminal mutant 2 
Martin Pule 
SFG.CD34epA2-
CD8STK.I2.eGFP 
QBEnd10 epitope - carboxy 
terminal mutant 3 
Martin Pule 
SFG.CD34epB1-
CD8STK.I2.eGFP 
QBEnd10 epitope - amino 
terminal mutant 1 
Martin Pule 
SFG.CD34epB2-
CD8STK.I2.eGFP 
QBEnd10 epitope - amino 
terminal mutant 2 
 
Martin Pule 
SFG.CD34.I2.eGFP Full length CD34 control Martin Pule 
SFG.rtx_Rp5-CD8stk-
tm.I2.eGFP 
Linear rituximab binding 
mimotope 
Martin Pule 
SFG.rtx_Rp3C-CD8stk-
tm.I2.eGFP 
Circular rituximab mimotope Martin Pule 
SFG.CD34epB3-
CD8STK.I2.eGFP 
QBEnd10 epitope - amino 
terminal mutant 3 
Martin Pule 
SFG.dCD20v1.I2.eGFP CD20 rituximab epitope with 
flanking residues 
Martin Pule 
SFG.dCD20v2.I2.eGFP CD20 rituximab epitope 
without flanking residues 
Martin Pule 
SFG.aGD2huK666-
HCH2CH3sec.I2.eBFP2 
Vector backbone used for 
secreted scFv constructs 
Simon Thomas & 
Kim Vigor 
SFG.CD34epB1A0.I2.eG
FP 
Carboxy and amino QBEnd10 
epitope B1A0 
Brian Philip 
SFG.CD34epB2A0.I2.eG
FP 
Carboxy and amino QBEnd10 
epitope B2A0 
Brian Philip 
SFG.CD34epB3A0.I2.eG
FP 
Carboxy and amino QBEnd10 
epitope B3A0 
Brian Philip 
SFG.dCD34ep-2A-rtx-
RP3X.I2.eGFP 
QR8 Brian Philip 
SFG.rtx-RP3X-2A-
dCD34ep.I2.eGFP 
RQ8 Brian Philip 
SFG.IL15-CD8-S-TM-A-
2A-TNFSF9.eBFP 
SFG.IL15_8Stk.4-1BBL.I2.eBFP2 Brian Philip 
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SFG.IL15-CD8-TM-A-2A-
TNFSF9.I2.eBFP 
SFG.IL15_8.4-1BBL.I2.eBFP2 Brian Philip 
SFG.RTXep_flush-
CD8tm.I2.eGFP 
R’.I2.eGFP Brian Philip 
SFG.RTXep-RTXep-
QBEND10-
CD8tm.I2.eGFP 
RRQ8.I2.eGFP Brian Philip 
SFG.RTXep-
QBEND10ep-RTXep-
CD8S-TM.I2.eGFP 
RQR8.I2.eGFP Brian Philip 
SFG.CD34B2A0.I2.eBFP Q8.I2.eBFP2 control construct Brian Philip 
SFG.CD20opt.I2.eGFP CD20opt.I2.eGFP 
Codon optimised CD20 control 
Brian Philip 
SFG.opt_rituxC-
HCH2CH3-
CD28OXZ.I2.eBFP2 
Rtx-C Brian Philip 
SFG.opt_rituxP-
HCH2CH3-
CD28OXZ.I2.eBFP2 
Rtx-P Brian Philip 
SFG.dCD34ngg-2A-
CD20.I2.eGFP 
CD34.2A.CD20.I2.eGFP control Brian Philip 
SFG.CD8stk-
3xFLAG.I2.eGFP 
 
Headless-8_FLAG.I2.eGFP Brian Philip 
SFG.Q-CD8stk-
3xFLAG.I2.eGFP 
Q8_FLAG.I2.eGFP Brian Philip 
SFG.RQR-CD8stk-
3xFLAG.I2.eGFP 
RQR8_FLAG.I2.eGFP Brian Philip 
SFG.opt_RtxC-
HCH2CH3sec.I2.eBFP2 
RtxC scFv secreted construct Brian Philip 
SFG.opt_RtxP-
HCH2CH3sec.I2.eBFP2 
RtxP scFv secreted construct Brian Philip 
SFGmR.RQR8-2A-
CnBx030 
Intermediary construct 
required for CAR/TCR co-
expression constructs 
Brian Philip 
SFG.RQR8-2A-
aGD2huK666-
HCH2CH3-CD28OXZ 
RQR8-GD2-CAR without 
S/MAR domain 
Brian Philip 
SFGmR.RQR8-2A-
aGD2huK666-
RQR8-GD2-CAR with S/MAR 
domain 
Brian Philip 
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HCH2CH3-CD28OXZ 
SFG.RQR8-2A-
TCR_WT1_hyb-B-2A-A 
RQR8-WT1-TCR without 
S/MAR domain 
Brian Philip 
SFGmR.RQR8-2A-
TCR_WT1_hyb-B-2A-A 
RQR8-WT1-TCR with S/MAR 
domain 
Brian Philip 
SFG.SRQR_CD4-D3D4-
TM-A.I2.eGFP 
RQR4.I2.eGFP Brian Philip 
SFG.mR.Q8 Q8 with S.MAR domain Brian Philip 
SFG.mR.RQR8 RQR8 with S.MAR domain Brian Philip 
SFG.Rtx_H_mIgG2a.I2.e
GFP 
Murine rituximab IgG2a heavy 
chain construct 
Brian Philip 
SFG.Rtx_L_mKappa.I2.e
BFP2 
Murine rituximab kappa light 
chain construct 
Brian Philip 
SFG.R-HCH2CH3-
CD28OXZ.I2.eGFP 
R-HCH2CH3.I2.eGFP Brian Philip 
SFG.RQR-GPI.I2.eGFP RQR-GPI.I2.eGFP Brian Philip 
SFGmR.RQR8-2A-
aGD2huK666-
HCH2CH3pvaa-
CD28Zeta 
RQR8.2A.GD2-CARpvaa  
(including Hombach mutation) 
Alicja Kopec 
SFG.Q-GPI.I2.eGFP Q-GPI.I2.eGFP Brian Philip 
SFG.Q-L-GPI.I2.eGFP Q-L-GPI.I2.eGFP Brian Philip 
SFG.HA-GPI.I2.eGFP HA-GPI.I2.eGFP Brian Philip 
SFG.Qv01-L-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12223) 
Emily Hardman 
SFG.Qv02-L-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12224) 
Emily Hardman 
SFG.Qv03-L-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12227) 
Emily Hardman 
SFG.Qv04-L-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12228) 
Emily Hardman 
SFG.Qv05-L-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12229) 
Emily Hardman 
SFG.QLC-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12230) 
Emily Hardman 
SFG.QLCD52-
GPI.I2.eGFP 
Q-GPI.I2.eGFP 
(MP12231) 
Emily Hardman 
SFG.QZL-GPI.I2.eGFP Q-GPI.I2.eGFP 
(MP12232) 
Emily Hardman 
SFG.myc-L-GPI.I2.eGFP myc.I2.eGFP Emily Hardman 
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SFG.V5-L-GPI.I2.eGFP V5.I2.eGFP Emily Hardman 
SFG.HSV-L-GPI.I2.eGFP HSV.I2.eGFP Emily Hardman 
SFG.T7-L-GPI.I2.eGFP T7.I2.eGFP Emily Hardman 
SFG.OLLAS-L-
GPI.I2.eGFP 
OLLAS.I2.eGFP Emily Hardman 
SFGmR.RQR8-2A-
aCD19_4g7_HL-
CD8STK-41BBZ 
RQR8.2A.aCD19 Gordon Cheung & 
Leila Mekkaoui 
SFG.V5-L-8.I2.eGFP V5-L.8.eGFP 
V5 epitope on CD8 stalk 
Dimitra Markantoni 
SFG.myc-L-8.I2.eGFP myc-L.8.eGFP 
myc epitope on CD8 stalk 
Dimitra Markantoni 
SFG.HA-L-8.I2.eGFP HA-L.8.eGFP 
HA epitope on CD8 stalk 
Dimitra Markantoni 
 
The development of retro- and lenti-viral vector systems offers great potential 
for clinical gene transfer applications. Retroviral vectors offer the capacity for 
transient  genetic experimentation or sustained transgene expression 
following stable integration into the host chromosome. Due to exclusive use of 
retroviral vectors in this body of research, further discussion will be limited to 
these. 
Retroviruses are single stranded RNA viruses which achieve replication 
through a double stranded DNA intermediate. Retroviral vectors, such as SFG28, 
derived from the Moloney murine leukaemia virus are commonly used for gene 
transfer applications. Retroviral expression plasmids offer a strategy to 
achieve sustained gene expression resulting from integration of the transgene 
into the DNA. Crudely bisected, the SFG retroviral expression vector can be 
visualised as a bipartite system as illustrated by Figure 109.  
Inclusion of an origin of replication (ori) and an antibiotic resistance gene, e.g. 
Ampicillin resistance (AmpR), within the vector backbone enables selective 
amplification of DNA within bacteria, whilst the transgenic cassette bounded 
by retroviral long term repeat (LTR) sequences enables transient and/or 
integrative transgene expression strategies.  
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Functional prokaryotic and eukaryotic components of the SFG retroviral vector can be roughly 
identified by bisecting the plasmid across the retroviral long terminal repeat (LTR) domains as 
illustrated. The vector backbone to the left contains prokaryotic regulatory components such as 
antibiotic resistance (AmpR) and the origin of replication (ori) necessary to facilitate plasmid 
amplification in bacterial culture under antibiotic selection. In contrast, the region bounded by 
retroviral LTR domains represents the eukaryotic expression cassette mediating transgene 
expression driven by the 5' LTR promoter facilitating either transient expression when plasmid 
DNA remains episomal or sustained expression following chromosomal integration. 
 
Application of a modular cloning design maintained by inclusion of unique 
restriction sites at key locations within the plasmid backbone enables efficient 
cloning strategies for subsequent construct generation. Epitope mapping and 
epitope tag construct clonings were all generated through SOE-PCR based DNA 
amplification, containing internal NcoI-MluI restriction sites to facilitate 
insertion upstream of an IRES sequence as illustrated by figure 107. Caveats 
for selection of restriction sites include: sites must be unique within the vector 
backbone and absent from the transgenic coding sequence, optimal restriction 
enzymes pairings should generate ‘sticky’ ends which are incompatible with 
each other, with chosen enzymes preferentially insensitive to DAM/DCM 
methylation.  
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Consistent inclusion of NcoI and MluI restriction sites in forward and reverse primers 
respectively facilitated a strategy to rapidly generate virtually identical constructs variant only 
in the sequence under investigation. Inclusion of the Encephalomyocarditis virus (ECMV) IRES 
sequence 3' to the primary transgene facilitating co-expression of the eGFP fluorescent marker 
gene enabled both identification of transgenic cells and assessment of transgene expression 
efficacy. LTR – Long terminal repeat, U3 – unique 3’ region, U5 – unique 5’ region, R – repeat 
motif, SD – Splice donor, SA – Splice acceptor, psi – viral envelope packaging signal, IRES – 
Internal ribosomal entry site, ori – origin of replication, AmpR – Ampicillin resistance 
 
 
The retroviral genome varies in format between the integrated provirus and 
the encapsulated viral genome. In the integrated pro-viral form, the retroviral 
long terminal repeat (LTR) sequences demarcate the viral genome, or 
transgenic cassette. LTR’s are composed of three elements: U3, R and U5, 
representing the U3 and U5 sequences, unique to the 3’ and 5’ termini of the 
viral genome respectively, and R sequences which are repeat sequences located 
in both LTR sequences302. The U3 domain contains the retroviral 
enhancer/promoter sequence driving downstream transgene expression from 
both LTR domains. SFG retroviral constructs utilise the Moloney murine 
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leukaemia virus LTR sequence as the promoter sequence to facilitate transgene 
expression. 
 
Replication of the retroviral genome requires two critical enzymatic abilities of 
the reverse transcriptase enzyme: the ability to use either RNA or DNA as 
template for nucleic acid polymerisation and RNase H nuclease activity which 
enables specific degradation of the RNA strand of RNA:DNA duplexes. 
 
As illustrated by Figure 111, the retroviral genome is bounded by the ‘R’ repeat 
domain located in the terminal repeat domains, however to establish the 
required full LTR domain present in the integrated proviral format, 
retroviruses must regenerate their enhancer/promoter sequence from the RNA 
template. This is achieved through two separate strand-transfer reactions. 
DNA synthesis toward the 5’ terminus commences following host tRNA primer 
binding to the primer binding site (PBS), generating a short anti-sense 
fragment composed of the 5’ R-U5 domain generating minus-strand strong 
stop DNA. Release of this fragment to enable the first strand transfer ‘jump’ is 
facilitated by the RNase H activity of retroviral reverse transcriptase. Binding 
of the minus-strand strong stop DNA intermediate to the 3’ end of the 
retroviral genome, thought to be facilitated by nucleocapsid protein, allows for 
DNA synthesis to continue coincident with RNase H activity in the 3’ to 5’ 
direction. The presence of a short polypurine tract (PPT) resistant to RNase H 
activity terminates degradation of the viral RNA genome at this location. As a 
result, a short RNA fragment localised to the PPT  acts as a primer for plus 
strand DNA synthesis toward the 3’ terminus of the minus-strand strong stop 
DNA, terminating shortly into the sequence for the tRNA primer generating 
plus strand strong stop DNA. RNase H activity then removes the tRNA primer 
exposing the complementary PBS site of the plus strand strong stop DNA 
which can then bind to the complementary PBS site present on minus-strand 
strong stop DNA which is the second strand transfer. The resulting primers 
can then act as template for each other allowing for amplification of the 
proviral DNA genome which is subsequently integrated into the host genome 
through the action of viral integrase302. 
 
The retroviral genome contains three crucial genes necessary for the retroviral 
replication lifecycle. The gag gene encodes core viral structural proteins 
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including matrix (MA), capsid (CA) and nucleocapsid (NC) while the pol gene 
encodes for viral replication enzymes including: protease (PR), reverse 
transcriptase (RT) and integrase (IN); lastly the env gene encodes for the 
envelope glycoprotein (ENV) which is further processed into transmembrane 
(TM) and surface (SU) subunits. Although these genes are required for viral 
replication and generation of infectious viral particles, they are not required 
for gene expression facilitated by integrating viral vectors. Hence, as 
illustrated by Figure 111, exclusion of the viral replication genes, supplied 
separately in trans during viral production allows for space to insert a 
transgenic cassette into a retroviral vector which can be generated into 
functional viral particles when the core viral genes are co-expressed in trans. 
 
The U3 domain contains most of the transcriptional control elements of the 
provirus including the promoter and enhancer with the site of transcription 
initiation located at the boundary of the U3-R domains. 
 
Retroviral vectors exploit the functional capacity of genomic integration whilst achieving safety 
through deletion of pathogenic portions of the viral genome (e.g. viral polymerase (pol) and 
envelope (env) genes. However, much of the gag gene remains due to co-localisation of the 
packaging signal psi (symbol) in this region which is essential to facilitate packaging of the 
transgenic cassette into viral particles. The retroviral genome, and by extension retroviral 
expression cassettes, are delineated by long terminal repeat domains which in the integrated 
proviral format are comprised of 3 domains: unique 5' and 3' regions flanking a repeat motif 
located in the middle. Transgene transcription is driven by the retroviral promoter located at the 
junction of the U3-R domains. 
 
 
A consensus sequence for optimal transcription initiation based on the 
research of Marilyn Kozak was located directly upstream of the transgenic 
cassette in the SFG vectors. Where the spicing by overlapping extension 
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cloning strategy required generation of the start codon for this cassette, the 
Kozak consensus sequence was included within the 5’ primer sequences to 
ensure effective DNA transcription303. 
 
Scaffold or Matrix attachment regions are DNA sequences which were 
identified to bind preferentially to the nuclear matrix based on nuclease 
digestion assays. Although S/MAR sequences appear to share some common 
structural features including an AT-rich sequence and inclusion of 
topoisomerase II consensus sequences, a defining consensus sequence for 
S/MAR elements remains to be established304. It has been observed that 
transgene expression in retrovirally transduced T-cells is decreased in 
mitotically quiescent cells. However, this effect can be offset by orientation 
specific incorporation of the human beta inteferon S/MAR region into Moloney 
murine leukaemia virus based vectors which has been demonstrated to 
improve transgene expression in primary human T-cells254. Where indicated, 
vectors including S/MAR regions used in this project contained the human 
beta interferon S/MAR to ensure sustained transgene expression. 
 
IRES elements and 2A sequences represent two alternative strategies to 
achieve bi/poly cistronic gene expression: 
 
 
IRES elements consist of cis acting RNA structures that possess the ability to 
directly recruit translational machinery to an internal position within an 
mRNA. Thus, inclusion of an IRES sequence enables bicistronic expression 
under control of a single promoter. This strategy allows for interrogation of a 
protein of interest coincident with a secondary protein such as the fluorescent 
protein eGFP, used as a marker gene to identify the transgene expressing 
population. Using this strategy, synthesis of a single mRNA containing an IRES 
element situated between open reading frames, is directed by the retroviral 
promoter. Translation of the upstream transgene occurs by cap-dependent 
ribosome scanning whereas translation of the downstream transgene results 
from direct recruitment of ribosomes to the IRES sequence in a cap 
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independent manner305. We have employed the commonly used 
Encephalomyocarditis virus (EMCV) IRES sequence in the SFG constructs used 
in this project, subsequently referred to as ‘I2’. 
 
 
Viral derived ‘2A’ peptide sequences are attractive alternatives to IRES 
elements for bicistronic expression. Although inclusion of IRES elements 
enables multiple proteins to be produced from a single mRNA transcript, this 
strategy suffers from a number of limitations. The downstream sequence is 
often translated at a much lower level that the upstream sequence and the 
impact of this effect can vary dependent on size of the upstream sequence; 
also, averaging 600 base pairs in length, IRES elements impact upon the size of 
a transgenic cassette. Finally, the expression of the downstream cistron can be 
sensitive to the positioning following the IRES element. In contrast, 2A 
sequences are -acting hydrolase elements which mediate co-translational 
cleavage of a nascent peptide sequence. The sequence of the 2A peptide acts 
to prevent the formation of a normal peptide bond between the terminal 
glycine and proline residues. This results in the ribosome skipping to the next 
codon resulting in peptide cleavage between the glycine and proline residues 
of the nascent protein306. As a result, the upstream sequence retains a residual 
2A sequence suffix, whilst the downstream sequence commences with the 
residual proline residue. Typically 20 amino acid residues in length, 2A 
peptide sequences are considerably smaller than IRES elements and offer 
equimolar expression of bi/poly-cistronic constructs. For constructs 
containing a 2A sequence, we used the 20 amino acid 2A sequence derived 
from the  virus; RAEGRGSLLTCGDVEENPGP307 selected based on 
the high efficiency of cleavage activity. 
 
 
In the SFG vector used in this project28, transgene expression is mediated by 
the retroviral promoter located in the U3 domain of the 5’ LTR. However, 
where necessary, cloning design included a portion of the psi packaging 
sequence to facilitate alternative restriction digest combinations e.g. 
BglII/AgeI-MluI. 
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Localisation of the 2A sequence in this orientation affords a simple cloning 
design for equimolar co-expression of alternative constructs alongside RQR8. 
This parental construct was used to generate the co-expression constructs for 
RQR8 along with the WT1 TCR and the GD2 CAR Figure 112.  
 
Vector engineering to establish unique restriction sites at key locations within the retroviral 
vector affords the potential to facilitate simple subcloning of subsequent constructs. Thus as 
illustrated, generation of novel CAR constructs can be readily achieved through NcoI-BamHI 
cloning which exchanges the binding specificity of an scFv into a retroviral CAR expression 
cassette backbone. 
 
Furthermore, as scaffold/matrix attachment regions (S/MAR’s) have been 
demonstrated to enhance transgene expression, a S/MAR domain derived from 
the human beta interferon gene was included into the vector backbone 
structure to compensate for high transcriptional burden of long open reading 
frames. (Previous work by Dr. Simon Thomas has demonstrated improved gene 
expression from SFG vectors containing S/MAR domains).  
 
The cloning design for single chain variable fragment (scFv) constructs 
employed an NcoI-BamHI restriction strategy placing the insert in frame into 
the scFv transgene illustrated by Figure 112. Due to the presence of a natural 
BamHI site proximal to the apex of the IgG1 stalk affords a simple strategy for 
scFv cloning through an NcoI-BamHI restriction strategy allowing for 
generation of alternative CAR’s through insertion of an alternative scFv cloned 
in-frame. This cloning strategy also facilitates a simple functional screening 
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strategy for gene synthesis constructs as frameshift mutations would likely 
result in non-functional protein products. An alternative construct containing 
a modified endodomain (parental construct cloned by Kim Vigor and Simon 
Thomas) enables production of secreted versions of scFv fragments to enable 
functional binding assays. 
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